Use these links to rapidly review the document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.    )

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12
RITE AID CORPORATION
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

[MISSING IMAGE: cv_ofcriteaid-4c.jpg]

[MISSING IMAGE: cv_ifcrite-4c.jpg]

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
LETTER FROM OUR INDEPENDENT BOARD CHAIR AND INTERIM CHIEF EXECUTIVE OFFICER
June [•], 2023
This past year has been one of challenge and change for our company, and we are especially grateful for the dedication of our associates to deliver on our mission to help our customers achieve whole health for life. We know there is a fundamental consumer need for pharmacy services—for both individuals and companies. At Rite Aid, we serve these needs through both our retail and PBM businesses. We have a trusted and iconic brand, an attractive retail footprint, and a long history of serving millions of customers built over the years largely through our pharmacists. The role of the pharmacist has become an increasingly important, trusted, and efficient option for the delivery of health care services to consumers—which is part of our core value proposition.
While we have all the right ingredients for success, we have been disappointed in our financial performance. We know we need to do better to deliver value to our stockholders. That is why we have taken a series of actions, including deciding to replace our CEO, searching for a new leader, and upleveling talent in critical areas. We have also implemented an established turnaround model that is geared to drive enterprise-wide performance acceleration and is expected to chart a new course for our business. This model is highly prescriptive and programmatic, with a rapid cadence and analytical rigor. We believe that this new operating model will enable us to organize effectively and efficiently to capture value and drive growth. We are impacting all areas of the business including Pharmacy, Front End, Elixir and overall operations, which we believe will position our core business for growth longer term.
We are moving with urgency and intense focus on those opportunities, and we look forward to sharing more with you at our 2023 Annual Meeting of Stockholders. The meeting will be held on August 18, 2023, and once again will be a virtual meeting to make the meeting more accessible to all of our stockholders.
You can attend the meeting at www.virtualshareholdermeeting.com/RAD2023 by using the 16-digit control number, which appears on your Notice of Internet Availability of Proxy Materials or the instructions that accompanied your proxy materials. You will have the ability to submit questions during the meeting via the meeting website. At the meeting, stockholders will vote on the proposals set forth in the Notice of Annual Meeting and the accompanying proxy statement.
[MISSING IMAGE: ph_brucegbodakenbox-pn.jpg]
[MISSING IMAGE: ph_elizabethburrbox-pn.jpg]
We are committed to driving growth and stockholder value and appreciate your support as we continue to execute our turnaround plan. We hope you and your families are safe and well.
Thank you for your investment in Rite Aid.
Sincerely,
[MISSING IMAGE: sg_brucebodaken-bw.jpg]
[MISSING IMAGE: sg_elizabethburr-bw.jpg]
Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

o


Preliminary Proxy Statement

o


Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ý


Definitive Proxy Statement

o


Definitive Additional Materials

o


Soliciting Material under §240.14a-12


RITE AID CORPORATION

(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

ý


No fee required.

o


Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:
(2)Aggregate number of securities to which transaction applies:
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)Proposed maximum aggregate value of transaction:
(5)Total fee paid:

o


Fee paid previously with preliminary materials.

o


Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.



(1)


Amount Previously Paid:
(2)Form, Schedule or Registration Statement No.:
(3)Filing Party:
(4)Date Filed:

Table of Contents

LOGO

June 7, 2019
Dear Fellow Stockholders:

        On behalf of the Board of Directors (the "Board") of Rite Aid Corporation ("Rite Aid" or the "Company"), I want to take this opportunity to invite you to attend our 2019 Annual Meeting of Stockholders. The meeting will be held at 8:30 a.m., local time, on Wednesday, July 17, 2019, at the office of Skadden, Arps, Slate Meagher & Flom LLP, Four Times Square, New York, NY 10036. At the meeting, stockholders will vote on the proposals set forth in the Notice of Annual Meeting and the accompanying proxy statement.

        At Rite Aid, we remain focused on taking actions to best position the Company to create long-term value for stockholders. These include actions to use our unique capabilities to help payors deliver a high level of care to patients, to re-imagine our front end to offer the selection of products and services that meet the needs of our target customers and to transform our processes and procedures to ensure strong cost discipline and achieve peak operational efficiency.

        Our actions to create long-term value for stockholders include our efforts to enhance the quality of our Board by bringing in fresh perspectives and valuable expertise and experience. A majority of Rite Aid directors have joined the Board in the past eight months, with Bob Knowling, Lou Miramontes and Arun Nayar joining in October 2018 and Busy Burr and Kate Quinn joining in April 2019. In addition to their wealth of knowledge and experience, these changes to our Board bring a diversity of thought, as well as enhance our Board's gender, racial, and ethnic diversity.

        As we have said previously, one of the Board's most important tasks is choosing the Company's Chief Executive Officer. In March, we announced a leadership transition and organizational restructuring to better align the structure and leadership of Rite Aid with its present scale. As part of this transition, we are currently in the process of searching for a new CEO. The Board recognizes the significance of this task and is conducting its process in a thoughtful and deliberate manner.

        Both before and since the 2018 Annual Meeting, we have increased our efforts to engage with many of our larger stockholders and we value the input they have provided. In response to votes held at the 2018 Annual Meeting and engagement thereafter, we have enhanced our corporate governance structures by requiring the separation of the Chairman of the Board and CEO positions and by providing stockholders with the right to call special meetings.

        With respect to executive compensation, we took steps to further align pay and performance, including increasing the emphasis on performance-based (rather than time-based) long-term incentives for fiscal 2019 and refining our peer group for fiscal 2020 to, among other things, remove industry peers that are no longer appropriate data points given their significantly larger scope of operations.

        We continue our efforts to ensure that Rite Aid's business is operated in a sustainable and socially responsible manner. In addition to moving forward on the sustainability and opioid-related reports that stockholders voted for at the 2018 Annual Meeting, in April 2019, we announced enhanced efforts to promote responsible access to tobacco products by increasing the age to purchase tobacco products to 21 and removing e-cigarettes and vaping products chain-wide. We are also continuing to enforce our chain-wide "ID All" policy that requires identification to purchase age-restricted items, including tobacco products. The Board continues to receive reports from management on sustainability and opioid-related matters.


Table of Contents

        As referenced above and described further in the accompanying proxy statement, we at Rite Aid have taken or are in the process of taking the actions that we said we would take—refreshing our Board, reinvigorating our corporate governance practices and policies, assessing management's performance, aligning pay for performance, overseeing the development of strategic initiatives, and being responsive to issues raised by our stockholders. We look forward to continuing to engage with you.

        Your vote is important to us. Please vote as soon as possible even if you plan to attend the Annual Meeting. We appreciate your continued ownership of Rite Aid shares and your support.

Sincerely,



GRAPHIC



BruceBRUCE G. Bodaken
ChairmanBODAKEN
Chair of the Board
ELIZABETH BURR
Interim Chief Executive Officer

Refer to the section titled "Cautionary“Cautionary Statement Regarding Forward-Looking Statements"Statements” for a discussion of risks and uncertainties that could cause actual results to differ materially from those projected.




Table of Contents

LOGO

RITE AID CORPORATION
P.O. BOX 3165
HARRISBURG, PENNSYLVANIA 17105



NOTICETABLE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on July 17, 2019

To Our Stockholders:

CONTENTS
[MISSING IMAGE: lg_riteaid-pn.jpg]
Rite Aid Corporation
PO Box 3165
Harrisburg, PA 17105
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
[MISSING IMAGE: tm217739d1-icon_calendarpn.jpg]WHEN
[MISSING IMAGE: ic_mic-pn.jpg]
VIRTUAL MEETING
[MISSING IMAGE: ic_pencil-pn.jpg]RECORD DATE

What:

Our 2019 Annual Meeting of Stockholders

When:

July 17, 2019 at 8:August 18, 2023
11:
30 a.m., local time

Eastern
Daylight Time
www.virtualshareholdermeeting.com/RAD2023Close of business on
June 27, 2023
AGENDA
ProposalBoard Recommendation

Where:

1

Office

Election of Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square
New York, NY 10036

Why:

At this Annual Meeting, stockholders will be asked to:

1.

Elect eightsix directors to hold office until the 20202024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified;

[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the Board’s nominees

22.RatifyRatification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm;firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR

33.Approve, on an advisory basis,Advisory vote to approve the compensation of our named executive officers as presented in the proxy statement;
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR

44.Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
ONE YEAR
5Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
6Consider and vote on a stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors, if properly presented at the Annual Meeting; andMeeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST

75.Transact such other business as mayConsider and vote on a stockholder proposal to adopt an executive compensation adjustment policy, if properly come beforepresented at the Annual Meeting or any adjournment or postponement of the Annual Meeting.
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST

        The close of

In addition, we will transact any other business on June 6, 2019 has been fixed as the record date for determining those Rite Aid stockholders entitled to voteproperly presented at the Annual Meeting. Accordingly, only stockholders of record at the close of business on that date will receive this notice of, and be eligible to vote at, the Annual Meeting andmeeting, including any adjournment or postponement of the Annual Meeting. The above items of business for the Annual Meeting are more fully described in the proxy statement accompanying this notice.

        Your vote is important.    Please read the proxy statement and the instructions on the enclosed proxy card and then, whether or not you plan to attend the Annual Meeting in person, and no matter how many shares you own, please submitthereof.


TABLE OF CONTENTS

VOTING
Have your proxy promptly by telephone or via the Internet in accordance with the instructions on the enclosed proxy card or by completing, datingvoting instruction form in hand, with your individual control number, and returning your proxy card infollow the envelope provided. This will not prevent you from voting in person at the Annual Meeting. It will, however, help to assure a quorum and to avoid added proxy solicitation costs.

        You may revoke your proxy at any time before the vote is taken by delivering to the Secretary of Rite Aid a written revocation or a proxy with a later date (including a proxy by telephone or via the Internet) or by voting your shares in person at the Annual Meeting, in which case your prior proxy would be disregarded.

instructions.
[MISSING IMAGE: ic_phone-pn.jpg]
PHONE
[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
INTERNET
[MISSING IMAGE: tm217739d1_icon-qrreaderpn.jpg]
MOBILE DEVICE
[MISSING IMAGE: ic_mail-pn.jpg]
MAIL
[MISSING IMAGE: ic_chat-pn.jpg]
VIRTUAL MEETING
Call
1-800-690-6903
(toll-free), 24/7
Visit
www.proxyvote.com,
24/7
Scan the
QR code
[MISSING IMAGE: tm228886d1-icon_qrcodebwlr.jpg]
Mark, sign and
date your proxy
card or voting
instruction form
and return it in
the postage-paid
envelope
During the virtual
meeting, go to

www.virtualshareholder
meeting.com/RAD2023
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE
STOCKHOLDER MEETING TO BE HELD ON AUGUST 18, 2023
Your vote is important. Please read the proxy statement carefully and submit your vote as soon as possible. The Notice of Availability is being mailed and the proxy materials made available on or about [June 29], 2023. The proxy statement and annual report, as well as the Company’s proxy card, are available at www.proxyvote.com.

TABLE OF CONTENTS

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
TABLE OF CONTENTS

Table of Contents


TABLE OF CONTENTS


Page

QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING

1

STOCKHOLDER ENGAGEMENT, MANAGEMENT TRANSITION, AND BOARD REFRESHMENT

7

PROPOSAL NO. 1 ELECTION OF DIRECTORS

9

BOARD OF DIRECTORS

9

DIRECTOR COMPENSATION TABLE FOR FISCAL YEAR 2019

25
Board Meeting Attendance
Director Nominations
Executive Sessions of Non-Management Directors
Communications with the Board of Directors
Environmental, Social & Governance Matters
Corporate Governance Materials
Certain Relationships and Related Transactions
Directors’ Compensation
26
Auditor Fees
Audit Committee Report
27

STOCKHOLDER PROPOSAL

28

PROPOSAL NO. 4 STOCKHOLDER PROPOSAL—SEEKING A BY-LAW AMENDMENT FOR A 10% OWNERSHIP THRESHOLD FOR STOCKHOLDERS TO CALL SPECIAL MEETINGS

28
31

EXECUTIVE COMPENSATION

33Compensation Discussion and Analysis

COMPENSATION DISCUSSION AND ANALYSIS

33Compensation Committee Report

COMPENSATION COMMITTEE REPORT

53

SUMMARY COMPENSATION TABLE

54

GRANTS OF PLAN-BASED AWARDS TABLE FOR FISCAL YEAR 2019

55

EXECUTIVE EMPLOYMENT AND SEPARATION AGREEMENTS

56Executive Compensation Tables

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR 2019 YEAR-END

5756

OPTION EXERCISES AND STOCK VESTED TABLE FOR FISCAL YEAR 2019

58

NONQUALIFIED DEFERRED COMPENSATION FOR FISCAL YEAR 2019

58

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

5860

PAY RATIO DISCLOSURE

6561

AUDIT COMMITTEE REPORT

61
61
67Pay Ratio Disclosure
69

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

69
70
80

CERTAIN RELATIONSHIPS

71

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

7280Questions and Answers

STOCKHOLDER PROPOSALS FOR THE 2020 ANNUAL MEETING OF STOCKHOLDERS

7387Important Notice Regarding Delivery of Stockholder Documents

INCORPORATION BY REFERENCE

74

OTHER MATTERS

7489Stockholder Proposals for the 2024 Annual Meeting

IMPORTANT NOTICE REGARDING DELIVERY OF STOCKHOLDER DOCUMENTS

7490Incorporation by Reference

ANNUAL REPORT

7591Other Matters

APPENDIX A

A-1Certain Information Regarding Participation in the Solicitation of Proxies

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

91Annual Report
92Cautionary Statement Regarding Forward-Looking Statements

i




TableTABLE OF CONTENTS
PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION DATED JUNE 16, 2023
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROXY STATEMENT SUMMARY
This Proxy Statement Summary highlights information contained elsewhere in this proxy statement. This summary does not contain all of Contents

LOGO

RITE AID CORPORATION
P.O. BOX 3165
HARRISBURG, PENNSYLVANIA 17105



PROXY STATEMENT



FOR THE ANNUAL MEETING OF STOCKHOLDERS
To Be Held on July 17, 2019



Important Notice Regarding the Availability of Proxy Materials forinformation you should consider, so please read the
Stockholder Meeting entire proxy statement carefully before voting. References to be Held on July 17, 2019:

The“Rite Aid,” “Rite Aid Corporation,” the “Company,” “we,” “us,” or “our” in this proxy statement and annual report, as well as the Company's proxy card,accompanying notice and letters to stockholders refer to Rite Aid Corporation and/or its affiliates. Rite Aid Corporation, a Delaware corporation, owns multiple subsidiary companies which operate Rite Aid stores and pharmacies and other affiliated companies. The term “affiliates” means direct and indirect subsidiaries of Rite Aid Corporation and partnerships and joint ventures in which such subsidiaries are available at
www.proxyvote.com.



partners. References herein to “associates” refer to employees of our affiliates.

This proxy statement is being furnished to you by the Board of Directors (the "Board"“Board” or "Board“Board of Directors"Directors”) of Rite Aid Corporation (the "Company" or "Rite Aid") to solicit your proxy to vote your shares at our 20192023 Annual Meeting of Stockholders (the "Annual Meeting"“Annual Meeting”). The Annual Meeting will be held on July 17, 2019August 18, 2023 at 8:11:30 a.m., local time,Eastern Daylight Time, by live audio webcast at www.virtualshareholdermeeting.com/RAD2023.
The following proposals will be on the agenda for the Annual Meeting:
ProposalBoard RecommendationSee Page
1Election of six directors to hold office until the 2024 Annual Meeting of Stockholder
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the Board’s nominees
2Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
3Advisory vote to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
4Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
ONE YEAR
5Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
6Consider and vote on a stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
7Consider and vote on a stockholder proposal to adopt an executive compensation adjustment policy, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
In addition, we will transact any other business properly presented at the office of Skadden, Arps, Slate, Meagher & Flom LLP, Four Times Square, New York, NY 10036.

        This proxy statement, the foregoing notice and the accompanying proxy card are first being mailed on or about June 7, 2019 to all holders of our common stock, par value $1.00 per share, entitled to vote at the Annual Meeting. At Rite Aid and in this proxy statement, we refer to our employees as associates.


QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING

Who is entitled to vote at the Annual Meeting?

        Holders of Rite Aid common stock as of the close of business on the record date, June 6, 2019, will receive notice of, and be eligible to vote at, the Annual Meeting andmeeting, including any adjournment or postponement thereof.


RITE AID CORPORATION   2023 Proxy Statement | 1

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
BUSINESS STRATEGY AND PERFORMANCE IN FISCAL YEAR 2023
Our Enterprise Strategy
As a healthcare company with a retail footprint operating in diverse communities throughout the country, we are positioned to create meaningful customer, client, and member experiences for the millions of lives we touch.
We are focused on three key strategic drivers of growth:
[MISSING IMAGE: ic_pharmacy-pn.jpg]
[MISSING IMAGE: ic_deepening-pn.jpg]
[MISSING IMAGE: ic_elixir-pn.jpg]
1.
Growing our pharmacy business by:

improving our access to networks,

strategically acquiring prescription files,

increasing medication adherence, and

making more clinical services available to our customers.
2.
Deepening our customer loyalty and engagement by:

improving our in-store experience,

optimizing our products and services,

leveraging personalized marketing and communications, and

expanding our digital solutions.
3.
Scaling our Elixir business by:

delivering on a value proposition unique to the mid-market including competitive pricing,

leveraging our platform to deliver white-label services,

optimizing our specialty pharmacy, and

improving our operational efficiency.
All of these are enabled by significant ongoing investments in our people and infrastructure, including our distributions centers, central fill operations, and systems for customer and client support.
Fiscal Year 2023 Performance and Operational Highlights(1)
$24.1B
Total Revenue
$429.2M
Adjusted EBITDA
$1.5B
Total Liquidity
6.9%
Increase in
Comparable
Same-Store
Prescriptions
(excluding COVID-19
impacts)
617K
Prescriptions Filled
Each Day, On Average
(including
immunizations), in Rite
Aid & Bartell Stores
6,300
Pharmacists Serving
Our Communities
2,300
Retail Pharmacy
Locations across 17
States
Over 60%
Growth in Third-Party
E-Commerce Business
(1)
As of March 4, 2023 (figures are rounded).

2 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
STOCKHOLDER ENGAGEMENT EFFORTS
At Rite Aid, we believe stockholder engagement is extremely important. We regularly seek the perspectives of our stockholders on issues important to them. Through our quarterly financial performance webcasts, analyst conferences, investor meetings and calls, we obtain and share stockholder feedback with our Board and committees. This feedback from stockholders, including views regarding Board composition, corporate governance matters and ESG matters, is extremely valuable to our Board of Directors and management.
Our engagement with stockholders occurs on a continuous basis, with calls and meetings happening throughout the year. During fiscal year 2023, we continued the increased outreach we began in fiscal year 2021 and enhanced our program to also include our retail stockholder base. As in the prior year, in fiscal year 2023 we also proactively offered Company-initiated meetings to our largest stockholders, representing over 40% of our outstanding shares. These meetings included an offer to speak with the Board Chairman, the Chair of our Compensation Committee, the then CEO, and the CFO. Our Compensation Committee considers investor perspectives when making decisions on executive compensation and DEI initiatives. Additionally, in fiscal year 2023, we began an annual retail stockholder call, providing our retail investors with the opportunity to ask and have management answer questions that are most important to them. This event proved popular, with robust retail stockholder participation and feedback.
[MISSING IMAGE: ic_cabal-pn.jpg]
[MISSING IMAGE: ic_colab-pn.jpg]
[MISSING IMAGE: ic_grpchat-pn.jpg]
WHO WE CONTACTEDHOW WE ENGAGEDWHAT WE DISCUSSED
Multiple times during fiscal year 2023, we individually reached out to the top stockholders who collectively own approximately
40%
of our outstanding stock.
If these stockholders are interested in meeting, they are offered meetings with our Board Chairman, the Chair of the Compensation Committee, the CEO, and CFO.
We biannually invite our largest
25
stockholders
to individual meetings to discuss items of importance to them, such as executive and Board compensation, corporate governance, and ESG matters.
The Chair of the Compensation Committee and senior management are available to participate upon request. We also regularly engage with all stockholders as part of our ongoing investor relations program.

Executive compensation.

Financial performance including the decline of the prior financial benefits of COVID-19 vaccines and testing.

The importance of environmental, social and governance (ESG) initiatives, particularly related to carbon emissions reductions and renewable energy strategies.

Rite Aid’s growth and business strategy in a post-COVID-19 world.

Continued expense management and cost control.

Further reduction of debt and free cash flow generation.

Board level oversight of diversity, equity and inclusion (DEI) strategy.

Human capital management matters including hiring, training, retaining a diverse workforce, and workplace safety.

RITE AID CORPORATION   2023 Proxy Statement | 3

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
BOARD OF DIRECTORS
Director Nominees
Committees
Director and Principal OccupationAgeDirector
Since
IndependentAuditCompensationNominating and
Governance
[MISSING IMAGE: ph_brucebodaken-4c.jpg]
BRUCE G. BODAKEN(1)
Former Chairman and Chief Executive
Officer, Blue Shield of California
71
2013;
[MISSING IMAGE: ic_stark-bw.jpg]
since
2018
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ph_elizabethbusyburr-4c.jpg]
ELIZABETH BURR(2)
Interim Chief Executive Officer, Rite Aid
Corporation
612019
[MISSING IMAGE: ph_bariharlam-4c.jpg]
BARI HARLAM
Co-Founder, Trouble LLC; and former
EVP, Chief Marketing Officer North
America, Hudson’s Bay Company
612020
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: ph_robertknowling-4c.jpg]
ROBERT E. KNOWLING, JR.(2)
Chairman, Eagles Landing Partners
672018
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ph_arunnayar-4c.jpg]
ARUN NAYAR(1)
Former Executive Vice President
and Chief Financial Officer,
Tyco International
722018
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ic_calculator-bw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: ph_katequinn-4c.jpg]
KATE B. QUINN
Vice Chairman and Chief
Administrative Officer, U.S. Bancorp
(retiring June 2023)
582019
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
(1)
Effective as of the Annual Meeting. At the close of businessMeeting, Mr. Miramontes will cease to serve on the record date, Rite Aid had outstandingAudit Committee and entitled to vote 53,828,701 sharesMr. Bodaken will begin serving on the Audit Committee. Mr. Nayar will serve as Chair of common stock. No other sharesthe Audit Committee.
(2)
Ms. Burr was a member of Rite Aid capital stock are entitled to notice of and to votethe Audit Committee until January 7, 2023, when she was appointed Interim Chief Executive Officer. Mr. Knowling joined the Audit Committee at that time.
[MISSING IMAGE: ic_committee-pn.jpg]
Committee Chair
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Committee Member
[MISSING IMAGE: ic_stark-bw.jpg]
Chair of the Board
[MISSING IMAGE: ic_calculator-bw.jpg]
Audit Committee Financial Expert

4 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
Board Attributes*
[MISSING IMAGE: pc_attribut-pn.jpg]
*
The compositions depicted illustrate calculations effective following the Annual Meeting.

What matters will be voted

BOARD AND GOVERNANCE HIGHLIGHTS
[MISSING IMAGE: ic_checkgreen-pn.jpg]
All Board members are independent except the Interim Chief Executive Officer
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Diverse chairs for Audit, Compensation and Nominating and Governance Committees
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Independent Chair of the Board
[MISSING IMAGE: ic_checkgreen-pn.jpg]
All directors elected annually
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Majority voting for directors in uncontested elections
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Proxy access provisions in bylaws
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Holders of 10% of outstanding stock may call a special meeting of stockholders
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Mandatory director retirement age of 75
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Meaningful stock ownership requirements for the Board and executive officers
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Anti-hedging and anti-pledging policy for the Board and all associates
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Annual evaluation of the Board and committees

RITE AID CORPORATION   2023 Proxy Statement | 5

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
EXECUTIVE COMPENSATION OVERVIEW
Philosophy and Objectives
Our executive compensation program is based on a pay-for-performance philosophy and is designed to accomplish the following goals:
[MISSING IMAGE: tm228886d2-tbl_philosopypn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]    WHAT WE DO
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]    WHAT WE DO NOT DO
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Conduct annual stockholder advisory vote on the compensation of our named executive officers
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain dialogue with stockholders on various topics, including executive pay practices
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Retain an independent executive compensation consultant to the Compensation Committee
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Ensure that a significant portion of executive officer total target remuneration is at risk
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Provide annual and long-term incentive plans with performance targets aligned to business goals
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require a designated level of stock ownership for all named executive officers and non-management directors
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require shares subject to the annual non-management director grant to be deferred until separation from service
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require equity awards to have a double trigger (qualifying termination of employment and change in control)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Complete an annual incentive compensation risk assessment
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain a formal clawback policy for executive officers
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Provide gross-up payments to cover personal income taxes or excise taxes related to executive severance benefits
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Permit executives to engage in hedging or pledging of Rite Aid securities
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Reward executives for imprudent, inappropriate, or unnecessary risk-taking
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Allow the repricing of equity awards without stockholder approval

6 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY
ENVIRONMENTAL, SOCIAL & GOVERNANCE EFFORTS
Rite Aid is committed to integrating Environmental, Social, and Governance (ESG) initiatives into our operations, not only to create value for our stockholders, customers, and associates, but also because we are deeply invested in our communities, and our customers want to support a company that supports their safety and our environment. As explained in our voluntary annual ESG report, our approach is broken into four pillars: Thriving Planet, Thriving Business, Thriving Workplace and Thriving Community.
[MISSING IMAGE: ic_world-pn.jpg]
[MISSING IMAGE: ic_home-pn.jpg]
[MISSING IMAGE: ic_hand-pn.jpg]
[MISSING IMAGE: ic_houseppl-pn.jpg]
THRIVING PLANETTHRIVING BUSINESSTHRIVING WORKPLACETHRIVING COMMUNITY
Reducing our environmental impact through:

Energy and fleet fuel management

Waste reduction and minimization

Supply chain optimization
Embedding sustainability throughout our value chain through:

Responsible sourcing

Product safety, quality, health and nutrition

Drug supply chain integrity

Data security and privacy
Optimizing our associate experience, development, opportunity and well-being across our organization through:

Workforce diversity and inclusion

Associate engagement and development

Total rewards

Health and safety

Labor practices
Improving health equity, outcomes and access to care in the communities we serve through:

Efforts to improve patient health outcomes at Rite Aid, Elixir and Health Dialog

Management of controlled substances

Community involvement
[MISSING IMAGE: ic_environmental-pn.jpg]
Environmental
Some of our quantitative fiscal year 2023 highlights include:
[MISSING IMAGE: tbl_environmental-pn.jpg]
Social
We continue to integrate sustainability into our sourcing process, collecting data on topics such as supplier diversity, product packaging, and chemical management to help inform sourcing decisions.
[MISSING IMAGE: ic_socialsupport-pn.jpg]
In fiscal year 2023, we continued collaborating with our own brand supplier partners to further advance our efforts in reducing and eliminating harmful chemicals in the products we sell.
Our clinical services team performed 724 health clinics in underserved areas with social vulnerability index (SVI) scores greater than 75%, demonstrating our focus on patient outcomes and access to care.
Human Capital Management Efforts
We are proud to employ over 47,000 associates as of the end of fiscal year 2023 across the United States, including Puerto Rico. Our associates are key to the success of our transformation as they are at the Annual Meeting?

        There are four proposals that are scheduled to be considered and voted on atcenter of supporting the Annual Meeting:

    Proposal No. 1: Elect eight directors to hold office until the 2020 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified;

    Proposal No. 2: Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm;

    Proposal No. 3: Conduct an advisory vote to approve the compensationwhole health of our named executive officerscustomers and communities. We are optimizing our workforce through enhanced communication and engagement through the following measures:

RITE AID CORPORATION   2023 Proxy Statement | 7

TABLE OF CONTENTS
PROXY STATEMENT SUMMARY

conducting annual engagement surveys on topics such as presentedcareer development, well-being, compensation, benefits, recognition, leader communications, and opportunities specific to diversity, equity and inclusion efforts, in this proxy statement;which more than 70% of our associates have participated;

continuing our efforts to attract top talent with sign-on bonuses, pay adjustments in hard to staff areas, and

unlimited paid time off to certain associates;
Proposal No. 4: Consider
operating as a stockholder proposal seekingremote-first employer for our corporate associates, allowing us to expand our talent pool and allow our corporate associates more flexibility to balance their work and family priorities;

developing success profiles for our associates to refine skills needed today and build capabilities for the future;

operating as an Accredited Provider of Continuing Pharmacy Education, which allows us to offer courses that count toward the continuing education licensing requirements of our pharmacists;

offering an accredited pharmacy technician certification program;

offering compensation and benefit programs to support, recognize and reward performance of our associates (including annual bonuses, 401(k) plans, health care benefits, paid time off, life and disability coverage, merchandise discounts, and many other services and programs);

offering associate wellness programs and tools for whole health in areas such as mental health, condition specific management programs, and financial wellness; and

offering an associate recognition program to celebrate the achievements of our teams and create a By-Law amendmentcommunity experience for our workforce.
Diversity, Equity & Inclusion Efforts
We are continuing to build momentum with Diversity, Equity & Inclusion (DEI) at Rite Aid and are seeing notable progress that we believe is adding value to our business. Our multi-year strategy is gaining traction with new programs and initiatives launched in fiscal year 2023, such as leadership development programs aimed specifically to advance diverse talent. We are discovering and addressing the unique needs of our workforce and empowering our people to perform at their very best.
We are taking an innovative approach to our DEI strategy, which we are executing through our recently launched Associate Experience program. The Associate Experience provides our associates with the programs, benefits, and resources that our associates have indicated are important to them, such as enhanced Total Rewards and improved information technology systems and resources. We believe the Associate Experience will enhance our talent attraction, retention, and development efforts, which will enable us to better fulfill our strategic initiatives and operational priorities.
As of December 31, 2022, 68% of associates self-reported as female. In addition, associates reported their race/ethnicity as: White 55%; Hispanic 15%; Black 13%; Asian 12%; and Other 5%. We are proud to have a 10% ownership threshold for stockholders to call special meetings.

TableBoard with 43% gender diversity and 43% ethnic/racial diversity.

[MISSING IMAGE: ic_governance-pn.jpg]
Our Nominating and Governance Committee of Contents

        Stockholders will also be asked to consider and vote at the Annual Meeting on any other matter that may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. At this time, the Board of Directors is unawarehas direct oversight and responsibility of any matters, other than those set forth above, that may properly come before the Annual Meeting.

What are the Board's voting recommendations?

        The Board recommends that you vote "FOR" the nomineesESG, while our Compensation Committee has direct oversight of the Board in the election of directors, "FOR" the ratification of Deloitte & Touche LLP as the Company's independent registered public accounting firm, "FOR" the approval, on an advisory basis, of the compensation of our named executive officers as presented in this proxy statement, and "AGAINST" the stockholder proposal.

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

        If your shares are registered directly in your name with our transfer agent, Broadridge Corporate Issuer Services, you are considered the "stockholder of record" with respectDEI. In fiscal year 2023, we provided quarterly updates to those shares.

        If your shares are held in a stock brokerage account or by a bank or other nominee, those shares are held in "street name" and you are considered the "beneficial owner" of the shares. As the beneficial owner of those shares, you have the right to direct your broker, bank, or nominee how to vote your shares, and you will receive separate instructions from your broker, bank, or other holder of record describing how to vote your shares.

How can I vote my shares before the Annual Meeting?

If you hold your shares in your own name, you may submit a proxy by telephone, via the Internet, or by mail.

    Submitting a Proxy by Telephone:  You can submit a proxy for your shares by telephone until 11:59 p.m. Eastern Daylight Time on July 16, 2019, by calling the toll-free telephone number on the enclosed proxy card, 1-800-690-6903. Telephone proxy submission is available 24 hours a day. Easy-to-follow voice prompts allow you to submit a proxy for your shares and confirm that your instructions have been properly recorded. Our telephone proxy submission procedures are designed to authenticate stockholders' identities by using individual control numbers.

    Submitting a Proxy via the Internet:  You can submit a proxy for your shares via the Internet until 11:59 p.m. Eastern Daylight Time on July 16, 2019, by accessing the website listed on the enclosed proxy card,www.proxyvote.com, and following the instructions you will find on the website. Internet proxy submission is available 24 hours a day. As with telephone proxy submission, you will be given the opportunity to confirm that your instructions have been properly recorded.

    Submitting a Proxy by Mail:  If you choose to submit a proxy for your shares by mail, simply mark the enclosed proxy card, date and sign it, and return it in the postage paid envelope provided.

        By casting your vote in any of the three ways listed above, you are authorizing the individuals listed on the proxy to vote your shares in accordance with your instructions. You may also attend the Annual Meeting and vote in person.

If your shares are held in the name of a bank, broker, or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted. The availability of telephonic or Internet voting will depend on the bank's, broker's, or other nominee's voting process. Please check with your bank, broker, or other nominee and follow the voting procedures your bank, broker, or other nominee provides to vote your shares. Also, please note that if the holder of record of


Table of Contents

your shares is a bank, broker, or other nominee and you wish to vote in person at the Annual Meeting, you must request a legal proxy from your bank, broker, or other nominee that holds your shares and present that proxy and proof of identification at the Annual Meeting; otherwise, you will not be able to vote in person at the Annual Meeting.

If I am the beneficial owner of shares held in "street name" by my broker, will my broker automatically vote my shares for me?

        New York Stock Exchange ("NYSE") rules applicable to brokers grant your broker discretionary authority to vote your shares without receiving your instructions on certain matters. Your broker has discretionary voting authority under NYSE rules to vote your shares on the ratification of Deloitte & Touche LLP as our independent registered public accounting firm. However, unless you provide voting instructions to your broker, your broker does not have discretionary authority to vote on the election of directors, the advisory vote on the compensation of our named executive officers, and the vote on the stockholder proposal.Accordingly, it is particularly important that beneficial owners instruct their brokers how they wish to vote their shares.

How will my shares be voted if I give my proxy but do not specify how my shares should be voted?

        If you provide specific voting instructions, your shares will be voted at the Annual Meeting in accordance with your instructions. If you hold shares in your name and sign and return a proxy card without giving specific voting instructions, your shares will be voted "FOR" the nominees of the Board in the election of directors, "FOR" the ratification of Deloitte & Touche LLP as the Company's independent registered public accounting firm, "FOR" the approval, on an advisory basis, of the compensation of our named executive officers, and "AGAINST" the stockholder proposal.

Could other matters be decided at the Annual Meeting?

        At this time, we are unaware of any matters, other than those set forth above, that may properly come before the Annual Meeting. If any other matters properly come before the Annual Meeting, the persons named in the enclosed proxy, or their duly constituted substitutes acting at the Annual Meeting or any adjournment or postponement of the Annual Meeting, will be deemed authorized to vote or otherwise act on such matters in accordance with their judgment.

Who may attend the Annual Meeting?

        All stockholders are invited to attend the Annual Meeting. Persons who are not stockholders may attend only if invited by the Board of Directors. If you are the beneficial owner of shares held in the name of your broker, bank, or other nominee, you must bring proof of ownership (e.g., a current broker's statement) in order to be admitted to the meeting. You can obtain directions to the Annual Meeting by contacting our Investor Relations Department at (717) 975-3710.

Can I vote in person at the Annual Meeting?

        Yes. If you hold shares in your own name as a stockholder of record, you may come to the Annual Meeting and cast your vote at the meeting by properly completing and submitting a ballot. If you are the beneficial owner of shares held in the name of your broker, bank, or other nominee, you must first obtain a legal proxy from your broker, bank, or other nominee giving you the right to vote those shares and submit that proxy along with a properly completed ballot at the meeting; otherwise, you will not be able to vote in person at the Annual Meeting.


Table of Contents

How can I change my vote?

        You may revoke your proxy at any time before it is exercised by:

    Delivering to the Secretary a written notice of revocation, dated later than the proxy, before the vote is taken at the Annual Meeting;

    Delivering to the Secretary an executed proxy bearing a later date, before the vote is taken at the Annual Meeting;

    Submitting a proxy on a later date by telephone or via the Internet (only your last telephone or Internet proxy will be counted), before 11:59 p.m. Eastern Daylight Time on July 16, 2019; or

    Attending the Annual Meeting and voting in person (your attendance at the Annual Meeting, in and of itself, will not revoke the proxy).

        Any written notice of revocation, or later dated proxy, should be delivered to:

Rite Aid Corporation
30 Hunter Lane
Camp Hill, Pennsylvania 17011
Attention: James J. Comitale, Secretary

        Alternatively, you may hand deliver a written revocation notice, or a later dated proxy, to the Secretary at the Annual Meeting before we begin voting.

        If your shares of Rite Aid common stock are held by a bank, broker, or other nominee, you must follow the instructions provided by the bank, broker, or other nominee if you wish to change your vote.

What is an "abstention" and how would it affect the vote?

        An "abstention" occurs when a stockholder sends in a proxy with explicit instructions to decline to vote regarding a particular matter. Abstentions are counted as present for purposes of determining a quorum. An abstention with respect to the election of directors is neither a vote cast "for" a nominee nor a vote cast "against" the nominee and, therefore, will have no effect on the outcome of the vote. Abstentions with respect to the ratification of Deloitte & Touche LLP as our independent registered public accounting firm, the advisory vote on compensation of our named executive officers, and the vote on the stockholder proposal will have the same effect as voting "against" the proposal.

What is a broker "non-vote" and how would it affect the vote?

        A broker non-vote occurs when a broker or other nominee who holds shares for the beneficial owner is unable to vote those shares for the beneficial owner because the broker or other nominee does not have discretionary voting power for the proposal and has not received voting instructions from the beneficial owner of the shares. Brokers will have discretionary voting power to vote shares for which no voting instructions have been provided by the beneficial owner only with respect to the ratification of Deloitte & Touche LLP as our independent registered public accounting firm. Brokers will not have such discretionary voting power to vote shares with respect to the election of directors, the advisory vote on the compensation of our named executive officers, and the vote on the stockholder proposal. Shares that are the subject of a broker non-vote are included for quorum purposes, but a broker non-vote with respect to a proposal will not be counted as a vote cast and will not be counted as a vote represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote. Accordingly, it is particularly important that beneficial owners of Rite Aid shares instruct their brokers how to vote their shares.


Table of Contents

What are the quorum and voting requirements for the proposals?

        In deciding the proposals that are scheduled for a vote at the Annual Meeting, each holder of common stock as of the record date is entitled to one vote per share of common stock. In order to take action on the proposals, a quorum, consisting of the holders of 26,914,351 shares (a majority of the aggregate number of shares of Rite Aid common stock) issued and outstanding and entitled to vote as of the record date for the Annual Meeting, must be present in person or by proxy. This is referred to as a "quorum." Proxies marked "Abstain" and broker non-votes will be treated as shares that are present for purposes of determining the presence of a quorum.

    Proposal No. 1—Election of Directors

        The affirmative vote of a majority of the total number of votes cast is required for the election of each director nominee named in Proposal No. 1. This means that the votes cast "for" that nominee must exceed the votes cast "against" that nominee. Any shares not voted (whether by abstention, broker non-vote or otherwise) will not be counted as votes cast and will have no effect on the outcome of the vote. For more information on the operation of our majority voting standard, see the section entitled "Board of Directors—Corporate Governance—Majority Voting Standard and Policy."

    Proposal No. 2—Ratification of Independent Registered Public Accounting Firm

        The affirmative vote of a majority of the shares represented at the meeting and entitled to vote is required for the ratification of Deloitte & Touche LLP as our independent registered public accounting firm in Proposal No. 2. Any shares represented and entitled to vote at the meeting and not voted (whether by abstention or otherwise) will have the same effect as a vote "against" the proposal.

    Proposal No. 3—Advisory Vote on Compensation of Named Executive Officers

        The affirmative vote of a majority of the shares represented at the meeting and entitled to vote is required for the approval of the advisory vote on the compensation of our named executive officers in Proposal No. 3. Any shares represented and entitled to vote at the meeting and not voted (whether by abstention or otherwise) will have the same effect as a vote "against" the proposal. Any broker non-votes with respect to the advisory vote on the compensation of our named executive officers will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.

    Proposal No. 4—Stockholder Proposal

        The affirmative vote of a majority of the shares represented at the meeting and entitled to vote is required for the approval of the stockholder proposal in Proposal No. 4. Any shares represented and entitled to vote at the meeting and not voted (whether by abstention or otherwise) will have the same effect as a vote "against" the stockholder proposal. Any broker non-votes with respect to the stockholder proposal will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.

What happens if a quorum is not present at the Annual Meeting?

        If the shares present in person or represented by proxy at the Annual Meeting are not sufficient to constitute a quorum, the stockholders by a vote of the holders of a majority of votes present in person or represented by proxy (which may be voted by the proxyholders) may, without further notice to any stockholder (unless a new record date is set), adjourn the meeting to a different time and place to permit further solicitations of proxies sufficient to constitute a quorum.


Table of Contents

Who will count the votes?

        Representatives of Broadridge Financial Solutions, Inc. will tabulate the votes and act as inspectors of election.

Who will conduct the proxy solicitation and how much will it cost?

        We are soliciting proxies from stockholders on behalf of our Board and will pay for all costs incurred by it in connection with the solicitation. In addition to solicitation by mail, the directors, officers and associates of Rite Aid and its subsidiaries may solicit proxies from stockholders of Rite Aid in person or by telephone, facsimile, or email without additional compensation other than reimbursement for their actual expenses.

        We have retained Morrow Sodali, LLC, a proxy solicitation firm, to assist us in the solicitation of proxies for the Annual Meeting. Rite Aid will pay Morrow Sodali a fee of approximately $20,000, plus reasonable out-of-pocket expenses.

        Arrangements also will be made with brokerage firms and other custodians, nominees, and fiduciaries for the forwarding of solicitation material to the beneficial owners of stock held of record by such persons, and we will reimburse such custodians, nominees, and fiduciaries for their reasonable out-of-pocket expenses in connection with the forwarding of solicitation materials to the beneficial owners of our stock.

If you have any questions about voting your shares or attending the Annual Meeting, please call our Investor Relations Department at (717) 975-3710.


Table of Contents


STOCKHOLDER ENGAGEMENT, MANAGEMENT TRANSITION, AND BOARD REFRESHMENT

        Since the termination of the Albertsons transaction in August 2018 and following the 2018 Annual Meeting, we have engaged in enhanced stockholder outreach efforts. These efforts provided an opportunity for independent directors to hear from stockholders directly regarding their perspectives and concerns. In addition, management has communicated with many retail stockholders and received their feedback. We greatly value the insightful input about the Company that our stockholders have provided in these and other exchanges over the past ten months. The feedback from these efforts has been summarized, shared, and considered by the Nominating and Governance Committee on our ESG reporting, strategy, risk and the full Board.

        Investors raised a number of concernsopportunity, compliance and the Board has taken significant steps to address these items. Specifically, the principal issues raised by our stockholders related to: (1) Board refreshment, (2) an evaluation of management, (3) corporate governance matters, and (4) the Company's sustainability efforts.

New Board Leadership and Composition

        In the course of our stockholder engagement meetings over the past ten months, stockholders expressed concerns regarding the lack of Board refreshment in recent years, as well as concerns regarding our Board governance. The Board reviewed its structure in light of the Company's current operating and governance environment and, effective at the 2018 Annual Meeting, Mr. Standley was succeeded as Chairman of the Board by Bruce G. Bodaken. Subsequently, in December 2018, the Board amended the Company's By-Laws to provide that the Chairman of the Board shall be a director who is independent under the NYSE listing standards and the Company's Corporate Governance Guidelines.

        The Board has significantly accelerated its efforts to change the composition of the Board. As part of this process, at the 2018 Annual Meeting, three of the eight independent directors did not stand for reelection and the Board nominated three new independent directors. As a continuation of this process, two new directors were appointed by the Board following the resignation of two of our directors in April 2019. The five directors who have joined the Board over the past eight months will continue to bring fresh perspectives to the Board. In addition, Mr. Standley has not been nominated for reelection at the Annual Meeting.

        As a result of these changes in the Board's composition, the average tenure of our independent directors has decreased from approximately eight years prior to the 2018 Annual Meeting to approximately four years, with a relatively even distribution among new directors and directors of longer tenure. Through the Board refreshment process, the Board has increased the racial and ethnic diversity on the Board, with half of the Board being racially and ethnically diverse following the Annual Meeting. The Board also made gender diversity a priority as part of its most recent phase of its refreshment, resulting in more than one-third of our Board being women following the Annual Meeting.

Management Transition

        One of the Board's most important tasks is choosing the Company's Chief Executive Officer. Following the 2018 Annual Meeting, the Board continued to engage in rigorous and thoughtful evaluation and discussion regarding the Chief Executive Officer and other management positions. In March 2019, the Company announced a leadership transition and organizational restructuring to better align its structure with the Company's operations and to reduce costs. As part of the leadership transition, the Company announced that the Board would be commencing a search process for a new Chief Executive Officer. Mr. Standley will continue to serve as Chief Executive Officer of the Company until the appointment of his successor but has not been nominated for reelection to the Board at the

benchmarking.
[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
For more information, please see Rite Aid’s 2022 CSR Report at https://s27.q4cdn.com/633053956/files/doc_downloads/2022/07/RA890751_ESG_Report_2022.pdfWebsite content is not incorporated into this proxy statement.


8 | RITE AID CORPORATION   2023 Proxy Statement

Table of Contents

Annual Meeting. The Company also announced additional management changes, which were effective in March 2019, and consolidated additional senior leadership roles that resulted in the elimination of certain positions.

Additional Corporate Governance Changes

        Since the 2018 Annual Meeting, the Board has considered and taken action with respect to certain corporate governance practices. In discussions with stockholders, some stockholders expressed a desire for Rite Aid stockholders to have the right to call a special meeting. In addition, our Nominating and Governance Committee has been monitoring trends and developments relating to special meeting rights. As a result of these discussions and trends, in April 2019, the Board amended the Company's By-Laws to permit special meetings of the stockholders of the Company to be called by stockholders holding at least 20% of the Company's common stock.

        At the 2018 Annual Meeting, stockholders approved a proposal requesting that Rite Aid prepare a sustainability report describing the Company's environmental, social and governance ("ESG") risks and opportunities. The Company anticipates that a report describing the Company's ESG risks and opportunities will be released prior to the Annual Meeting. Additional details regarding the Company's consideration of sustainability matters and the related business initiatives the Company has undertaken in recent years are described in the section entitled "Board of Directors—Sustainability."

        At the 2018 Annual Meeting, stockholders approved a proposal requesting that Rite Aid prepare a report describing the corporate governance changes the Company has implemented since 2012 to more effectively monitor and manage financial and reputational risks related to the opioid crisis. The Company anticipates that a report describing the Company's approach to oversight of opioid matters will be released by October 1, 2019. Additional details regarding the Company's oversight of opioid matters and the related business initiatives the Company has undertaken in recent years are described in the section entitled "Board of Directors—Opioid Matter Oversight."


Table of Contents

TABLE OF CONTENTS
PROPOSAL NO. 1

ELECTION OF DIRECTORS

General

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 1—ELECTION OF DIRECTORS
Our By-Laws provide that the Board of Directors may be composed of up to 15 members, with the number to be fixed from time to time by the Board. The Board has fixed the number of directors at eightsix effective as of the Annual Meeting, and there are eightthe Board has nominated six nominees for director at our Annual Meeting.

Director Nominees

All directors are elected annually.

The Board of Directors, based on the recommendation of the Nominating and Governance Committee, has nominated Bruce G. Bodaken, Elizabeth 'Busy' Burr, Robert E. Knowling, Jr., Kevin E. Lofton, Louis P. Miramontes, Arun Nayar, Katherine Quinn, and Marcy Symsthe following individuals to be elected directors at the Annual Meeting. Meeting:

Bruce G. Bodaken

Robert E. Knowling, Jr.

Elizabeth Burr

Arun Nayar

Bari Harlam

Kate B. Quinn
Each of the nominees for director to be elected at the Annual Meeting currently serves as a director of the Company. Mr. Standley will continue to serve as Chief Executive Officer of the Company until the appointment of his successor but has not been nominated for reelection at the Annual Meeting.

Each director elected at the Annual Meeting will hold office until the 20202024 Annual Meeting of Stockholders. Each director elected at the Annual MeetingStockholders and will serve until his or her successor is duly elected and qualified.

If any nominee at the time of election is unable or unwilling tocannot serve or is otherwise unavailable for election, and as a consequence thereof other nominees areanother nominee is designated, then the persons named in the proxyproxies or their substitutes will have the discretion and authority to vote or to refrain from voting for such other nomineesnominee in accordance with their judgment.


RECOMMENDATION

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE ELECTION OF EACH OF THE NOMINEES LISTED ABOVE.


BOARD OF DIRECTORS

judgment, or the Board may reduce the size of the Board.

The following table sets forth certain information as of May 31, 2019June 1, 2023 with respect to our director nominees. If elected, the term of each of the following persons will expire at the 2020 Annual Meeting of Stockholders.

NameAgePosition with Rite AidYear First
Became Director
Bruce G. Bodaken71Chair2013
Elizabeth Burr61Interim Chief Executive Officer and Director2019
Bari Harlam61Director2020
Robert E. Knowling, Jr.67Director2018
Arun Nayar72Director2018
Kate B. Quinn58Director2019
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote on the enclosed proxy card FOR the election of each of our nominees listed above.

RITE AID CORPORATION   2023 Proxy Statement | 9

TABLE OF CONTENTS
PROPOSAL 1—ELECTION OF DIRECTORS
Name
 Age Position with Rite Aid Year First
Became
Director
 
Bruce G. Bodaken  67 Chairman  2013 
Elizabeth 'Busy' Burr  57 Director  2019 
Robert E. Knowling, Jr.   63 Director  2018 
Kevin E. Lofton  64 Director  2013 
Louis P. Miramontes  64 Director  2018 
Arun Nayar  68 Director  2018 
Katherine Quinn  54 Director  2019 
Marcy Syms  68 Director  2005 
Board Attributes*

[MISSING IMAGE: pc_attribut-pn.jpg]

Table of Contents

Board Composition

*
The compositions depicted illustrate calculations effective following the Annual Meeting.
The Board is committed to ensuring that it is composed of a highly capable and diverse group of directors who are well-equipped to oversee the success of the business and effectively represent the interests of stockholders. As a result of strategic changes in Board composition over the last five years, approximately 33% of the director nominees are racially or ethnically diverse and 50% of the director nominees are women. In addition to enhancing the Board believes that having directors with both longerBoard’s racial, ethnic and shorter tenures on the Board helps transition the knowledge of the more experienced directors while providing a broad, fresh set of perspectives and a Board withgender diversity, these changes bring a diversity of experiencesthought and viewpoints. As discussed inexperience to the section entitled "Stockholder Engagement, Management Transition, and Board Refreshment" above, the Board has significantly accelerated its efforts to change the composition of the Board over the past eight months.Board. All of the nominees of the Board, other than Ms. Burr, due to her position as interim Chief Executive Officer, are independent directors.

        As a result of these changes in the Board's composition, the average tenure

Five of our independent directors has decreased from approximately eight years prior to the 2018 Annual Meeting to approximately four years, with a relatively even distribution among new directors and directors of longer tenure. In addition, half of the Board will be racially and ethnically diverse following the Annual Meeting. The Board also made gender diversity a priority as part of its most recent phase of its refreshment, resulting in more than one-third ofsix current director nominees have joined our Board beingsince 2018, all of whom are either women following the Annual Meeting.

or racially or ethnically diverse.
Director Tenure*Board Racial and Ethnic Diversity*

GRAPHIC


GRAPHIC

Board Gender Diversity*

GRAPHIC

[MISSING IMAGE: fc_directors-pn.jpg]
*
The compositions depicted include calculations effective following the Annual Meeting.

In assessing Board composition and selecting and recruiting director candidates, the Board seeks to maintain an engaged, independent Board with broad experience and judgment that is committed to representing the long-term interests of our stockholders. The Nominating and Governance Committee considers a wide range of factors, including the size of the Board, the experience and expertise of existing Board members, other positions the director candidate has held or holds (including other


Table of Contents

board memberships), and the candidate'scandidate’s independence. In addition, the Nominating and Governance Committee takes into account a candidate'scandidate’s ability to contribute to the diversity of background and experience represented on the Board, and it reviews its effectiveness in balancing these considerations when assessing the composition of the Board. The


10 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
PROPOSAL 1—ELECTION OF DIRECTORS
Board Skills and Nominating and Governance Committee will continue to evaluate the composition of the Board as a whole as part of its ongoing refreshment in the coming year.

        Since the 2018 Annual Meeting, the Nominating and Governance Committee sought to continue the process of recruiting additional Board members whose qualifications align with the Company's refreshment process and long-term strategy. After considering a number of candidates and comprehensively reviewing these candidates' abilities and qualifications in sourcing candidates to fill the vacancies on the Board due to Joseph B. Anderson's and Michael N. Regan's resignations, the Nominating and Governance Committee recommended Busy Burr and Katherine Quinn for appointment to the Board. The Board appointed both candidates as directors in April 2019.

Experiences

The chart below summarizes the qualifications, attributes, skills and skillsexperiences for each of our director nominees. The fact that we do not list a particular experience or qualification for a director nominee does not mean that nominee does not possess that particular experience or qualification.

Skills and Experiences
DirectorBoard and
Corporate
Governance
Current or
Former CEO
Finance and
Accounting
Health Care
Industry
Management
and
Business
Operations
Retail
Industry
Bruce G. Bodaken [MISSING IMAGE: ic_stark-bw.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Elizabeth Burr
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Bari Harlam
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Robert E. Knowling, Jr.
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Arun Nayar
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Kate B. Quinn
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
[MISSING IMAGE: ic_check-pn.jpg]
Total of 6 Director Nominees632363
100%50%33%50%100%50%

RITE AID CORPORATION   2023 Proxy Statement | 11

TABLE OF CONTENTS
PROPOSAL 1—ELECTION OF DIRECTORS
Skills and Experience
BodakenBurrKnowlingLoftonMiramontesNayarQuinnSyms

Current/Former CEO

XXXX

Management/Business Operations

XXXXXXXX

Retail Industry

XXX

Healthcare Industry

XXXX

Finance/Accounting

XXX

Board/Corporate Governance

XXXXXXXX
DIRECTOR NOMINEES

Director Biographies

Following are the biographies for our director nominees, including information concerning the particular experience, qualifications, attributes, or skills that led the Nominating and Governance Committee and the Board to conclude that such person should serve on the Board:

        Bruce G. Bodaken.    Mr. Bodaken servedBoard, as Chairman and Chief Executive Officer of Blue Shield of California from 2000 through 2012. Previously, Mr. Bodaken servedwell as President and Chief Operating Officer of Blue Shield of California from 1995 to 2000, and as Executive Vice President and Chief Operating Officer from 1994 to 1995. Prior to joining Blue Shield of California, Mr. Bodaken served as Senior Vice President and Associate Chief Operating Officer of F.H.P., Inc., a managed care provider, from 1990 to 1994 and held various positions at F.H.P. from 1980 to 1990. Currently, Mr. Bodaken sitstheir Committee assignments in fiscal year 2023:

BRUCE G. BODAKEN
Mr. Bodaken shares in-depth knowledge of the health insurance and managed care industries with the Board of Directors, serving in executive leadership positions for over 20 years.
Experience

Chairman and Chief Executive Officer of Blue Shield of California from 2000 through 2012.

President and Chief Operating Officer of Blue Shield of California from 1995 to 2000, and as Executive Vice President and Chief Operating Officer from 1994 to 1995.

Senior Vice President and Associate Chief Operating Officer of F.H.P., Inc., a managed care provider, from 1990 to 1994 and held various positions at F.H.P. from 1980 to 1990.

Visiting Lecturer at the University of California School of Public Health from 2013 to 2016 teaching graduate courses on health care reform.

Visiting Scholar at the Brookings Institute from 2013 to 2015 focused on value-based care design.

Director and member of the compensation committee of iRhythm Technologies, Inc. and formerly a member of the board of directors of WageWorks, Inc.
[MISSING IMAGE: ph_brucebodaken-4c.jpg]
Age 71
Director since 2013
Chair since 2018
Committees

Executive (Chair)

Nominating and Governance
ELIZABETH BURR
Ms. Burr brings to the Board of Directors extensive experience in the health industry, innovation, business strategy, and brand management.
Experience

Current Interim Chief Executive Officer of Rite Aid Corporation.

Former President and Chief Commercial Officer at Carrot Inc., a digital health care company with solutions that combine behavioral science, clinical expertise, and proprietary technology, from 2019 through 2021.

Chief Innovation Officer and Vice President of Healthcare Trend and Innovation at Humana from 2015 to 2018, where she led the design, build, and adoption of new product platforms in digital health, provider experience, and telemedicine. Founder of Humana’ Health Ventures, Humana’s strategic venture investing practice.

Former Managing Director of Citi Ventures, Citigroup’s global venture group, from 2011—2015. Prior to Citigroup, she spent seven years in investment banking at Morgan Stanley and Credit Suisse First Boston.

Former Vice President of Global Brand Management at Gap, Inc., where she was responsible for aligning the product, store, online, advertising, and merchandising efforts for the four Gap brands around the world.

Member of the boards of directors of Mr. Cooper Group Inc., a company that provides mortgage servicing, origination, and transaction-based services, Satellite Healthcare, a nonprofit provider of kidney dialysis services, and SVB Financial Group, a company that offers investment banking and funds management services in the technology, life sciences and health care, private equity and venture capital industries.
[MISSING IMAGE: ph_elizabethbusyburr-4c.jpg]
Age 61
Director since 2019

12 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
PROPOSAL 1—ELECTION OF DIRECTORS
BARI HARLAM
Ms. Harlam is a former C-suite business leader, marketer, educator, and author, and a pioneer in customer loyalty who provides the Board of Directors with her experience in digital marketing and data analytics.
Experience

Co-founder of Trouble LLC, a pro-social, experience brand.

Executive Vice President, Chief Marketing Officer North America at Hudson’s Bay Company from 2018 to 2020.

Executive Vice President, Membership, Marketing and Analytics at BJ’s Wholesale Club from 2012 to 2016.

Chief Marketing Officer at Swipely, now Upserve, from 2011 to 2012.

Senior Vice President, Member Engagement at CVS Health from 2000 to 2011.

Early in her career, was a Professor at Columbia University and the University of Rhode Island, and Adjunct Professor at the Wharton School, University of Pennsylvania.

Member of the Board of Directors of Eastern Bankshares, Inc., Aterian, and OneWater Marine Inc.
[MISSING IMAGE: ph_bariharlam-4c.jpg]
Age 61
Director since 2020
Committees

Nominating and Governance (Chair)
ROBERT E. KNOWLING, JR.
Mr. Knowling brings to the Board extensive experience in executive management and leadership roles, including experience leading companies through periods of high growth and organizational turnaround. In addition, his service on a number of other public company boards of directors enables Mr. Knowling to share insights with the Board regarding corporate governance best practices.
Experience

Chairman of Eagles Landing Partners, which specializes in helping senior management formulate strategy, lead organizational transformations, and re-engineer businesses, and also serves as an advisor-coach to chief executive officers.

Chief Executive Officer of Telwares, a provider of telecommunications expense management solutions, from 2005 to 2009.

Chief Executive Officer of the New York City Leadership Academy, an independent nonprofit corporation created by Chancellor Joel I. Klein and Mayor Michael R. Bloomberg that is chartered with developing the next generation of principals in the New York City public school system, from 2001 to 2005.

Chairman and Chief Executive Officer of SimDesk Technologies, a computer software company, from 2001 to 2003.

Previously was Chairman, President and Chief Executive Officer of Covad Communications, a Warburg Pincus private equity-backed start-up company.

Serves on the board of directors of CECO Environmental Corp. and Stride, Inc. In the last five years, he served on the board of directors of Roper Technologies Inc., Citrix, Stride, and Convergys.
[MISSING IMAGE: ph_robertknowling-4c.jpg]
Age 67
Director since 2018
Committees

Audit

Compensation

RITE AID CORPORATION   2023 Proxy Statement | 13

TABLE OF CONTENTS
PROPOSAL 1—ELECTION OF DIRECTORS
ARUN NAYAR
Mr. Nayar brings over 35 years of financial management experience to the Board of Directors. His experience as a chief financial officer provides useful insights into operational and financial metrics relevant to the Company’s business.
Experience

Retired in 2015 as Executive Vice President and Chief Financial Officer of Tyco International, a $10+ billion fire protection and security company, where he was responsible for managing the company’s financial risks and overseeing its global finance functions, including its tax, treasury, mergers and acquisitions, audit, and investor relations teams. Mr. Nayar joined Tyco as senior vice president and treasurer in 2008, and was also Chief Financial Officer of Tyco’s ADT Worldwide. From 2010 until 2012, Mr. Nayar was senior vice president, Financial Planning & Analysis, Investor Relations, and treasurer.

Previously was in leadership positions with PepsiCo, Inc., most recently as Chief Financial Officer of Global Operations and, before that, as vice president and assistant treasurer—Corporate Finance.

Senior Advisor to McKinsey & Company and a Senior Advisor to a private equity firm, BC Partners, from 2016 to 2020.

A member of the board of directors of Amcor Plc, a manufacturer of responsible packaging products, and GFL Environmental Inc., a leading North American environmental services company. He previously served on the board of TFI International.
[MISSING IMAGE: ph_arunnayar-4c.jpg]
Age 72
Director since 2018
Committees

Audit

Compensation

Executive
KATE B. QUINN
Ms. Quinn brings to the Board of Directors extensive experience in business strategy, marketing, customer experience, retail operations, and health benefits.
Experience

Vice Chair and Chief Administrative Officer of U.S. Bancorp since 2017, responsible for leading strategy, reputation and digital transformation, Ms. Quinn joined U.S. Bancorp in 2013 as executive vice president and Chief Strategy and Reputation Officer. She will be retiring from U.S. Bancorp in June 2023.

Former senior vice president and Chief Marketing Officer at Anthem, a health benefits company, where she directed the company’s marketing, customer communications, digital, customer experience, and retail strategies. She previously served as Anthem’s vice president of corporate marketing.

Earlier in her career, Ms. Quinn served as Chief Marketing and Strategy Officer at a division of The Hartford, following leadership roles in strategy and product development at CIGNA and PacifiCare Health Systems, respectively.

Member of Board of Trustees of United Way U.S.A. and Fastbreak Foundation. She previously served on the board of Ontrak, Inc.
[MISSING IMAGE: ph_katequinn-4c.jpg]
Age 58
Director since 2019
Committees

Compensation (Chair)

Nominating and Governance

14 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
CORPORATE GOVERNANCE AND BOARD MATTERS
BOARD LEADERSHIP STRUCTURE
The Board has determined that Mr. Bodaken will continue to serve as Chair of the Board.
As Chair, Mr. Bodaken’s responsibilities include:

presiding at all meetings of the Board, including executive sessions of the non-management directors

the authority to call meetings of the Board and of the non-management directors

serving as liaison between the Chief Executive Officer and independent directors and facilitating communications between other members of the Board and the Chief Executive Officer (any director is free to communicate directly with any associate, including with the Chief Executive Officer; the Chair’s role is to attempt to improve such communications if they are not entirely satisfactory)

working with independent directors and the Chief Executive Officer in the preparation of and approving Board meeting agendas and schedules, and the information to be provided to the Board

chairing the annual review of the performance of the Chief Executive Officer

otherwise consulting with the Chief Executive Officer on matters relating to corporate governance and Board performance, and

if requested, ensuring that he is available, when appropriate, for consultation and direct communication with stockholders.
Company By-Laws provide that the board of WageWorks, Inc., and is a member of its audit committee. He is also a director and member of the Compensation Committee of iRhythm Technologies, Inc.

        Mr. Bodaken brings to the Board in-depth knowledge of the health insurance and managed care industries and more than 20 years of executive leadership skills.

        Busy Burr.    Ms. Burr most recently served as the chief innovation officer and vice president of healthcare trend and innovation at Humana where she was responsible for driving the design, build and adoption of new product platforms in digital health, provider experience, and telemedicine to improve health outcomes, create superior member experiences, and improve health care costs. She also founded Humana's strategic investing practice, Humana Health Ventures. Prior to joining Humana in 2015, Ms. Burr was managing director of Citi Ventures and led large-scale business transformation efforts as the global head of Citi's Business Incubation Function-DesignWorks. Earlier in her career, Ms. Burr spent seven years in investment banking at Morgan Stanley and Credit Suisse First Boston and previously served as vice president of global brand management at Gap, Inc. Ms. Burr holds an MBA


Table of Contents

from Stanford University and a bachelor's degree in Economics from Smith College. Ms. Burr serves on the Boards of Mr. Cooper Group and Satellite Healthcare and is a member of the Smith College Business Network Advisory Board.

        Ms. Burr brings to the Board extensive experience in the health industry, innovation, business strategy and brand management. Her experience and insights in these areas are directly relevant to the Company's business.

        Robert E. Knowling, Jr.    Mr. Knowling is currently Chairman of Eagles Landing Partners, which specializes in helping senior management formulate strategy, lead organizational transformations, and re-engineer businesses. Mr. Knowling also serves as an advisor-coach to chief executive officers. Mr. Knowling previously served as Chief Executive Officer of Telwares, a JP Morgan Chase/One Equity Partners Private Equity-owned company from 2005 to 2009. From 2001 to 2005, Mr. Knowling was Chief Executive Officer of the New York City Leadership Academy, an independent nonprofit corporation created by Chancellor Joel I. Klein and Mayor Michael R. Bloomberg that is chartered with developing the next generation of principals in the New York City public school system. From 2001 to 2003, Mr. Knowling was Chairman and Chief Executive Officer of SimDesk Technologies, Inc. Prior to this, Mr. Knowling was Chairman, President and Chief Executive Officer of Covad Communications, a Warburg Pincus Private Equity-backed start-up company. Mr. Knowling currently serves on the board of directors of K12 Inc. and Roper Technologies Inc. Mr. Knowling previously served as a director of Convergys Corporation until 2018, Ariba, Inc. until 2012, Heidrick & Struggles International, Inc. until 2015, Hewlett-Packard Company until 2005, and The Immune Response Corporation until 2005.

        Mr. Knowling brings to the Board extensive experience in executive management and leadership roles, including experience leading companies through periods of high growth and organizational turnaround. In addition, his service on other boards of directors of a number of publicly-traded companies enables Mr. Knowling to share insights with the Board regarding corporate governance best practices.

        Kevin E. Lofton.    Mr. Lofton was named Chief Executive Officer of Chicago-based CommonSpirit Health ("CSH"), effective February 1, 2019. CSH is the result of a merger between Catholic Health Initiatives ("CHI") and Dignity Health. With $29 billion in revenues, CSH is one of the largest health delivery systems in the United States. Mr. Lofton joined CHI in 1998 and served as CEO from 2003 until January 2019. Mr. Lofton previously served as Chief Executive Officer of the UAB Hospital in Birmingham and Howard University Hospital in Washington, D.C. Mr. Lofton is also a director and member of the audit and compensation committees of Gilead Sciences, Inc.

        Mr. Lofton brings to the Board an in-depth knowledge and understanding of the healthcare industry and valuable executive leadership skills from senior management and leadership roles in healthcare systems and hospitals.

        Louis P. Miramontes.    Mr. Miramontes worked at KPMG LLP from 1976 to 2014, where he served in many leadership roles, including Managing Partner of the San Francisco office and Senior Partner for KPMG's Latin American region. Mr. Miramontes was also an audit partner directly involved with providing audit services to public and private companies, which included working with client boards of directors and audit committees regarding financial reporting, auditing matters, SEC compliance, and Sarbanes-Oxley regulations. Mr. Miramontes currently serves on the board of directors of Lithia Motors, Inc., one of the largest providers of personal transportation solutions in the U.S., and Oportun, Inc., a mission-driven financial services company.

        Mr. Miramontes brings to the Board extensive experience in accounting, financial reporting, and corporate governance. His experience as an audit partner provides useful insights into financial and regulatory matters relevant to the Company's business.


Table of Contents

        Arun Nayar.    Mr. Nayar retired in December 2015 as Executive Vice President and Chief Financial Officer of Tyco International, a $10+ billion fire protection and security company, where he was responsible for managing the company's financial risks and overseeing its global finance functions, including its tax, treasury, mergers and acquisitions, audit, and investor relations teams. Mr. Nayar joined Tyco as Senior Vice President and Treasurer in 2008 and was also Chief Financial Officer of Tyco's ADT Worldwide. From 2010 until 2012, Mr. Nayar was Senior Vice President, Financial Planning & Analysis, Investor Relations, and Treasurer. Prior to joining Tyco, Mr. Nayar spent six years at PepsiCo, Inc., most recently as Chief Financial Officer of Global Operations and, before that, as Vice President and Assistant Treasurer—Corporate Finance. Mr. Nayar currently serves on the Board of Directors of Bemis Company, Inc., a manufacturer of packaging products, and TFI International Inc., a leader in the transportation and logistics industry. Bemis Company, Inc. has announced a combination with Amcor Limited and has announced that Mr. Nayar will be a member of the board of the combined company, Amcor plc, upon consummation of the transaction. Mr. Nayar is also a Senior Advisor to McKinsey & Company and to a private equity firm, BC Partners. He also serves as a board member of privately-held GFL Environmental, a BC Partners portfolio company.

        Mr. Nayar brings over 35 years of financial experience to the Board. His experience as a chief financial officer provides useful insights into operational and financial metrics relevant to the Company's business.

        Katherine Quinn.    Ms. Quinn has served as vice chairman and chief administrative officer of U.S. Bancorp since April 2017 and is responsible for leading human resources, strategy, and corporate affairs at the company. Ms. Quinn joined U.S. Bancorp in 2013 as executive vice president and chief strategy and reputation officer. Prior to joining U.S. Bancorp, Ms. Quinn most recently served as senior vice president and chief marketing officer at Anthem, a health benefits company, where she directed the company's marketing, customer communications, digital, customer experience, and retail strategies. She previously served as Anthem's vice president of corporate marketing. Earlier in her career, Ms. Quinn served as chief marketing and strategy officer at a division of The Hartford, following leadership roles in strategy and product development at CIGNA and PacifiCare Health Systems, respectively. Ms. Quinn earned an MBA from University of Phoenix and a bachelor's degree from Hunter College. In addition to her role at U.S. Bancorp, Ms. Quinn presently serves as a memberChair of the Board of Directors of Taylor Corporation and the Board of Trustees for both United Way U.S.A. and Fraser, a non-profit organization serving children and adults with special needs. She previously served as a member of the Board of Trustees for Minnesota Public Radio until May 2019.

        Ms. Quinn brings to the Board extensive experience in business strategy, marketing, customer experience, and health benefits. Her experience and insights in these areas are directly relevant to the Company's business.

        Marcy Syms.    Ms. Syms served as a director of Syms Corp, a chain of retail clothing stores, from 1983, when she was named President and COO, until 2012. Ms. Syms became CEO of Syms Corp in 1998 and was named Chair in 2010. In November 2011, Syms Corp and its subsidiaries filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code and ceased all retail operations. Ms. Syms is also a founding member of the board of directors of the Syms School of Business at Yeshiva University. Currently, Ms. Syms serves as President of the Sy Syms Foundation. Ms. Syms served as Founder and President of the TPD Group LLC, a multi-generational succession planning company, from 2013 to 2018. Ms. Syms is also a member of the board of directors of Benco Dental.

        Ms. Syms brings to the Board over 18 years of experience as a chief executive officer of a chain of retail stores, including an array of skills in strategic planning, marketing, and human resources matters similar to those faced by the Company.


Table of Contents

Board Leadership

        Mr. Bodaken became Chairman of the Board effective at the 2018 Annual Meeting. The Board has determined that Mr. Bodaken will continue to serve as Chairman of the Board.

        In December 2018, the Board amended the Company's By-Laws to provide that the Chairman of the Board shallmust be a director who is independent under the NYSE listing standards and the Company'sCompany’s Corporate Governance Guidelines. The Board believes that separation of the Chairmanpositions of Chair of the Board and Chief Executive Officer positions best serves the needs of the Company and its stockholders. The Board believes that Mr. Bodaken will continue to provide excellent independent leadership of the Board in his role as Chairman.

        As Chairman, Mr. Bodaken's responsibilities subsume the responsibilities of the Lead Independent Director and include:

    presiding at all meetings of the Board, including executive sessions of the non-management directors;

    the authority to call meetings of the Board and of the non-management directors;

    serving as a liaison between the Chief Executive Officer and independent directors and facilitating communications between other members of the Board and the Chief Executive Officer (any director is free to communicate directly with the Chief Executive Officer; the Chair's role is to attempt to improve such communications if they are not entirely satisfactory);

    working with the Chief Executive Officer in the preparation of and approving Board meeting agendas and schedules, and the information to be provided to the Board;

    chairing the periodic review of the performance of the Chief Executive Officer;

    otherwise consulting with the Chief Executive Officer on matters relating to corporate governance and Board performance; and

    if requested by major stockholders, ensuring that he is available, when appropriate, for consultation and direct communication.

Corporate Governance

        We recognize that good corporate governance is an important means of protecting the interests of our stockholders, associates, customers, suppliers, and the community. The Board of Directors, through the Nominating and Governance Committee, monitors corporate governance developments and proposed legislative, regulatory, and stock exchange corporate governance reforms. In April 2019, the Board enhanced our corporate governance by amending the Company's By-Laws to permit special meetings of stockholders of the Company to be called by stockholders holding at least 20% of the Company's common stock.

        Website Access to Corporate Governance Materials.    Our corporate governance information and materials, including our Corporate Governance Guidelines, current charters for each of the Audit Committee, Compensation Committee, Nominating and Governance Committee, and Executive Committee, our Code of Ethics for the CEO and Senior Financial Officers, our Code of Ethics and Business Conduct, our Stock Ownership Guidelines, and our Related Person Transaction Policy are posted on our website atwww.riteaid.com under the headings "Corporate Info—Governance" and are available in print upon request to Rite Aid Corporation, 30 Hunter Lane, Camp Hill, Pennsylvania 17011, Attention: Secretary. The information on our website is not, and shall not be deemed, a part of this proxy statement. The Board regularly reviews corporate governance developments and will modify these materials and practices from time to time as warranted.

Chair.

DIRECTOR INDEPENDENCE

Table of Contents

        Codes of Ethics.    The Board has adopted a Code of Ethics that is applicable to our Chief Executive Officer and senior financial officers. The Board has also adopted a Code of Ethics and Business Conduct that applies to all of our officers, directors, and associates. Any amendment to either code or any waiver of either code for executive officers or directors will be disclosed promptly on our website atwww.riteaid.com under the headings "Corporate Info—Governance—Code of Ethics."

        Director Independence.

For a director to be considered independent under the NYSE corporate governance listing standards, the Board of Directors must affirmatively determine that the director does not have any direct or indirect material relationship with the Company, including any of the relationships specifically proscribed byidentified in the NYSE independence standards. The Board considers all relevant facts and circumstances in making its independence determinations. Only independent directors may serve on our Audit Committee, Compensation Committee, and Nominating and Governance Committee.

As a result of this review, the Board affirmatively determined that the following directors, including each director serving on the Audit Committee, the Compensation Committee, and the Nominating and Governance Committee, satisfy the independence requirements of the NYSE listing standards: Bruce G. Bodaken, Busy Burr, Robert E. Knowling, Jr., Kevin E. Lofton, Louis P. Miramontes, Arun Nayar, Katherine Quinn, and Marcy Syms. The

Bruce G. Bodaken

Robert E. Knowling, Jr.

Kate B. Quinn

Bari Harlam

Arun Nayar
In addition, the Board also determined that Joseph B. Anderson and Michael N. Regan, who served as directors until April 2019, and David R. Jessick, Myrtle Potter, and Frank A. Savage, who served as directors until October 30, 2018, also satisfied the independence requirements of the NYSE listing standards. The Board also determined that the members of the Audit Committee satisfy the additional independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the additional NYSE independence requirements for audit committee members. In addition, the Board has determinedmembers and that the members of the Compensation Committee satisfy the additional NYSE independence requirements for compensation committee members.

As interim CEO, Ms. Burr is not an independent director at this time. The Board previously determined that Kevin E. Lofton, who served as a director until the 2022 Annual Meeting, and Louis P. Miramontes, who will serve as a director until the 2023 Annual Meeting, satisfied the independence requirements of the NYSE listing standards.
There is no family relationship between any of the nominees and executive officers of Rite Aid.


RITE AID CORPORATION   2023 Proxy Statement | 15

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
CORPORATE GOVERNANCE PRACTICES
We recognize that good corporate governance is an important means of promoting the long-term interests of our stockholders, associates, customers, suppliers, and the community. The Board of Directors, including through the Nominating and Governance Committee, monitors corporate governance developments and proposed legislative, regulatory, and stock exchange corporate governance reforms.
Majority Voting Standard and Policy.Policy
Under the Company'sCompany’s By-Laws, a nominee for director in uncontested elections of directors (as is the case for this Annual Meeting) will be elected to the Board if the votes cast "for"“for” such nominee'snominee’s election exceed the votes cast "against"“against” such nominee'snominee’s election. In contested elections, directors will be elected by a plurality of votes cast. For this purpose, a contested election means any meeting of stockholders for which (i) the Secretary of the Company receives a notice that a stockholder (or group of stockholders) has nominated a person for election to the Board in compliance with the advance notice requirements for stockholder nominees for director or the proxy access requirements, in each case as set forth in the By-Laws and (ii) such nomination has not been withdrawn by such stockholder (or group of stockholders) on or prior to the 14th day preceding the date the Company first mails its notice of meeting for such meeting to the stockholders.

Under the Company'sCompany’s Corporate Governance Guidelines, a director who fails to receive the required number of votes for reelection in accordance with the By-Laws will, within five days following certification of the stockholder vote, tender his or her written resignation to the ChairmanChair of the Board for consideration by the Board, subject to the procedures set forth in the guidelines.

Codes of Ethics
The Board Oversighthas adopted a Code of Risk Management

Ethics that is applicable to our Chief Executive Officer and senior financial officers. The Company has also adopted a Code of Business Ethics and Conduct that applies to all of our officers, directors, and associates. Any amendment to either code or any waiver of either code for executive officers or directors will be disclosed promptly on our website at www.riteaid.com.

Anti-Hedging and Anti-Pledging Policies
The Company’s directors, officers and other associates are prohibited from engaging in hedging or monetization transactions, such as zero-cost collars, equity swaps, exchange funds and forward sale contracts, with respect to our securities. Because hedging transactions might allow a director, officer or other associate to continue to own our securities, whether obtained through our equity compensation plans or otherwise, without the full risks and rewards of ownership, such hedging transactions are prohibited. Directors, officers and other associates are also prohibited from holding in a margin account, or otherwise pledging, Company securities as collateral for a loan.
BOARD OVERSIGHT OF RISK MANAGEMENT
The Board of Directors, as a whole and through the various committees of the Board, oversees the Company'sCompany’s management of risk, focusing primarily on fivefour areas of risk:risk (1) strategic, (2) operational, (3) financial, performance,and (4) regulatory compliance.
The Board considers and discusses risks in connection with strategic, operating, financial, reporting, legalcompliance, specific approval matters, and regulatory, and strategic and reputational.

other special risk topics such as cybersecurity. The Board may delegate responsibility for oversight of selected risks to the appropriate Board committee as described below.

Management of the Company is responsible for developing and implementing the Company'sCompany’s plans and processes for risk management. The Board believes that its leadership structure, described above,


Table of Contents

supports the risk oversight function of the Board. The Board of Directors, at least annually, reviews with management its plans and processes for managing risk. The Board also receives periodic updates from the Company'sCompany’s ethics and compliance and internal assurance services departments with regard to the overall effectiveness of the Company's risk management programCompany’s compliance and internal audit programs and significant areas of risk to the Company, focusing onCompany.

The Board delegated to the fiveAudit Committee oversight of the Company’s compliance program, and therefore the Committee has the primary areasoversight role with respect to many of risk set forth above as well as other areasthe risks of risk identified from time to time by either the Board, a Board committee, or management.

        In addition, theCompany. The Board and the Audit Committee also receive periodic updates from the Company's Chief Financial Officer,Company’s Chief Information Officer and/or Chief Information Security Officer on cybersecurity matters, including information services security and security controls


16 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
over credit card, customer, associate, and patient data. These updates also include information regarding the Rite Aid Information Security Program, managed by Rite Aid'sAid’s Chief Information Security Officer, which is designed to protect information and critical resources from a wide range of threats in order to ensure business continuity, minimize business risk, and maximize return on investments and business opportunities. The objective in the development and implementation of the Information Security Program is to create effective administrative, technical, and physical safeguards in order to protect the data of Rite Aid and its subsidiaries and the data of any customers and clients of these entities.

In addition, other Board committees consider risks within their respective areas of responsibility and advise the Board of any significant risks. For example, the Compensation Committee considers risks relating to the Company's compensation programs and policies and the Audit Committee focuses on assessing and mitigating financial reporting risks, including risks related to internal control over financial reporting andas well as legal and regulatory compliance, risks.

Compensation-Related Risk Assessment

cyber risk and enterprise risk management.

The Compensation Committee considers risks relating to the Company’s compensation programs and policies, reviews all incentive plans relative to established criteria and conducts an assessment to ensure that none of our incentive plans encourage excessive risk-taking by our executives or associates. Together with executive management, the Compensation Committee has considered the risks arising from the Company's compensation programs for its executives and associates and has concluded that the compensation policies are not reasonably likely to have a material adverse effect on the Company.

The Compensation Committee reviews the risk profile and the relationship between the Company'sCompany’s compensation programs to the overall risk profile of the Company. Some of the features of our compensation incentive programs that limit risk include:


Delivery of compensation through an appropriate mix of base salary, short-term cash incentive bonuses,awards, long-term awards, and benefits.


Use of a mix of long-term incentive vehicles that reward both stock price appreciation and financial operating performance and have different risk profiles.


Incorporation of measures in the performance awards to assess how efficientlyour ability to drive stock performance through profitability, leverage reduction and effectively we deploy our assets (return on net assets)growth, and to compare our stock performance against the Russell 3000 Index (total stockholder return).

Stock
Meaningful stock ownership guidelinesrequirements for executives.
The Compensation Committee has considered the risks arising from the Company’s compensation policies and practices for its executives and associates and has concluded that promote executive stock ownership.

Committees of the Board of Directors

compensation policies and practices are not reasonably likely to have a material adverse effect on the Company.


RITE AID CORPORATION   2023 Proxy Statement | 17

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors has four standing committees: the Audit Committee, the Compensation Committee, the Nominating and Governance Committee, and the Executive Committee. Current copies of the charters for each of these committees are available on our website atwww.riteaid.com under the headings "Corporate Info—Governance—Corporate Governance Committees—Committee Charters."


[MISSING IMAGE: tm217739d1-tbl_committeepn.jpg]

Table of Contents

[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
Current copies of the charters for each of these committees are available on our website at www.riteaid.com under the headings “Corporate—Governance—Corporate Governance Committees—Committee Charters.”

The current members of the committees are identified in the following table.

Committees
DirectorIndependentAuditCompensationExecutiveNominating and
Governance
Bruce G. Bodaken(1) [MISSING IMAGE: ic_stark-bw.jpg]
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Elizabeth Burr(2)
Bari Harlam
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
Robert E. Knowling, Jr.(2)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Louis P. Miramontes(1)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg][MISSING IMAGE: ic_calculator-bw.jpg]
Arun Nayar(1)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg][MISSING IMAGE: ic_calculator-bw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Kate B. Quinn
[MISSING IMAGE: ic_checkgreen-pn.jpg]
[MISSING IMAGE: ic_committee-pn.jpg]
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Number of Meetings in Fiscal 202310708
(1)
Director
AuditCompensationNominating and
Governance
Executive
Bruce G. BodakenXChair
Busy BurrX
Robert E. Knowling, Jr. Chair
Kevin E. LoftonChair
Louis P. MiramontesChairX
Arun NayarXX
Katherine QuinnX
John T. StandleyX
Marcy SymsX

Effective as of the Annual Meeting, Mr. Miramontes will cease to serve on the Audit Committee and Mr. Bodaken will begin serving on the Audit Committee.    The Audit Committee, which held nine meetings during fiscal year 2019, currently consists of Louis P. Miramontes (Chair), Busy Burr, and Arun Nayar. The Board has determined that each of these individuals is an independent director under the NYSE listing standards and satisfies the additional independence requirements of Rule 10A-3 under the Exchange Act and the additional requirements Mr. Nayar will serve as Chair of the NYSE listing standards for audit committee members. See the section entitled "Corporate Governance—Director Independence" above. The Board has determined that each of these individuals is also "financially literate" under the applicable NYSE listing standards. The Board has determined that both Louis P. Miramontes and Arun Nayar qualify as an "audit committee financial expert" as that term is defined under applicable SEC rules.

        The functionsAudit Committee.

(2)
Ms. Burr was a member of the Audit Committee include the following:

    Appointing, compensating, and overseeing our independent registered public accounting firm ("independent auditors");

    Overseeing management's fulfillment of its responsibilities for financial reporting and internal control over financial reporting; and

    Overseeing the activities of the Company's internal audit function.

        The independent auditors and internal auditors meet withuntil January 7, 2023, when she was appointed Interim Chief Executive Officer. Mr. Knowling joined the Audit Committee with and withoutat that time.

[MISSING IMAGE: ic_committee-pn.jpg]
Committee Chair
[MISSING IMAGE: tm228886d1-icon_memberbw.jpg]
Committee Member
[MISSING IMAGE: ic_stark-bw.jpg]
Chair of the Board
[MISSING IMAGE: ic_calculator-bw.jpg]
Audit Committee Financial Expert

18 | RITE AID CORPORATION   2023 Proxy Statement

CORPORATE GOVERNANCE AND BOARD MATTERS
AUDIT COMMITTEEMeetings in Fiscal 2023: 10
Members

Louis P. Miramontes, Chair(1)

Robert E. Knowling, Jr.

Arun Nayar
Qualifications
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each member of the Audit Committee is an independent director under the NYSE listing standards and satisfies the additional independence requirements for audit committee members. The Board also has determined that Mr. Bodaken, who will begin serving on the Audit Committee effective as of the Annual Meeting, satisfies these additional independence requirements. See the section entitled “Corporate Governance—Director Independence” above.
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each of these individuals is also “financially literate” under the applicable NYSE listing standards.
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each of Louis P. Miramontes and Arun Nayar qualifies as an “audit committee financial expert” as that term is defined under applicable SEC rules.
Principal ResponsibilitiesCharter
The functions of the Audit Committee include the following:

Appointing, compensating, and overseeing our independent registered public accounting firm (“independent auditors”);

Overseeing management’s fulfillment of its responsibilities for financial reporting and internal control over financial reporting;

Overseeing the activities of the Company’s internal audit function; and

Reviewing the Company’s cybersecurity, information security and technology risks
For additional information, see the Audit Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Audit Committee Charter.”
Audit Committee Report
The Audit Committee Report is located in “Proposal 2—Ratification of the Appointment of Independent Registered Public Accounting Firm” under the caption “Audit Committee Report.”
(1)
Effective as of the presence of management representatives. For additional information, see the section entitled "Audit Committee Report," as well asAnnual Meeting, Mr. Miramontes will cease to serve on the Audit Committee's charter, which is postedCommittee and Mr. Bodaken will begin serving on our website atwww.riteaid.com under the headings "Corporate Info—Audit Committee. Mr. Nayar will serve as Chair of the Audit Committee.

RITE AID CORPORATION   2023 Proxy Statement | 19

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
COMPENSATION COMMITTEEMeetings in Fiscal 2023: 7
Members

Kate B. Quinn, Chair

Robert E. Knowling, Jr.

Arun Nayar
Qualifications
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each member of the Compensation Committee is an independent director under the NYSE listing standards and satisfies the additional independence requirements for compensation committee members. See the section entitled “Corporate Governance—Director Independence” above.
Principal Responsibilities
The functions of the Compensation Committee include the following:

Administering Rite Aid’s equity incentive plans;

Reviewing and approving the base salaries of executive officers and reviewing and recommending to the Board the base salary of the CEO (along with other compensation elements as deemed necessary);

Reviewing and approving goals and objectives relevant to the incentive-based compensation of executive officers, evaluating the performance of executive officers, and determining and approving the incentive-based compensation of executive officers;

Setting corporate performance targets under all annual bonus and long-term incentive compensation plans and determining annually the individual bonus award opportunities for executive officers;

Reviewing and approving executive officers’ employment agreements and severance arrangements;

Reviewing the Company’s succession planning for the CEO and other executive officers; and

Reviewing and making recommendations to the Board on employee engagement and DEI initiatives, objectives and progress.
Independent Compensation Consultant
As provided in its charter, the Compensation Committee has the authority to engage an external compensation consultant and to determine the scope of any services provided. The Compensation Committee may terminate the engagement at any time. The external compensation consultant reports to the Compensation Committee Chair.
Charter
For additional information, see the Compensation Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Compensation Committee Charter.”
Compensation Committee Report
The Compensation Committee Report is located at the end of the “Compensation Discussion and Analysis” under the caption “Compensation Committee Report.”
Compensation Committee Charters."

        Compensation Committee.Interlocks and Insider Participation

The Compensation Committee which held four meetings during fiscal year 2019, currently consists of Kate B. Quinn (Chair), Robert E. Knowling, Jr. (Chair), and Arun Nayar. In addition to the current members, Louis P. Miramontes and Katherine Quinn. The Board has determined that each of these individuals is an independent director underalso served on the NYSE listing standards and satisfies the additional independence requirements of the NYSE listing standards for compensation committee members. See the section entitled "Corporate Governance—Director Independence" above.

        The functionsCompensation Committee during fiscal year 2023. During fiscal year 2023, no member of the Compensation Committee include the following:

    Administering Rite Aid's stock option and other equity incentive plans;

    Reviewing and approving the base salarieswas an employee, former employee, or executive officer of the Company's executive officers and reviewingCompany, nor does any such member have any interlocking relationships as defined by applicable SEC rules.

20 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
NOMINATING AND GOVERNANCE COMMITTEEMeetings in Fiscal 2023: 8
Members

Bari Harlam, Chair

Bruce G. Bodaken

Kate B. Quinn
Qualifications
[MISSING IMAGE: ic_checkgreen-pn.jpg]
The Board has determined that each member of the Nominating and Governance Committee is an independent director under the NYSE listing standards. See the section entitled “Corporate Governance—Director Independence” above.
Principal Responsibilities
The functions of the Nominating and Governance Committee include the following:

Identifying and recommending to the Board individuals qualified to serve as Rite Aid directors;

Recommending to the Board individual directors to serve on committees of the Board;

Advising the Board with respect to matters of Board composition and procedures;

Developing and recommending to the Board a set of corporate governance principles applicable to Rite Aid and overseeing corporate governance matters generally;

Overseeing the annual evaluation of the Board and management;

Reviewing and approving or ratifying related person transactions in which the Company is a participant; and

Overseeing the ESG policies, trends and activities of the Company.
Charter
For additional information, see the Nominating and Governance Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Nominating and Governance Committee Charter.”
EXECUTIVE COMMITTEEMeetings in Fiscal 2023: 0
Members

Bruce G. Bodaken, Chair

Arun Nayar
Principal ResponsibilitiesCharter
The Executive Committee did not meet during fiscal year 2023.
The Executive Committee, except as limited by Delaware law, is empowered to exercise all of the powers of the Board of Directors.
For additional information, see the Executive Committee’s charter on our website at www.riteaid.com, under the headings “Corporate—Governance—Our Policies—Corporate Governance Committees—Executive Committee Charter.”
Board the base salary of the CEO;

Reviewing and approving the Company's goals and objectives relevant to the incentive-based compensation of the Company's executive officers (including the CEO), evaluating the

Table of Contents

      performance of the Company's executive officers (including the CEO) in light of these goals and objectives, and determining and approving the incentive-based compensation of the Company's executive officers (including the CEO) based on such evaluation;

    Setting corporate performance targets under all annual bonus and long-term incentive compensation plans as appropriate and determining annually the individual bonus award opportunities for the Company's executive officers; and

    Reviewing and approving all executive officers' employment agreements and severance arrangements.

        The Compensation Committee reviews the performance of the Company's executive personnel, including the Company's named executive officers, and develops and makes recommendations to the Board of Directors with respect to executive compensation policies. The Compensation Committee is empowered by the Board of Directors to award to executive officers appropriate bonuses, stock options, stock appreciation rights, and stock-based awards. The details of the processes and procedures for the consideration and determination of the compensation of our named executive officers are described in the section entitled "Executive Compensation—Compensation Discussion and Analysis." The objectives of the Compensation Committee are to support the achievement of desired Company performance, to provide compensation and benefits that will attract and retain superior talent, to reward performance, and to fix a portion of compensation to the outcome of the Company's performance.

        As provided in its charter, the Compensation Committee has the authority to engage an external compensation consultant and to determine the scope of any services provided. The Compensation Committee may terminate the engagement at any time. The external compensation consultant reports to the Compensation Committee Chair.

        Since June 2010, the Compensation Committee has utilized Exequity LLP as its independent consultant. With respect to fiscal year 2019, Exequity LLP reviewed recommendations and analysis prepared by management and provided advice and counsel to the Compensation Committee. Exequity LLP does not provide any other services to the Company. The Compensation Committee has assessed the independence of Exequity LLP, taking into consideration the factors set forth in the NYSE listing standards and SEC rules, and determined that the engagement of Exequity LLP does not raise any conflicts of interest.

        Nominating and Governance Committee.Refreshment

The Nominating and Governance Committee which held eight meetings during fiscal year 2019, currently consistsconsiders the periodic rotation of Kevin Lofton (Chair), Bruce G. Bodaken,Committee members and Marcy Syms. The Board has determined that eachCommittee Chairs to introduce fresh perspectives and to broaden and diversify the views and experience represented on the Committees. Through this periodic refreshment, the Nominating and Governance Committee considers, among other things, the benefits from continuity and depth of these individuals is an independent director underexperience with the NYSE listing standards. Seebenefits of fresh perspectives and exposing our directors to different aspects of our business.
As part of the section entitled "Corporate Governance—Director Independence" above.

        The functionsCommittee refreshment process, in June 2022, Arun Nayar joined the Compensation Committee, Louis P. Miramontes’ service on the Compensation Committee ended and Bari Harlam became Chair of the Nominating and Governance Committee. In addition, in January 2023 in connection with her appointment as interim CEO, Ms. Burr’s service on the Audit Committee includeended, and Robert E. Knowling, Jr. joined the following:

    Identifying and recommending to theAudit Committee.
BOARD MEETING ATTENDANCE
The Board individuals qualified to serve as Rite Aid directors;

Recommending to the Board individual directors to serve on committees of the Board;

Advising the Board with respect to matters of Board composition and procedures;

Developing and recommending to the Board a set of corporate governance principles applicable to Rite Aid and overseeing corporate governance matters generally;

Overseeing the annual evaluation of the Board and management; and

Reviewing and approving or ratifying related person transactions in which the Company is a participant.

Table of Contents

        Executive Committee.    The members of the Executive Committee currently are Bruce G. Bodaken (Chair), Arun Nayar, and John T. Standley. The Executive Committee did not meetDirectors held 12 meetings during fiscal year 2019. The Executive Committee, except as limited by Delaware law, is empowered to exercise all2023. Each director attended at least 75% of the powersaggregate number of meetings of the Board of Directors.

NominationDirectors and meetings held by all committees on which such director served during the period for which such director served.


RITE AID CORPORATION   2023 Proxy Statement | 21

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
It is our policy that directors are invited and encouraged to attend the annual meeting of Directors

stockholders. All directors serving on the Board or nominated to serve on the Board at the time of the meeting attended the 2022 Annual Meeting of Stockholders.

DIRECTOR NOMINATIONS
The Nominating and Governance Committee identifies potential candidates by asking current directors and executive officers to notify the committee if they become aware of persons, meeting the criteria described below, who have had a change in circumstances that might make them available to serve on the Board—for example, retirement as a CEO or CFO of a public company or exiting government or military service. The Nominating and Governance Committee also, from time to time, may engage firms that specialize in identifying director candidates.
The Nominating and Governance Committee will consider director candidates recommended by stockholders. In considering such recommendations, the Nominating and Governance Committee will take into consideration the needs of the Board and the qualifications of the candidate. The Nominating and Governance Committee may also take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been held. To have a candidate considered by the Nominating and Governance Committee, a stockholder must submit the recommendation in writing and must include the following information:


The name of the stockholder and evidence of the person'sperson’s ownership of Rite Aid stock, including the number of shares owned and the length of time of ownership; and


The name of the candidate, the candidate'scandidate’s resume or a listing of his or her qualifications to be a Rite Aid director, and the person'sperson’s consent to be named as a director if selected by the Nominating and Governance Committee and nominated by the Board.

The stockholder recommendation and information described above must be sent to Rite Aid Corporation, 30 Hunter Lane, Camp Hill, Pennsylvania 17011,PO Box 3165 Harrisburg, PA 17105, Attention: Corporate Secretary. The Nominating and Governance Committee will accept recommendations of director candidates throughout the year. Generally, in order for a recommended director candidate to be considered for nomination to stand for election at an upcoming annual meeting of stockholders, the recommendation must be received by the Secretary not fewer than 120 days prior to the anniversary date of Rite Aid'sAid’s most recent annual meeting of stockholders. In the event an annual meeting is held on a date that is not within 25 days of such anniversary date, recommendations will be considered by the Nominating and Governance Committee in due course.

        The Board seeks to maintain an engaged, independent Board with broad experience and judgment that is committed to representing the long-term interests of our stockholders. The Nominating and Governance Committee believes that the minimum qualifications for serving as a Rite Aid director are that a candidate demonstrate, by significant accomplishment in his or her field, an ability to make a meaningful contribution to the Board's oversight of Rite Aid's business and affairs and have an impeccable record and reputation for honest and ethical conduct in his or her professional and personal activities. In addition, the Nominating and Governance Committee examines a candidate's specific experiences and skills, availability in light of other commitments, potential conflicts of interest, and independence from management and the Company. The Nominating and Governance Committee also takes into account a candidate's ability to contribute to the diversity of background and experience represented by the Board. The Nominating and Governance Committee assesses its achievement of diversity through the review of Board composition as part of the Board's annual self-assessment process.

        The Nominating and Governance Committee identifies potential candidates by asking current directors and executive officers to notify the committee if they become aware of persons, meeting the criteria described above, who have had a change in circumstances that might make them available to serve on the Board—for example, retirement as a CEO or CFO of a public company or exiting government or military service. The Nominating and Governance Committee also, from time to time, may engage firms that specialize in identifying director candidates. As described above, the committee will also consider candidates recommended by stockholders.


Table of Contents

The Nominating and Governance Committee may review publicly available information, conduct an interview and/or check references to assess the person'sperson’s accomplishments and qualifications in light of the needs of the Board and the accomplishments and qualifications of any other candidates that the committee might be considering. The committee'scommittee’s evaluation process does not vary based on whether or not a candidate is recommended by a stockholder, although, as stated above, the Board may take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been held.

        Russell Reynolds Associates,

The Board seeks to maintain an executive search consulting firm, assistedengaged, independent Board with broad experience and judgment that is committed to representing the long-term interests of our stockholders. The Nominating and Governance Committee believes that the minimum qualifications for serving as a Rite Aid director are:

that a candidate demonstrates, by significant accomplishment in his or her field, an ability to make a meaningful contribution to the Board’s oversight of Rite Aid’s business and affairs, and

that a candidate has an impeccable record and reputation for honest and ethical conduct in his or her professional and personal activities.
In addition, the Nominating and Governance Committee examines a candidate’s specific experiences and skills, availability in sourcing director candidateslight of other commitments, potential conflicts of interest, and independence from management and the Company. The Nominating and Governance Committee also takes into account a candidate’s ability to contribute to the diversity of background and experience represented by the Board. The Nominating and Governance Committee assesses its achievement of diversity through the review of Board composition as part of the continuation of the Board's accelerated refreshmentBoard’s annual self-assessment process. With respect to the two additions to the Board in April 2019, Busy Burr and Katherine Quinn were both vetted and recommended by Russell Reynolds Associates to the Nominating and Governance Committee for the Committee's consideration for appointment as independent directors.

Executive Sessions of Non-Management Directors


22 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
EXECUTIVE SESSIONS OF NON-MANAGEMENT DIRECTORS
In order to promote discussion among the non-management directors, regularly scheduled executive sessions (i.e., meetings(meetings of non-management directors without management present) are held to review such topics as the non-management directors determine.regularly. Mr. Bodaken, our ChairmanChair of the Board, presides at our executive sessions. The non-management directors met in executive session 14 times during fiscal year 2019.

Communications with the Board of Directors

COMMUNICATIONS WITH THE BOARD OF DIRECTORS
The Board has established a process to receive communications from stockholders and other interested parties. Stockholders and other interested parties may contact any member (or all members) of the Board, any Board committee, or any chair of any such committee by mail or electronically. To communicate with the Board of Directors, the non-management directors, a committee of directors, or any individual directors, including our Independent Chairman of the Board, correspondencemail. Correspondence should be addressed to the Board of Directors or any such individual directors, or committee of directors by either name or title. All such correspondence should be sent to Rite Aid Corporation, c/o Secretary, P.O. Box 3165, Harrisburg, Pennsylvania 17105. To communicate with any of the directors electronically, stockholders should go to our website atwww.riteaid.com. Under the headings "Corporate Info—Governance—Board of Directors—Contact the Board of Directors" you will find an on-line form, as well as an email address, that may be used for writing an electronic message to the Board, the non-management directors, any individual directors, or any committee of directors. Please follow the instructions on the website in order to send your message.

All such correspondence should be
sent to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
c/o Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
All communications received as set forth above will be opened by the Corporate Secretary for the purpose of determining whether the contents represent a messagelegitimate communication to the directors,directors. Such communications, other than business solicitations or advertisements, junk mail and depending on the factsmass mailings, new product suggestions, product complaints, product inquiries, resumes and circumstances outlined in the communication,other forms of job inquiries, spam, and surveys, will be distributed to the Board, the non-management directors, an individual director, or a committee of directors, as appropriate.
ENVIRONMENTAL, SOCIAL & GOVERNANCE MATTERS
The Secretary will make sufficient copies ofdisclosure in our voluntary annual ESG report is intended to align with the contents to send to each director whoSustainability Accounting Standards Board (SASB) framework and is a member of the Board or of the committee to which the envelope or email is addressed.

Directors' Attendance at Board, Committee,broken into four pillars: Thriving Planet, Thriving Business, Thriving Workplace and Annual Meetings

        The Board of Directors held 26 meetings duringThriving Community.

In fiscal year 2019. Each incumbent director attended at least 75% of the aggregate of the meetings2023, we provided quarterly updates on ESG matters to our Nominating and Governance Committee of the Board of Directors and meetings held by all committees on which such director served, during the period for which such director served.


Table of Contents

        It isDirectors. In addition, our policy that directors are invited and encouraged to attend the annual meeting of stockholders. Eight of our nine directors serving on the Board or nominated to serve on the Board at the time of the meeting attended the 2018 Annual Meeting of Stockholders.

Corporate Sustainability

        At the 2018 Annual Meeting, stockholders approved a proposal requesting that Rite Aid prepare a sustainability report describing the Company's environmental, social, and governance (ESG) risks and opportunities. A report describing the Company's ESG risks and opportunities will be released prior to the Annual Meeting. When available, the report will be posted on our website atwww.riteaid.com under the headings "Corporate Info—Investor Relations."

        At Rite Aid, we are dedicated to integrating Environmental, Social, and Governance initiatives into our operations, not only to retain value for our shareholders, our customers, and our associates, but also because "integrity in all we do" is one of our core values.

        We have a corporate social responsibility committee Committee, comprised of senior level leadership stakeholders with cross functional leadership across the organization, with representation within the Company. The corporate social responsibility committee produces our annual CSR reportfrom legal, finance, internal assurance, human resources, facilities, operations and leads progress on sustainability initiativesmore, met regularly to discuss reporting strategy, disclosure topics and programs throughout the company. Our corporate social responsibility committee provides corporate social responsibility updateskey performance indicators.

[MISSING IMAGE: ic_computer-pn.jpg]
Further information about our commitment to sustainability is available on our website under the headings “Corporate—Investor Relations—Sustainability.” Website content is not incorporated into this proxy statement.

RITE AID CORPORATION   2023 Proxy Statement | 23

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
CORPORATE GOVERNANCE MATERIALS
Website Access to our Board.

        Our Code of Business Ethics and Conduct outlines our core values and describes additional corporate policies on ESG issues, including polices in the areas of, among others, customer and worker safety and environmental management, including energy and waste minimization. We expect our officers, directors, and associates to uphold the standards set forth in the Code of Business Ethics and Conduct at work every day.

        We conduct our business in compliance with applicable environmental, health, and safety regulations. We view conserving energy, avoiding the unnecessary generation of waste, and carrying out company activities in ways that preserve and promote a clean, safe, and healthy environment as the environmental and social sustainability priorities for our business.

        We view adopting green business principles as part of our overall business strategy and believe it is a conscientious decision for our business, our community, and the environment. Over the past five years, we have made significant investments in energy efficiency and waste reduction initiatives and have committed to building new and remodeled stores to meet or exceed the national building code standards for energy efficiency. For example, in striving to conserve energy and avoid the unnecessary generation of waste, we have installed LED lighting to reduce our annual electric consumption by 18 million KWh, completed a redesign of our Thrifty Ice Cream Plant in El Monte, California, which included upgrades to a safer refrigeration system and to lighting and HVAC systems to reduce our annual electric consumption by eight million kWh, and installed a 1098 kW solar system at our distribution center in Lancaster, California that produces 30% of the location's power needs. Over the past three years, we have seen a steady decrease in energy consumption in our retail stores and have reduced our total energy consumption in our retail stores during that period by 19,031,630 kWh on a comparable store basis. In addition, Rite Aid utilizes best-in-class architectural and engineering design firms that employ Building Council LEED™-accredited staff in order to help us develop our new store designs that meet or exceed the national building code standards for energy efficiency.

        We have established a Chemical Policy and, in 2018, we expanded our Restricted Substances List as part of our ongoing efforts to meet customer expectations for chemical management and product safety. We have been working closely with our supplier partners to eliminate eight chemicals of high concern from formulated private brand items since 2016, and we expect to eliminate these chemicals from our private brand items by 2020. We have also expanded our Restricted Substances List to bring

Corporate Governance Materials
[MISSING IMAGE: ic_computer-pn.jpg]
Our corporate governance information and materials are posted on our website at riteaid.com/corporate/governance. Website content is not incorporated into this proxy statement.

CORPORATE GOVERNANCE GUIDELINES

AUDIT COMMITTEE CHARTER

COMPENSATION COMMITTEE CHARTER

EXECUTIVE COMMITTEE
CHARTER

NOMINATING AND GOVERNANCE COMMITTEE CHARTER

CODE OF ETHICS FOR THE CEO AND SENIOR FINANCIAL OFFICERS

CODE OF BUSINESS ETHICS AND CONDUCT

STOCK OWNERSHIP GUIDELINES

RELATED PERSON TRANSACTION POLICY

INSIDER TRADING POLICY

CERTIFICATE OFINCORPORATION

BY-LAWS OF RITE AID
CORPORATION

NYSE DOCUMENTS—ANNUAL CEO CERTIFICATION

NYSE DOCUMENTS—SECTION 303A WRITTEN AFFIRMATIONS OF COMPLIANCE
These documents are also available in print upon request, free of charge, by writing to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105

Table of Contents

the total number of restricted chemicals from eight to 69. To assist stakeholders in understanding the impact of these initiatives, in 2019 we will begin reporting progress towards 100% elimination of the eight chemicals of high concern from our private brand products and the number of new products launched in a year that are free of the eight chemicals of high concern. Our long-term goal is to extend the Chemical Policy to cover all of the products sold in our stores. In 2019, we plan to extend the chemical program to cover formulated products like over-the-counter medications, vitamins and supplements, as well as food and beverages.

        We have also implemented "Responsible Sourcing Guidelines" (and objectives) to promote supply chains that support responsible forest management, the appropriate use of recycled content and responsible sourcing, including transparency, protocols, and mechanisms to track the wood fiber in the supply chain from its origin to the forest products supplied to Rite Aid and its customers. Our initial goal is to address the largest volume of forest products used in Rite Aid's daily business operations, such as advertising circular papers, copy and print paper and the pharmacy bags and labels used by our pharmacy and distribution centers. We have already made significant progress in achieving our goal, with 100% of the paper purchased for our advertising circulars being sourced from responsibly managed, forest-based suppliers that are compliant with independent forest certification standards.

        Further information about our commitment to sustainability is available on our website under the headings "Corporate Info—Environmental Responsibility" and "Corporate Info—Chemical Policy."

Opioid Matter Oversight

The Board the Company's management, and the Company's employees recognize the opioid epidemic that is afflicting Americans across the United States as a serious public health issue, and we have publicly expressed our commitment to addressing opioid abuse in the communities we serve. At the 2018 Annual Meeting, stockholders approved a proposal requesting that Rite Aid prepare a report describing theregularly reviews corporate governance changes the Company has implemented since 2012 to more effectively monitordevelopments and manage financialwill modify these materials and reputational risks related to the opioid crisis. The Company anticipates that a report describing the Company's approach to oversight of opioid matters will be released by October 1, 2019.

        The Board and management review the Company's plans and processes for managing risk at least annually. The Board oversees risk management and considers specific risk topics on an ongoing basis, including the risks associated with opioid medications. The Board also receives periodic updates from internal subject matter experts with regard to the overall effectiveness of the Company's risk management program and significant areas of risk to the Company, focusing on the five primary areas of risk set forth above as well as other areas of risk identifiedpractices from time to time by the Board, a Board committee, or management,as warranted.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Review and including risks related to opioid dispensing and the statusApproval of ongoing initiatives to combat addiction risk in the communities Rite Aid serves. In addition, each Board committee regularly reports to the full Board on risks within their respective areas of responsibility. For example, the Compensation Committee annually reviews the Company's compensation plans, programs, and policies as they relate to the Company's risk management. Rite Aid management will continue to keep the Board updated on a regular basis concerning opioid dispensing-related activities and initiatives to combat addiction.

        At Rite Aid, we takeRelated Person Transactions

Under our role as a community healthcare provider very seriously. This means going beyond simply complying with state laws and regulations to also raise awareness about important issues like prescription drug safety and drug abuse prevention. We are also committed to raising awareness about important issues like drug abuse prevention and prescription drug safety while advocating for increased access to education, treatment, and proper medication disposal. As one of health care's most accessible practitioners, pharmacists are uniquely positioned to help educate their patients and communities about promoting prescription safety. We are committed to working with our customers,


Table of Contents

local law enforcement, community groups, and both federal and state agencies to help reduce the opioid epidemic that is impacting our communities throughout the United States. Rite Aid's comprehensive strategy to address opioid and other drug abuse and misuse includes:

    Educating our patients so they understand the risks of opioid abuse starting with their first opioid prescription, including providing all patients with new opioid prescriptions with mandatory counseling on their prescription from Rite Aid pharmacists.

    Making DisposeRx, a first-of-its-kind opioid disposal solution, available at all of Rite Aid's pharmacies nationwide. Rite Aid provides DisposeRx packets to patients with new opioid prescriptions and offers DisposeRx packets to patients with chronic opioid prescriptions every six months. DisposeRx packets contain a biodegradable powder that, when mixed with water in the prescription vial, dissolves drugs, forming a viscous gel which may be safely discarded in the trash.

    Making naloxone, a medication that can be used to reverse the effects of an opioid overdose, available without a prescription at all of Rite Aid's pharmacies nationwide.

    Supporting the Centers for Disease Control and Prevention guidelines for prescribing opioids, including limiting acute opioid prescriptions to a seven-day supply, limiting the daily dosage of opioids dispensed based on the strength of the opioid, and requiring the use of immediate-release formulations of opioids before extended-release opioids are dispensed.

    Providing ongoing education and training of Rite Aid pharmacists, including risk factors for opioid abuse, how to identify symptoms of an overdose and what to do in the event of an overdose, an overview of the naloxone therapies available, and proper administration of each and recommendations for follow-up care.

    Participating in prescription drug monitoring programs, assuring that all pharmacists are registered for the programs in their respective state(s) of practice, and including a "red flag" process for pharmacists to regularly review prescriptions for patients.

    Adding resources on drug safety and disposal onwww.riteaid.com under the headings "Pharmacy & Immunizations—Drug Safety & Disposal." Visitors can search for a disposal site in their community, learn how to properly dispose of medication at home, access resources provided by the Food and Drug Administration and the Drug Enforcement Administration ("DEA"), and find information on treatment for drug abuse and addiction.

    Continuing its process to identify physicians with questionable prescription writing practices and, when appropriate, proactively discontinuing filling controlled substances for certain prescribers.

    Continuing to support National Take-Back Days to encourage our patients to bring their unused or unwanted medications to designated sites sponsored by local law enforcement and the DEA for proper handling.

    Developing the KidsCents Safe Medication Disposal program that is supported through the Rite Aid Foundation, which provides medication disposal units, free of charge, to local and state law enforcement agencies and enables individuals to drop off unwanted or expired medications in secure, safe locations. The Rite Aid Foundation committed $1 million to this initiative and, to date, over 450 units have been installed across the country since the launch of the program in August 2017.

    Adding 100 new Safe Medication Disposal units in select Rite Aid stores nationwide.

    Through the Rite Aid Foundation, committing $1.7 million over three years in partnership with EVERFI, a leading education technology company, to educate high school students to make safe and healthy decisions about prescription drugs. The digital prescription drug abuse prevention

Table of Contents

      course is the flagship initiative of the Prescription Drug Safety Network, the nation's first public-private initiative to combat prescription drug abuse by providing prevention education to schools.

        Further information about medication safety and disposal is available on our website under the headings "Pharmacy & Immunizations—Drug Safety & Disposal."

Directors' Compensation

        Each non-management director receives an annual payment of $100,000 in cash, payable quarterly in arrears. In addition, (i) the Lead Independent Director received an additional annual payment of $25,000 (for so long as the Board had a Lead Independent Director); (ii) the Independent Chairman of the Board receives an additional annual payment of $100,000; (iii) the Chair of the Audit Committee receives an additional annual payment of $20,000; (iv) the Chairs of the Compensation Committee andwritten policy, the Nominating and Governance Committee eachis responsible for the review, approval, or ratification of “related person transactions” between the Company or its subsidiaries and related persons. Under SEC rules, a related person is, or any time since the beginning of the last fiscal year was, a director, an executive officer, a nominee for director, a more than 5% stockholder of the Company, or an immediate family member (as defined under applicable SEC rules) of any of the foregoing. A related person transaction is any transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the Company or a subsidiary is a participant, the amount involved exceeds $120,000, and a related person had, has or will have a direct or indirect material interest.

Directors, executive officers and nominees must complete an annual questionnaire and disclose all potential related person transactions involving themselves and their immediate family members that are known to them.
Throughout the year, directors and executive officers must notify the Corporate Secretary and Chief Accounting Officer of any potential related person transactions as soon as they become aware of any such transaction. The Corporate Secretary and Chief Accounting Officer inform the Nominating and Governance Committee of any related person transaction of which they are aware. The Corporate Secretary and Chief Accounting Officer are responsible for conducting a preliminary analysis and review of potential related person transactions and presentation to the Nominating and Governance Committee for review, including provision of additional information to enable proper consideration by the Nominating and Governance Committee.

24 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
The Corporate Secretary and Chief Accounting Officer determine whether the proposed transaction should be submitted to the Nominating and Governance Committee for consideration at the next committee meeting or, if the Corporate Secretary and Chief Accounting Officer, in consultation with the Chief Executive Officer or Chief Financial Officer, determine that it is not practicable or desirable for the Company to wait until the next committee meeting, to the Chair of the Nominating and Governance Committee (who will possess delegated authority to act between committee meetings). As necessary, the Nominating and Governance Committee reviews approved related person transactions on a periodic basis throughout the duration of the transaction to ensure that the transactions remain in the best interests of the Company. The Nominating and Governance Committee may, in its discretion, engage outside counsel to review certain related person transactions. In addition, the Nominating and Governance Committee may request that the full Board of Directors consider the approval or ratification of related person transactions if the Nominating and Governance Committee deems it advisable.
[MISSING IMAGE: ic_computer-pn.jpg]
A copy of our full policy concerning transactions with related persons is available on the Governance section of our website at www.riteaid.com under the headings “Corporate—Governance—Our Policies—Related Person Transactions.” Website content is not incorporated into this proxy statement
Directors’ Compensation
Non-Management Director Service
Annual Cash Retainer
($)
(1)
Annual Stock Award
($)
Non-management director100,000160,000
Additional annual retainers, for service as:��
Chair of the Board165,000
Committee Chairs

Audit Committee
25,000

Compensation Committee
25,000

Nominating and Governance Committee
25,000
Audit Committee Member (other than the Chair)10,000
(1)
Fees payable quarterly in arrears.
The elements of Rite Aid’s fiscal year 2023 compensation program for our non-management directors are summarized above. The Compensation Committee, with the assistance of Mercer, the committee’s compensation consultant, regularly reviews our non-management director compensation and evaluates the competitiveness and reasonableness of the compensation program in light of general trends and practices. The Compensation Committee makes recommendations based on such review to our Board, which determines whether any changes should be made to our non-management director compensation program. Based on its review, in fiscal year 2023 the Compensation Committee recommended, and the Board determined, beginning in April 2022, to increase the Compensation Committee Chair’s annual cash retainer to better reflect market competitiveness, from $20,000 to $25,000, and that no other changes to the non-management director compensation program were needed.
Non-management directors receive an additional annual cash payment of $10,000;$100,000, payable quarterly in arrears and (v) each member of the Audit Committee (other than the Chair) receives an additional annual payment of $10,000. Non-management directors also receive an annual award of restricted stock units valued at $120,000 (withunder the numberCompany’s Amended and Restated 2020 Omnibus Equity Incentive Plan. The annual award of shares subject to the grant calculated by dividing 120,000 by the closing price of our commonrestricted stock on the day before the date of grant, rounded to the nearest whole share). Prior to 2019, the annual grant provided for vesting with respect to 80% on the first anniversary of the grant and 10% on each of the second and third anniversaries of the grant. The Compensation Committee undertook a review of non-management director compensation in December 2018. The Compensation Committee engaged with independent compensation consultant Exequity LLP to provide a recommendation of our overall director compensation as compared to our new peer group as discussed in the section entitled "The Compensation Committee's Process—Assessment of Company performance." As a result of the recommendation to, and approval by, the Board of Directors,units for fiscal year 2019 the amount of each of the annual cash retainer and annual stock-based award described above remain unchanged. The annual stock-based award for fiscal year 2019 vests2023 vested on the date of grant and the shares subject to the grant will become payable on a deferred basis upon the separation from service of the director.
A non-management director may also defer cash fees under the Rite Aid Corporation Director Deferred Compensation Plan. Cash fees deferred are allocated to a bookkeeping account for the non-management director and notionally invested in accordance with the director’s election among a subset of investment funds available under the Company’s 401(k) savings plan. A non-management director’s deferral is paid on the director’s separation from service in a single lump sum. None of our non-management directors elected to defer cash fees earned in respect of fiscal year 2023.

RITE AID CORPORATION   2023 Proxy Statement | 25

TABLE OF CONTENTS
CORPORATE GOVERNANCE AND BOARD MATTERS
Directors who are officers and/or Rite Aid associates receive no separate compensation for service as directors or committee members. Directors are reimbursed for travel and lodging expenses associated with attending Board of Directors and Board committee meetings.

Non-management directors are subject to our Stock Ownership Guidelines discussed on pages 51 to 52.

in the Compensation Discussion and Analysis under the caption “Director and Officer Stock Ownership Guidelines.”

Director Compensation Table of Contents


DIRECTOR COMPENSATION TABLE FOR FISCAL YEAR 2019

for Fiscal Year 2023

The following Director Compensation Table sets forth fees, awards, and other compensation paid to or earned by our non-management directors who served during the fiscal year ended March 2, 2019:

4, 2023:
Name(1)
Fees Earned
or Paid in
Cash
($)
Stock
Awards
($)
(2),(3)
Option
Awards
($)
Non-Equity
Incentive
Plan
Compensation
($)
Change In
Nonqualified
Deferred
Compensation
($)
All Other
Compensation
($)
Total
($)
Bruce G. Bodaken265,000159,997424,997
Bari Harlam112,637159,997272,635
Robert E. Knowling, Jr.104,556159,997264,553
Kevin E. Lofton(4)62,50062,500
Louis P. Miramontes125,000159,997284,997
Arun Nayar110,000159,997269,997
Kate B. Quinn(5)123,750159,997283,747
Name
 Fees
Paid in
Cash ($)
 Stock
Awards
($)(1)(2)
 Option
Awards
($)
 Non-Equity
Incentive Plan
Compensation
($)
 Change In
Nonqualified
Deferred
Compensation
($)
 All Other
Compensation
($)
 Total ($) 

Joseph B. Anderson, Jr. 

  108,288  120,000          228,288 

Bruce G. Bodaken

  117,120  120,000          237,120 

Robert E. Knowling

  18,832  120,000          138,832 

Kevin E. Lofton

  110,000  120,000          230,000 

Louis P. Miramontes

  25,524  120,000          145,524 

Arun Nayar

  18,832  120,000          138,832 

Michael N. Regan

  130,973  120,000          250,973 

Marcy Syms

  112,163  120,000          232,163 

David R. Jessick(3)

  99,457            99,457 

Myrtle Potter(3)

  82,880            82,880 

Frank A. Savage(3)

  82,880            82,880 

(1)
(1)
Elizabeth Burr served as a director during fiscal year 2023 through January 7, 2023 until her appointment as interim CEO of the Company on such date. Ms. Burr’s compensation as a director and for her service as interim CEO during fiscal year 2023 is reflected in the Summary Compensation Table, found on page 56 of this proxy statement.
(2)
Represents the grant date fair value of stock awards granted in February 2019 in respect of fiscal year 20192023 in accordance with Financial Accounting Standards Board ("FASB"(“FASB”) Topic 718. For information regarding the assumptions used in determining the fair value of an award, please refer to Note 1718 to our financial statements contained in the Company'sCompany’s Annual Report on Form 10-K asfor the fiscal year ended March 4, 2023, filed with the SEC on April 25, 2019. Delivery of theMay 1, 2023. The restricted stock unit awards are immediately vested upon grant; however, shares underlying the restricted stock awards is deferredunits are held and not delivered until the directors'directors’ separation from services.

(2)
The numberservice.
(3)
As of March 4, 2023, no unvested restricted stock unit awards outstanding as of March 2, 2019 for each director is detailed inand no stock option awards were held by any director.
(4)
Mr. Lofton resigned from the table below.Board effective July 27, 2022.
(5)
Ms. Quinn’s Compensation Committee chair retainer increased from $20,00 to $25,000 annually on April 6, 2022.

26 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 2—RATIFICATION OF THE
APPOINTMENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
Name
Grant DateNumber of
Stock
Awards (#)

Joseph B. Anderson, Jr. 

June 22, 201677

July 17, 2017519

Bruce G. Bodaken

June 22, 201677

July 17, 2017519

Kevin E. Lofton

June 22, 201677

July 17, 2017519

Michael N. Regan

June 22, 201677

July 17, 2017519

Marcy Syms

June 22, 201677

July 17, 2017519

David R. Jessick(3)

Myrtle Potter(3)

Frank A. Savage(3)

(3)
Each of Ms. Potter and Messrs. Jessick and Savage served as a member of the Board through the date of our 2018 Annual Meeting. Any outstanding, unvested shares were cancelled upon their separation from the Board.

Table of Contents


PROPOSAL NO. 2

RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The accounting firm of Deloitte & Touche LLP ("(“Deloitte & Touche"Touche”) has been selected as the independent registered public accounting firm for the Company for the fiscal year ending February 29, 2020.March 2, 2024. Deloitte & Touche has audited the accounts and records of Rite Aid and its subsidiaries since 2000. Although the selection of accounting firms does not require ratification, the Board of Directors has directed that the appointment of Deloitte & Touche be submitted to the stockholders for ratification due to the significance of their appointment by the Company. If the stockholders do not ratify the appointment of Deloitte & Touche, the Audit Committee will consider the appointment of another independent registered public accounting firm. A representative of Deloitte & Touche will be present at the Annual Meeting, will have the opportunity to make a statement, and will be available to respond to appropriate questions.


RECOMMENDATION

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR"
THE RATIFICATION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2020.


Table of Contents


PROPOSAL NO. 3

ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

        In accordance with the requirements of Section 14A of the Exchange Act, we are including in this proxy statement a resolution, subject to stockholder vote, to approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers (as defined in the section entitled "Executive Compensation—Compensation Discussion and Analysis").

        Prior to voting, stockholders should carefully review our discussion of the compensation of our Named Executive Officers, as presented in the Compensation Discussion and Analysis, tables, and narrative disclosure on pages 33 to 66, as well as the discussion of modifications made as a result of stockholder outreach efforts on pages 36 to 37, and the discussion regarding the Compensation Committee on pages 17 to 18.

        The Company's primary compensation goals for our Named Executive Officers are to attract, motivate, and retain the most talented and dedicated executives and to align the interests of our Named Executive Officers with the interests of our stockholders. The Company's compensation programs are designed to reward our Named Executive Officers for the achievement of annual and long-term strategic and operational goals and the achievement of increased total stockholder return, while at the same time avoiding the encouragement of unnecessary or excessive risk-taking. The Company encourages stockholders to review the executive compensation disclosure in the Compensation Discussion and Analysis section and executive compensation tables in this proxy statement for complete details of its compensation program for its Named Executive Officers, changes made since the prior fiscal year, and how the program is designed to achieve the Company's compensation objectives.

        We believe that the Company's compensation programs for its Named Executive Officers have operated to appropriately align pay with performance and enabled the Company to attract and retain talented executives within our industry, while at the same time avoiding the encouragement of unnecessary or excessive risk-taking.

        We are asking our stockholders to indicate their support for the compensation of our Named Executive Officers as described in this proxy statement. This proposal, commonly known as a "say-on-pay" proposal, gives you as a stockholder the opportunity to express your views on our fiscal year 2019 compensation for our Named Executive Officers. This vote is not intended to address any specific item of compensation; rather, the vote relates to the overall compensation of our Named Executive Officers as described in this proxy statement in accordance with the compensation disclosure rules of the SEC.

        Accordingly, the following resolution is submitted for a stockholder vote at the Annual Meeting:

        "RESOLVED, that the stockholders approve, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's Proxy Statement for the 2019 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables, and the narrative discussion."

        Although this is an advisory vote which will not be binding on the Compensation Committee or the Board, the Compensation Committee and the Board will carefully review the results of the stockholder vote. The Compensation Committee will consider stockholders' concerns and take them into account in future determinations concerning compensation of its Named Executive Officers. The Board therefore recommends that you indicate your support for the compensation of the Company's Named Executive Offices in fiscal year 2019, as outlined in the above resolution.


RECOMMENDATION

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR"
THE APPROVAL OF THE COMPENSATION OF ITS NAMED EXECUTIVE OFFICERS,
AS DISCLOSED IN THIS PROXY STATEMENT.


Table of Contents


STOCKHOLDER PROPOSAL

        We expect the following proposal (Proposal No. 4 on the proxy card) to be presented by stockholders at the Annual Meeting. The proposal and supporting statement may contain assertions about Rite Aid or other statements that we believe are incorrect. We have not attempted to refute all of these inaccuracies, and the Company is not responsible for the content of the proposal. The Board has recommended a vote against the proposal for the reasons set forth following the proposal.


PROPOSAL NO. 4

STOCKHOLDER PROPOSAL—SEEKING A BY-LAW AMENDMENT FOR A 10% OWNERSHIP
THRESHOLD FOR STOCKHOLDERS TO CALL SPECIAL MEETINGS

        Steven Krol, who owns approximately 12,763 shares of common stock (based on information provided to us by Mr. Krol and adjusted to reflect the reverse stock split that occurred in April 2019) and whose address will be provided by the Company promptly upon oral or written request, has notified us that he intends to present the following proposal at the Annual Meeting. The Board of Directors strongly opposes adoption of the proposal and asks stockholders to review the Board's response, which follows the proposal and the proponent's supporting statement below.

Stockholder Proposal and Supporting Statement


Table of Contents


THE BOARD OF DIRECTORS' STATEMENT IN OPPOSITION

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE
"AGAINST" THIS
PROPOSAL FOR THE FOLLOWING REASONS:

        The Board believes this stockholder proposal is unnecessary as our stockholders already have the right to call special meetings.

        As discussed on pages 7 to 8 of this proxy statement, the Company has had a more robust stockholder engagement program in recent months. After carefully considering feedback from our stockholders, in April 2019, the Board amended our By-Laws to permit special meetings of the stockholders to be called by stockholders of record holding at least 20% of the Company's common stock. The Board believes that a 20% ownership threshold for the right to call special meetings strikes a reasonable and appropriate balance between enhancing stockholder rights and protecting against the risk that a small group of stockholders, including stockholders with special interests, could call special meetings.

        Allowing a small group of stockholders to call special meetings could be detrimental to the interests of a majority of our stockholders and other stakeholders. The Company's current 20% ownership threshold provides a reasonable number of stockholders with a meaningful right to require the Company to hold a special meeting without exposing the Company and its stockholders to unreasonable expense and disruption. These costs can be significant, including the costs of preparing and distributing proxy materials and the diversion of Board and management attention from the oversight and management of our business. Because special meetings require a considerable investment in resources, they should be limited to circumstances where a meaningful number of stockholders believe a matter is sufficiently urgent or extraordinary that it must be addressed between annual meetings. We believe a 20% threshold strikes the necessary balance between enhancing our stockholders' ability to act on important matters in between annual meetings and protecting the Company and other stockholders by allowing only a meaningful group of stockholders to exercise this right.

        The Board believes that the Company's current special meeting stockholder right should be evaluated in the context of our demonstrated commitment to best practices and accountability and responsiveness to our stockholders. Our governance practices, including ways to communicate with our Board, are described on pages 14 to 24 of this proxy statement. In particular, as described on page 20 of this proxy statement, stockholders and other interested parties may contact any member (or all members) of the Board, any Board committee or any chair of any such committee by mail or electronically.

        We actively engage with our stockholders throughout the year, and we share feedback from those discussions with our entire Board. At times, our directors participate in those discussions and speak to stockholders directly. Following engagement with our stockholders, the Board accelerated the Board refreshment process, nominating three new independent directors at the 2018 Annual Meeting and appointing two new independent directors in April 2019. In addition, the Board has a history of being responsive to stockholders, amending our By-Laws in April 2015 to adopt a proxy access right and in December 2018 to require that the Chairman of the Board be an independent director. Additionally, following the 2018 annual meeting, the Company is working to produce reports on the Company's consideration of sustainability matters and the Company's approach to oversight of opioid matters, which are discussed on pages 21 to 24 of this proxy statement.


Table of Contents

        In view of the existing right of stockholders to call special meetings and our other sound governance practices that ensure accountability of the Board and management to stockholders, the Board believes this stockholder proposal is unnecessary and not in the best interests of stockholders.


RECOMMENDATION

FOR THE REASONS SET FORTH ABOVE, THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS THAT YOU VOTE "AGAINST" THE STOCKHOLDER PROPOSAL SEEKING A
BY-LAW AMENDMENT FOR A 10% OWNERSHIP THRESHOLD FOR STOCKHOLDERS TO CALL
SPECIAL MEETINGS.


Table of Contents


EXECUTIVE OFFICERS

        Officers are appointed annually by the Board of Directors and serve at the discretion of the Board of Directors. Set forth below is information, as of May 31, 2019, regarding the current executive officers of Rite Aid.

Name
AgePosition with Rite Aid

John T. Standley(1)

56Chief Executive Officer

Bryan B. Everett

46Chief Operating Officer

Matthew Schroeder

49Chief Financial Officer

Jocelyn Z. Konrad

49Executive Vice President, Pharmacy and Retail Operations

Brian Hoover

54Chief Accounting Officer

Ben Bulkley

56Chief Executive Officer of EnvisionRxOptions

(1)
On March 12, 2019, the Company announced that the Board was commencing a search process for a new Chief Executive Officer.

        John T. Standley.    Mr. Standley, Chief Executive Officer, has been Chief Executive Officer since June 2010 and was President from September 2008 until June 2013. Mr. Standley served as Chairman of the Board from June 21, 2012 through October 30, 2018. He was the Chief Operating Officer from September 2008 until June 2010. He also served as a consultant to Rite Aid from July 2008 to September 2008. From August 2005 through December 2007, Mr. Standley served as Chief Executive Officer and was a member of the board of directors of Pathmark Stores, Inc. From June 2002 to August 2005, he served as Senior Executive Vice President and Chief Administrative Officer of Rite Aid and, in addition, in January 2004 was appointed Chief Financial Officer of Rite Aid. He had served as Senior Executive Vice President and Chief Financial Officer of Rite Aid from September 2000 to June 2002 and had served as Executive Vice President and Chief Financial Officer of Rite Aid from December 1999 until September 2000. Mr. Standley served on the SUPERVALU INC. board of directors from May 2013 to July 2015 and on the board of directors of CarMax, Inc. from August 2017 to January 2018. Mr. Standley currently serves on the National Association of Chain Drug Stores' board of directors and is a member of the Board's Executive Committee.

        Bryan B. Everett.    Mr. Everett was appointed Chief Operating Officer as of March 12, 2019. Prior to his promotion to this position, Mr. Everett served as Chief Operating Officer of Rite Aid Stores since September 1, 2017. Prior to that position, Mr. Everett served as the Executive Vice President of Store Operations since joining the Company on August 3, 2015. Previously, Mr. Everett served as the Senior Vice President of Store Operations at Target Corporation, overseeing the support functions and strategy for all stores. From February 2011 to March 2014, Mr. Everett served as the Senior Vice President of Target stores in the north region, with responsibility for total operations of 457 stores. Mr. Everett held multiple senior leadership positions in stores, operations, and merchandising at Target since 2002. Prior to joining Target, Mr. Everett held leadership positions in the grocery industry with Aldi Foods and Fleming Wholesale.

        Jocelyn Z. Konrad.    Ms. Konrad was appointed Executive Vice President, Pharmacy and Retail Operations effective March 12, 2019, after serving in the role as Executive Vice President, Pharmacy since August 3, 2015. Prior positions at Rite Aid include Regional Pharmacy Vice President, President of Healthcare Initiatives and most recently, Group Vice President of Pharmacy Initiatives and Clinical Services. Prior to joining Rite Aid, Ms. Konrad served as a District Manager for Eckerd Pharmacy from 1997 through 2007. From 1992 to 1997, she served as a pharmacist for Thrift Drug Pharmacy. Ms. Konrad is a registered pharmacist and holds a Bachelor of Science degree from Philadelphia College of Pharmacy and Science.


Table of Contents

        Matthew Schroeder.    Mr. Schroeder was appointed Chief Financial Officer as of March 12, 2019. Prior to his promotion to this position, Mr. Schroeder served as Senior Vice President, Chief Accounting Officer and Treasurer of Rite Aid Corporation since 2017. Mr. Schroeder joined Rite Aid in 2000 as Vice President of Financial Accounting and served as Group Vice President of Strategy, Investor Relations and Treasurer from 2010 to 2017. Prior to joining the Company, Mr. Schroeder worked for Arthur Andersen, LLP, where he held several positions of increasing responsibility, including audit senior and audit manager. He also currently serves as treasurer and a member of the board of directors of The Rite Aid Foundation.

        Brian Hoover.    Mr. Hoover was appointed Chief Accounting Officer as of March 12, 2019. Prior to his promotion to this position, Mr. Hoover served as Group Vice President and Controller of the Company since 2017. Prior to that position, Mr. Hoover served as Vice President, Financial Reporting and Accounting from 2008 to 2017. Over the past 24 years, Mr. Hoover has served in various positions of increasing responsibility at the Company in financial analysis, category management and marketing, budgeting, and accounting.

        Ben Bulkley.    Mr. Bulkley was appointed Chief Executive Officer of EnvisionRxOptions as of February 21, 2019. Prior to joining the Company, he most recently served as chief executive officer and co-founder of Trellis Rx, a private equity-backed company that builds specialty pharmacies for health systems. Prior to Trellis Rx, Mr. Bulkley led the specialty businesses of Aetna Inc., including its pharmacy, behavioral health, and TPA businesses. Mr. Bulkley has also served as chief operating officer of Allscripts Health Solutions, Inc., a healthcare IT platform provider focused on connected care; senior vice president of global commercial operations at Invitrogen, a provider of life sciences technologies for disease research and drug discovery; and vice president and general manager of global services in the IT division of General Electric Company's Healthcare business.


Table of Contents


EXECUTIVE COMPENSATION

COMPENSATION DISCUSSION AND ANALYSIS

Introduction

        We encourage you to read this Compensation Discussion and Analysis for a detailed discussion and analysis of our fiscal year 2019 executive compensation program for the individuals named below. We refer to these individuals throughout this Compensation Discussion and Analysis and the accompanying tables as our "Named Executive Officers."

Name
Title

John T. Standley

Chief Executive Officer

Kermit Crawford(1)

President and Chief Operating Officer

Darren W. Karst(2)

Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer

Bryan B. Everett(3)

Chief Operating Officer, Rite Aid Stores

Jocelyn Z. Konrad(4)

Executive Vice President, Pharmacy

(1)
Mr. Crawford left the Company as of March 12, 2019.

(2)
Mr. Karst left the Company as of May 31, 2019.

(3)
Mr. Everett was promoted to Chief Operating Officer of the Company effective March 12, 2019.

(4)
Ms. Konrad was promoted to Executive Vice President, Pharmacy and Retail Operations effective March 12, 2019.

Executive Summary

        Rite Aid is the third largest retail drugstore chain in the United States based on revenues and number of stores and has Pharmacy Benefits Management ("PBM") operations through EnvisionRxOptions and its affiliates. As of March 2, 2019, we operated 2,469 retail drugstores in 18 states across the country.

        We, along with the retail pharmacy industry as a whole, continue to face challenges in relying significantly on third party payors. Over the past several years, third party payors, including the Medicare Part D plans and the state-sponsored Medicaid and related managed care Medicaid agencies, have changed the eligibility requirements of participants and have successfully reduced reimbursement rates, causing a reduction in our Adjusted EBITDA.

        Fiscal year 2019 was impacted by two significant events:

        Additionally, after fiscal year end, we implemented a leadership transition plan that will significantly change our Named Executive Officers for fiscal year 2020.


Table of Contents

        On February 18, 2018, Rite Aid entered into an Agreement and Plan of Merger (the "Merger Agreement") with Albertsons Companies, Inc. and the Merger Subs. Based on the lack of our stockholder support, on August 8, 2018, Rite Aid, Albertsons, and the Merger Subs entered into a Merger Termination Agreement pursuant to which the parties mutually agreed to terminate the Merger Agreement. Subject to limited customary exceptions, the Merger Termination Agreement mutually released the parties from any claims of liability to one another relating to the contemplated merger. With the termination of the merger, Rite Aid is no longer subject to the interim operating covenants and restrictions in the Merger Agreement.

        On September 18, 2017, we entered into an Amended and Restated Asset Purchase Agreement ("APA") with WBA. Pursuant to the terms and subject to the conditions set forth in the APA, WBA agreed to purchase from Rite Aid 1,932 stores, three distribution centers, related inventory, and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash-free, debt-free basis.

        We completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA and have received cash proceeds of $4.157 billion. On September 13, 2018, we completed the sale of one of our distribution centers and related assets to WBA for proceeds of $61.2 million. The transfer of the two remaining distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the APA.

        We have agreed to provide transition services under the Transitional Services Agreement ("TSA") to WBA for up to three years after the initial closing of the sale. Under the terms of the TSA, we provide various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general, and administrative activities. The initial term of the TSA was to continue until October 17, 2019. On May 1, 2019, WBA provided Rite Aid with written notice that it was extending the TSA for two additional six-month periods, which extends the end date of the TSA to October 17, 2020. Pursuant to the TSA, WBA paid TSA fees of $80.2 million during the fifty-two week period ended March 2, 2019 and $8.4 million in the fifty-two week period ended March 3, 2018, which are reflected as a reduction to selling, general, and administrative expenses.

        As previously announced, since the close of the 2019 fiscal year, we have executed on a leadership transition plan and an organizational restructuring to better align our Company's structure with the Company's size and operations and to reduce costs. As part of the leadership transition, the Board has commenced a search process for a new CEO. John Standley will remain CEO until the appointment of his successor. Bryan Everett, Chief Operating Officer of Rite Aid Stores, has been promoted to Chief Operating Officer of the Company, succeeding Kermit Crawford, who has left the Company. Matt Schroeder, formerly our Chief Accounting Officer and Treasurer, has been promoted to Chief Financial Officer. Mr. Schroeder succeeded Darren Karst, who left the Company this spring after supporting a brief transition. Jocelyn Konrad, Executive Vice President, Pharmacy, has been promoted to Executive Vice President, Pharmacy and Retail Operations. In addition, the Company announced actions that will reduce managerial layers and consolidate roles across the organization, resulting in the elimination of approximately 400 full-time positions, or more than 20% of the corporate positions located at the Company's headquarters and across the field organization.


Table of Contents

        Despite our executive leadership team's continued focus on driving our business, we were faced with continued prescription reimbursement rate challenges that we were unable to fully offset, which is an issue that has also impacted the broader retail pharmacy industry and which has negatively impacted our Adjusted EBITDA. Additionally, the extended duration of the WBA merger and asset sale process, the establishment of TSA services, the attempted merger with Albertsons, and the resulting uncertainty had a negative impact on our fiscal year 2019 results. Below is additional detail related to key financial indicators used as performance measures in our incentive programs for fiscal year 2019. All amounts, unless stated otherwise, are for continuing operations:

        We believe strongly that pay should align with performance, and this focus is reflected in our executive compensation programs. We seek to provide our Named Executive Officers with opportunities to earn total direct compensation (base salary, annual incentives, and long-term incentives) that is generally comparable to compensation levels provided to peer company executives and executives within other similarly sized retailers more broadly. With the compensation programs' strong focus on performance and the continued operating pressures related to the WBA and Albertsons transactions, prior to fiscal year 2019, we provided some of our executive officers with retention awards in an effort to retain them during the time of uncertainty. See the Wind-Down of Retention section on pages 49 to 50 for further discussion of these efforts.

        Because of our desire to reinforce a performance-based culture, the Company emphasizes a regular compensation mix that is comprised primarily of variable pay. As a result, base salary makes up the smallest portion of total direct compensation for the Named Executive Officers, with variable pay in the form of annual and long-term incentives comprising the large, remaining portion. The compensation mix varies by position, taking into account each position's ability to influence Company results, as well as competitive practice. See page 42 for a graphical representation of pay mix by executive.


Table of Contents

        In July of 2017, our stockholders voted to hold an advisory vote on executive compensation every year. Consistent with that vote, the Board resolved to hold an advisory "say-on-pay" vote every year in connection with its annual meeting of stockholders.

        At our 2018 Annual Meeting, held October 30, 2018 after the termination of the Albertsons transaction, approximately 16.5% of shares voted in favor of the compensation of our Named Executive Officers. The Compensation Committee took the disapproval of our executive compensation by our stockholders very seriously. The outcome of our 2018 say-on-pay vote was a clear signal that our stockholders took issue with some aspects of our executive compensation program, and we were determined to understand stockholder perspectives on this program and committed to making constructive changes in response.

        After the termination of the Albertsons transaction, we engaged in enhanced stockholder outreach efforts. Investors' main concern with matters of compensation was the use of retention awards and the mid-year adjustment to the fiscal year 2018 annual incentive performance target. At that time, while the Compensation Committee was focused on a performance-based culture, it also recognized the importance of keeping management engaged during a time of significant challenges, including supporting the TSA processes, and entering into the Albertsons Merger Agreement. The decision to use retention awards was also made with the knowledge that much of the previously granted performance-based awards were tracking below target metrics and had a high likelihood of not having any realizable value, which heightened the risk that we would be unable to attract and retain the talent needed to run our business. For a comparison of the Named Executive Officers' realized long-term performance pay to the compensation shown in the Summary Compensation Table disclosure, see the discussion under the caption "Realized Long-Term Incentive Awards" on pages 42 to 43.

        We have continued to engage with stockholders since August 2018 and following the 2018 Annual Meeting, including on compensation matters. Based on the "say-on-pay" voting results and the feedback we received from stockholders, the Company took action to review all compensation programs in place and incorporate design changes into the compensation structures to ensure stronger stockholder alignment going forward.


Table of Contents

What We Heard from Stockholders

Actions We Took in Response

Our stockholders generally did not approve of the use of retention awards.

We did not enter into any new individual retention agreements with any of our Named Executive Officers in fiscal year 2019 and have no plans to enter into any such new retention agreements in fiscal year 2020.

Our stockholders generally did not approve of a mid-year adjustment to our fiscal year 2018 annual incentive plan to reflect the impact of the significant events and operational challenges occurring in the first half of fiscal year 2018.

We did not make any adjustments to our incentive plans for fiscal year 2019 and do not intend to make any mid-year adjustments to our incentive plans for fiscal year 2020.

[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote FOR the ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2024.

Our stockholders expressed a general discomfort with a lack of alignment between Company performance and pay.

While we understand the concern based on reported pay, the realized value of our performance-based long-term pay was aligned with stockholder return. See the impact on Realized Long-Term Incentives on pages 42 to 43.

We refined our peer group for fiscal year 2020 to (among other changes) remove CVS Health Corp. and Walgreens Boots Alliance, Inc.; even though each organization is a direct competitor from both business and talent acquisition perspectives, the Compensation Committee determined that these organizations are no longer appropriate peers given their significantly larger scope of operations.

We increased the emphasis on performance-based long-term incentives in fiscal year 2019, such that Performance-Based Restricted Cash Units represented 70% of the total long-term incentive opportunity, and time-based restricted stock represented 30% of the total long-term incentive opportunity.

As in the past, the Compensation Committee will continue to review the results of future advisory say-on-pay votes and will consider stockholder concerns and take them into account in future determinations regarding the compensation of our Named Executive Officers.

        We used Adjusted EBITDA as the primary financial metric in our annual incentive plan and long-term performance awards in fiscal year 2019. We believe this was appropriate because EBITDA growth has historically shown a strong positive correlation with three-year and five-year total stockholder return for Rite Aid and its peer group and represented the best indicator of Rite Aid's operating performance based on our financial situation and corporate structure. In establishing performance measures for our fiscal year 2019 incentive programs, we recognized that there were substantial reductions in prescription reimbursement rates that would have to be overcome.


Table of Contents

        Our Consolidated Adjusted EBITDA (which consists of Adjusted EBITDA from continuing operations plus Adjusted EBITDA from the stores sold to Walgreens up to each store's respective sale date), for short-term incentive calculation purposes, for fiscal year 2019 was $563 million, which was below our annual plan target of $645 million, but above the threshold performance level of $548 million. Based on performance against the goal, and as described in more detail below under "Cash Incentive Bonuses," our Named Executive Officers were paid bonuses at 58% of target for fiscal year 2019 performance. See Appendix A for a reconciliation of our Adjusted EBITDA, which is a non-GAAP measure, to net income under GAAP.

        With respect to long-term performance awards, a return on net asset ratio continued to be a component of the performance assessment. The Compensation Committee believes that return on net assets is a key indicator of our corporate performance, as it measures how efficiently and effectively we deploy our assets (return on net assets) and focuses management on the need to improve the Company's financial condition over time. Additionally, the Compensation Committee has maintained a plan provision subjecting the long-term performance award to positive or negative modification based on our relative stockholder return versus the Russell 3000 Index over the three-year performance period.

        The performance targets for the long-term incentive awards granted to our Named Executive Officers in the form of performance stock in fiscal year 2019 are discussed in detail below. See "Long-Term Incentive Program—Performance Awards" on pages 47 to 49.

Objectives of Our Executive Compensation Program

        All of our executive compensation and benefits programs are within the purview of the Compensation Committee, which bases these programs on the same objectives that guide the Company in establishing all of its compensation programs. The Compensation Committee also administers the Company's equity incentive compensation plans. In establishing or approving the compensation of our Named Executive Officers in any given year, the Compensation Committee is generally guided by the following objectives:


Table of Contents

The Compensation Committee's Processes

        The Compensation Committee has established a number of processes to assist it in ensuring that the Company's executive compensation program is achieving its objectives. Among those are:

        Assessment of Company performance.    The Compensation Committee uses Company performance measures in two ways.

        First, in assessing the linkage between actual total compensation and performance, the Compensation Committee considers various measures of Company and industry performance, such as comparable store sales growth, EBITDA growth, return on sales, debt leverage ratios, return on average invested capital and net assets, and total stockholder return. In determining performance relative to the Company's peer group (as discussed further below), the Compensation Committee does not apply a formula or assign these performance measures relative weights. Instead, it makes a subjective determination after considering such measures collectively.

        Second, as described in more detail below, the Compensation Committee has established specific Company target incentive/award levels and performance measures that determine the size of payouts under the Company's two formula-based incentive programs—the annual cash incentive bonus program and performance awards granted under the Company's long-term incentive program.

        Assessment of competitive compensation levels.    The Compensation Committee, with the help of its independent compensation consultant Exequity LLP, assesses the Company's programs relative to a peer group of organizations and published survey data. The peer group, updated in fiscal year 2018 to reflect the reduction in size of Rite Aid following the planned divestiture of stores and distribution centers to WBA, was approved by the Compensation Committee in September 2017 after a comprehensive review. Because the Company has a limited number of publicly-traded direct competitors and because pharmacy sales (which account for over two-thirds of the Company's revenue) are governed by third-party contracts, we reviewed potential peers relative to multiple criteria including:


Table of Contents

        The resulting peer companies, which are considered to be the best representation of our target labor market, are listed below.


Fiscal Year 2019 Peer Group

AUDITOR FEES
Peer Company
Revenues
($ Millions)

CVS Health Corp

184,765

Walgreens Boots Alliance, Inc. 

120,453

Best Buy Co., Inc. 

42,151

Macy's, Inc. 

24,837

Dollar General Corp. 

23,471

Dollar Tree, Inc. 

22,246

AutoNation, Inc. 

21,535

Kohl's Corporation

19,095

Sears Holdings Corp. 

16,702

SuperValu, Inc. 

14,649

J.C. Penney Company, Inc. 

12,506

Bed Bath & Beyond Inc. 

12,167

DaVita Inc. 

10,884

Office Depot Inc. 

10,240

LabCorp Holdings

10,206

Owens & Minor, Inc. 

9,686

        The peer group was further reviewed, updated, and approved by the Compensation Committee in February 2019 to reflect the changes in the peer group, as a result of mergers and delisting of certain members of the fiscal year 2019 peer group, and further consideration of relevant size using Company comparisons to revenue, market capitalization, and EBITDA. Among other changes, we decided to remove CVS Health Corp. and Walgreens Boots Alliance, Inc. from the peer group, even though each organization is a direct competitor from both business and talent acquisition perspectives, because the Compensation Committee determined that these organizations are no longer appropriate peers given their significantly larger scope of operations.


Updated Fiscal Year 2020 Peer Group(1)

Peer Company
Revenues
($ Millions)

Best Buy Co., Inc. 

43,441

Macy's, Inc. 

25,141

Dollar General Corp. 

25,105

Dollar Tree, Inc. 

22,979

AutoNation, Inc. 

21,685

Kohl's Corporation

19,474

The Gap. 

16,735

Laboratory Corporation of America Holdings

14,060

Community Health Systems, Inc. 

13,760

Bed Bath & Beyond Inc. 

12,437

J.C. Penney Company, Inc. 

12,001

DaVita Inc. 

11,365

Office Depot Inc. 

10,928

Owens & Minor, Inc. 

9,686

(1)
Revenue reflects trailing 12-month data through February 2018 as available per Standard & Poor's Capital IQ.

Table of Contents

        The Compensation Committee compares the compensation levels of Rite Aid's Named Executive Officers to peer company compensation levels in the aggregate, and also compares the pay of individual executives if the jobs are sufficiently similar to make the comparison meaningful. Had the updated fiscal year 2020 peer group been used for all fiscal year 2019 compensation decisions, the analysis would have supported like decisions being made.

        In addition to peer group data, the Compensation Committee reviews market data based on specific functional responsibility for each executive from published survey data. The survey analysis targets data from similarly sized retail organizations based on each executive's functional responsibility. The surveys used in the analysis include Mercer's2018 Executive Remuneration Suite, Mercer's2018 Retail Compensation and Benefits Survey, and Towers Watson's2018 Survey Report on Top Management Compensation.

        The Compensation Committee uses peer group and survey data primarily to ensure that the executive compensation program as a whole is competitive, meaning generally within 25% of the median range of comparative pay of the market when Rite Aid achieves targeted performance levels. The incentive plans were further designed in such a way that executives can earn above competitive levels for superior performance and below competitive levels if performance is below expectations. The Compensation Committee assesses overall alignment of the compensation program rather than benchmarking a specific target position with consideration of factors, such as Company and individual performance, how executive roles function within Rite Aid, concerns about executive retention, and availability of equity compensation. The Compensation Committee assesses Rite Aid's performance relative to its peer group on both a one- and three-year basis and observed alignment of performance with actual total direct compensation levels for the executives in the aggregate.

        In fiscal year 2019, management engaged Mercer, a compensation consultant, to provide management with compensation information for certain executive officers. Pursuant to the terms of its retention, Mercer reported directly to management, although the Compensation Committee did review recommendations and an analysis prepared by management and Mercer in determining fiscal year 2019 compensation for the Named Executive Officers.

        Total compensation review.    The Compensation Committee reviews each named executive's base pay, annual bonus, and long-term incentives annually with the guidance of the Compensation Committee's independent compensation consultant. Following the fiscal year 2019 review, the Compensation Committee determined that the target level and components of compensation for fiscal year 2019 were competitive and reasonable in the aggregate.

Components of Executive Compensation for Fiscal Year 2019

        For fiscal year 2019, the regular compensation program for our Named Executive Officers consisted of four primary components: (i) base salary, (ii) a cash incentive bonus opportunity under the Company's annual incentive bonus plan, (iii) long-term incentives consisting of restricted stock and performance-based restricted cash units, and (iv) a benefits package, including a supplemental executive retirement program ("SERP"). The Company terminated the SERP as of March of 2019. A significant portion of total compensation under the fiscal year 2019 program is variable, meaning a significant portion is subject to performance and is comprised of target annual incentives and target long-term incentives.

        The program was intended to appropriately balance the mix of cash and equity compensation, the mix of currently-paid and longer-term compensation, and the security of base benefits in a way that best furthers the compensation objectives discussed above. The chart below shows the overall mix of base salary, target annual incentives, target long-term incentives, and contributions under the SERP for Messrs. Standley, Crawford, Karst, Everett, and Ms. Konrad.


Table of Contents


Target Total Remuneration(1)

Compensation Component as a % of Total Remuneration for Fiscal Year 2019

GRAPHIC


(1)
Target Total Remuneration represents the sum of base salary, target annual incentives, target long-term incentives, and SERP contributions. Target Total Compensation does not include (i) the value of broad-based benefits provided to all employees, (ii) components of all other compensation (except the SERP) shown in the Summary Compensation Table, and (iii) retention awards. The Company terminated the SERP as of March of 2019.

Realized Long-Term Incentive Awards

        A significant portion of our long-term incentive awards are subject to performance metrics. This is an important aspect of our Named Executive Officers' and other executives' compensation aligning their interests with those of our stockholders. While equity-based awards are reported in the summary compensation table at target value in the year granted, the value realized is dependent on the actual performance over the measurement period. The realized value from our performance-based long-term


Table of Contents

equity awards where the measurement period ended during the current reported results are as noted in the chart below.

 
  
  
 Standley(1)
  
 Crawford(2)
  
 Karst
  
 Everett(3)
  
 Konrad(4)
  

 

 

Total Target Value of Performance Awards Reported in Summary Compensation Table in fiscal years 2015 - 2017

   $16,986,250   n/a   $1,915,750   $345,938   n/a  

 

 

Total Realized Value in fiscal years 2017 - 2019 of Performance Awards Reported in Compensation Summary Compensation Table in fiscal years 2015 - 2017

   
$

2,661,291
   

n/a

   
$

   
$

   

n/a

  

(1)
Mr. Standley's results include the special performance award granted in fiscal year 2016 related to the integration of EnvisionRx, which was realized in July 2017 with a then market value of $2,661,291.

(2)
Mr. Crawford was first employed by Rite Aid in fiscal year 2018 and did not receive any performance awards for fiscal years 2015-2017.

(3)
Mr. Everett's results reflect compensation reported for fiscal year 2017 only, the year in which he became a Named Executive Officer.

(4)
Ms. Konrad was not a Named Executive Officer for fiscal years 2015-2017.

Base Salary

        Base salary is one element of an executive's annual cash compensation during employment. The value of base salary reflects the executive's long-term performance, skill set, and the market value of that skill set. In setting base salaries for fiscal year 2019, the Compensation Committee considered the following factors:

        Pay levels at comparable companies.As noted above, the Compensation Committee uses peer group data to test for the reasonableness and competitiveness of base salaries, but it also exercises subjective judgment in view of the Company's compensation objectives.

        Internal relativity.    Meaning the relative pay differences for different job levels.

        Individual performance.    Except for increases associated with promotions or increased responsibility, increases in base salary for executives from year to year are generally limited to minimal adjustments to reflect individual performance.

        Consideration of the mix of overall compensation.    Consistent with our compensation objectives, as executives progress to higher levels in the organization, a greater proportion of overall compensation is directly linked to Company performance and stockholder returns. Mr. Standley's target total compensation, for example, is more heavily weighted toward short- and long-term incentive compensation (approximately 85% in the aggregate as shown in the bar chart above) than that of the other Named Executive Officers.

        The Compensation Committee reviewed the Named Executive Officers' base salaries in April of fiscal year 2019 and considered the principles described above under "The Compensation Committee's


Table of Contents

Processes" in establishing the Named Executive Officers' base salaries for the fiscal year as noted in the chart below.

Executive
 Base Salary at
End of FY 2018
 Increase or
Change from
Prior Fiscal Year
 Rationale

John T. Standley

 $1,220,550   Potential merger

Kermit Crawford

 $1,000,000   Potential merger

Darren W. Karst

 $850,750  2.5%Performance

Bryan B. Everett

 $618,000  3.0%Performance

Jocelyn Z. Konrad

 $461,250  2.5%Performance

Cash Incentive Bonuses

        The Company established an annual incentive plan in order to incentivize the Named Executive Officers to meet the Company's Adjusted EBITDA target for fiscal year 2019. The Compensation Committee establishes a target percentage of salary for each participant at the beginning of the fiscal year and approves the financial goals required for the Company to pay an award. Payouts for the Named Executive Officers are then determined by the Company's financial results for the year relative to the predetermined performance measures. As shown in the Summary Compensation Table under "Non-Equity Incentive Plan Compensation," incentives were paid to Named Executive Officers for fiscal year 2019 performance.

        Bonus targets.    Targets for each Named Executive Officer were determined based on job responsibilities, internal relativity, and peer group and survey data. The Compensation Committee's objective was to set bonus targets such that total annual cash compensation (including base salary and annual incentive assuming a target payout) was generally aligned with the market with a substantial portion of that compensation linked to corporate performance. Consistent with our executive compensation philosophy, individuals with greater job responsibilities had a greater proportion of their total cash compensation tied to Company performance through the incentive plan. The Compensation Committee, as a result, established the following targets for fiscal year 2019:


Annual Incentive Opportunity

Executive
 Threshold Payout
(as a % of Salary)
 Target Payout
(as a % of Salary)
 Maximum Payout
(as a % of Salary)
 

John T. Standley

  100% 200% 400%

Kermit Crawford

  87.5% 175% 350%

Darren W. Karst

  62.5% 125% 250%

Bryan B. Everett

  50% 100% 200%

Jocelyn Z. Konrad

  37.5% 75% 150%

        The Compensation Committee believes that using Adjusted EBITDA as the measure for the annual incentive plan appropriately encourages officers, including the Named Executive Officers, to focus on improving operating results which ultimately drive stockholder value. EBITDA growth has historically shown a strong positive correlation with three-year and five-year total stockholder return for Rite Aid and its peer group. The majority of Rite Aid's peer companies use an EBITDA measure in their annual incentive plans. Based on Rite Aid's current financial situation and capital structure, the Compensation Committee believes that Adjusted EBITDA is the best indicator of Rite Aid's operating performance. The measure is tracked regularly and is clearly understood by the officers. Officers can impact the measure by taking actions to improve the operating performance of our stores. In addition, the Company regularly communicates Adjusted EBITDA to the investment community.


Table of Contents

        Under the plan formula, payouts can range from 0% to 200% of bonus targets depending on Company performance. The Compensation Committee established an Adjusted EBITDA performance target of $645 million for fiscal year 2019, based on the financial plan targets. This performance level target, based on the financial plan, was 15% above our fiscal year 2018 performance of $560 million. Because of the recognized prescription reimbursement rate challenges, the Compensation Committee also established in the performance target for fiscal year 2019 a threshold at which management could be rewarded at 50% of bonus target at achievement of Adjusted EBITDA of $548 million (85% of target), and the Compensation Committee approved a maximum at which management could be rewarded at 200% of bonus target at achievement of Adjusted EBITDA of $710 million (110% of target).

        In fiscal year 2019, challenges caused by the uncertainty of the proposed Albertsons merger as well as the ultimate termination of the merger agreement, the WBA Transactions, as well as continued prescription reimbursement rate pressures all had a negative impact on our fiscal year 2019 results, and Rite Aid's actual Consolidated Adjusted EBITDA was $563 million, which was below the target performance level, but above the threshold performance level, resulting in bonus payments at 58% of the performance target. Consolidated Adjusted EBITDA consists of Adjusted EBITDA from continuing operations plus Adjusted EBITDA from the stores sold to Walgreens up to each store's respective sale date. As discussed in greater detail in Appendix A, we define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing and impairment, goodwill impairment, inventory write-downs related to store closings, debt retirements, the WBA merger termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, severance and costs related to distribution center closures, gain or loss on sale of assets, and revenue deferrals related to our customer loyalty program). We reference this particular non-GAAP financial measure not only as a basis for incentive compensation but also in our corporate decision-making because it provides supplemental information that facilitates internal comparisons to the historical operating performance of prior periods and external comparisons to competitors' historical operating performance.


Fiscal Year 2019 Annual Incentive Plan Performance Goal

Performance Level
 Adjusted EBITDA
Goal (millions)
 Resulting Payout
as a % of
Target Award
 

Threshold

 $548  50%

Target

 $645  100%

Maximum

 $710  200%

Actual Performance

 $563  58%

Long-Term Incentive Program

        Long-term incentive target opportunity.    The purpose of the regular long-term incentive program is to support the long-term perspective necessary for continued success in our business and focus our Named Executive Officers on creating long-term, sustainable stockholder value. Our annual long-term


Table of Contents

incentive ("LTI") target opportunities for each Named Executive Officer as of the date of grant on January 4, 2019 are shown below:


Long-Term Incentive Target Opportunities

Executive
Target Opportunity
(as a % of Salary)

John T. Standley

500%

Kermit Crawford

425%

Darren W. Karst

250%

Bryan B. Everett

200%

Jocelyn Z. Konrad

150%

        The Compensation Committee reviewed available peer group data and found that the design of the long-term incentive program is reasonably aligned with general retail industry market practice. Target grant values for individual executive officers were established based on individual performance and internal relativity. Consistent with the Company's compensation philosophy, executive officers at higher levels received a greater proportion of total pay in the form of long-term incentives.

        Long-term incentive mix.    In fiscal year 2019 we used the following types of awards and increased the percentage of the award that is subject to performance:

Vehicle
Approximate
Proportion of 2019
Long-Term
Incentive Target
Opportunity
Purpose

Performance-Based Cash Units

70%Links compensation to multi-year operating results on key measures tied to stockholder value creation.

Restricted Stock

30%Supports retention and provides a vehicle with more stability and less risk. Aligns executive and stockholder interests and focuses executives on value creation.

        In determining the overall mix of long-term incentive vehicles, the following factors were considered:

        The Compensation Committee's process for setting grant dates is discussed below. On the approval date, those values are converted to the equivalent number of shares based on the closing price of the Company's common stock on the date of approval.


Table of Contents

        Grant timing.    The Compensation Committee has a policy that, in the normal course, annual long-term incentive awards (other than special or new hire grants) will be approved by the Compensation Committee once a year at its annual meeting held in connection with the annual stockholders' meeting, with a grant date equal to the later of the second business day after release of the Company's first quarter earnings or the date of approval. Grants are made to the Named Executive Officers at the same time as awards are made to all other associates as part of the annual grant process. With the delay in our fiscal year 2018 annual stockholders meeting and the changing of board members, resulting in new members of the Compensation Committee, the Committee took action in its December, 2018 meeting to grant fiscal year 2019 awards with an effective date of January 4, 2019.

        Special awards.    From time to time, the Company may make grants in addition to the annual equity grant, including those to Named Executive Officers. Typically, these grants include awards to new hires, promotional awards, or retention awards. Special awards can also be utilized to provide special performance incentives in connection with specific corporate or financial goals of the Company. No special awards were made to our Named Executive Officers in fiscal year 2019.

Performance Awards

        Performance awards granted to the Named Executive Officers under the regular long-term incentive program are in the form of units, which are denominated in a target number of shares and payable in Company stock or cash, if designated, or are denominated with a target unit value equal to $1.00. Company performance goals are established and achievable over the prescribed performance period. Payouts can range from 0% (for performance below threshold) to 250% of target (for performance at or above maximum). Performance awards are intended to align interests of executives with those of stockholders through the use of measures the Company believes drive its long-term success. Performance awards are normally granted annually and are structured as a targeted number of units based on the Company's achievement of specific performance levels with payout occurring after a three-year period.

        For the 2017 performance award grants (the "2017-2019 Plan"), the Compensation Committee based 80% of the award on the achievement of three-year (fiscal year 2017-fiscal year 2019) cumulative Adjusted EBITDA goals and the remaining 20% on three-year (fiscal year 2017-fiscal year 2019) return on net asset goals. The Compensation Committee also added a provision for each cycle, subjecting the award to modification based on our relative stockholder return versus the Russell 3000 Index over the respective three-year measuring periods. The Compensation Committee believes this provision further aligns the interests of our executives with those of our stockholders and adds an additional incentive for them to create sustainable long-term value for the Company.

        Under the 2017-2019 Plan, participants had the opportunity to earn shares of Rite Aid stock, contingent on cumulative Company financial performance for the three-year period spanning fiscal year 2017-fiscal year 2019. Such financial performance is based 80% on the Adjusted EBITDA goals and 20% on return on net asset goals. In addition, in order to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/–25% based on our relative stockholder return versus the Russell 3000 Index over the three-year measuring period. For fiscal years 2017-2019, actual Adjusted EBITDA of $1,871 million was below the three-year performance threshold of $3,135 million. Actual return on net assets was 1.5% compared to a target of 5.1%. Accordingly, no awards were earned under the 2017-2019 Plan.


Table of Contents

        For the 2018 performance award grants ("2018-2020 Plan"), the Compensation Committee also based 80% of the award on the achievement of Adjusted EBITDA goals and the remaining 20% on return on net assets performance. However, due to the significant uncertainty during the transition of our business in 2018, the 2018-2020 Plan financial performance goals are based on the accumulation of one-year goals set for 2019 and 2020 only. As in prior cycles, the Compensation Committee added a provision subjecting the award to modification based on our relative stockholder return versus the Russell 3000 Index over the full 2018-2020 performance period.

        Under the 2018-2020 Plan, participants have the opportunity to earn cash payments after the end of fiscal year 2020, contingent on performance relative to accumulated one-year Company financial performance goals for each of fiscal year 2019 and fiscal year 2020. Such financial performance is based 80% on the Adjusted EBITDA goals and 20% on return on net asset goals. The value of a unit is tied to the stock price with a maximum value of 300% of the grant date stock price. This aligns the interests of our executives with those of our stockholders. In addition, in order to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/– 25% based on our relative stockholder return versus the Russell 3000 Index over the three-year vesting period.

        For the 2019 performance award grants ("2019-2021 Plan"), the Compensation Committee also based 80% of the award on the achievement of Adjusted EBITDA goals and the remaining 20% on return on net assets performance. However, due to the delay in grant timing and the significant uncertainty during the transition of our business in 2019, as well as prescription reimbursement rate challenges, the 2019-2021 Plan financial performance goals are based on the accumulation of one-year goals set for 2020 and 2021 only. As in prior cycles, the Compensation Committee added a provision subjecting the award to modification based on our relative stockholder return versus the Russell 3000 Index over the full 2019-2021 performance period.

        Under the 2019-2021 Plan, participants have the opportunity to earn cash payments after the end of fiscal year 2021, contingent on performance relative to accumulated one-year Company financial performance goals for each of fiscal year 2020 and fiscal year 2021. Such financial performance is based 80% on the Adjusted EBITDA goals and 20% on return on net asset goals. The value of a unit is equal to $1.00. These performance targets align the interests of our executives with those of our stockholders. In addition, in order to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/– 25% based on our relative stockholder return versus the Russell 3000 Index over the three-year vesting period. As shownoutlined in the table below, payouts can range from 0% (for performance below threshold) to 250% ofwe incurred the target number of units (for performance at or above maximum). 37.5% of the target unit award can be earned for performance at threshold levels.


Table of Contents


2019-2021 Plan: Performance Units

Executive(a)
 Threshold
Award
($)
 Target
Award
($)
 Maximum
Award
($)
 

John T. Standley(1)

 $1,601,963 $4,271,900 $10,679,750 

Kermit Crawford(2)

 $1,115,625 $2,975,000 $7,437,500 

Darren W. Karst(2)

 $558,300 $1,488,800 $3,722,000 

Bryan B. Everett

 $324,450 $865,200 $2,163,000 

Jocelyn Z. Konrad

 $181,613 $484,300 $1,210,750 

(1)
Mr. Standley will forfeit this award upon his departure from the Company.

(2)
Mr. Crawford forfeited this award with his departure from the Company on March 12, 2019, and Mr. Karst forfeited this award upon his departure from the Company on May 31, 2019.

Restricted Stock

        Restricted stock grants are intended to support retention of executives and focus them on long-term performance because they generally vest over a multi-year period (three years or longer) and are tiedfollowing fees, including expenses billed to the value of our stock. The risk profile of restricted stock is aligned with stockholders, as it can motivate executives to both increase and preserve stock price. The table below summarizes 2019 restricted stock awards:


2019 Restricted Stock Awards

Executive
 Award Value
($)
 # of Shares 

John T. Standley

 $1,830,829  118,885 

Kermit Crawford(1)

 $1,274,966  82,790 

Darren W. Karst(2)

 $638,099  41,435 

Bryan B. Everett

 $370,832  24,080 

Jocelyn Z. Konrad

 $207,592  13,480 

(1)
Mr. Crawford forfeited this award with his departure from the Company on March 12, 2019.

(2)
Mr. Karst forfeited a portion of this award pursuant to his separation agreement upon his departure from the Company on May 31, 2019.

Winding Down Retention Efforts in Fiscal Year 2019

        In addition to the fiscal year 2018 regular compensation program for the Named Executive Officers, Rite Aid also entered into individual retention agreements with each of the Named Executive Officers, as well as other key associates who are not named executive officers, to enhance employee retention and promote corporate performance, amidst significant volatility and uncertainty related to restructuring the company. The retention agreements with each Named Executive Officer, other than Messrs. Standley and Crawford, generally provided for the lump-sum payment of the retention awards


(a)
Because Mr. Crawford did not commence employment with the Company until after the date the 2018- 2020 Plan was established, he did not participate in the 2018-2020 Plan. As previously disclosed, on his October 2, 2017 start date, Mr. Crawford received 1,000,000 stock options and 975,610 restricted shares.

Table of Contents

in equal installments on August 1, 2018 and May 1, 2019, subject to continued employment through such retention date or upon an earlier qualifying termination.

        The retention agreement with Mr. Crawford generally provided for the lump-sum payment of the retention award on October 1, 2019, subject to continued employment through such retention date or an earlier qualifying termination of employment. Mr. Crawford forfeited this award with his departure on March 12, 2019.

        The retention agreement with Mr. Standley generally provided for the lump-sum payment of the retention award (x) on the completion of the Albertson's merger if Mr. Standley has not been appointed to serve as chief executive officer of the combined company or (y) on the date that the Rite Aid Board of Directors determines that the transactions contemplated by the Merger Agreement will not be consummated, in each case, subject to continued employment through each such retention date or an earlier qualifying termination of employment. Due to the termination of the Merger Agreement on August 8, 2018, Mr. Standley received the $3,000,000 retention payment to which he was entitled under his retention agreement.

        Under the remaining retention agreements granted in fiscal year 2018, in the aggregate, Mr. Karst earned a retention payment of $830,250, Mr. Everett earned a retention payment of $600,000 and Ms. Konrad earned a retention payment of $450,000. 50% of the retention amount for each officer, other than Messers. Standley and Crawford, was paid in fiscal year 2019 based on continued employment on August 1, 2018, and the remaining 50% was paid based on continued employment on May 1, 2019.

        Based on stockholder discussions and clarity around the business strategy, Rite Aid did not enter into any new individual retention agreements for any of the Named Executive Officers in fiscal year 2019 and does not believe it will enter into any new retention agreements in fiscal year 2020.

Post-Retirement Benefits

        Supplemental Executive Retirement Program.    During fiscal year 2019, each of the Named Executive Officers received benefits under a defined contribution supplemental executive retirement plan or SERP. Under the SERP, Rite Aid credited each participant with a specific sum to an individual account established for each participant, on a monthly basis while the participant is employed. The amount credited was equal to 2% of the participant's annual base compensation. The participants are able to select among a choice of earnings indexes, and their accounts are credited with earnings that mirror the investment results of such indexes. Participants vested in their accounts at the rate of 20% per year for each calendar year of participation in the SERP at a five-year rolling rate with the entire account balance for each participant vesting upon death or total disability of the participant, termination without cause during the 12-month period following a "change in control" of the Company as defined in the SERP or upon termination of employment at age 60 or greater with at least five years of participation in the SERP. Effective February 25, 2019, the Company terminated the SERP such that there will be no future contributions or accruals as of March 2019. Existing SERP benefits have been fully vested and will be paid out in accordance with plan terms. SERP payments may be delayed due to certain tax rules or deferral elections made by the executive.

Other Post-Employment and Change in Control Benefits

        To attract highly skilled executives and to provide for certainty of rights and obligations, Rite Aid has historically provided employment agreements to its executive officers, including our Named Executive Officers. The terms of the employment agreements are described in more detail under the caption "Executive Employment Agreements." Additional information regarding the severance and change in control benefits provided under the employment agreements is described under the section entitled "Executive Compensation—Potential Payments Upon Termination or Change in Control."


Table of Contents

Deductibility Cap on Executive Compensation

        The Compensation Committee is aware that Section 162(m) of the Internal Revenue Code of 1986, as amended (the "Code"), treats certain elements of executive compensation in excess of $1,000,000 a year payable to our Chief Executive Officer and three other most highly compensated executives (and, effective beginning in 2018, our Chief Financial Officer) as an expense not deductible by the Company for federal income tax purposes. The exception providing that payments to these individuals in excess of the $1,000,000 limit will be deductible if such payments are performance-based was repealed beginning in 2018, as further described below.

        H.R.1, formally known as the "Tax Cuts and Jobs Act," enacted on December 22, 2017, substantially modifies Section 162(m) by, among other things, eliminating the performance-based exception to the $1 million deduction limit effective as of January 1, 2018. As a result, beginning in 2018, compensation paid to our Named Executive Officers in excess of $1 million will generally be nondeductible, whether or not it is performance-based. While the Compensation Committee plans to continue taking actions intended to limit the impact of Section 162(m), it also believes that tax deductibility is only one of several relevant considerations in setting compensation. Therefore, in order to maintain the flexibility to provide compensation programs for our Named Executive Officers that will best incentivize them to achieve our key business objectives and create sustainable long-term stockholder value, the Compensation Committee reserves the right to pay compensation that may not be deductible to the Company if it determines that doing so would be in the best interests of the Company.

        H.R.1 also includes a transition rule under which the changes to Section 162(m) described above will not apply to compensation payable pursuant to a written binding contract that was in effect on November 2, 2017 and is not subsequently materially modified. To the extent applicable to our existing contracts and awards, the Compensation Committee may choose to avail itself of the transition rule.

Policy Regarding Recoupment of Certain Compensation

        The Company has adopted a formal compensation recovery or "clawback" policy for its executive officers, including all Named Executive Officers. Pursuant to this policy, the Board of Directors may seek to recoup certain incentive compensation, including cash bonuses and equity incentive awards paid based upon the achievement of financial performance metrics, from executives in the event that the Company is required to restate its financial statements.

Prohibition on Margin Accounts and Hedging and Similar Transactions

        Our executive officers and directors, including the Named Executive Officers, are subject to an insider trading policy that, among other things, prohibits them from holding Company securities in a margin account, and also prohibits them from engaging in put or call options, short selling, or similar hedging activities involving our stock. We prohibit these transactions because they may reduce the individual's incentive to improve our performance, focus the individual on short-term performance at the expense of long-term objectives, and misalign the individual's interests with those of our stockholders generally.

Director and Officer Stock Ownership Guidelines

        Our Stock Ownership Guidelines have been established in order to further the investment of our non-management directors, executive officers, and Senior Vice Presidents in the success of the Company and to encourage a long-term perspective in managing the Company. During the 2019 fiscal


Table of Contents

year, except for the Non-Management Directors which increased from two to five times annual cash retainer in our January 2019 board meeting, the stock ownership requirements were as follows:

Position
Minimum Ownership Requirements (Number of Share Equivalents)
Chief Executive Officerlesser of 1,400,000 share equivalents or 5 times base salary
President(1)lesser of 700,000 share equivalents or 3 times base salary
Senior Executive Vice Presidentslesser of 700,000 share equivalents or 3 times base salary
Executive Vice Presidentslesser of 200,000 share equivalents or 2 times base salary
Senior Vice Presidentslesser of 100,000 share equivalents or 1 times base salary
Non-Management Directors(2)lesser of 150,000 share equivalents or 5 times annual cash retainer

(1)
If the President is also the Chief Executive Officer, the Chief Executive Officer amount will apply.

(2)
Other than an Executive Chairman, who will be subject to the same requirement as the Chief Executive Officer.

        Effective as of April 10, 2019, we have revised our stock ownership guidelines to remove the reference to a specific number of shares to be held. The current stock ownership requirements are:

Position
Minimum Ownership Requirements

Chief Executive Officer

5 times base salary

Chief Operating Officer

3 times base salary

Senior Executive Vice Presidents

3 times base salary

Executive Vice Presidents

2 times base salary

Senior Vice Presidents

1 times base salary

Non-Management Directors

5 times annual cash retainer

        Newly appointed or promoted executives who are or become subject to our Stock Ownership Guidelines and newly elected non-management directors have five years from the time they are appointed, promoted, or elected, as the case may be, to meet the stock ownership requirements. Currently, all of our Named Executive Officers have achieved the minimum holding ownership requirement or have not yet served for five years.

        For the purposes of determining stock ownership levels, the following forms of equity interests in the Company are included:

        Restricted stock and restricted stock units, whether or not vested, and shares owned count as one (1) share equivalent per share beneficially owned and stock options, whether or not vested, count as one-half (.5) share equivalent per stock option.

        The Compensation Committee is responsible for interpreting and administering the Stock Ownership Guidelines, and may, from time to time, reevaluate and revise the Stock Ownership Guidelines, including when there are changes to the Company's capital structure or where implementation of the Stock Ownership Guidelines would cause a non-management director, executive officer, or Senior Vice President to incur a hardship due to his or her unique financial circumstances.


Table of Contents


COMPENSATION COMMITTEE REPORT

        The Compensation Committee of the Board of Directors has reviewed and discussed the foregoing Compensation Discussion and Analysis with management and, based on that review and discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.


*
Mr. Bodaken served on the Compensation Committee throughout our 2019 fiscal year and until April 10, 2019. Ms. Katherine Quinn joined the Compensation Committee and the Board on April 10, 2019, but did not participate in the review or recommendation of the Compensation Discussion and Analysis.

Table of Contents


SUMMARY COMPENSATION TABLE

        The following summary compensation table sets forth the cash and non-cash compensation for the fiscal years ended March 2, 2019, March 3, 2018,4, 2023 and March 4, 2017, respectively, paidFebruary 26, 2022 by our independent registered public accounting firm, Deloitte & Touche LLP, the member firms of Deloitte Touche Tohmatsu and their respective affiliates.

Year Ended
Fee CategoryMarch 4, 2023
($ millions)
February 26, 2022
($ millions)
Audit fees(1)2.22.3
Audit-related fees(2)0.2
Tax fees(3)
All other fees
Total fees2.22.5
(1)
Audit fees. Represents fees for audit of annual financial statements and reviews of interim financial statements, registration statement filings and comfort letters related to or earned by (i) our principal executive officer, (ii) our principal financial officer, and (iii)various refinancing activities.
(2)
Audit-related fees. The fees for the three most highly compensated executive officers of the Company other than the principal executive officer or the principal financial officer who were serving at the end of the 2019 fiscal year (collectively, the "Named Executive Officers").

Name and Principal Position(1)
 Fiscal
Year
 Salary
($)
 Bonus
($)
 Stock
Awards
($)(2)
 Option
Awards
($)(2)
 Non-Equity
Incentive
Plan
Compensation
($)(3)
 Change In
Pension
Value and
Nonqualified
Deferred
Compensation
Earnings
($)(4)
 All Other
Compensation
($)(5)
 Total
($)
 

John T. Standley

  2019  1,220,550    1,830,829    1,440,249  53,994  3,320,207  7,865,829 

(CEO)

  2018  1,219,857    5,640,243    1,825,943  314,545  319,874  9,320,462 

  2017  1,184,500    6,095,121      481,309  311,025  8,071,955 

Kermit Crawford

  
2019
  
1,000,000
  
  
1,274,966
  
  
1,032,500
  
  
252,000
  
3,559,466
 

(President & COO)

  2018  403,846    2,000,000  1,080,000  729,167  18,921  1,175,000  5,406,934 

Darren W. Karst

  
2019
  
850,356
  
  
638,099
  
  
627,428
  
  
707,424
  
2,823,306
 

(Senior Executive VP,

  2018  829,856    1,534,638    776,284  49,056  782,185  3,972,019 

CFO & CAO)

  2017  809,751    1,667,368      52,907  269,584  2,799,610 

Bryan B. Everett

  
2019
  
617,654
  
  
370,832
  
  
364,620
  
  
475,600
  
1,828,706
 

(COO, Rite Aid Stores)

  2018  533,784    1,626,434    392,700  17,891  413,475  2,984,284 

  2017  461,250    712,768      16,768  151,086  1,341,872 

Jocelyn Z. Konrad

  
2019
  
461,034
  
  
207,592
  
  
204,103
  
  
358,250
  
1,230,979
 

(Executive VP, Pharmacy)

  2018  427,846    571,326    252,450  33,665  124,000  1,409,287 

(1)
Mr. Standley entered into a separation agreement with the Company as of March 12, 2019 and, pursuant to that agreement, will remain in his current role until a successor is named or until his earlier termination. Mr. Crawford left the Company effective March 12, 2019. Mr. Karst entered into a separation agreement with the Company as of March 12, 2019 and pursuant to that agreement, left the Company as of May 31, 2019 after a transition period. For a description of the separation agreements entered into with Messrs. Standley, Crawford, and Karst, please see the narrative under the caption "Potential Payments Upon Termination or Change in Control."

(2)
The amounts reported reflect the aggregate grant date fair value of each stock award and option award computed in accordance with FASB ASC Topic 718. For information regarding the assumptions used in determining the fair value of an award, please refer to Note 17 of the Company's Annual Report on Form 10-K as filed with the SEC on April 25, 2019, Note 17 of the Company's Annual Report on Form 10-K as filed with the SEC on April 26, 2018, and Note 16 of the Company's Annual Report on Form 10-K as filed with the SEC on May 3, 2017.

(3)
The amounts in the "Non-Equity Incentive Plan Compensation" column for fiscal year 2019 represent annual cash incentive bonuses for performance in fiscal year 2019.

(4)
Represents above-market earnings (over 120% of the "applicable federal rate"), if applicable, under the Company's defined contribution supplemental executive retirement plans.

(5)
The amounts in the "All Other Compensation" column for fiscal year 2019 consist of the following:
Name
 Financial
Planning
($)
 Supplemental
Executive
Retirement
Plan
Allocations
($)
 Housing/
Transportation
Expenses
($)(a)
 Automobile
Allowance
($)
 401(k)
Matching
Contributions
($)
 Retention/
Inducement
Award Paid
($)
 

Mr. Standley

  4,275  292,932    12,000  11,000  3,000,000 

Mr. Crawford

    240,000    12,000     

Mr. Karst

  5,000  203,360  60,778  12,000  11,000  415,000 

Mr. Everett

  5,000  147,600    12,000  11,000  300,000 

Ms. Konrad

    110,250    12,000  11,000  225,000 

(a)
Mr. Karst is reimbursed for certain housing and transportation expenses pursuant to his employment agreement. The Company determines the incremental cost of said expenses based on the out-of-pocket amounts paid for rent, utilities, and travel.

Table of Contents


GRANTS OF PLAN-BASED AWARDS TABLE FOR FISCAL YEAR 2019

        The following table summarizes grants of plan-based awards made to Named Executive Officers during our fiscal year ended March 2, 2019. As previously announced, we implemented a reverse stock splitFebruary 26, 2022 represent fees for audits of our common stock at a reverse stock split ratio of 1-for-20. Our common stock began trading on a split-adjusted basis on the NYSE at the market open on April 22, 2019. Accordingly, all share amounts presented reflect the reverse stock split.

employee benefit plans’ financial statements.
(3)
Tax fees. Represents fees for tax compliance advice and planning.
 
  
  
  
  
  
  
  
  
  
  
  
 Grant
Date
Fair
Value
of Stock
and
Option
Awards
($)(3)
 
 
  
  
 Estimated Future Payouts
Under Non-Equity
Incentive Plan Awards(1)
 Estimated Future
Payouts Under Equity
Incentive Plan Awards
  
  
 Exercise
or Base
Price of
Option
Awards
($/Sh)
 
 
  
  
 All
Other
Stock
Awards
(#)(2)
 All
Other
Option
Awards
(#)
 
Name
 Grant
Date
 Date of
Board
Action
 Threshold
($)
 Target
($)
 Max
($)
 Threshold
(#)
 Target
(#)
 Max
(#)
 

John T. Standley(6)

  1/4/2019  12/6/2018  1,601,963  4,271,900  10,679,750        118,885      1,830,829 

        1,220,550  2,441,100  4,882,200                   

Kermit Crawford(4)

  1/4/2019  12/6/2018  1,115,625  2,975,000  7,437,500        82,790      1,274,966 

        875,000  1,750,000  3,500,000                   

Darren W. Karst(5)

  1/4/2019  12/6/2018  558,300  1,488,800  3,722,000        41,435      638,099 

        531,719  1,063,438  2,126,875                   

Bryan B. Everett

  1/4/2019  12/6/2018  324,450  865,200  2,163,000        24,080      370,832 

        309,000  618,000  1,236,000                   

Jocelyn Z. Konrad

  1/4/2019  12/6/2018  181,613  484,300  1,210,750        13,480      207,592 

        172,969  345,938  691,875                   

(1)
On January 4, 2019, each Named Executive Officer received a grant of cash-based performance units that will be earned based upon the achievement of an Adjusted EBITDA goal for fiscal years 2020 and 2021. Vesting for the performance units will occur, provided the performance targets have been met, on February 27, 2021 (the end of the Company's fiscal year 2021), provided that the Named Executive Officer is continuously employed at the Company through the date of the earnings release. The second row of the table reflects the opportunity for each Named Executive Officer to earn an annual cash incentive bonus, as discussed in the Compensation Discussion and Analysis under the caption "Cash Incentive Bonuses." Actual cash incentives earned for the fiscal year are shown in the Summary Compensation Table above.

(2)
On January 4, 2019, the Named Executive Officers received a grant of restricted stock, as described in the Compensation Discussion and Analysis, under the caption "Components of Executive Compensation for Fiscal Year 2019—Restricted Stock." These restricted shares will vest as follows based on continued employment:
Name
Restricted
Shares
(#)
Vesting Schedule

Mr. Standley

118,885One-third on each of first three anniversaries of grant date

Mr. Crawford

82,790One-third on each of first three anniversaries of grant date

Mr. Karst

41,435One-third on each of first three anniversaries of grant date

Mr. Everett

24,080One-third on each of first three anniversaries of grant date

Ms. Konrad

13,480One-third on each of first three anniversaries of grant date
(3)
Represents the grant date fair value, measured in accordance with FASB ASC Topic 718 of stock awards made in fiscal year 2019. Grant date fair values are calculated pursuant to assumptions set forth in Note 17 of the Company's 2019 Annual Report on form 10-K filed with the SEC on April 25, 2019.

(4)
Mr. Crawford forfeited his 2019 plan based awards with his departure on March 12, 2019.

(5)
Mr. Karst forfeited his January 4, 2019 non-equity incentive plan award, a portion of his January 4, 2019 restricted stock grant, and is eligible for a prorated portion of any earned fiscal year 2020 annual cash incentive, pursuant to his March 12, 2019 separation agreement.

(6)
Mr. Standley will forfeit his January 4, 2019 non-equity incentive plan award and be eligible for a prorated portion of any earned fiscal year 2020 annual cash incentive upon his departure and pursuant to his March 12, 2019 separation agreement.

Table of Contents


EXECUTIVE EMPLOYMENT AND SEPARATION AGREEMENTS

        Rite Aid entered into employment agreements with each of the Named Executive Officers, which govern the material terms of their employment and were in effect during the Company's last completed fiscal year.

        Salary and Incentive Bonus.    The respective agreements provide each executive with a base salary and an incentive compensation target (which may be reviewed periodically for increase by the Compensation Committee). As part of the announced leadership transition, Bryan Everett was promoted to Chief Operating Officer as of March 12, 2019. Effective as of March 12, 2019, Mr. Everett's annual base salary was increased to $750,000, Mr. Everett's target annual bonus opportunity was set at 125% of his base salary and his target long-term incentive compensation award opportunity was set at 250% of his base salary. Jocelyn Konrad was promoted to the position of Executive Vice President, Pharmacy & Retail Operations, effective March 12, 2019. In connection with this promotion, Ms. Konrad's base salary was increased to $600,000, her target annual bonus opportunity was set at 100% of base salary, and her target long-term incentive compensation award opportunity was set at 200% of her base salary.

        Other Benefits.    Pursuant to their employment agreements, each of the Named Executive Officers is also entitled to participate in Rite Aid's welfare benefits, fringe benefit and perquisite programs, and savings plans.

        Term Under Active Employment Agreements.    The term of employment for each of Mr. Everett and Ms. Konrad commenced on the effective date of his or her employment agreement, as follows: Mr. Everett, June 22, 2015; and Ms. Konrad, August 3, 2015. The employment agreement for each of Mr. Everett and Ms. Konrad has an initial term of two years (each such period, the "Initial Term"). These agreements will automatically renew for successive one-year terms (each, a "Renewal Term"), unless either the executive or Rite Aid provides the other with a notice of nonrenewal at least 180 days, with respect to Ms. Konrad, and 120 days, with respect to Mr. Everett, prior to the expiration of the Initial Term or a Renewal Term, as applicable.

        Restrictive Covenants.    The employment agreement of each Named Executive Officer prohibits the officer from competing with Rite Aid during his or her employment period and for a period of one year thereafter.

        Termination and Change in Control Benefits.    The provisions of the employment agreements relating to termination of employment, and the terms of the separation agreements entered into with each of Messrs. Standley, Crawford, and Karst, are described under the caption "Potential Payments Upon Termination or Change in Control" below.


Table of Contents


OUTSTANDING EQUITY AWARDS AT FISCAL YEAR 2019 YEAR-END

        The following table summarizes the number of securities underlying outstanding equity awards for the Named Executive Officers. As previously announced, we implemented a reverse stock split of our common stock at a reverse stock split ratio of 1-for-20. Our common stock began trading on a split-adjusted basis on the NYSE at the market open on April 22, 2019. Accordingly, all share amounts and option exercise prices presented reflect the reverse stock split.

 
 Option Awards Stock Awards 
Name
 Date of
Grant
 Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1)(2)
 Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
 Option
Exercise
Price
($)
 Option
Expiration
Date
 Number
of
Shares
or
Units of
Stock
That
Have
Not
Vested
(#)(1)(3)
 Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(4)
 Equity
Incentive
Plan
Awards:
# of
Unearned
Shares or
Units That
Have Not
Vested
(#)(1)(5)
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares or
Units of
Stock That
Have Not
Vested
($)(4)
 

John T. Standley

  6/25/2009  29,030      24.80  6/25/2019         

  1/21/2010  127,750      30.40  1/21/2020         

  6/23/2010  71,430      21.40  6/23/2020         

  6/27/2011  118,079      24.80  6/27/2021         

  6/27/2011  70,175      24.80  6/27/2021         

  6/25/2012  68,965      26.40  6/25/2022         

  6/24/2013  46,815      55.20  6/24/2023         

  6/23/2014  33,925      141.60  6/23/2024         

  6/24/2015  21,349  7,116    173.60  6/24/2025         

  6/22/2016            6,385  93,221     

  7/17/2017             44,030  642,838  66,045  964,257 

  1/4/2019             118,885  1,735,721     

Kermit Crawford

  
10/2/2017
  
12,500
  
37,500
  
  
41.00
  
10/2/2027
  
32,520
  
474,796
  
  
 

  1/4/2019          1/4/2029  82,790  1,208,734     

Darren W. Karst

  
8/20/2014
  
10,390
  
  
  
128.60
  
8/20/2024
  
  
  
  
 

  6/24/2015  5,865  1,955    173.60  6/24/2025         

  6/22/2016             1,747  25,501       

  7/17/2017             11,980  174,908  17,970  262,362 

  1/4/2019             41,435  604,951     

Bryan Everett

  
6/24/2015
  
2,505
  
835
  
  
173.60
  
6/24/2025
  
  
  
  
 

  6/22/2016             747  10,901       

  7/17/2017             5,140  75,044  7,710  112,566 

  9/6/2017             13,333  194,666     

  1/4/2019             24,080  351,568     

Jocelyn Z. Konrad

  
6/25/2009
  
300
  
  
  
24.80
  
6/25/2019
  
  
  
  
 

  6/27/2011  1,655      24.80  6/27/2021         

  6/25/2012  1,690      26.40  6/25/2022         

  6/24/2013  675      55.20  6/24/2023         

  6/23/2014  330      141.60  6/23/2024         

  6/24/2015  435  145     173.60  6/24/2025         

  6/22/2016             647  9,441       

  7/17/2017             4,460  65,116  6,690  97,674 

  1/4/2019             13,480  196,808     

(1)
Refer to "Potential Payments Upon Termination or Change in Control" below for circumstances under which the terms of the vesting of equity awards would be accelerated.

(2)
Stock options will generally vest in equal installments on each of the first four anniversaries of the grant date, based on continued employment. With respect to the restricted stock awards listed above, one-third of the restricted shares will vest on each of the first three anniversaries of the grant date, based on continued employment.

(3)
Restricted shares will generally vest one-third on each of the first three anniversaries of the grant date.

(4)
Determined with reference to $14.60, the closing price of a share of Rite Aid common stock on the last trading day before March 3, 2019 to reflect the reverse stock split.

(5)
Performance units granted on July 17, 2017 will be earned based upon the achievement of an Adjusted EBITDA and Return on Net Assets goals for fiscal years 2019 and 2020. Vesting for the performance units will occur, provided the performance target has been met, on February 29, 2020 (the end of the Company's fiscal year 2020), provided that the Named Executive Officer is continuously employed at the Company through the date of the earnings release for fiscal year 2020.

Table of Contents


OPTION EXERCISES AND STOCK VESTED TABLE FOR FISCAL YEAR 2019

        The following table summarizes for each Named Executive Officer the stock option exercises and shares vested during fiscal year 2019. As previously announced, we implemented a reverse stock split of our common stock at a reverse stock split ratio of 1-for-20. Our common stock began trading on a split-adjusted basis on the NYSE at the market open on April 22, 2019. As the following information reports transactions that occurred during the fiscal year 2019, the number of shares and options disclosed are on a pre-reverse stock split basis. Any stock holdings resulting from the below transactions, as of April 22, 2019, have been adjusted for the reverse stock split accordingly.

 
 Option Awards Stock Awards 
Name
 Number of Shares
Acquired on
Exercise (#)
 Value
Realized on
Exercise ($)
 Number of Shares
Acquired on
Vesting (#)
 Value
Realized on
Vesting ($)
 

John T. Standley

  168,800  43,888  623,200 $1,104,759 

Kermit Crawford

      325,204 $373,985 

Darren W. Karst

      169,899 $301,266 

Bryan B. Everett

      199,667 $281,337 

Jocelyn Z. Konrad

      57,533 $100,607 


NONQUALIFIED DEFERRED COMPENSATION FOR FISCAL YEAR 2019

        The following table sets forth the nonqualified deferred compensation activity for each Named Executive Officer during fiscal year 2019:

Name
 Executive
Contributions in
Last FY ($)
 Registrant
Contributions in
Last FY ($)(2)
 Aggregate
Earnings in
Last FY
($)(2)
 Aggregate
Withdrawals /
Forfeitures ($)
 Aggregate
Balance at Last
FYE ($)
 

John T. Standley(1)

    292,932  176,028    4,259,058 

Kermit Crawford(1)

    240,000  (16,385)   323,768 

Darren W. Karst(1)

    203,360  (4,061)   993,583 

Bryan B. Everett(1)

    147,600  (11,488)   478,692 

Jocelyn Z. Konrad(1)

    110,250  1,066    547,644 

(1)
Amounts shown relate to a defined contribution supplemental executive retirement plan covering the Named Executive Officers in the fiscal year. Please refer to the Compensation Discussion and Analysis under the caption "Post-Retirement Benefits" for a description of the material terms of this plan.

(2)
Amounts shown were reported to the extent required in the "All Other Compensation" column of the Summary Compensation Table for fiscal year 2019.


POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

        As discussed above under the caption "Executive Employment Agreements," the Company has entered into employment agreements with each of the Named Executive Officers. Upon written notice, the employment agreement of each of the Named Executive Officers is terminable by either Rite Aid or the individual officer seeking termination. Since the end of the last completed fiscal year, the Company has entered into separation agreements with certain of our Named Executive Officers, which are discussed below, as applicable.


Table of Contents

Mr. John Standley

        Circumstances Resulting in Severance.    Pursuant to his employment agreement with the Company, if Mr. Standley had been terminated by the Company without "cause" or if he had terminated his employment for "good reason" (as such terms are defined in his employment agreement), then he would have been entitled to receive:

Pursuant to the separation agreement entered into on March 12, 2019, Mr. Standley will be entitled to the severance benefits described above under the caption "Circumstances Resulting in Severance" upon selection of his successor in the role of Chief Executive Officer and the termination of his employment.

        If Rite Aid had terminated Mr. Standley for "cause," or he had terminated his employment without "good reason":

        If Mr. Standley's employment had been terminated as a result of his death or "disability" (as such term is defined in his employment agreement), he (or his estate, as the case may be) would have been entitled to receive all accrued but unpaid salary and benefits payable under death or disability benefit plans in which he participates, a pro-rata bonus (paid at the same time it is paid to other eligible participants in the bonus plan and based on actual achievement of performance targets for the fiscal year), continued health insurance (or reimbursement for the cost of such benefits) for two years for Mr. Standley and/or his or her immediate family, as applicable, vesting of all stock options, and vesting of an amount of restricted stock that would have vested had he remained employed for three years following the date of termination.

Mr. Kermit Crawford

        Mr. Kermit Crawford, former President and Chief Operating Officer of the Company, departed the Company by mutual agreement pursuant to the leadership transition effectuated on March 12, 2019. The Separation Agreement with Mr. Crawford provides for a separation payment equal to $5,000,000 payable in equal installments over a 24 month period subject to executing a general release of claims in favor of the Company. Mr. Crawford was also relieved of his obligation to repay $520,073


Table of Contents

to the Company, which represents the repayment obligation with respect to the cash-based inducement award paid to Mr. Crawford upon his hire.

        Circumstances Resulting in Severance.    Pursuant to his employment agreement with the Company, if Mr. Crawford had been terminated by Rite Aid without "cause" or if he had terminated his employment for "good reason" (as such terms are defined in the employment agreement), then:

Mr. Darren Karst

        Circumstances Resulting in Severance.    Pursuant to his employment agreement with the Company, if Mr. Karst had been terminated by Rite Aid without "cause" or if he were to terminate his employment for "good reason" (as such terms are defined in the employment agreement), then:

Pursuant to the separation agreement entered into on March 12, 2019, Mr. Karst became entitled to the severance benefits described above under the caption "Circumstances Resulting in Severance" upon the termination of his transition period of employment on May 31, 2019.

Mr. Bryan Everett

        Circumstances Resulting in Severance.    Pursuant to his employment agreement with the Company, if Mr. Everett is terminated by Rite Aid without "cause" or if he terminates his employment for "good reason" (as such terms are defined in the applicable employment agreement), then:


Table of Contents

In addition, Mr. Everett's employment agreement provides that if termination occurs following the start of Rite Aid's fiscal year and if the Board of Directors determines that Rite Aid achieved or exceeded its annual performance targets for the fiscal year, Mr. Everett is entitled to an amount equal to his target annual bonus, pro-rated to reflect the number of days in the fiscal year prior to the termination.

Ms. Jocelyn Konrad

        Circumstances Resulting in Severance.    Pursuant to her employment agreement with the Company, if Ms. Konrad is terminated by Rite Aid without "cause" or if she terminates her employment for "good reason" (as such terms are defined in the applicable employment agreement), then:

In addition, Ms. Konrad's employment agreement provides that if termination occurs following the start of Rite Aid's fiscal year and if the Board of Directors determines that Rite Aid achieved or exceeded its annual performance targets for the fiscal year, she is entitled to an amount equal to her target annual bonus, pro-rated to reflect the number of days in the fiscal year prior to the termination.

        Termination for Cause or Without Good Reason.    If Rite Aid were to terminate any of the Named Executive Officers for "cause," or if any of the Named Executive Officers were to terminate his or her employment without "good reason" (with the exception of Mr. Standley, whose termination provisions are described above):

        Treatment of Final Tranche of Retention Awards.    If the employment of Messrs. Karst and Everett and Ms. Konrad had been terminated by the Company without "cause" or by the executive with "good reason" as of March 2, 2019, then the retention amounts of $415,125, $300,000, and $225,000


Table of Contents

respectively, would have been paid out to the executives under the executives' respective retention agreements prior to the scheduled payment date of May 1, 2019.

        Termination as a Result of Death or Disability.    If the employment of any of the Named Executive Officers (with the exception of Mr. Standley, whose termination provisions are described above) were to be terminated as a result of death or "disability" (as such term is defined in each employment agreement), the officer will be entitled to receive all accrued but unpaid salary and benefits payable under death or disability benefit plans in which the officer participates, continued health insurance (or reimbursement for the cost of such benefits) for two years for the officer and/or his or her immediate family, as applicable, vesting of all stock options and vesting of an amount of restricted stock that would have vested had the officer remained employed for two years following the date of termination. Messrs. Karst and Crawford will also be entitled to receive a pro-rata bonus, based on actual achievement of performance targets for the fiscal year, which is paid at the same time that it is paid to other eligible participants in the bonus plan.

        Distributions Upon Termination.    Upon the termination of employment of any of the Named Executive Officers, the officer would generally become entitled to receive a distribution of his or her vested account balance under the supplemental executive retirement plan, which has been terminated by the Company. Pursuant to applicable tax regulations, any such distributions will generally be delayed for a period of six months following the Named Executive Officer's separation from service. The account balance of each Named Executive Officer is shown in the "Nonqualified Deferred Compensation for Fiscal Year 2019" table above. For more information regarding the supplemental executive retirement plan, refer to the Compensation Discussion and Analysis under the caption "Post-Retirement Benefits."

Change in Control Arrangements.

        Under Employment Agreements.    Under Mr. Standley's employment agreement, upon a change in control, all of his stock options awarded pursuant to his employment agreement and all stock options awarded pursuant to the Company's executive equity program then held by him will immediately vest and become exercisable. Severance benefits would not be triggered pursuant to a change in control unless it is followed by Mr. Standley's termination of employment under the circumstances resulting in severance described above. Similarly, severance benefits would not be triggered pursuant to a change in control unless it is followed by Mr. Karst's, Mr. Crawford's, Mr. Everett's, or Ms. Konrad's termination of employment, respectively, under the circumstances resulting in severance described above.

        For purposes of the employment agreements with the Named Executive Officers, where applicable, the term "change in control" generally means an acquisition of 35% or more of the Company's combined voting power; the incumbent directors (generally including current directors and future directors whose election or nomination is approved by the Board) ceasing to constitute a majority of the Board; the consummation of a merger or similar transaction, other than (i) such a transaction in which the voting securities outstanding immediately prior to such transaction continue to represent at least 60% of the voting power of the Company immediately after the transaction or (ii) a recapitalization or similar transaction in which no person becomes the beneficial owner of 35% or more of the Company's combined voting power; or the stockholders approve a plan of complete liquidation or dissolution of the Company.

        Mr. Standley's employment agreement provides that he will receive an additional payment to reimburse him for any excise taxes imposed pursuant to Section 4999 of the Code, together with reimbursement for any additional taxes incurred by reason of such payments. The employment agreements with Messrs. Karst, Crawford, and Everett and Ms. Konrad provide that any portion of any payment that is subject to tax imposed by Section 4999 of the Code will be reduced to the extent


Table of Contents

necessary so that the Named Executive Officer would retain a greater amount on an after-tax basis than had the excise tax been imposed on the unreduced amount of the payments.

        Under Rite Aid's Equity Program.    Pursuant to the terms of the Company's equity program, unless otherwise provided in a Named Executive Officer's employment agreement or individual award agreement, if outstanding equity awards are assumed or substituted in connection with a change in control, the change in control will not cause the vesting of such awards to accelerate unless the change in control is followed by a qualifying termination of employment within the 24-month period following the change in control. All outstanding equity awards granted pursuant to the Company's equity program that are not assumed or substituted in connection with a change in control will become fully vested and exercisable, free of applicable restrictions, and all performance criteria will be deemed to have been achieved at target levels, upon the occurrence of the change in control.

        For purposes of Rite Aid's equity program, a "change in control" means, in general: (i) a person or entity acquires securities of Rite Aid representing 50% or more of the combined voting power of Rite Aid; (ii) an unapproved change in the majority membership of the Board; (iii) consummation of a merger or consolidation of Rite Aid or any subsidiary of Rite Aid, other than a merger or consolidation that results in the Rite Aid voting securities continuing to represent at least 60% of the combined voting power of the surviving entity or its parent, or a merger or consolidation effected to implement a recapitalization or similar transaction involving Rite Aid in which no person or entity acquires at least 35% of the combined voting power of Rite Aid; or (iv) stockholder approval of a plan of complete liquidation or dissolution of Rite Aid or the consummation of an agreement for the sale or disposition of all or substantially all of Rite Aid's assets, other than a sale or disposition to an entity, at least 60% of the combined voting power of which is owned by Rite Aid stockholders in substantially the same proportions as their ownership of Rite Aid immediately prior to such sale. For more information regarding the equity program, refer to the Compensation Discussion and Analysis under the caption "Long-Term Incentive Program."

        Quantification of Payments Described.    The termination and change in control payments that would have been made to the Named Executive Officers had their employment been terminated as of March 2, 2019 under the circumstances described in the tables below are quantified in the tables below.

John T. Standley(1)
 Death ($) Disability ($) Termination
Without Cause
or Quit for
Good Reason
($)
 Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
 

2 × Base Salary

  n/a  n/a  2,441,100  2,441,100 

2 × Bonus

  n/a  n/a  4,882,200  4,882,200 

Pro-Rated Incentive Bonus for Past Fiscal Year

  1,440,249  1,440,249  1,440,249  1,440,249 

Benefits

  29,850  29,850  29,850  29,850 

Vesting of Equity(2)

  3,960,011  3,960,011  3,960,011  7,987,600(3)

280G Gross Up

  n/a  n/a  n/a   

Table of Contents


Kermit Crawford(1)
 Death ($) Disability ($) Termination
Without Cause
or Quit for
Good Reason
($)
 Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
 

2 × Base Salary

  n/a  n/a  2,000,000  2,000,000 

2 × Bonus

  n/a  n/a  3,500,000  3,500,000 

Pro-Rated Incentive Bonus for Past Fiscal Year

  1,032,500  1,032,500  1,032,500  1,032,500 

Benefits

  20,101  20,101  20,101  20,101 

Vesting of Equity(2)

  1,955,755  1,955,755  1,955,755  4,658,531(3)

280G Gross Up

  n/a  n/a  n/a  n/a 


Darren W. Karst(1)
 Death ($) Disability ($) Termination
Without Cause
or Quit for
Good Reason
($)
 Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
 

2 × Base Salary

  n/a  n/a  1,701,500  1,701,500 

2 × Bonus

  n/a  n/a  2,126,875  2,126,875 

Pro-Rated Incentive Bonus for Past Fiscal Year

  627,428  627,428  627,428  627,428 

Benefits

  21,580  21,580  21,580  21,580 

Vesting of Equity(2)

  1,274,855  1,274,855  1,274,855  2,633,026(3)

280G Gross Up

  n/a  n/a  n/a  n/a 


Bryan B. Everett
 Death ($) Disability ($) Termination
Without Cause
or Quit for
Good Reason
($)
 Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
 

2 × Base Salary

  n/a  n/a  1,236,000  1,236,000 

2 × Bonus

  n/a  n/a  1,236,000  1,236,000 

Pro-Rated Incentive Bonus for Past Fiscal Year

  364,620  364,620  364,620  364,620 

Benefits

  28,575  28,575  28,575  28,575 

Vesting of Equity(2)

  878,434  878,434  878,434  1,642,649(3)

280G Gross Up

  n/a  n/a  n/a  n/a 


Jocelyn Z. Konrad
 Death ($) Disability ($) Termination
Without Cause
or Quit for
Good Reason
($)
 Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
 

2 × Base Salary

  n/a  n/a  922,500  922,500 

2 × Bonus

  n/a  n/a  n/a  n/a 

Pro-Rated Incentive Bonus for Past Fiscal Year

  204,103  204,103  204,103  204,103 

Benefits

  28,055  28,055  28,055  28,055 

Vesting of Equity(2)

  432,312  432,312  432,312  881,663(3)

280G Gross Up

  n/a  n/a  n/a  n/a 

(1)
Pursuant to the Company's restructuring initiative implemented in March of 2019, Messrs. Standley, Crawford, and Karst have entered into separation agreements which will govern termination payments, subject to the execution of a general release of claims in favor of the

Table of Contents

(2)
Includes the value of equity awards and performance awards held by the officer that would become vested under the applicable circumstances. The value of stock options shown is based on the excess of $0.73, the closing price of a share of Rite Aid common stock on the last trading day before March 2, 2019, over the exercise price of such options, multiplied by the number of unvested stock options held by the officer that would become vested under the applicable circumstances. The value of restricted stock and performance awards that are settled in stock shown is determined by multiplying $0.73, the closing price of a share of Rite Aid common stock on the last trading day before March 2, 2019 and the number of shares of restricted stock and the number of performance awards that are settled in stock held by the officer that would become vested under the applicable circumstances.

(3)
The value would also apply upon a change in control under the assumption that outstanding equity awards are not assumed or substituted in the change in control transaction, resulting in full vesting upon the change in control, as described above in the "Potential Payments Upon Termination or Change in Control—Change in Control Arrangements" narrative.


PAY RATIO DISCLOSURE

        As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K under the Exchange Act, we are providing the following information about the relationship of the annual total compensation of our employees other than our Chief Executive Officer (our "CEO") and the annual total compensation of our CEO. This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described below. Of our total employee base of 53,594 associates employed as of March 2, 2019 (i.e., the last day of the 2019 fiscal year, consistent with our use of March 3, 2018, the last day of the 2018 fiscal year, with respect to our 2018 pay ratio disclosure), we determined that the 2019 annual total compensation of the median employee, other than our CEO, was $31,025 and our CEO's 2019 annual total compensation was $7,880,751. The ratio of these amounts is 254:1.

        To identify the median employee among our associates other than the CEO, we used wages taxable for federal medical health insurance purposes for the period from March 4, 2018 through March 2, 2019, with such amounts annualized for those permanent employees who were hired during the year. After identifying the median employee (who is a full-time Picker at our Liverpool, New York Distribution Center), we calculated annual total compensation for such employee using the same methodology we use to determine Mr. Standley's annual total compensation in the Summary Compensation Table for fiscal year 2019. Previously, in order to calculate annual total compensation of the median employee in our 2018 disclosure, we also took into account the compensation provided under non-discriminatory health and welfare plans by including actual contributions to a union-sponsored health fund for the median employee, and, as required by SEC rules, for Mr. Standley, we took into account the actuarial value of the health and welfare benefits for salaried employees that are self-insured by the Company. For this year's disclosure, we chose the simplest permitted method of calculating annual total compensation, using the rules for completing the Summary Compensation


Table of Contents

Table, because the union-sponsored health fund was not applicable to the median employee for fiscal year 2019.

        The SEC rules for identifying the median employee and calculating the pay ratio based on that employee's annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices. As such, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may utilize different methodologies, exclusions, estimates, and assumptions in calculating their own pay ratios.


Table of Contents


AUDIT COMMITTEE REPORT

The Board of Directors has adopted a written charter of the Audit Committee which further describes the role of the Audit Committee. The Audit Committee, among other things, appoints and engages our independent registered public accounting firm and oversees our financial reporting and internal control over financial reporting processes on behalf of the Board. Management has the primary responsibility for our financial statements, our accounting principles and our internal control over financial reporting. Our independent registered public accounting firm is responsible for auditing our financial statements and expressing an opinion as to their conformity with accounting principles generally accepted in the United States. Our independent registered public accounting firm also is responsible for expressing an opinion on the effectiveness of our internal control over financial reporting.


RITE AID CORPORATION   2023 Proxy Statement | 27

TABLE OF CONTENTS
PROPOSAL 2—RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
In fulfilling its oversight responsibilities, the Audit Committee met nine10 times during fiscal year 2019.

2023.

During those meetings, the Audit Committee:


Met with our internal auditors and independent registered public accounting firm, with and without management present, to discuss the overall scope and plans for their respective audits, the results of their examinations, their evaluations of our internal control over financial reporting and the overall quality of our financial reporting.


Reviewed and discussed with management and our independent registered public accounting firm, for their respective purposes, the audited financial statements included in our Annual Report on Form 10-K for fiscal year 2019.2023. The discussions included the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the financial statements and the Annual Report on Form 10-K for fiscal year 2019.

2023.

Reviewed the unaudited interim financial statements and Forms 10-Q prepared each quarter by the Company.


Received management representations that the Company'sCompany’s financial statements were prepared in accordance with accounting principles generally accepted in the United States of America.


Reviewed and updated the Audit Committee charter.


Reviewed and discussed with our independent registered public accounting firm those matters required to be communicateddiscussed by the standardsapplicable requirements of the Public Company Accounting Oversight Board ("PCAOB"(“PCAOB”), as well as critical accounting policies and practices, alternative accounting treatments, and other material written communications between management and our independent registered public accounting firm, as required by Rule 2-07 of Regulation S-X under the Securities Exchange Act of 1934, as amended.

SEC.
Discussed with our independent registered public accounting firm the matters required to be discussed by Statement on Auditing Standards No. 1301,Communications with Audit Committees, as adopted by the PCAOB.


Discussed with our independent registered public accounting firm matters relating to their independence and received the written disclosures and the letter from our independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountant'saccountant’s communications with the Audit Committee concerning independence. The Audit Committee has considered whether the level of non-audit related services provided by our independent registered public accounting firm is consistent with maintaining their independence.

Table of Contents

Pre-approved audit, other audit-related and tax services performed by our independent registered public accounting firm.

In addition to pre-approving the audit and other audit-relatedaudit related and tax services performed by our independent registered public accounting firm, the Audit Committee requests fee estimates associated with each proposed service. Providing a fee estimate for a service incorporates appropriate oversight and control of the independent registered public accounting firm relationship. On a quarterly basis, the Audit Committee reviews the status of services and fees incurred year-to-date against pre-approved services and fee estimates.

        As outlined in the table below, we incurred the following fees, including expenses billed to the Company for the fiscal years ended March 2, 2019 and March 3, 2018 by our independent registered public accounting firm, Deloitte & Touche LLP, the member firms of Deloitte Touche Tohmatsu, and their respective affiliates.

 
 Year Ended 
Description of Fees
 March 2,
2019
 March 3,
2018
 
 
 (Amounts in
millions)

 

Audit Fees, including audit of annual financial statements and reviews of interim financial statements, registration statement filings, and comfort letters related to various refinancing activities

 $2.4 $3.4 

Audit-Related Fees, acquisition-related due diligence procedures and audits of employee benefit plans' financial statements

 $0.2 $1.0 

Tax Fees, tax compliance advice and planning

 $0.0 $0.1 

All Other Fees

 $0.0 $0.0 

Total

 $2.6 $4.5 

Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended March 2, 20194, 2023 for filing with the SEC.

THE AUDIT COMMITTEE
Louis P. Miramontes, Chair

Arun Nayar*


*
Ms. Busy Burr joinedNayar
Robert E. Knowling, Jr.

28 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 3—ADVISORY VOTE ON THE
COMPENSATION OF OUR NAMED EXECUTIVE
OFFICERS
In accordance with the Audit Committeerequirements of Section 14A of the Exchange Act, stockholders have the opportunity to approve on an advisory, nonbinding basis the compensation of the named executive officers disclosed in this proxy statement. This is commonly referred to as a “say on pay” advisory vote. The Board of Directors recommends that you vote “FOR” this proposal.
As discussed in greater detail in the “Compensation Discussion and Analysis” ​(CD&A) section of this proxy statement, our executive compensation program is designed to attract, motivate, and retain the most talented and dedicated executives and to align the interests of our named executive officers with the interests of our stockholders. The Company’s compensation program is designed to:

reward our named executive officers for the achievement of annual and long-term strategic and operational goals and the achievement of increased total stockholder return, and

avoid the encouragement of unnecessary or excessive risk-taking.
The Company encourages stockholders to review the executive compensation disclosure in the CD&A and executive compensation tables in this proxy statement for complete details of its compensation program for its named executive officers and how the program is designed to achieve the Company’s compensation objectives.
We are asking our stockholders to indicate their support for the compensation of our named executive officers as described in this proxy statement. This vote is not intended to address any specific item of compensation; rather, the vote relates to the overall compensation of our named executive officers as described in this proxy statement.
The Board is presenting this proposal, which gives stockholders the opportunity to endorse or not endorse our executive pay program, on an advisory basis, by voting on the following resolution:
RESOLVED, that the stockholders of the Company approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed pursuant to Item 402 of Securities and Exchange Commission Regulation S-K, including the Compensation Discussion and Analysis, the compensation tables and narrative disclosures.”
Although the advisory vote is non-binding, the Board of Directors values the opinions of stockholders. The Compensation Committee will review the results of the vote and will consider stockholders’ concerns and take into account the outcome of the vote when considering future decisions concerning our executive compensation program.
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote FOR the approval of the compensation of its named executive officers, as disclosed in this proxy statement.

RITE AID CORPORATION   2023 Proxy Statement | 29

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 4—ADVISORY VOTE ON THE
FREQUENCY OF FUTURE ADVISORY VOTES ON
THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS
Section 14A of the Exchange Act requires that we include in this proxy statement a non-binding stockholder vote on whether future advisory votes on the compensation of our named executive officers should occur every one, two or three years. Stockholders have the option to vote for any one of the three options, or to abstain on the matter. In July 2017, our stockholders voted to hold an advisory vote on executive compensation every year. The next advisory vote on the frequency of future advisory votes on the compensation of our named executive officers is expected to be held at the 2029 annual meeting. For the reasons discussed below, the Board recommends that future advisory votes on the compensation of our named executive officers take place every “ONE YEAR.”
After careful consideration and input from our stockholders, our Board has determined that an advisory vote on executive compensation that occurs annually is the most appropriate alternative for the Company. In formulating its recommendation, our Board considered that an annual advisory vote on executive compensation will allow stockholders to provide us with their direct input on our compensation philosophy, policies and practices as disclosed in the proxy statement every year. Additionally, an annual advisory vote on executive compensation is consistent with our policy of seeking input from, and engaging in discussions with, our stockholders on corporate governance matters and our executive compensation philosophy, policies and practices. We will continue to engage with our stockholders regarding our executive pay programs between stockholder advisory votes as part of our governance process.
The Company recognizes that stockholders may have different views as to the best approach for the Company, and therefore the Company and Board encourage stockholders to express their preferences as to the frequency of an advisory vote on the compensation of our named executive officers.
This vote is advisory and not binding on the Company or the Board, but the Board and the Compensation Committee will take into account the outcome of the vote when making decisions about how often the Company conducts advisory votes on the compensation of our named executive officers.
The proxy card provides stockholders with the opportunity to choose among four options (holding the vote every one, two or three years, or abstaining). The frequency (every one, two or three years) receiving the greatest number of votes, even if not a majority, will be considered the preference of our stockholders.
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote for ONE YEAR as the preferred frequency of future advisory votes on the compensation of our named executive officers.

30 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
Letter from the Chair of Our Compensation Committee
DEAR FELLOW STOCKHOLDERS:
On behalf of the Compensation Committee of the Board of Directors of Rite Aid, I would like to share with you the Committee’s perspective on our recent CEO transition, say-on-pay results, stockholder engagement, and the impact of our financial performance on executive pay.
Rite Aid’s fiscal year 2023 financial performance results were lower than we anticipated, which is reflected in the pay outcomes for our executive team and is in alignment with the experience of Rite Aid stockholders. However, the year ended on a positive note with strong fourth quarter results and a strategic turnaround plan in place that is designed to drive future growth. As we engage in our search for a permanent CEO, we understand the importance of continuing to motivate and retain our dedicated leaders who are prepared to deliver on our new strategy to grow the Company and create long-term stockholder value.
[MISSING IMAGE: ph_katherinekatebbox-pn.jpg]
CEO Transition
In January of this year, the Board of Directors appointed Ms. Burr, then a member of the Company’s Board, as interim CEO, and Ms. Donigan, our former President and CEO, departed the Company. Given her experience in the health and retail industries, including expertise in innovation, business strategy, retail and brand management, Ms. Burr is well suited to prepare Rite Aid for future growth while we conduct a search for a permanent CEO. To compensate Ms. Burr for her services as interim CEO, the Company is providing her a base salary of $300,000 a month, which the Board will review if she remains in the role for more than six months. As interim CEO, Ms. Burr does not receive short- or long-term incentive awards, employee benefits, or severance benefits. Also, she is not receiving compensation for her service as a director.
Say on Pay and Stockholder Outreach
The Compensation Committee is committed to gathering your feedback each year through our say-on-pay vote results and stockholder engagement efforts and to consider this important information in making executive pay decisions. Stockholder support for our executive compensation program in fiscal year 2023 was approximately 77%, a decline from approximately 83% in fiscal year 2022. We were disappointed in this result and responded with a rigorous stockholder engagement campaign, reaching out to stockholders holding over 40% of our outstanding shares to seek feedback on our pay program. Attending these meetings provided me and other Rite Aid leaders, including our Board Chair, CEO, and CFO, an opportunity to listen to any concerns raised by our stockholders and to gain insight into your perspectives on our executive pay plans. In part in response to this feedback, we made changes to our fiscal year 2023 pay program, including:

Incorporating new performance metrics into our annual and long-term incentive plans to eliminate overlapping metrics between the two plans

Revising the annual incentive plan metrics to remove total revenue and focus on two metrics that drive stockholder value: Adjusted EBITDA and Operating Cash Flow

Replacing the relative total shareholder return (TSR) modifier in our long-term incentive plan with a 25%-weighted Relative TSR metric to enhance the incentive to create sustainable long-term value and increase alignment of the interests of our executives with those of our stockholders
We will continue to reach out to our stockholders to gather feedback on executive pay and governance matters as part of our ongoing stockholder engagement process. We appreciate your valuable input.

RITE AID CORPORATION   2023 Proxy Statement | 31

TABLE OF CONTENTS
LETTER FROM THE CHAIR OF OUR COMPENSATION COMMITTEE
Fiscal Year 2023 Performance
The Company faced several challenges in fiscal year 2023 that impacted our financial results, including a reduction in revenue from COVID-19 vaccines and testing, and the loss of a large commercial client at Elixir. However, our executive team demonstrated its resilience by meeting several operational goals, including growing our market share in pharmacy and front-end lines of business, increasing our third-party e-commerce business, launching our first Rx-focused small-format stores, and improving our rebates at Elixir. We also reduced our operating costs through expense control and closing underperforming stores. These accomplishments helped us continue to make progress toward our goal of transforming Rite Aid into a leading pharmacy services company.
To improve financial performance and enhance stockholder value, our leadership team has established a turnaround plan designed to prepare for future challenges and drive earnings growth. We have already demonstrated the potential of this new approach, with fiscal year 2023 fourth quarter results at the higher end of Company guidance, due to positive results in retail pharmacy, non-COVID-19 script growth, expense control and improvement at Elixir.
Fiscal Year 2023 Compensation Outcomes
Given our financial results for fiscal year 2023 were lower than we expected, the Company did not meet the Adjusted EBITDA or Operating Cash Flow threshold performance levels under our annual incentive plan. As a result, our senior leadership team received no annual incentive plan payouts.
In setting the fiscal year 2023 performance targets for the annual incentive plan, the Compensation Committee chose challenging goals to motivate executives to achieve the Company’s short-term financial objectives and enhance stockholder value. Fiscal year 2023 annual incentive plan targets and results were as follows:

The Adjusted EBITDA target was set at $520 million, which was above the fiscal year 2022 target of $490 million and the fiscal year 2022 actual performance of $506 million. Actual fiscal year 2023 performance was $429.2 million, which was below the plan’s threshold of $442 million.

The Operating Cash Flow performance target was set at $8 million based on the financial plan targets. Actual fiscal year 2023 Operating Cash Flow was negative $276.3 million, which was below the threshold of negative $45 million.
For the long-term incentive plan, our executives received a combination of time-vested restricted stock (45%) and performance stock units (55%). The performance stock units vest over a three-year period based 75% on meeting three performance goals related to growth: Cumulative Scripts (30%), Elixir membership (30%), and Total Front-end Revenue (15%). These metrics were chosen to provide executives with enhanced line of sight to their goals and to focus the leadership team on growth and profitability. The remaining 25% is based on the Company’s TSR compared to the Russell 3000 Index to enhance alignment of long-term executive pay with stockholder experience.
Consistent with our pay-for-performance philosophy, our named executive officers did not receive an annual incentive plan award for fiscal year 2023.
In Closing
The Compensation Committee is committed to establishing pay programs that will continue to drive sustainable financial growth and create long-term stockholder value. We value your feedback and appreciate your continued support.
Sincerely,
[MISSING IMAGE: sg_katherinekatebquinn-bw.jpg]
KATHERINE “KATE” B. QUINN
Compensation Committee Chair

32 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS
CD&A Contents
Introduction
We encourage you to read this Compensation Discussion and Analysis for a detailed discussion and analysis of our fiscal year 2023 executive compensation program for all individuals serving as Chief Executive Officer (“CEO”) during our last completed fiscal year, the Chief Financial Officer (“CFO”) and the three most highly compensated executive officers of the Company other than the CEO and CFO serving as of the end of our last completed fiscal year, as named below. We refer to these individuals throughout this Compensation Discussion and Analysis and the accompanying tables as our “Named Executive Officers” or “NEOs.”
Elizabeth Burr(1)
Heyward Donigan(2)
Matthew Schroeder
Interim Chief Executive OfficerFormer President and Chief Executive OfficerExecutive Vice President, Chief Financial Officer
Paul Gilbert(3)
Justin Mennen
Andre Persaud(4)
Former Executive Vice President, Chief Legal Officer & SecretaryExecutive Vice President, Chief Digital and Technology OfficerFormer Executive Vice President, Chief Retail Officer
(1)
Ms. Burr was appointed interim CEO effective January 7, 2023.
(2)
Ms. Donigan departed the Company on January 7, 2023.
(3)
Mr. Gilbert departed the Company on April 10, 2019, but7, 2023.
(4)
Mr. Persaud departed the Company on March 6, 2023.

RITE AID CORPORATION   2023 Proxy Statement | 33

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Executive Summary
Our Company
Rite Aid Corporation is on the front lines of delivering health care services and retail products to over one million Americans daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. In fiscal year 2023, we provided an array of whole being health products and services for the entire family through over 2,300 retail pharmacy locations across 17 states. Through Elixir, our pharmacy services company, we provided access to life saving and life enhancing prescriptions, and managed pharmacy benefits, pharmacy costs and healthcare outcomes to our members.
Leadership Transition
On January 7, 2023, the Board of Directors appointed Elizabeth Burr, then a member of the Company’s Board, as interim CEO, and Heyward Donigan, our former President and CEO, departed from the Company on that date. Rite Aid has initiated a search to identify a permanent CEO and has retained a leading executive search firm. Ms. Burr has extensive experience in the health and retail industries, and proven expertise in innovation, business strategy, retail and brand management and is prepared to execute on the Company’s business strategy.
In addition, two executives departed after the end of the 2023 fiscal year. Andre Persaud, Executive Vice President, Chief Retail Officer, departed from the Company on March 6, 2023, and Paul Gilbert, Executive Vice President, Chief Legal Officer and Secretary, departed from the Company on April 7, 2023. See “Executive Compensation: Potential Payments Upon Termination or Change in Control—Named Executive Officer Departures” for additional details regarding Ms. Donigan’s and Messrs. Persaud’s and Gilbert’s departures from the Company.
Strategy Execution
As a healthcare company with a retail footprint operating in diverse communities throughout the country, we are positioned to create meaningful customer, client, and member experiences for the millions of lives we touch.
We are focused on three key strategic drivers of growth:
1.
Growing our pharmacy business by improving our access to networks, strategically acquiring prescription files, increasing medication adherence, and making more clinical services available to our customers.
2.
Deepening our customer loyalty and engagement, by improving our in-store experience, optimizing our products and services, leveraging personalized marketing and communications, and expanding our digital solutions.
3.
Scaling our Elixir business by delivering on a value proposition unique to the mid-market including competitive pricing, leveraging our platform to deliver white-label services, optimizing our specialty pharmacy, and improving our operational efficiency.
Each of these strategic imperatives is furthered by our significant ongoing investments in our people and infrastructure, including our distributions centers, central fill operations, and systems for customer and client support.
Stockholder Vote on Executive Compensation and Stockholder Engagement
Stockholder endorsement of the design and administration of our executive compensation programs was evidenced by a vote of approval of our named executive officers’ compensation at our 2022 annual meeting of stockholders by approximately 77% of the votes cast. We recognize that the favorable vote regarding our named executive officers’ compensation was not as high as had been achieved in the prior fiscal year. The Compensation Committee considered the current program in effect, and it was determined that certain changes

34 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
would be made, as discussed below, to increase the effectiveness of our executive compensation design and administration. Our intention was to continually drive improved company performance and we remain committed to a significant focus on our stockholder outreach. In fiscal year 2023, we continued the same rigor to address any stockholder feedback we received through our scheduled outreach and any stockholder meetings we had during the ordinary course of business. The Compensation Committee will continue to review the results of future advisory say on pay votes and consider stockholder concerns in NEO compensation decisions and governance practices.
During the 2023 fiscal year, we reached out to stockholders holding over 40% of our stock to gather feedback on our pay and governance policies and practices. Our meetings were conducted virtually through online video conferencing or teleconference. We also held our first ever retail stockholder meeting, allowing our retail stockholders to submit various questions that were answered in a video streamed format through our investor relations website.
The feedback we received from stockholders reinforced the actions we have taken over the past couple of years. With stockholder input in mind, the Company continues its commitments to the following:

Diversified financial metrics between our annual bonus and our three-year long term incentive plans,

Developed three-year DEI strategy roadmap and began execution on initial initiatives, and

Continued stockholder outreach.
RESPONSE TO STOCKHOLDER FEEDBACK. For fiscal year 2023, the Compensation Committee revised the metrics in the annual and long-term incentive plans. By diversifying the performance metrics across Rite Aid’s performance-based program of annual and long-term incentives, the Company seeks to ensure that the program drives Company performance across multiple metrics and that the variable pay components are appropriately challenging. The annual incentive plan metrics were revised to focus on improving operating results which ultimately drive stockholder value. Adjusted EBITDA and Operating Cash Flow were selected as metrics to minimize overlap with the long-term incentive plan and because they provide executives with line of sight to their goals and are measures executives are able to impact. They also enhance alignment with stockholder value creation. Adjusted EBITDA is the most heavily weighted measure at 70% and Operating Cash Flow, weighted 30%, is a critical metric for our Company as it represents the cash we generate from our normal business operations to support and grow our business. Total revenue was eliminated as an annual incentive plan metric in fiscal year 2023.
The Compensation Committee incorporated new performance metrics for the performance-based units granted under the long-term incentive plan in fiscal year 2023. The metrics were revised to eliminate overlap with the annual plan, relate more directly to stockholder return and provide a greater focus on three metrics related to growth: Cumulative Scripts, Elixir Membership and Total Front-end Revenue. These growth metrics provide executives a greater line of sight to their goals and are tangible metrics in their day-to-day work. The financial metrics of our long-term success for the 2023 awards are weighted as follows:

TSR relative to the Russell 3000 Index, weighted 25%

30-day Cumulative Scripts, weighted 30%

Two-year Elixir Membership, weighted 30%

Two-year Total Front-end Revenue, weighted 15%
For 2023, the Compensation Committee added the 25%-weighted Relative TSR metric to provide an incentive for executives to create sustainable long-term value for the Company and to enhance the alignment of the interests of our executives with those of our stockholders. This metric replaces the relative TSR modifier of +/− 25% that was in place in prior years.
SAY ON PAY FREQUENCY VOTE. We believe that a stockholder advisory vote every year on the compensation of our named executive officers most closely aligns with the interests of stockholders. Stockholders have an opportunity to vote on the frequency of the advisory vote on executive compensation this year in Proposal 4 (Advisory Vote on the Frequency of Advisory Votes to Approve Named Executive Officer Compensation). At our 2017 annual meeting of stockholders, our stockholders voted to hold an advisory vote on named executive officer compensation every year. The Compensation Committee accepted the stockholders’ recommendation,

RITE AID CORPORATION   2023 Proxy Statement | 35

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
and stockholders will have another opportunity to consider and approve, in a non-binding advisory vote, the compensation of our named executive officers at the Annual Meeting. The Compensation Committee recommends stockholders vote to approve an annual say on pay vote at the Annual Meeting.
Stockholder Engagement Efforts
The Company engaged with stockholders in fiscal year 2023, as follows:
YEAR-ROUND EFFORTS.

Solicit feedback and seek to understand investor perspectives on issues of importance to them

Hold quarterly earnings calls

Monitor investor relations website and other related correspondence

Attend analyst conferences and participate in meetings with current stockholders and potential investors

Hold a call with management specifically targeted toward retail stockholders

Communicate company strategy and progress on various retail stockholder forums

Update our investor relations website
LATE SPRING / EARLY SUMMER EFFORTS.

Communicate pay decisions and changes to our pay program to our stockholders through our annual report and proxy statement

Extend first biannual invitation to our largest stockholders (together constituting holders of at least 40% or more of our outstanding shares of common stock) to discuss matters to be voted on at our upcoming annual meeting of stockholders

Discuss with stockholders’ topics of interest such as company performance, executive compensation, governance, DEI and ESG
LATE SUMMER / EARLY FALL EFFORTS.

Evaluate results of stockholder voting including our annual say on pay proposal and proxy advisor recommendations to establish the priorities for our stockholder engagement and to ensure that any significant concerns are identified and addressed

Assess results and review recommendations based on the Company’s strategic priorities
LATE FALL / EARLY WINTER EFFORTS.

Review stockholder and proxy advisory policy changes and recent feedback to identify common concerns and themes
LATE WINTER / EARLY SPRING EFFORTS.

Respond to stockholder feedback or concerns and evolving practices by modifying our programs or enhancing our disclosure as appropriate

Extend second biannual invitation to discuss current concerns with our largest stockholders (together constituting holders of at least 40% or more of our outstanding shares of common stock)
2023 Fiscal Year Key Business Highlights
In fiscal year 2023, Rite Aid continued to position the Company for future growth and expense efficiency by focusing on implementing our strategic initiatives aimed at operating as a fully-integrated healthcare company with a retail footprint. The Company faced several challenges in fiscal year 2023, primarily related to a reduction in revenue and gross profit from COVID-19 vaccines and testing and the loss of a large commercial client at Elixir as previously announced. However, the Company is making progress in its turnaround program to drive performance acceleration that is expected to help mitigate future challenges related to reimbursement, COVID-19

36 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
headwinds and enrollment at Elixir, and to drive meaningful EBITDA growth over the long term. For example, fiscal year 2023 fourth quarter results were at the higher end of Company guidance and exceed fiscal year 2022 fourth quarter results, driven by strong non-COVID-19 script growth, good expense control and improvement in procurement economics at Elixir.
Our financial highlights in fiscal year 2023 included:

Revenues of $24.1 billion, declined compared to prior year revenues of $24.6 billion

Retail comparable same store prescriptions increased 3.5%—comparable same store prescriptions, excluding COVID-19 impacts, increased 6.9%

Same store front-end sales, excluding tobacco, increased 1.6%

Elixir Adjusted EBITDA margins expanded by 62 bps

Net loss per share was $13.71, compared to prior year net loss per share of $9.96

Adjusted EBITDA was $429.2 million
Our key accomplishments in fiscal 2023 included:

Growing our market share in both the pharmacy and front-end lines of business

Reducing our operating SG&A costs by over $240 million, through implementation of expense control initiatives and the closing of about 150 underperforming stores

Growing our third-party e-commerce business by over 60% by deepening our relationships with an expanding range of partners

Improving our rebates at Elixir, enabling us to expand gross margin and become more competitive in the marketplace

Improving our capital structure which included paying off approximately $280 million of our 7.5% Senior Secured Notes, $52 million of our 7.7% Notes, and $27 million of our 6.875% Notes
In fiscal 2023, prescription drug sales accounted for over 71% of our total drugstore sales. We believe that our pharmacy operations will continue to represent a significant part of our business due to a combination of our efforts to expand the role of our over 6,400 pharmacists as whole-being health advocates; demographic trends such as an aging population and increased life expectancy; our focus on growth customers, particularly women between the ages of 25 to 49 who take care of themselves, their children, aging parents, and even pets; anticipated growth in the federally funded Medicare Part D prescription program as “baby boomers” continue to enroll; increased regulatory efforts to improve access and affordability of prescription drugs; and, the discovery of new and better prescription drug and over-the-counter therapies.
In addition, we offer a wide assortment of front-end merchandise to complement our pharmacy services and to provide convenience to our customers. We carry a full assortment of front end products, which accounted for the remaining nearly 29% of our total drug store sales in fiscal 2023. Front end products include over the counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, pet care, and numerous other every day and convenience products.

RITE AID CORPORATION   2023 Proxy Statement | 37

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Below are the details related to key financial indicators used as performance measures in our incentive programs for fiscal year 2023:
ADJUSTED EBITDA:
OPERATING CASH FLOW:

Our Adjusted EBITDA from continuing operations for fiscal year 2023 was $429.2 million or 1.8 percent of revenues, compared to $505.9 million or 2.1 percent of revenues for fiscal year 2022.

The decrease in Adjusted EBITDA from continuing operations was due primarily to a decrease of $104.6 million in the Retail Pharmacy segment partially offset by an increase of $27.8 million in the Pharmacy Services segment.

The decrease in the Retail Pharmacy Segment Adjusted EBITDA was due to decreased gross profit, partially offset by a decrease in SG&A expenses of $164.5 million. Gross profit was negatively impacted by the decline in COVID-19 vaccinations and testing, partially offset by the increase in non-COVID-19 prescriptions sold. SG&A expenses benefitted from lower payroll, occupancy, and other operating costs due to store closures and cost control initiatives, partially offset by an extra week.

The increase in the Pharmacy Services Segment Adjusted EBITDA was due to increased gross profit resulting from improved procurement economics, reductions in SG&A expense and the absence of prior year receivable reserves and write-downs, partially offset by lower membership.

Our Operating Cash Flow performance for the Rite Aid annual bonus plan calculation for fiscal year 2023 was negative $276.3 million. The Operating Cash Flow calculation for the purpose of our compensation metrics included cash flow from operating activities less capital expenditures. The Company did not achieve the $8 million target due to not achieving target EBITDA, higher than expected interest expense and other negative impacts from working capital changes.

Capital expenditures were negative $225 million as we continued to invest in store construction, relocation and remodel projects; technology enhancements; and prescription file buys.
See Appendix A for a reconciliation of our Adjusted EBITDA, which is a non-GAAP measure, to net income under GAAP.
Our Executive Compensation Philosophy
We believe strongly that pay should align with performance, and this focus is reflected in our executive compensation program. We seek to provide our NEOs with opportunities to earn total direct compensation (base salary, annual incentives, and long-term incentives) that is generally comparable to compensation levels provided to peer company executives and executives within other similarly-sized retailers and health services companies more broadly. Because of our desire to reinforce a performance-based culture, the Company emphasizes a compensation mix that is comprised primarily of variable pay. As a result, base salary makes up the smallest portion of total direct compensation for the NEOs, with variable pay in the form of annual and long- term incentives comprising the largest portion. The compensation mix varies by position, taking into account each position’s ability to influence Company results, as well as competitive practice.
Pay Mix
Our executive compensation program aims to appropriately balance the mix of cash and equity compensation, the mix of currently-paid and longer-term compensation, and the security of base benefits in a way that best furthers the compensation objectives discussed above. However, based on share usage constraints over the past few years, the mix of pay for our top executives has necessarily been weighted less toward equity compensation than is typical of our peers. Commencing in fiscal year 2021, we increased the relative weighting of the equity portion of executives’ target total remuneration opportunities to ensure greater alignment with stockholder interests and promote the retention of key new executive talent. Those equity opportunities consist of both performance-based equity that rewards executives based on Rite Aid’s financial achievements, and time-vested equity to promote the retention of critical executive talent and appropriately enhance current ownership levels.
The charts below show the overall mix of base salary, target annual incentives, and target long-term incentives for fiscal year 2023 for our former CEO, Ms. Donigan, and for our other NEOs, Messrs. Schroeder, Gilbert, Mennen

38 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
and Persaud. The majority of our NEOs’ target total direct compensation opportunity in fiscal year 2023 was provided in the form of performance-based compensation (variable pay), 89% for Ms. Donigan and 74% on average for our other NEOs serving at the end of the prior fiscal year. For fiscal year 2023, our interim CEO, Ms. Burr, was not eligible for the annual or long-term incentive plan and received all of her compensation as base salary so her compensation is excluded from the charts below. (See “CEO Transition-Related Compensation Decisions” below for a discussion of Ms. Burr’s compensation.)
Total Target Compensation
[MISSING IMAGE: pc_totaltarget-pn.jpg]
Compensation Governance and Best Practices
The table below summarizes compensation governance and best practices Rite Aid follows.
[MISSING IMAGE: ic_check-pn.jpg]WHAT WE DO
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]WHAT WE DO NOT DO
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Conduct annual stockholder advisory vote on the compensation of our named executive officers
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain dialogue with stockholders on various topics, including executive pay practices
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Retain an independent executive compensation consultant to the Compensation Committee
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Ensure that a significant portion of executive officer total target remuneration is at risk
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Provide annual and long-term incentive plans with performance targets aligned to business goals
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require a designated level of stock ownership for all named executive officers and non-management directors
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require shares subject to the annual non-management director grant to be deferred until separation from service
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Require equity awards to have a double trigger (qualifying termination of employment and change in control)
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Complete an annual incentive compensation risk assessment
[MISSING IMAGE: ic_checkgreen-pn.jpg]
Maintain a formal clawback policy for executive officers
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Provide gross-up payments to cover personal income taxes or excise taxes related to executive severance benefits
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Permit executives to engage in hedging or pledging of Rite Aid securities
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Reward executives for imprudent, inappropriate, or unnecessary risk-taking
[MISSING IMAGE: tm228886d1-icon_crossred4c.jpg]
Allow the repricing of equity awards without stockholder approval
Our Fiscal Year 2023 Pay Decisions
In establishing performance measures for our fiscal year 2023 incentive programs, we diversified our financial metrics between our annual bonus and our three-year long-term incentive plans, in part in response to stockholder feedback.
ANNUAL BONUS PLAN. The Rite Aid annual bonus plan metrics were Adjusted EBITDA (70%) and Operating Cash Flow (30%). Operating Cash Flow replaced Free Cash Flow to increase the focus on the cash we generate from our normal business operations to support and grow our business. Total Revenue was removed from the annual bonus plan, and growth metrics were added to the long-term incentive plan, as discussed below, to enhance the focus of our NEOs on long-term growth.

RITE AID CORPORATION   2023 Proxy Statement | 39

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
For fiscal year 2023, Rite Aid’s bonus plan established an Adjusted EBITDA threshold of $442 million and an Operating Cash Flow threshold of negative $45 million. The Operating Cash Flow calculation, for the purpose of our compensation metrics, included elements of cash flow that the management team has some level of control over (Adjusted EBITDA plus or minus the change in inventory less capital expenditures).
Our Adjusted EBITDA performance for the Rite Aid annual bonus plan calculation for fiscal year 2023 was $429.2 million, which was below our threshold of $442 million. Operating Cash Flow was negative $276.3 million, which was below the threshold performance of negative $45 million due to lower EBITDA than planned, higher interest expense than planned and other working capital changes.
Performance below threshold for each metric resulted in no payout for the NEOs under the annual bonus plan for 2023.
The table below illustrates the performance targets that were set under the annual bonus plan and the actual performance against such targets in fiscal year 2023. Performance under the annual incentive plan was based on achieving below threshold results for Adjusted EBITDA and Operating Cash Flow and resulted in a 0% payout.
Performance LevelWeightingThreshold
(50%)
Target
(100%)
Maximum
(200%)
Actual
Performance
Achievement% of Weighted
Target
Attainment
Adjusted EBITDA (millions)70%$442$520$598$429.2Below threshold0%
Operating Cash Flow (millions)30%$(45)$8$86$(276.3)Below threshold0%
Total Resulting Payout0%
LONG-TERM INCENTIVE PLAN. The Compensation Committee structured the Long-Term Incentive Plan to include grants in the form of 45% restricted stock and 55% share-settled performance units for our Named Executive Officers. The restricted stock grants will vest ratable in 1/3 increments over three years, based on continued employment. The performance units cliff vest after three years based on meeting performance goals measured at the end of the performance period. The performance units are conditioned on performance against four performance metrics: Relative Total Shareholder Return (TSR) versus the Russell 3000 Index (weighted 25%); 30-day Cumulative Script Goals (weighted 30%); two-year Elixir Memberships (weighted 30%); and two-year Total Front-end Revenue (weighted 15%). These metrics are distinct from the metrics used for Rite Aid’s annual bonus plan.
Objectives of Our Executive Compensation Program
All of our executive compensation and executive benefits programs are within the purview of the Compensation Committee, which bases these programs on the same objectives that guide the Company in establishing all of its compensation programs. The Compensation Committee also administers the Company’s equity incentive compensation plans. In establishing or approving the compensation of our Named Executive Officers in any given year, the Compensation Committee is generally guided by the following objectives:

Compensation is based on the level of job responsibility, individual performance, and corporate performance, and fosters the long-term focus required for success in the pharmacy, health care services and retail health care industry. As associates progress to higher levels in the organization, an increasing proportion of their pay is linked to Company performance and stockholder returns and to longer-term performance because they are in a position to have greater influence on longer-term results.

Compensation reflects the value of the job in the marketplace. To attract and retain a highly skilled, diverse work force, we must remain competitive with the pay of other employers who compete with us for talent in the current, highly competitive market.

Compensation rewards performance. Our programs deliver compensation that is related to our corporate performance. Where corporate performance falls short of expectations, the programs deliver lower-tier compensation. In addition, the objectives of pay-for-performance and retention must be balanced. Even in periods of temporary downturns in overall corporate performance, the programs continue to ensure that successful, high-achieving associates will remain motivated and committed to the Company to support the stability and future needs of the Company.

40 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION

To be effective, performance-based compensation programs enable associates to easily understand how their efforts can affect their pay, both directly through individual performance accomplishments and indirectly through contributing to the Company’s achievement of its strategic and operational goals.

Compensation programs reward performance relative to consistent measures and goals at all levels of the organization. While the programs and individual pay levels will always reflect differences in job responsibilities, geographies, and marketplace considerations, the overall structure of compensation and benefit programs are broadly similar across the organization.

Compensation and benefit programs attract and retain associates who are interested in being a part of the Rite Aid team.
Compensation Committee’s Processes
In making executive pay decisions, the Compensation Committee assesses Company performance and reviews competitive compensation levels at a peer group of companies to ensure the Company’s executive compensation program is achieving its objectives.
The Compensation Committee uses Company performance measures in two ways:

In assessing the linkage between actual total compensation and performance, the Compensation Committee considers various measures of Company and industry performance, such as comparable store sales and script count growth, pharmacy services segment revenue growth, EBITDA growth, debt leverage ratios, return on average invested capital and net assets, relevant strategic initiatives, and total stockholder return. In determining performance relative to the Company’s peer group (as discussed further below), the Compensation Committee does not apply a formula or assign these performance measures relative weights. Instead, it makes a subjective determination after considering such measures collectively.

The Compensation Committee has established specific Company target incentive/award levels and performance measures that determine the size of payouts under the Company’s two formula-based incentive programs—the annual cash incentive bonus program and long-term incentive program.
Peer Group and Competitive Pay
For fiscal year 2023, the Compensation Committee, with the help of its independent compensation consultant, Mercer, assessed the Company’s programs relative to a peer group of organizations and published survey data. Because the Company has a limited number of publicly-traded direct competitors and because pharmacy sales (which account for over two-thirds of the Company’s retail revenue) are governed by third-party contracts, we reviewed potential peers relative to multiple criteria including:

INDUSTRY: Retail, health care services/pharmacy, and pharmacy benefits management (adjacent industries with similar operating models and/or product mix were considered);

BUSINESS MODEL CHARACTERISTICS: Health care services and pharmacy benefits management offerings, pharmacy retail, small ticket retail, and grocery/convenience store operating models, national presence (users and/or employees); and

COMPANY SIZE: Companies of similar size based on revenue (.25x to 4x the revenue of Rite Aid).
After reviewing potential peers relative to the criteria above, it was determined the peer group would be the same as the one used to set 2022 compensation. The peer group was last updated in 2022 to better align with the Company’s size based on revenue and to better reflect the industry of the Company. The peer group used to set pay in fiscal year 2023 includes the following 14 companies:

RITE AID CORPORATION   2023 Proxy Statement | 41

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Fiscal Year 2023 Peer Group
Peer Company
Revenue
($ Millions)
(1)
Centene Corporation114,130
Target Corporation103,348
Humana Inc.82,201
Albertsons Companies, Inc.68,956
Alimentation Couche-Tard Inc.53,194
Best Buy Co., Inc.52,333
Dollar General Corporation33,984
Molina Healthcare, Inc.24,656
AutoZone, Inc.14,630
Laboratory Corporation of America Holdings16,555
Bed Bath & Beyond Inc.9,176
DICK’S Sporting Goods, Inc.12,067
Ulta Beauty, Inc.8,100
Sprouts Farmers Market, Inc.6,209
75th Percentile72,267
Median29,320
25th Percentile11,344
Rite Aid24,308
Percentile Rank46th
(1)
Represents financials for trailing 12-month period as of 11/10/2021 from Standard & Poor’s Capital IQ.
The Compensation Committee compares the compensation levels of Rite Aid’s NEOs to peer company compensation levels in the aggregate and compares the pay of individual executives if the jobs are sufficiently similar to make the comparison meaningful.
In addition to peer group data, the Compensation Committee reviews market data based on specific functional responsibility for each executive from published survey data. The survey analysis targets data from similarly sized retail organizations based on each executive’s functional responsibility. The surveys used in the analysis include Mercer’s 2022 Executive Remuneration Suite, Mercer’s 2022 Retail Compensation and Benefits Survey, Mercer’s US IHN Healthcare System and Hospital Executives Survey and WTW General Executives Survey.
The Compensation Committee considers peer group and survey data to evaluate the degree to which the executive compensation program as a whole is competitive, and generally aims to establish target total direct compensation opportunities that are appropriately aligned with the medians of these comparator groups. The incentive plans were designed so executives can earn above competitive pay levels for superior performance and below competitive pay levels if performance is below expectations. The Compensation Committee assesses overall alignment of the compensation program rather than benchmarking a specific target position with consideration of factors, such as Company and individual performance, how executive roles function within Rite Aid, concerns about executive retention, and competitive positioning of equity compensation. The Compensation Committee assesses Rite Aid’s performance relative to its peer group on both a one- and three- year basis and observed alignment of performance with actual total direct compensation levels for the executives in the aggregate.
The Compensation Committee retained Mercer (US) LLC, a wholly-owned subsidiary of Marsh & McLennan Companies, Inc. (“MMC”), as its independent compensation consultant for fiscal year 2023. Mercer’s fees for executive compensation consulting in fiscal year 2023 were $469,262. Rite Aid also paid Mercer fees for other services of approximately $26,000 in fiscal year 2023. Rite Aid management retained an MMC affiliate for risk

42 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
management and business consulting services resulting in fees of approximately $658,226. The Compensation Committee conducted an independence assessment of Mercer, including considering the fees for other services provided by Mercer and its affiliates to the Company, consistent with NYSE listing standards, and concluded that the engagement of Mercer did not raise any conflicts of interest or similar concerns.
With respect to fiscal year 2023, Mercer reviewed recommendations and analysis prepared by management and provided advice and counsel to the Compensation Committee for the applicable periods during which they were engaged.
TOTAL COMPENSATION REVIEW. The Compensation Committee reviews each named executive officer’s base pay, annual bonus, and long-term incentives annually with input from the Compensation Committee’s independent compensation consultant. Following the fiscal year 2023 review, the Compensation Committee determined base salary levels were not aligned with the market and increased base salaries as shown in the Base Salary chart below to remain competitive.
Components of Executive Compensation for Fiscal Year 2023
For fiscal year 2023, the regular compensation program for our Named Executive Officers consisted of four primary components: (i) base salary, (ii) a cash incentive bonus opportunity under the Company’s annual incentive bonus plan, (iii) long-term incentives consisting of restricted stock and performance-based units, and (iv) a benefits package, including retirement and welfare benefits (which are generally provided to all associates of Rite Aid on a non-discriminatory basis), and limited perquisites. A significant portion of total compensation under the fiscal year 2023 program is variable, meaning it is subject to meeting specified performance goals and is comprised of target annual incentives and target long-term incentives.
Our executive compensation program aims to appropriately balance the mix of cash and equity compensation, the mix of currently-paid and longer-term compensation, and the security of base benefits consistent with the compensation objectives discussed above. Share usage constraints over the past few years, has caused the mix of pay for our top executives to be weighted less toward equity compensation than is typical of our peers. For fiscal year 2023, we leveraged the equity plan stockholders approved at the 2022 Annual Meeting to continue to provide a significant portion of executives’ target total remuneration opportunities in equity to ensure greater alignment with stockholder interests and promote the retention of key new executive talent. Our NEOs’ equity opportunities consist of both performance-based equity that rewards executives based on Rite Aid’s financial achievements, and time-vested equity that promotes retention of critical executive talent and enhances current ownership levels.
Base Salary
Base salary is one element of an executive’s annual cash compensation and reflects the executive’s long-term performance, skill set, and the market value of that skill set. In setting base salaries for fiscal year 2023, the Compensation Committee considered the following factors:

Base salary levels at peer group companies to test for reasonableness and competitiveness

Subjective judgment in view of the Company’s compensation objectives

Relative internal pay levels and pay equity

Individual performance

Promotions or increased responsibility

Overall pay mix

Preference towards increased performance-based pay
Consistent with our compensation objectives, as executives progress to higher levels in the organization, a greater proportion of overall compensation is directly linked to Company performance and stockholder returns.
For 2023, the Compensation Committee reviewed the Named Executive Officers’ base salaries, considering the principles described above under “The Compensation Committee’s Processes.” The Compensation Committee

RITE AID CORPORATION   2023 Proxy Statement | 43

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
determined that increases in base salaries were necessary to reasonably maintain market competitiveness and to reflect increases in executives’ responsibilities. Specifically, Andre Persaud’s base salary was increased 17% to continue to bring him closer to market competitive levels, compensate him for taking on additional responsibilities and in an effort to retain this key executive. Justin Mennen’s base salary was increased 7% to reflect his new role as Chief Digital and Technology Officer and to maintain market competitiveness. On average, NEO salaries have remained close to the peer group median.
Ms. Burr’s base salary is $300,000 per month to compensate her for serving as interim CEO of the Company until a replacement is appointed. Ms. Burr’s compensation was determined by the Compensation Committee based on conversations with Mercer, referencing both median market total cash compensation levels and the cash compensation of the former CEO as well as the limited duration expected for the role. The Compensation Committee determined her base salary considering that, while serving as interim CEO, Ms. Burr will not receive compensation payable to non-employee members of the Board and she will not participate in the Company’s executive annual or long-term incentive plans. If Ms. Burr serves as interim CEO for more than six months, the Board will review her monthly salary. For details on her compensation, see “CEO Transition-Related Compensation Decisions.”
The table below details base salaries for our Named Executive Officers as of the end of fiscal year 2023 and describes the rationale for base salary increases:
ExecutiveBase Salary at
End of FY 2022
Base Salary
at End of
FY 2023
Change from
Prior Fiscal
Year
Rationale
Elizabeth Burr(1)N/A$3,600,000None
Heyward Donigan(2)$1,150,000$1,184,5003%To maintain market competitiveness
Matthew Schroeder$748,000$769,9253%To maintain market competitiveness
Paul Gilbert(3)$602,000$619,8543%To maintain market competitiveness
Justin Mennen$510,000$545,7007%To maintain market competitiveness;
significantly below median for the position
Andre Persaud(4)$500,000$586,00017%To maintain market competitiveness;
significantly below median for the position
(1)
Elizabeth Burr was appointed interim CEO effective January 7, 2023.
(2)
Heyward Donigan departed the Company on January 7, 2023.
(3)
Paul Gilbert departed the Company on April 7, 2023.
(4)
Andre Persaud departed the Company on March 6, 2023.
Annual Incentive Awards
The Company’s annual incentive plan is designed to be consistent with the goals of our executive compensation philosophy to drive performance and increase stockholder value and reward the NEOs for meeting the Company’s financial objectives. For each fiscal year, the Compensation Committee establishes a target percentage of salary for each participant at the beginning of the fiscal year and approves the financial goals required for the Company to pay an award. Payouts for the NEOs are based on the Company’s financial results for the year relative to the predetermined performance measures.
ANNUAL INCENTIVE TARGET OPPORTUNITIES. Target opportunities for each NEO were based on job responsibilities, internal relativity, and peer group and survey data. The Compensation Committee’s objective was to set bonus targets so total annual cash compensation (including base salary and annual incentive assuming a target payout) was generally aligned with the market with a substantial portion of that compensation linked to corporate performance.
Consistent with our executive compensation philosophy, individuals with greater job responsibilities had a greater proportion of their total cash compensation tied to Company performance through the incentive plan. Under the plan formula, payouts can range from 0% to 200% of target depending on Company performance. The

44 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
NEOs’ incentive targets did not increase in fiscal year 2023. The Compensation Committee established the following threshold, target and maximum payouts as a percentage of base salary for fiscal year 2023:
Annual Incentive Opportunity
ExecutiveThreshold Payout
(as a % of Salary)
Target Payout
(as a % of Salary)
Maximum Payout
(as a % of Salary)
Elizabeth Burr(1)0%0%0%
Heyward Donigan(2)100%200%400%
Matthew Schroeder50%100%200%
Paul Gilbert(3)37.5%75%150%
Justin Mennen50%100%200%
Andre Persaud(4)50%100%200%
(1)
Our interim CEO, Elizabeth Burr, did not participate in the review2023 Rite Aid Annual Incentive Plan.
(2)
Based on actual achievement against the metrics established under the 2023 Rite Aid Annual Incentive Plan, Heyward Donigan did not receive a payout under the 2023 Rite Aid Annual Incentive Plan consistent with other plan participants.
(3)
Paul Gilbert departed the Company on April 7, 2023 and is not eligible for a payout under the 2023 Rite Aid Annual Incentive Plan.
(4)
Andre Persaud departed the Company on March 6, 2023 and is not eligible for a payout under the 2023 Rite Aid Annual Incentive Plan.
ANNUAL INCENTIVE PLAN METRICS. To drive appropriate performance through the Annual Incentive Plan and to continue to balance stockholders’ concerns that the plan should use more than a single performance metric, the Compensation Committee retained the Adjusted EBITDA performance metric (weighted 70%) and replaced the Free Cash Flow metric with Operating Cash Flow (weighted 30%). Adjusted EBITDA is the most heavily weighted measure because it appropriately encourages the NEOs to focus on improving operating results which ultimately drive stockholder value. Operating Cash Flow is a critical metric for our Company as it represents the cash we generate from our normal business operations to support and grow our business. Adjusted EBITDA and Operating Cash Flow were selected as metrics to minimize overlap with the long-term incentive plan and because they provide executives with line of sight to their goals and are measures executives are able to impact. They also enhance alignment with stockholder value creation.
The target performance level for the Adjusted EBITDA target of $520 million for fiscal year 2023 was set above the fiscal year 2022 target of $490 million and the fiscal year 2022 actual performance of $506 million. The Compensation Committee also established a threshold at which management could be rewarded at 50% of bonus target at achievement of Adjusted EBITDA of $442 million (above the fiscal year 2022 threshold), and a maximum at which management could be rewarded at 200% of bonus target at achievement of Adjusted EBITDA of $598 million (above the fiscal year 2022 target of $539 million). The performance goals were set at these levels so that the plan continues to motivate executives to achieve the Company’s short-term financial objectives and to support executive retention during these challenging times. Given the challenges in fiscal year 2023, the Company did not meet the threshold performance levels for Adjusted EBITDA or recommendationOperating Cash Flow and the NEOs received $0 payouts under the annual bonus plan.

RITE AID CORPORATION   2023 Proxy Statement | 45

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Annual Incentive
Plan Metrics
WeightingDescription
Adjusted EBITDA
[MISSING IMAGE: pc_adjustedebitda-pn.jpg]
Adjusted EBITDA is the more heavily weighted measure because it appropriately encourages the NEOs to focus on improving operating results which ultimately drive stockholder value. EBITDA growth has historically shown a strong positive correlation with three-year and five-year total stockholder return for Rite Aid and its peer group. The majority of Rite Aid’s peer companies use an EBITDA measure in their annual incentive plans. Based on Rite Aid’s current financial situation and capital structure, the Compensation Committee believes that Adjusted EBITDA is the best indicator of Rite Aid’s operating performance. The measure is tracked regularly and is clearly understood by the officers and they can impact the measure by taking actions to improve the operating performance of our stores. In addition, the Company regularly communicates Adjusted EBITDA to the investment community.
The Compensation Committee established an Adjusted EBITDA performance target of $520 million for fiscal year 2023, based on the financial plan targets. The Compensation Committee established a threshold at which management could be rewarded at 50% of bonus target at achievement of Adjusted EBITDA of $442 million (85% of target), and a maximum at which management could be rewarded at 200% of bonus target at achievement of Adjusted EBITDA of $598 million (115% of target).
In fiscal year 2023, Consolidated Adjusted EBITDA was $429.2 million, which was below threshold due to a reduction in revenue from COVID-19 vaccines and testing, store closures and the loss of a large commercial client at Elixir.
Consolidated Adjusted EBITDA consists of Adjusted EBITDA from continuing operations. As discussed in greater detail in Appendix A, we define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility exit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation settlements, severance, restructuring-related costs, costs related to facility closures, gain or loss on sale of assets, gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). We emphasize Adjusted EBITDA, a non-GAAP financial measure, as a basis for incentive compensation and also in our corporate decision-making because it provides information that facilitates internal comparisons to the historical operating performance of prior periods and external comparisons to competitors’ historical operating performance.

46 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Annual Incentive
Plan Metrics
WeightingDescription
Operating Cash Flow
[MISSING IMAGE: pc_operatingcashflow-pn.jpg]
Operating cash flow is defined as cash flow from operating activities minus capital expenditures.
Operating Cash Flow is a critical metric for our Company as it represents the cash we generate to support and grow our business, and includes benefits generated from ongoing inventory and working capital management. A key aspect of our market value and future opportunities are derived from our ability to continue to reduce total debt outstanding and our corresponding leverage ratio.
Based on our current debt position, we believe Operating Cash Flow is the best indicator of our ability to continue to meet our debt obligations, pay down debt and to enhance the Company’s capital structure. The use of Operating Cash Flow provides executives enhanced line of sight and aligns our management to the key objective of delivering enhanced stockholder value.
The Compensation Committee established an Operating Cash Flow performance target of $8 million for fiscal year 2023, based on the financial plan targets. In addition, the Compensation Committee established a threshold at which management could be rewarded at 50% of bonus target at achievement of Operating Cash Flow of negative $45 million, and a maximum at which management could be rewarded at 200% of bonus target at achievement of Free Cash Flow of $86 million.
In fiscal year 2023, Operating Cash Flow as defined for the purpose of the compensation metric was negative $276.3 million, which was below the threshold for payout. Operating Cash Flow was impacted by a decrease in Adjusted EBITDA, an increase in interest expense and other changes in working capital.
The threshold, target, maximum and actual performance against the goals for the annual incentive plan for fiscal year 2023 are each set out in the table below. For fiscal year 2023, our Adjusted EBITDA for the Rite Aid annual bonus plan calculation was $429.2 million, which was below our threshold of $442 million and Operating Cash Flow was negative $276.3 million, which was below the threshold of negative $45 million, due to lower than planned EBITDA, higher than planned interest expenses and lower than expected working capital benefits due to inventory inflation.
Fiscal Year 2023 Rite Aid Annual Incentive Plan Performance Goal
Performance
Level
WeightingThreshold
(50%)
Target
(100%)
Maximum
(200%)
Actual
Performance
AchievementResulting Weighted
Payout
as a % of
Target Award
Adjusted EBITDA (millions)70%$442$520$598$429.2Below threshold0%
Operating Cash Flow (millions)30%$(45)$8$86$(276.3)Below threshold0%
Total Resulting Payout0%
Adjusted EBITDA and Operating Cash Flow performance relative to the goals listed above resulted in short-term incentive plan payouts of 0% of target award opportunities for fiscal year 2023.

RITE AID CORPORATION   2023 Proxy Statement | 47

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
The actual plan payouts and their percentage of target for fiscal year 2023 are set out in the table below:
Fiscal Year 2023 Rite Aid Annual Incentive Plan Payouts
ExecutiveTarget Bonus Opportunity% of TargetCalculated Payout
Elizabeth Burr(1)$00%$0
Heyward Donigan(2)$2,369,0000%$0
Matthew Schroeder$769,9250%$0
Paul Gilbert(3)$464,8910%$0
Justin Mennen$545,7000%$0
Andre Persaud(4)$586,0000%$0
(1)
Ms. Burr did not participate in the 2023 Rite Aid Annual Incentive Plan.
(2)
Based on actual achievement against the metrics established under the 2023 Rite Aid Annual Incentive Plan, Heyward Donigan did not receive a payout under the 2023 Rite Aid Annual Incentive Plan consistent with other participants.
(3)
Mr. Gilbert was not eligible to receive the fiscal year 2023 Annual Incentive Plan award as a result of his departure from the Company on April 7, 2023, prior to the payment date.
(4)
Mr. Persaud was not eligible to receive the fiscal year 2023 Annual Incentive Plan award as a result of his departure from the Company on March 6, 2023, prior to the payment date.
Long-Term Incentive Program
The purpose of the auditedlong-term incentive program is to support the long-term perspective necessary for continued success in our business and focus our NEOs on creating long-term, sustainable stockholder value.
LONG-TERM INCENTIVE TARGET OPPORTUNITY. Our annual long-term incentive (“LTI”) target opportunities for each NEO are shown below:
Long-Term Incentive Target Opportunities
ExecutiveTarget Opportunity
(as a % of Salary)
Elizabeth Burr(1)0%
Heyward Donigan(2)600%
Matthew Schroeder250%
Paul Gilbert(3)150%
Justin Mennen150%
Andre Persaud(4)175%
(1)
Our interim CEO, Ms. Burr, is not eligible for the Long-Term Incentive Program.
(2)
Ms. Donigan is no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards as a result of her departure on January 7, 2023.
(3)
Mr. Gilbert is no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards, as a result of his departure on April 7, 2023.
(4)
Mr. Persaud is no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards, as a result of his departure on March 6, 2023.
The Compensation Committee reviewed peer group data and found that the design of the long-term incentive program is reasonably aligned with general retail industry market practice. Target grant values for individual executive officers were established based on individual performance, ability to effect results and internal relativity. Consistent with the Company’s compensation philosophy, executive officers at higher levels received a

48 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
greater proportion of total pay in the form of long-term incentives. For fiscal year 2023, the Company maintained each NEOs’ target opportunities, which were last increased in fiscal year 2021 to provide a larger portion of their total target compensation in the form of equity and create better alignment with Company performance and stockholders’ interests.
LONG-TERM INCENTIVE MIX. Under the LTI program, we grant a combination of performance-based units and restricted stock. Restricted stock grants generally vest over a multi-year period (three years or longer) and are tied to the value of our stock. Performance-based awards, where the ultimate payout may vary, require Rite Aid to count more shares against the number of shares available for issuance if above-target performance is achieved to the benefit of all stakeholders. We are also careful to manage share usage and are sensitive to our share burn rate and dilution. We have maintained the equity mix of performance-based units at 55% in fiscal year 2023, in light of these considerations. Performance-based compensation provides an upside for extraordinary performance and less or no compensation when the pre-established performance objectives are not achieved. An adequate share reserve is needed to grant variable performance-based units which can be earned at or above target depending on performance.
VehicleApproximate Proportion of
2023 Long-Term Incentive
Target Opportunity
Purpose
Performance-Based Units
[MISSING IMAGE: tm217739d1-pc_vehiclepbupn.jpg]
Links compensation to multi-year operating results on key measures tied to stockholder value creation
Restricted Stock
[MISSING IMAGE: tm217739d1-pc_vehiclerestpn.jpg]
Supports retention and provides a vehicle with more stability and less risk. Aligns executive and stockholder interests and focuses executives on value creation
In determining the overall mix of long-term incentive vehicles, the following factors were considered:

Risk/reward tradeoffs: Using multiple long-term incentive vehicles can balance the need for a strong performance-based program against risk to executives.

Performance measurement: Using a combination of vehicles allows the Company to focus executives on both stock price appreciation and achievement of consistent operating results, which we believe leads to creation of value for stockholders.

Management of share usage and market practice: Rite Aid considers market practice concerning both share usage and competitive long-term incentive levels. Rite Aid uses either a stock-based performance vehicle or a cash-based performance vehicle which is aligned with peer companies and retailers of similar size. The target LTI mix has been selected to align the compensation opportunity for executives and associates with our stockholder return.
The Compensation Committee’s process for setting grant dates is discussed below. On the approval date, those values are converted to the equivalent number of shares based on the closing price of the Company’s common stock on the date of approval.
GRANT TIMING. The Compensation Committee has a policy that, in the normal course, annual long-term incentive awards (other than special or new hire grants) will be approved by the Compensation Committee once a year at its annual meeting held in connection with the annual stockholders’ meeting, with a grant date of the later of the second business day after release of the Company’s first quarter earnings or the date of approval. Grants are made to the NEOs at the same time awards are made to all other associates as part of the annual grant process.
SPECIAL AWARDS. From time to time, the Company may make grants in addition to the annual equity grant, including to NEOs. Typically, these grants include awards such as new hire inducement awards, promotional awards, or retention awards. Special awards can also be used to provide performance incentives in connection with specific corporate or financial statementsgoals of the Company. In 2023, a special one-time award of $255,000 in

RITE AID CORPORATION   2023 Proxy Statement | 49

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
restricted stock was granted to Justin Mennen to reflect his increased responsibilities for the digital business without a corresponding salary increase for the change in duties and to encourage his retention given the importance of his more significant role. The award will vest in full after three years if he remains employed with the Company.
Performance Awards
Performance awards are intended to align the interests of the executives with those of stockholders through the use of measures the Company believes drive its long-term success. Performance awards are normally granted annually and are structured as a targeted number of units based on the Company’s achievement of specific performance levels with payout generally occurring after a three-year period.
2023 Performance-based Units
For the 2023 performance-based unit grants (“2023-2025 Plan”), the Compensation Committee incorporated new performance metrics as the financial indicators of our long-term success. In 2023, the metrics were revised to eliminate overlap with the annual plan, relate more directly to stockholder return and provide a greater focus on three metrics related to growth: Cumulative Scripts, Elixir Membership and Total Front-end Revenue. These growth metrics provide executives a greater line of sight to their goals and are more tangible metrics in their day-to-day work. Also, by diversifying the performance metrics across Rite Aid’s performance-based program of annual and long-term incentives, the Company seeks to ensure that the program drives Company performance across multiple metrics and that the variable pay components are suitably challenging. The 2023 awards are based on the following four performance metrics:

TSR relative to the Russell 3000 Index (weighted 25%)

30-day Cumulative Scripts (excluding controlled substances) (weighted 30%)

Two-year Elixir Membership (excluding Elixir Insurance) (weighted 30%)

Two-year Total Front-end Revenue (excluding Pharmacy, tobacco and Elixir Insurance) (weighted 15%)
The Compensation Committee decided to use two-year performance periods for the Elixir Membership and Total Front-end Revenue given the timing of our CEO transition and the challenges of setting three-year performance metrics in a volatile market environment.
For 2023, the Compensation Committee added a 25%-weighted Relative TSR metric to provide an incentive for executives to create sustainable long-term value for the Company and to enhance the alignment of the interests of our executives with those of our stockholders. At the same time, the Committee eliminated the relative TSR modifier of +/− 25% that was in place in prior years.
As shown in the table below, payouts can range from 0% (for performance below threshold) to 150% of the target number of units (for performance at or above maximum), with 37.5% earned for performance at the threshold levels.
2023-2025 Plan: Performance-based Units
ExecutiveThreshold Award
($)
Target Award
($)
Maximum Award
($)
Elizabeth Burr(1)000
Heyward Donigan(2)1,465,8193,908,8505,863,274
Matthew Schroeder396,9921,058,6451,587,968
Paul Gilbert(2)191,765511,374767,060
Justin Mennen168,826450,202675,303
Andre Persaud(2)196,709524,557786,836
(1)
Ms. Burr is not eligible to participate in the Long-Term Incentive Plan.

50 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
(2)
Ms. Donigan, Mr. Gilbert and Mr. Persaud are no longer eligible to earn the fiscal year 2023-2025 long-term performance-based unit awards granted to each executive on July 27, 2022 as a result of each executive’s departure from the Company.
2022 Performance-based Units
For the 2022 performance-based unit grants (“2022-2024 Plan”), the Compensation Committee maintained the metrics used in the 2021-2023 Plan. Revisions were made to the weighting to better balance the incentives toward profitability, growth and financial health. The 2022 awards were based on the following performance metrics:

Three-year Leverage Ratio weighted 34% (continued from FY21 Plan Design but decreased from 50% to 34%)

Three-Year Cumulative Revenue weighted 33% (continued from FY21 Plan Design but increased from 25% to 33%)

Three-Year Cumulative Scripts weighted 33% (continued from FY21 Plan Design but increased from 25% to 33%)
As in prior years, to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/− 25% based on our relative stockholder return versus the Russell 3000 Index over the three-year cliff vesting period, which ends after certification of fiscal year 2024 results.
As shown in the table below, payouts can range from 0% (for performance below threshold) to 187.5% of the target number of units (for performance at or above maximum), with 37.5% earned for performance at the threshold levels.
2022-2024 Plan: Performance-based Units
ExecutiveThreshold Award
($)
Target Award
($)
Maximum Award
($)
Heyward Donigan(1)1,423,1203,794,9887,115,602
Matthew Schroeder385,6871,028,4971,928,433
Paul Gilbert(1)186,243496,647931,213
Justin Mennen157,777420,739788,886
Andre Persaud(1)180,467481,245902,335
(1)
Ms. Donigan, Mr. Gilbert and Mr. Persaud are no longer eligible to earn the fiscal year 2022-2024 long-term performance-based unit awards granted to each executive on July 7, 2021 as a result of each executive’s departure from the Company.
2021 Performance-based Units
For the 2021 performance-based unit grants (“2021-2023 Plan”), the Compensation Committee established performance metrics that were the financial indicators of our long-term success. The 2021 awards were earned based on the following performance metrics:

Three-year Leverage Ratio weighted 50%

Two-Year Cumulative Revenue weighted 25%

Two-Year Cumulative Scripts weighted 25%
As in prior years, to further align the interests of our executives with those of our stockholders and add an additional incentive for them to create sustainable long-term value for the Company, the Compensation Committee also determined to subject the award to modification of +/− 25% based on our relative stockholder return versus the Russell 3000 Index over the three-year cliff vesting period, which ended after certification of fiscal year 2023 results.

RITE AID CORPORATION   2023 Proxy Statement | 51

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
As shown in the table below, payouts can range from 0% (for performance below threshold) to 187.5% of the target number of units (for performance at or above maximum), with 37.5% earned for performance at the threshold levels.
The following charts summarize the financial performance calculation and the cash payment that was earned:
Financial Performance Calculation: 2021-2023 Plan
Component
Metric
Component
Weighting
Threshold
Performance
(50% Payout)
Target
Performance
(100% Payout)
Maximum
Performance
(200% Payout)
Actual
Performance
Component
Payout %
2021-2023
Leverage Ratio
[MISSING IMAGE: tm228886d1-pc_ebitdapn.jpg]
4.5%4.0%3.5%6.49%0%
2021-2022
Cum. Revenue
[MISSING IMAGE: tm228886d1-pc_ratiopn.jpg]
$16,885$17,774$20,440$17,08915.4%
2021-2022
Cum. Scripts
(in millions)
[MISSING IMAGE: tm228886d2-pc_ratio1bw.jpg]
422.1444.3511.0459.227.8%
Weighted Sub-Total43.2%
TSR Relative to
Russell 3000
ModifierSee Note (a)
below.
-25%
Final Calculated
Payout
32.4%
(a)
The TSR of negative 72.37% over the performance period ended March 4, 2023 corresponded to a percentile rank of 8th (2,407 out of 2,607), which was in the bottom third and resulted in a TSR multiple of .75x.
2021-2023 Plan Payouts
ExecutiveShares Underlying
Award at Target
(#)
Payout
(%)
Calculated Payout/
Shares Settled
(#)
Matthew Schroeder49,76332.416,123
Justin Mennen22,96832.47,441
Restricted Stock—Awards Under Fiscal Year 2023 Plan
Restricted stock grants are intended to support retention of executives and focus them on long-term performance because they vest over a multi-year period (ratably over the three years from the date of grant) and are tied to the value of our stock. The risk profile of restricted stock is aligned with stockholders, as it can motivate executives to both increase and preserve stock price. The table below summarizes 2023 restricted stock awards:

52 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
2023 Restricted Stock Awards
ExecutiveAward Value
($)
Number of Shares
(#)
Heyward Donigan(1)3,198,144429,858
Matthew Schroeder866,165116,420
Paul Gilbert(2)418,39656,236
Justin Mennen623,14775,509
Andre Persaud(3)429,18457,686
(1)
Ms. Donigan is not eligible for one-third of the restricted stock awards granted on July 27, 2022 as a result of her separation from the Company on January 7, 2023.
(2)
Mr. Gilbert is not eligible for the restricted stock awards granted on July 27, 2022 as a result of his separation from the Company on April 7, 2023.
(3)
Mr. Persaud is not eligible for the restricted stock awards granted on July 27, 2022 as a result of his separation from the Company on March 6, 2023.
CEO Transition-Related Compensation Decisions
On January 7, 2023, the Board appointed Ms. Burr as interim CEO in connection with the related departure of Heyward Donigan, our former President and CEO. The Company entered into an offer letter with Ms. Burr, dated as of January 7, 2023, which provides Ms. Burr a base salary of $300,000 a month while serving as interim CEO of the Company. While serving as interim CEO of the Company, Ms. Burr will not receive the compensation payable to non-employee members of the Board and she will not participate in the Company’s short- or long-term incentive plans, 401(k) plan, group medical, dental and vision insurance plans. Ms. Burr’s compensation was determined by the Compensation Committee based on conversations with Mercer, referencing both median market total cash compensation levels and the cash compensation of the former CEO as well as the limited duration expected for the role. If Ms. Burr serves as interim CEO for more than six months, the Board will review her monthly salary. For details on her offer letter, see “Executive Employment Agreements—Interim CEO Offer Letter with Elizabeth Burr.”
The Board determined that Ms. Donigan’s departure from the Company constituted a termination without cause under her employment agreement with us, entitling her to the severance benefits provided under the employment agreement. For details regarding the severance benefits provided to Ms. Donigan under the separation agreement entered into upon her departure from the Company, see “Executive Compensation: Potential Payments Upon Termination or Change in Control—Named Executive Officer Departures.”
Post-Employment and Change in Control Benefits
To attract highly skilled executives and to provide for certainty of rights and obligations, Rite Aid has historically provided employment agreements to its executive officers, including our Named Executive Officers. The terms of the employment agreements are described in more detail under the caption “Executive Employment Agreements.” Additional information regarding the severance and change in control benefits provided under the employment agreements is described under the section entitled “Executive Compensation—Potential Payments Upon Termination or Change in Control.”
Other Benefits
Our compensation program for our Named Executive Officers also features other benefits, including participation in our 401(k) savings plan, a tax-qualified defined contribution plan under which participants can save for retirement subject to IRS limits, and life, disability and health insurance benefits on the same general terms as other participants in these programs. We provide very limited perquisites to officers of the Company including the Named Executive Officers pursuant to the officer’s employment agreements, such as financial planning and automobile allowances.

RITE AID CORPORATION   2023 Proxy Statement | 53

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Deductibility Cap on Executive Compensation
To maintain flexibility and the ability to pay competitive compensation, we do not require all compensation to be deductible. Section 162(m) of the Internal Revenue Code generally limits to $1.0 million the amount of remuneration that the Company may deduct in any calendar year for certain executive officers. Prior to 2018, we structured our annual incentive awards and long-term incentive awards with the intention of meeting the exception to this limitation for “performance-based” compensation, as defined in Section 162(m), so that these amounts could be fully deductible for income tax purposes. The performance-based exception was eliminated effective January 1, 2018, and compensation paid to our NEOs in excess of $1.0 million will not be deductible unless it qualifies for transition relief applicable to certain arrangements in place as of, and not modified after, November 2, 2017. To maintain the flexibility to provide compensation programs for our NEOs that will best incentivize them to achieve our key business objectives and create sustainable long-term stockholder value, the Compensation Committee reserves the right to pay compensation that may not be deductible to the Company if it determines that doing so would be in the best interests of the Company.
Policy Regarding Recoupment of Certain Compensation
The Company has adopted a formal compensation recovery or “clawback” policy for its executive officers, including all NEOs, which covers all compensation paid or awarded. Under the policy, the Board of Directors may seek to recoup from executives certain incentive compensation, including cash bonuses and equity incentive awards paid based on the achievement of financial performance metrics, in the event the Company is required to restate its financial statements. In March 2020, the Board amended the Company’s clawback policy to (1) expand its scope to cover executive officers’ misconduct in violation of law, Company policy or the code of conduct, including an executive officer’s material failure to exercise his or her assigned oversight responsibilities, that results in material financial, operational or reputational harm to the Company (collectively, “Detrimental Harm”) and (2) require public disclosure of recoupment of compensation where the underlying facts are disclosed, subject to certain legal and privacy rights considerations. The Board of Directors may seek to recoup, or cause to be forfeited, all or a portion of the bonus, incentive compensation or equity-based compensation received by, or awarded in respect of the period of misconduct in cases of Detrimental Harm.
In 2022, the SEC adopted final rules implementing the incentive-based compensation recovery provisions of the Dodd-Frank Act. The Company intends to review and revise its current recoupment policies and/or adopt a new recoupment policy, as necessary to comply with the new requirements once the NYSE listing standards become effective.
Prohibition on Margin Accounts and Hedging and Similar Transactions
Our directors, officers and other associates are prohibited from engaging in hedging or monetization transactions, such as zero-cost collars, equity swaps, exchange funds and forward sale contracts, with respect to our securities. Because hedging transactions might allow a director, officer or other associate to continue to own our securities, whether obtained through our equity compensation plans or otherwise, without the full risks and rewards of ownership, such hedging transactions are prohibited. Directors, officers and other employees are also prohibited from holding in a margin account, or otherwise pledging, Company securities as collateral for a loan.
Director and Officer Stock Ownership Guidelines
Our Stock Ownership Guidelines have been established to further the investment of our non-management directors, executive officers, and Senior Vice Presidents in the success of the Company and to encourage a long-term perspective in managing the Company.

54 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
The current stock ownership requirements are:
PositionMinimum Ownership Requirements
Chief Executive Officer5 times base salary
Senior Executive Vice Presidents3 times base salary
Executive Vice Presidents2 times base salary
Senior Vice Presidents1 times base salary
Non-Management Directors5 times annual cash retainer
Newly appointed or promoted executives who are or become subject to our Stock Ownership Guidelines and newly elected non-management directors have five years from the time they are appointed, promoted, or elected, to meet the stock ownership requirements. In June 2022, the plan was modified to provide that participants are considered to be in compliance with the guidelines if they have previously met the requirements, as long as the individual’s number of shares did not decrease. Given how new each of our Named Executive Officers is in his or her role, and how modest current equity holdings are as a result, it will be critical to continue to promote the alignment of our Named Executives Officers’ interests with those of our stockholders.
For purposes of determining stock ownership levels, the following forms of equity interests in the Company are included:

Shares owned outright by the participant or his or her immediate family members residing in the same household;

Restricted stock and restricted stock units whether or not vested; and

Shares underlying Rite Aid stock options whether or not vested.
Restricted stock and restricted stock units, whether or not vested, and shares owned count as one (1) share equivalent per share beneficially owned and stock options, whether or not vested, count as one-half (.5) share equivalent per stock option.
The Compensation Committee is responsible for interpreting and administering the Stock Ownership Guidelines, and may, from time to time, reevaluate and revise the Stock Ownership Guidelines, including when there are changes to the Company’s capital structure or where implementation of the Stock Ownership Guidelines would cause a non-management director, executive officer, or Senior Vice President to incur a hardship due to his or her unique financial circumstances.
COMPENSATION COMMITTEE REPORT
The Compensation Committee of the Board of Directors has reviewed and discussed the foregoing Compensation Discussion and Analysis with management and based on that review and discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in our Annual Report on Form 10-Kthis proxy statement.
THE COMPENSATION COMMITTEE
Kate B. Quinn, Chair
Robert E. Knowling, Jr.
Arun Nayar

RITE AID CORPORATION   2023 Proxy Statement | 55

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION TABLES
Summary Compensation Table
The following summary compensation table sets forth the cash and non-cash compensation for the fiscal year ended March 2,4, 2023 paid to or earned by (i) all persons who served as our principal executive officer, (ii) all persons who served as our principal financial officer, and (iii) the three most highly compensated executive officers of the Company other than the principal executive officer or the principal financial officer who were serving at the end of the 2023 fiscal year (collectively, the “Named Executive Officers”). The summary compensation table also sets forth the cash and non-cash compensation for the fiscal years ended February 26, 2022 and February 27, 2021, respectively, for such individuals who were Named Executive Officers in the applicable fiscal year or as otherwise required by SEC rules.
Name and
Principal Position
Fiscal
Year
Salary
($)
Bonus
($)
Stock
Awards
($)
(1)
Non-Equity
Incentive
Plan 
Compensation
($)
(2)
All Other
Compensation
($)
(3)
Total
($)
Elizabeth Burr(4)
(interim CEO)
2023588,462159,997110,000858,459
Heyward Donigan(5)
(Former President
and CEO)
20231,043,7137,106,993617,1058,767,811
20221,126,9236,547,4272,208,00029,1579,911,507
20211,000,0001,160,0007,389,08722,0009,571,087
Matthew Schroeder
(Executive VP, CFO)
2023796,9211,924,81025,6002,747,331
2022732,9431,774,444912,99116,6833,437,061
2021648,177377,0582,001,211137,41212,0003,175,858
Justin Mennen(6)
(Executive VP, Chief
Digital and Technology
Officer)
2023562,4321,073,34925,2551,661,036
2022510,000764,983367,20012,7261,654,909
2021500,000217,500923,63613,6551,654,791
Paul Gilbert(7)
(Former Executive
VP, Chief Legal
Officer, and Secretary)
2023641,566929,76926,5751,597,910
2022600,154856,856433,44018,5601,909,010
Andre Persaud(8)
(Former Executive
VP, Chief Retail
Officer)
2023570,058953,74126,7501,550,549
(1)
The amounts reported reflect the aggregate grant date fair value of each stock award computed in accordance with FASB ASC Topic 718 under the assumptions noted. For information regarding the assumptions used in determining the fair value of an award shown in this column, please refer to Note 18 of the Company’s Annual Report on Form 10-K as filed with the SEC on May 1, 2023, Note 18 of the Company’s Annual Report on Form 10-K as filed with the SEC on April 25, 2022, and Note 18 of the Company’s Annual Report on Form 10-K as filed with the SEC on April 27, 2021. The value presented for fiscal year 2023 includes the grant date fair value of restricted stock awards (restricted stock units for Ms. Burr, granted while serving as a director of the Company) and performance awards at target, as shown in the chart below. Assuming the maximum level of achievement under the performance awards, the grant date fair value of such awards for each of the Named Executive Officers are estimated to be as follows: Ms. Donigan, $5,863,274; Mr. Schroeder, $1,587,968; Mr. Gilbert, $767,060; Mr. Mennen, $675,303; and Mr. Persaud, $786,836. The performance awards are subject to liability accounting under FASB ASC Topic 718 and the value reported represents the value for the reporting period ended March 4, 2023, assuming the stock price of $3.58.

56 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
NameRestricted Stock
Units
($)
Restricted Stock
Award
($)
Performance Award
Target Performance
($)
Total Stock
Award
($)
Ms. Burr(a)159,997159,997
Ms. Donigan(b)3,198,1443,908,8507,106,993
Mr. Schroeder866,1651,058,6451,924,810
Mr. Mennen623,147450,2021,073,349
Mr. Gilbert(b)418,396511,374929,769
Mr. Persaud(b)429,184524,557953,741
(a)
Represents the grant date value of restricted stock units granted in fiscal year 2023 while serving as a director of the Company.
(b)
Ms. Donigan, Mr. Gilbert and Mr. Persaud each forfeited the performance award shown upon their departure from the Company on January 7, 2023, April 7, 2023 and March 6, 2023, respectively.
(2)
Represents annual cash incentive bonuses earned in the applicable fiscal year.
(3)
The amounts in the “All Other Compensation” column for fiscal year 2023 consist of the following:
NameFinancial
Planning
($)
COBRA
Payment
($)
Severance
($)
Automobile
Allowance
($)
Director
Fees
($)
(a)
401(k) Match
($)
Ms. Burr110,000
Ms. Donigan(b)10,00037,413546,69211,00012,000
Mr. Schroeder1,60012,00012,000
Mr. Mennen1,25512,00012,000
Mr. Gilbert2,57512,00012,000
Mr. Persaud2,75012,00012,000
(a)
Represents fees earned and paid in cash for Ms. Burr’s service as a director during fiscal year 2023.
(b)
Ms. Donigan departed the Company on January 7, 2023. Details regarding her separation and release agreement entered into pursuant to Section 5.3 of Ms. Donigan’s employment agreement are provided below under the caption “Potential Payments Upon Termination or Change in Control—Named Executive Officer Departures.” The severance amount reported in this table does not include the value of any accelerated vesting of equity awards Ms. Donigan was entitled to receive upon her departure. For a summary of such amounts, see same caption below.
(4)
Ms. Burr has been a director of the Company since 2019 and was appointed interim CEO effective January 7, 2023. The compensation reported in this table reflects cash fees earned and restricted stock units granted in fiscal year 2023 while serving as a director of the Company, and $588,462 in base salary earned while serving as interim CEO. See “Executive Employment Agreements” below, for additional details related to the terms of Ms. Burr’s compensation while serving as interim CEO.
(5)
Ms. Donigan joined the Company on August 12, 2019 and departed on January 7, 2023.
(6)
Mr. Mennen joined the Company in December 2018. He was previously a Named Executive Officer of the Company in fiscal year 2021 and, accordingly, we are disclosing the cash and non-cash compensation for each of the Company’s three prior completed fiscal years.
(7)
Mr. Gilbert first became a Named Executive Officer of the Company in fiscal year 2022 and departed on April 7, 2023 after the end of our 2023 fiscal year.
(8)
Mr. Persaud joined the Company in February 2020 and departed on March 6, 2023 after the end of our 2023 fiscal year.

RITE AID CORPORATION   2023 Proxy Statement | 57

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Grants of Plan-Based Awards Table for Fiscal Year 2023
The following table summarizes grants of plan-based awards made to Named Executive Officers during our fiscal year ended March 4, 2023.
Estimated Future Payouts
Under Non-Equity
Incentive Plan Awards
(1)
Estimated Future
Payouts Under Equity
Incentive Plan Awards
(2)
NameGrant DateThreshold
($)
Target
($)
Max
($)
Threshold
(#)
Target
(#)
Max
(#)
All Other
Stock
Awards
(#)
(3)
Grant Date Fair
Value of Stock
and Option
Awards
($)
(4)
Elizabeth Burr7/27/202221,505(5)159,997
Heyward Donigan7/27/2022197,019525,383985,0933,908,850
7/27/2022429,8583,198,144
1,184,5002,369,0004,738,000
Matthew Schroeder7/27/202253,359142,291266,7961,058,645
7/27/2022116,420866,165
384,963769,9251,539,850
Justin Mennen7/27/202222,69260,511113,458450,202
3/22/202226,000254,800
7/27/202249,509368,347
272,850545,7001,091,400
Paul Gilbert7/27/202225,77568,733128,874511,374
7/27/202256,236418,396
232,445464,891929,781
7/27/202226,43970,505132,197524,557
Andre Persaud7/27/202257,686429,184
272,500586,0001,090,000
(1)
Reflects each such officer’s opportunity to earn an annual cash incentive bonus, as discussed in the Compensation Discussion and Analysis under the caption “Annual Incentive Awards.” No annual cash incentives were earned for the 2023 fiscal year, as shown in the Summary Compensation Table.
(2)
On July 27, 2022, each Named Executive Officer (with the exception of Ms. Burr) received a grant of performance stock units that will be earned at the end of the Company’s 2025 fiscal year based upon the achievement of a two-year cumulative revenue goal and two-year Elixir membership goal, subject to a +/- 25% TSR modifier, provided that the Named Executive Officer is continuously employed at the Company through the date the Compensation Committee certifies the fiscal 2025 earnings results.
(3)
On July 27, 2022, the Named Executive Officers (with the exception of Ms. Burr) received a grant of restricted stock, as described in the Compensation Discussion and Analysis, under the caption “Components of Executive Compensation for Fiscal Year 2023-Restricted Stock Awards Under Fiscal Year 2023 Plan.” These grants will vest based on continued employment with respect to one third on each of the first three anniversaries of the grant date.
(4)
Represents the grant date fair value, measured in accordance with FASB ASC Topic 718 of stock awards made in fiscal year 2023. Grant date fair values are calculated pursuant to assumptions set forth in Note 18 of the Company’s Annual Report on form 10-K filed with the SEC on May 1, 2023. The performance awards are subject to liability accounting under FASB ASC Topic 718 and the value reported represents the value for the reporting period ended March 4, 2023, assuming the stock price of $3.58.
(5)
Represents the annual award of restricted stock units for fiscal year 2023, granted in connection with Ms. Burr’s service as a director of the Company. The restricted stock units were vested on the date of grant and the shares subject to the grant will become payable on a deferred basis upon her separation from service as a director.
Executive Employment Agreements
Rite Aid entered into employment agreements with each of the Named Executive Officers, which governed the material terms of their employment and were in effect during the Company’s last completed fiscal year during the duration of the Named Executive Officer’s employment with us.

58 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Interim CEO Offer Letter with Elizabeth Burr
TERM; BASE SALARY; INCENTIVES. The Company entered into an offer letter with Ms. Burr, dated as of January 7, 2023. The offer letter provides Ms. Burr with a base salary of $300,000 per month while serving as interim CEO of the Company. Ms. Burr will not receive the compensation payable to non-employee members of the Board while serving as interim CEO of the Company. The offer letter also provides that Ms. Burr will not participate in or receive benefits under the Company’s employee benefit plans and programs including, but not limited to, the Company’s bonus incentive plans, 401(k) plan, group medical, dental and vision insurance plans. If Ms. Burr serves as interim CEO for more than six (6) full months, the Board will review the monthly salary and consider in good faith whether to increase the monthly salary for interim CEO service in excess of six (6) months.
Employment Agreement with Former CEO Heyward Donigan
TERM; BASE SALARY; INCENTIVES. The Company entered into an employment agreement with Ms. Donigan, dated as of August 8, 2019. The agreement provided Ms. Donigan with a base salary and an incentive compensation target. The following base salary amount and incentive targets applied to Ms. Donigan during fiscal 2023: base salary was increased to $1,184,500, her target annual bonus opportunity was set at 200% of base salary, and her target long-term incentive compensation award opportunity continued to be set at 600% of her base salary. See “Named Executive Officer Departures—Separation Agreement with Heyward Donigan” below for details on her separation agreement.

Employment Agreements with Matthew Schroeder, Justin Mennen, Paul Gilbert and Andre Persaud
IN GENERAL. Each of the employment agreements entered into with Messrs. Schroeder, Mennen, Gilbert and Persaud, respectively, provide for a term of employment that is automatically renewed from year to year, unless either party provides the other with 120 (180 for Mr. Schroeder) days’ notice of an intent not to renew.
SALARY AND INCENTIVES. The respective agreements provide each executive with a base salary and incentive compensation targets (which may be reviewed periodically for increase by the Compensation Committee). The following base salary amounts and incentive targets applied to the Named Executive Officers during fiscal year 2023: Mr. Schroeder’s base salary was increased to $769,925, his target annual bonus opportunity was set at 100% of base salary, and his target long-term incentive compensation award opportunity was set at 250% of his base salary; Mr. Mennen’s base salary was increased to $545,700, his target annual bonus opportunity was set at 100% of base salary, and his target long-term incentive compensation award opportunity was set at 150% of his base salary; Mr. Gilbert’s base salary was increased to $619,854, his target annual bonus opportunity was set at 75% of base salary, and his target long-term incentive compensation award opportunity was set at 150% of his base salary; and Mr. Persaud’s base salary was increased to $586,000, his target annual bonus opportunity was set at 100% of base salary, and his target long-term incentive compensation award opportunity was set at 175% of his base salary.
See “Named Executive Officer Departures—Paul Gilbert Departure” and “Named Executive Officer Departures—Andrew Persaud Departure” below for details on their departures following the end of fiscal year 2023.
Terms Applicable to All Named Executive Officers Under Employment Agreements (Other than Ms. Burr)
OTHER BENEFITS. Pursuant to their employment agreements, while employed, each of the Named Executive Officers is entitled to participate in Rite Aid’s tax-qualified savings plan, welfare benefits, fringe benefit and perquisite programs as in effect from time to time.
RESTRICTIVE COVENANTS. The employment agreement of each Named Executive Officer prohibits the officer from competing with Rite Aid during his or her employment period and for a period of one year (two years for Mr. Schroeder) thereafter.

RITE AID CORPORATION   2023 Proxy Statement | 59

TABLE OF CONTENTS

EXECUTIVE COMPENSATION
TERMINATION AND CHANGE IN CONTROL BENEFITS. The provisions of the employment agreements relating to termination of employment are described under the caption “Potential Payments Upon Termination or Change in Control” below.
Outstanding Equity Awards at Fiscal Year 2023 Year-End
The following table summarizes the number of securities underlying outstanding equity awards for the Named Executive Officers as of the end of fiscal year 2023.
Option AwardsStock Awards
NameDate of
Grant
Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)
Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
Option
Exercise
Price
($)
Option
Expiration
Date
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
(2)(3)
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)
(4)
Equity
Incentive
Plan
Awards:
# of
Unearned
Shares or
Units That
Have Not
Vested
(#)
(2)(5)
Equity
Incentive
Plan 
Awards:
Market or
Payout
Value of
Unearned
Shares or
Units of
Stock That
Have Not
Vested
($)
(4)
Elizabeth Burr(1)
Heyward Donigan8/12/2019502,9137.024/7/2023
Matthew Schroeder6/24/201369455.206/24/2023
6/23/2014740141.606/23/2024
6/24/2015745173.606/24/2025
7/8/202013,57148,58449,763178,152
7/7/202137,226133,26968,248244,328
7/27/2022116,420416,784142,291509,402
Justin Mennen7/8/20206,26422,42522,96882,225
7/7/202115,22854,51627,91999,950
3/22/202226,00093,080
7/27/202249,509177,24260,511216,629
Paul Gilbert(6)
8/17/202011,20040,096
7/7/202117,97664,35432,956117,982
7/27/202256,236201,32568,733246,064
Andre Persaud(7)
7/8/20205,95021,30121,81978,112
7/7/202117,41862,35631,934114,324
7/27/202257,686206,51670,505252,408
(1)
Elizabeth Burr did not have any outstanding equity awards at 2023 fiscal year-end.
(2)
Refer to “Potential Payments Upon Termination or Change in Control” below for circumstances under which the terms of the vesting of equity awards would be accelerated.
(3)
Restricted shares will generally vest one-third on each of the first three anniversaries of the grant date, based on continued employment.
(4)
Determined with reference to $3.58, the closing price of a share of Rite Aid common stock on the last trading day before March 4, 2023.
(5)
For a discussion of the terms and conditions of the performance units granted on July 27, 2022, see “Compensation Discussion and Analysis, Long-Term Incentive Program, 2023 Performance Based Units.” For a discussion of the terms and conditions of the performance units granted on July 7, 2021, see “Compensation Discussion and Analysis, Long-Term Incentive Program, 2022 Performance Based Units.” For a discussion of the terms and conditions of the performance units granted on July 8, 2020, see “Compensation Discussion and Analysis, Long-Term Incentive Program, 2021 Performance Based Units.”
(6)
Mr. Gilbert forfeited all outstanding equity upon his departure from the Company due to resignation effective April 7, 2023.
(7)
Mr. Persaud forfeited all outstanding equity upon his departure from the Company due to resignation effective March 6, 2023.

60 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Option Exercises and Stock Vested Table for Fiscal Year 2023
The following table summarizes for each Named Executive Officer the stock option exercises and shares vested during fiscal year 2023.
Option AwardsStock Awards
NameNumber of Shares
Acquired on Exercise
(#)
Value Realized on
Exercise
($)
Number of Shares
Acquired on Vesting
(#)
(1)
Value Realized on
Vesting
($)
(2)
Elizabeth Burr(3)21,505159,997
Heyward Donigan687,7983,562,927
Matthew Schroeder42,785310,277
Justin Mennen21,912184,403
Paul Gilbert20,188158,547
Andre Persaud20,661129,262
(1)
Represents the number of Contentsshares of restricted stock and earned performance shares held by each Named Executive Officer that vested during the fiscal year.
(2)
The value reported is the closing market price of a share of our common stock on the NYSE on the date of vesting multiplied by the number of shares that vested on that date.
(3)
Represents the annual award of restricted stock units for fiscal year 2023, granted in connection with Ms. Burr’s service as a director of the Company prior to her appointment as interim CEO. The restricted stock units were vested on the date of grant and the shares subject to the grant will become payable on a deferred basis upon her separation from service.
Pension; Nonqualified Deferred Compensation
The Company does not maintain a non-qualified deferred compensation plan for the benefit of the Named Executive Officers and none of the Named Executive Officers participate in a defined benefit pension plan maintained by the Company.
Potential Payments Upon Termination or Change in Control
As discussed above under the caption “Executive Employment Agreements,” the Company has entered into employment agreements with each of the Named Executive Officers. Upon written notice, the employment agreement of each of the Named Executive Officers is terminable by either Rite Aid or the individual officer seeking termination. The circumstances resulting in severance entitlements under the employment agreements is discussed below. During the last completed fiscal year, the Company entered into a separation agreement with its former CEO. Also, two Named Executive Officers resigned following the end of the last fiscal year, as discussed below in the caption “Named Executive Officer Departures.”
Description of Triggering Events—Individual Agreements
MS. ELIZABETH BURR.
Ms. Burr is not entitled to any severance under the terms of her offer letter dated January 7, 2023, entered into in connection with her appointment as interim CEO.
MS. HEYWARD DONIGAN.
Circumstances Resulting in Severance. In connection with Ms. Donigan’s termination of employment by Rite Aid without “cause” ​(as such term is defined in her employment agreement) Ms. Donigan became entitled to the following severance benefits in accordance with the terms of her employment agreement, upon her execution of a general release of claims in favor of the Company and continuing compliance with the restrictive covenants.

RITE AID CORPORATION   2023 Proxy Statement | 61

TABLE OF CONTENTS

EXECUTIVE COMPENSATION
See “Named Executive Officer Departures—Separation Agreement with Heyward Donigan” below for additional details on her separation agreement:

she was entitled to receive a severance amount equal to two times the sum of her annual base salary and target bonus, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount is payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would have been paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

she was entitled to receive a payment equal to the cost of continued health benefits under COBRA for two years following the termination, paid in a lump sum; and

any unvested stock options immediately vested and became exercisable, generally, for a period of 90 days following her termination of employment and the restrictions on time-based restricted stock immediately lapsed, each to the extent the options would have vested and restrictions would have lapsed, had she remained employed by Rite Aid for two years following the qualifying termination.
MR. MATTHEW SCHROEDER.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Schroeder is terminated by Rite Aid without “cause” or if he terminates his employment for “good reason” (as such terms are defined in his employment agreement), then:

he will be entitled to receive a severance amount equal to two times the sum of the annual base salary and target bonus, a pro-rata target bonus for the fiscal year of termination, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would be payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid at the same time that payments are made to other bonus-eligible associates;

he will be entitled to receive continued health benefits for two years following the termination; and

any unvested stock options will immediately vest and be exercisable, generally, for a period of 90 days following the termination of employment to the extent the options would have vested had he remained employed by Rite Aid for two years following the termination.
MR. JUSTIN MENNEN.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Mennen is terminated by Rite Aid without “cause” or if he terminates his employment for “good reason” ​(as such terms are defined in his employment agreement), then:

he will be entitled to receive a severance amount equal to two times his annual base salary as of the date of termination of employment, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would be payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

he will be entitled to receive continued health benefits for one year following the termination; and

any unvested stock options will immediately vest and be exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on the restricted common stock will immediately lapse, each to the extent the options would have vested and restrictions would have lapsed, had he remained employed by Rite Aid for one year following the termination.
The foregoing severance benefits are subject to Mr. Mennen’s execution of a general release of claims in favor of the Company and compliance with restrictive covenants.
MR. PAUL GILBERT.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Gilbert had been terminated by Rite Aid without “cause” or if he had terminated his employment for “good reason” ​(as such terms are defined in his employment agreement), then:

62 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION

he would have been entitled to receive a severance amount equal to two times his annual base salary, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would have been payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

he would have been entitled to receive a payment equal to the cost of continued health benefits under COBRA for two years following the termination; and

any unvested stock options would have immediately vested and become exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on time-based restricted stock would have immediately lapsed, each to the extent the options would have vested and restrictions would have lapsed, had he remained employed by Rite Aid for two years following the termination.
The foregoing severance benefits would be subject to Mr. Gilbert’s execution of a general release of claims in favor of the Company and compliance with restrictive covenants.
MR. ANDRE PERSAUD.
Circumstances Resulting in Severance. Pursuant to his employment agreement with the Company, if Mr. Persaud had been terminated by Rite Aid without “cause” or if he had terminated his employment for “good reason” ​(as such terms are defined in his employment agreement), then:

he would have been entitled to receive a severance amount equal to two times his annual base salary as of the date of termination of employment, a pro-rata bonus for the fiscal year of termination based on actual performance, and any accrued but unpaid salary and benefits through the date of termination. The severance amount would be payable in installments over the two-year period following the termination; any pro-rata bonus for the fiscal year would be paid following determination of performance at the same time that payments are made to other bonus-eligible associates;

he would have been entitled to receive continued health benefits for eighteen months following the termination; and

any unvested stock options would have immediately vested and become exercisable, generally, for a period of 90 days following the termination of employment and the restrictions on the restricted common stock would have immediately lapsed, each to the extent the options would have vested and restrictions would have lapsed, had he remained employed by Rite Aid for one year following the termination.
The foregoing severance benefits would be subject to Mr. Persaud’s execution of a general release of claims in favor of the Company and compliance with restrictive covenants.
Named Executive Officer Termination as a Result of Death or Disability
If the employment of any of the Named Executive Officers (with the exception of Ms. Burr) were to be terminated as a result of death or “disability” ​(as such term is defined in each employment agreement), the officer will be entitled to receive all accrued but unpaid salary and benefits payable under death or disability benefit plans in which the officer participates, continued health insurance (or reimbursement for the cost of such benefits) for two years (one year in the case of Messrs. Gilbert, Mennen and Persaud) for the officer and/or his or her immediate family, as applicable, vesting of all stock options and, for all Named Executive Officers other than Mr. Schroeder, vesting of an amount of restricted stock that, in each case, would have vested had the officer remained employed for one year (two years for Ms. Donigan and Mr. Schroeder) following the date of termination. Ms. Burr does not participate in Rite Aid’s employee benefit plans.
Change in Control Arrangements
UNDER EMPLOYMENT AGREEMENTS—DOUBLE TRIGGER ARRANGEMENTS. Severance benefits are not triggered pursuant to a change in control unless the change in control is followed by a termination of the Named Executive Officer’s employment under the circumstances resulting in severance described above. The Named

RITE AID CORPORATION   2023 Proxy Statement | 63

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Executive Officer’s severance entitlement is governed by their individual employment agreements with the Company. Ms. Burr’s arrangements with the Company do not include severance entitlements.
The employment agreements with the Named Executive Officers (other than Ms. Burr) provide that any portion of any payment that is subject to tax imposed by Section 4999 of the Code will be reduced to the extent necessary so that the Named Executive Officer would retain a greater amount on an after-tax basis than had the excise tax been imposed on the unreduced amount of the payments.
UNDER RITE AID’S EQUITY PROGRAM. Pursuant to the terms of the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan, unless otherwise provided in a Named Executive Officer’s employment agreement or individual award agreement, if outstanding equity awards are assumed or substituted in connection with a change in control, the change in control will not cause the vesting of such awards to accelerate unless the change in control is followed by a qualifying termination of employment within the 24-month period following the change in control. In the event of a qualifying termination of employment within the 24-month period following a change in control, all outstanding awards granted pursuant to the Company’s equity program will become fully vested and exercisable, free of applicable restrictions, and all awards that are subject to performance-based conditions will vest pro-rata based on the participant’s service during the applicable performance period, assuming the target level of performance. All outstanding equity awards granted pursuant to the Company’s equity program that are not assumed or substituted in connection with a change in control transaction will become fully vested and exercisable, free of applicable restrictions, and all awards that are subject to performance-based conditions will be deemed to be achieved at target levels. The foregoing treatment upon a change in control is reflected in the form of award agreements currently utilized in connection with long-term incentive awards under the Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan. In addition, the employment agreements maintained by Rite Aid do not provide for accelerated vesting of any performance-based awards, including upon qualifying termination of employment (with or without a change in control).
For purposes of Rite Aid’s equity program, including any inducement awards, a “change in control” means, in general: (i) a person or entity acquires securities of Rite Aid representing 50% or more of the combined voting power of Rite Aid; (ii) an unapproved change in the majority membership of the Board; (iii) consummation of a merger or consolidation of Rite Aid or any subsidiary of Rite Aid, other than a merger or consolidation that results in the Rite Aid voting securities continuing to represent 50% or more of the combined voting power of the surviving entity or its parent, or a merger or consolidation effected to implement a recapitalization or similar transaction involving Rite Aid in which no person or entity acquires at least 35% of the combined voting power of Rite Aid; or (iv) stockholder approval of a plan of complete liquidation or dissolution of Rite Aid or the consummation of an agreement for the sale or disposition of all or substantially all of Rite Aid’s assets, other than a sale or disposition to an entity, at least 60% of the combined voting power of which is owned by Rite Aid stockholders in substantially the same proportions as their ownership of Rite Aid immediately prior to such sale. For more information regarding the equity program, refer to the Compensation Discussion and Analysis under the caption “Long-Term Incentive Program.”
Quantification of Payments Described
The tables below quantify the termination and change in control payments that would have been made to the Named Executive Officers (other than Ms. Donigan, who separated from the Company prior to the end of the fiscal year and became entitled to severance under the terms of her employment agreement (as described under “Named Executive Officer Departures—Separation Agreement with Heyward Donigan” below) and Messrs. Gilbert and Persaud, who resigned from the Company following the end of the fiscal year and did not receive any severance payments in connection with such resignation consistent with the terms of their employment agreements), had their employment been terminated as of March 4, 2023 under the circumstances described in the tables below. Consistent with Ms. Burr’s offer letter entered into in connection with her appointment as interim CEO, none of the below potential separation payments or benefits are applicable.

64 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Elizabeth BurrDeath
($)
Disability
($)
Termination Without
Cause or Quit for
Good Reason
($)
Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
Base Salary
Bonus
Pro-Rated Incentive Bonus Earned for Past Fiscal Year
Benefits
Vesting of Equity
Matthew SchroederDeath
($)
Disability
($)
Termination Without
Cause or Quit for
Good Reason
($)
Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
2 × Base Salaryn/an/a1,539,8501,539,850
2 × Bonusn/an/a1,539,8501,539,850
Pro-Rated Incentive Earned Bonus for Past Fiscal Year
Benefits58,05258,05258,05258,052
Vesting of Equity(1)459,711459,711459,7111,530,518(2)
Justin MennenDeath
($)
Disability
($)
Termination Without
Cause or Quit for
Good Reason
($)
Termination Without
Cause or Quit for Good
Reason Following a
Change in Control
($)
2 × Base Salaryn/an/a1,091,4001,091,400
Bonusn/an/an/an/a
Pro-Rated Incentive Earned Bonus for Past Fiscal Year
Benefits17,48817,48817,48817,488
Vesting of Equity(1)108,764108,764108,764746,068(2)
(1)
Includes the value of service-based restricted stock awards held by the Named Executive Officer that would become vested under the applicable circumstances. The value of restricted stock shown is determined by multiplying $3.58, the closing price of a share of Rite Aid common stock on the last trading day before March 4, 2023 and the number of shares of restricted stock that are settled in stock held by the officer that would become vested under the applicable circumstances.
(2)
This value would apply based upon a qualifying termination following a change in control or upon a change in control under the assumption that outstanding equity awards are not assumed or substituted in the change in control transaction, resulting in full vesting upon the change in control, as described above in the “Potential Payments Upon Termination or Change in Control-Change in Control Arrangements” narrative. In addition to the amounts stated above in respect of service-based restricted stock, figure includes the value of pro-rata performance-based equity awards held by such officer, assuming the target level of performance. The value shown is determined by multiplying $3.58, the closing price of a share of Rite Aid common stock on the last trading day before March 4, 2023 and the number of shares of restricted stock and performance-based stock held by the officer that would become vested under the applicable circumstances.

RITE AID CORPORATION   2023 Proxy Statement | 65

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Named Executive Officer Departures
SEPARATION AGREEMENT WITH HEYWARD DONIGAN.
As a result of the decision made by the Board on the strategic priorities of the Company and to appoint Ms. Burr as interim CEO until the appointment of a permanent chief executive officer, Ms. Donigan’s employment with the Company was terminated on January 7, 2023. As previously disclosed on Form 8-K, the circumstances of Ms. Donigan’s departure from the Company constituted a termination without cause for purposes of Ms. Donigan’s employment agreement with us, and, in accordance with the terms of Section 5.3 of her employment agreement, we entered into a separation agreement with Ms. Donigan as of January 7, 2023 providing for the following severance benefits: (i) payment of $7,107,000 representing two times the sum of her then current base salary and annual target bonus, payable in equal installments over 24 months, (ii) a pro-rata bonus for the 2023 fiscal year based on actual performance, payable at the same time as bonuses are paid to the Company’s executive team generally (which amount was $0 based on actual performance for the 2023 fiscal year and accordingly, no pro-rata bonus was paid), (iii) $37,413 representing payments equal to the aggregate cost of COBRA continuation for a total of 24 months, (iv) reimbursement of legal fees incurred in connection with the review of the separation agreement up to $10,000, (v) accelerated vesting with respect to those stock options and time-based restricted stock awards that would have vested within the two-year period following the termination (with an aggregate value of $1,649,623 at the time of vesting) and (vi) $97,356, representing payment of base salary in lieu of providing 30 days’ notice of termination. The foregoing severance benefits described in clauses (i) - (v) were subject to Ms. Donigan’s execution of a general release of claims in favor of the Company and continuing compliance with restrictive covenants.
PAUL GILBERT DEPARTURE.
Mr. Gilbert resigned from the Company effective April 7, 2023. Mr. Gilbert did not receive any severance in connection with his separation.
ANDRE PERSAUD DEPARTURE.
Andre Persaud resigned from the Company effective March 6, 2023. Mr. Persaud did not receive any severance in connection with his separation.

66 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
PAY RATIO DISCLOSURE
As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K under the Exchange Act, we are providing the following information about the relationship of the annual total compensation of our employees other than Heyward Donigan, our former Chief Executive Officer (our “CEO” for purposes of the pay ratio disclosure) and the annual total compensation of our CEO. This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described below. We determined that the 2023 annual total compensation of the median employee, other than our CEO, was $32,850 and our CEO’s 2023 annual total compensation for pay ratio purposes was $8,950,543. The ratio of these amounts is 272:1.
To identify the median employee among our associates other than the CEO, we used wages taxable for federal medical health insurance purposes for the calendar year 2022, with such amounts annualized for those permanent employees who were hired during the year. After identifying the median employee (who is a full-time technician in training) as of the determination date, December 31, 2022, we calculated annual total compensation for such employee using the same methodology we use to determine Named Executive Officer annual total compensation in the Summary Compensation Table for fiscal year 2023.
The Company had two CEOs who served during fiscal year 2023, one of whom is an interim CEO. We accordingly calculated the CEO’s annual total compensation by selecting Ms. Donigan as the CEO serving in that position on the final day of our payroll year, December 31, 2022, which was the same date selected to identify the median team member, and annualized appropriate portions of Ms. Donigan’s annual total compensation for fiscal year 2023 (i.e., Ms. Donigan’s base salary and automobile allowance because no annual incentive award was payable in respect of fiscal year 2023) and added the grant date fair value of stock awards (i.e., long-term incentives) and all other compensation paid in fiscal year 2023. Because the CEO’s compensation was annualized solely for purposes of this calculation, the CEO’s annual total compensation found in this section is not the same as the compensation disclosed in the Summary Compensation Table beginning on page 56. This calculation resulted in the annual total compensation for Ms. Donigan in fiscal year 2023 of $8,950,543 for purposes of the pay ratio provided in the first paragraph above.
The SEC rules for identifying the median employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices. As such, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may use different methodologies, exclusions, estimates, and assumptions in calculating their own pay ratios.
EQUITY COMPENSATION PLAN INFORMATION

TABLE

The following table provides information as of March 2, 2019,4, 2023, with respect to the compensation plans under which our common stock may be issued. As previously announced, we implemented a reverse stock split
Plan CategoryNumber of Securities
to be issued upon
exercise of
outstanding options,
warrants and rights
(a)
Weighted-Average
exercise price of
outstanding options,
warrants and rights
(b)
(1)
Number of Securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in
column (a))
(c)
(2)
Equity Compensation plans approved by
stockholders
(3)
1,244,973(4)$112.933,627,626
Equity compensation plans not approved
by stockholders
(5)
502,913$7.020
Total(6)1,747,886$12.853,627,626
(1)
The weighted average exercise price does not take into account the shares issuable upon settlement of our common stock at a reverse stock split ratio of 1-for-20. Our common stock began trading on a split-adjusted basis on the NYSE at the market open on April 22, 2019. Accordingly, all share amounts presented reflect the reverse stock split.

outstanding

RITE AID CORPORATION   2023 Proxy Statement | 67

Plan Category
 Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights
 Weighted-Average
Exercise Price of
Outstanding
Options, Warrants
and Rights
 Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
(Excluding Securities
Reflected in Column (a))
 
 
 (a)
 (b)
 (c)
 

Equity compensation plans approved by stockholders

  1,035,886 $50.13  1,343,329 

Equity compensation plans not approved by stockholders(1)

       

Total(2)

  1,035,886 $50.13  1,343,329 

TABLE OF CONTENTS
(1)
These plans include
EXECUTIVE COMPENSATION
vested Director restricted stock units (“RSUs”), which settle upon separation from service, or unvested, unearned performance stock units (“PSUs”), which have no exercise price.
(2)
Of the Company's 1999 Plan, under which 500,0003,627,626 shares of common stockshown in column (c), there are authorized2,501,811 shares available for the grant of awards other than stock options ator stock appreciation rights, applying the discretionfungible share ratio of 1.45 set forth in the Compensation Committee,Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan.
(3)
Pursuant to the 2001Company’s Amended and Restated 2020 Omnibus Equity Incentive Plan underand prior equity plans.
(4)
Includes 402,476 RSUs and 813,207 PSUs. The remaining balance consists of outstanding stock options.
(5)
Includes nonqualified stock options granted pursuant to the Employment Inducement Award Agreement for Ms. Donigan, which 1,000,000 shares of common stock are authorizedis exempt from stockholder approval requirements pursuant to NYSE Listed Company Manual Rule 303A.08. The Employment Inducement Award Agreement provided for the grantaward of nonqualified stock options also at the discretionto Ms. Donigan in connection with her recruitment by us, as previously disclosed. The options expired unexercised as of the Compensation Committee. Both plans provide for the Compensation Committee to determine both when and in what manner options may be exercised; however, option terms may not extend for more than 10 years from the applicable date of grant. The plans provide that stock options may only be granted with exercise prices that are not less than the fair market value of a share of common stock on the date of grant. No securities remain available for future issuance under either the 1999 Plan or the 2001 Plan.

(2)
April 7, 2023.
(6)
On a fully diluted basis, which reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, the number of shares of common stock outstanding was 54,016,056.56,628,875.

        Of

PAY VERSUS PERFORMANCE
The following table reports the 1,343,329 shares remaining, there are 926,434 shares availablecompensation of our Principle Executive Officer (“PEO” or “CEO”) and the average compensation of the other non-CEO NEOs as reported in the Summary Compensation Table for the grantpast three fiscal years, as well as Compensation Actually Paid (“CAP”) as calculated under new SEC Pay-Versus-Performance disclosure requirements, and certain performance measures required by the rules. The disclosure covers our three most recent fiscal years, which will expand incrementally over the next two years to a rolling five years. Dollar amounts reported as CAP are computed in accordance with Item 402(v) of awards other than stock optionsRegulation S-K, and the Board believes that it is important to recognize that these amounts do not reflect the actual amount of compensation earned by or stock appreciation rights.


SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

        Section 16(a)paid to our CEO and non-CEO NEOs during the applicable years.

Fiscal
Year
Summary
Compensation
Table Total for
Heyward
Donigan
(1)
($)
Summary
Compensation
Table Total for
Elizabeth
Burr
(1)
($)
Compensation
Actually Paid
to Heyward
Donigan
(2)
($)
Compensation
Actually Paid
to Elizabeth
Burr
(2)
($)
Average
Summary
Compensation
Table Total for
Non-PEO
Named
Executive
Officers
(1)
($)
Average
Compensation
Actually Paid
to Non-PEOs
Named
Executive
Officers
(3)
($)
Value of initial fixed $100
investment based on:
Net
Income
(5)
($)
Adjusted
EBITDA
(6)
($)
Total
Shareholder
Return
($)
Peer Group
Total
Shareholder
Return
(4)
($)
20238,767,811858,459(1,877,638)858,4591,889,206638,34628.63139.14(749,936)429,180
20229,911,507(1,881,568)3,082,2191,048,26368.28140.98(538,478)505,905
20219,571,08712,857,7742,878,7702,782,908143.76113.59(100,070)437,665
(1)
Our CEO for fiscal year 2023 was Ms. Donigan until her departure from the Company on January 7, 2023, with Ms. Burr acting as interim CEO for the remainder of the Exchange Act requires Rite Aid's2023 fiscal year, and for each of fiscal years 2021 and 2022 our CEO was Ms. Donigan. Our non-CEO NEOs for fiscal year 2023 were Messrs. Schroeder, Mennen, Gilbert and Persaud; for fiscal year 2022, Messrs. Schroeder, Gilbert, Peters and Ms. Konrad; and for fiscal year 2021, Messrs. Schroeder, Peters, Mennen, Robson and Ms. Konrad.
(2)
The amounts in the following table represent each of the amounts deducted and added to the equity award values for each PEO for the applicable year, for purposes of computing the CAP amount:

68 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
FY21FY22FY23
AdjustmentsHeyward
Donigan
($)
Elizabeth
Burr
($)
Heyward
Donigan
($)
Elizabeth
Burr
($)
Heyward
Donigan
($)
Elizabeth
Burr
($)
Deduction for amounts reported under the
“Stock Awards” and “Option Awards”
columns in the Summary Compensation
Table for covered fiscal year
(7,389,087)(6,547,427)(7,106,993)(159,997)
Increase for fair value as of the end of the
covered fiscal year of all awards granted
during year that remain unvested as of
year end
7,122,1064,233,26800
Increase for awards that are granted and
vest in the same year, the fair value as of
the vesting date
00997,271159,997
Increase/deduction for change in fair
value from prior year-end to current
year-end of awards granted in any prior
fiscal year that are unvested as of the end
of the covered fiscal year
3,312,904(8,135,158)00
Increase/deduction for change in fair
value from prior year-end to vesting date
of awards granted in any prior fiscal year
that vested during the covered fiscal year
240,764(1,343,759)(1,324,518)0
Deduction of fair value of awards granted
in any prior fiscal year that were forfeited
during the covered fiscal year
00(3,211,209)0
Increase based on dividends or other earnings paid during the covered fiscal year prior to the vesting date of award0000
Increase based on incremental fair value
of awards modified during year
0000
Total Adjustments3,286,687(11,793,075)(10,645,449)0
(Subject to rounding.)
(3)
The following table represents each of the amounts deducted and added to the equity award values for the non-CEO NEOs for the applicable year for purposes of computing the CAP amount.
FY21FY22FY23
AdjustmentsAverage non-
PEO NEOs
Average non-
PEO NEOs
Average non-
PEO NEOs
Deduction for amounts reported under the “Stock Awards” and
“Option Awards” columns in the Summary Compensation
Table for covered fiscal year
(1,776,460)(1,571,617)(1,220,417)
Increase for fair value as of the end of the covered fiscal year
of all awards granted during year that remain unvested as of
year end
1,418,482982,441479,787
Increase for awards that are granted and vest in the same year, the fair value as of the vesting date000
Increase/deduction for change in fair value from prior year-end
to current year-end of awards granted in any prior fiscal year
that are unvested as of the end of the covered fiscal year
214,003(1,231,819)(455,907)
Increase/deduction for change in fair value from prior year-end
to vesting date of awards granted in any prior fiscal year that
vested during the covered fiscal year
117,159(212,962)(54,322)
Deduction of fair value of awards granted in any prior fiscal year that were forfeited during the covered fiscal year(66,920)00
Increase based on dividends or other earnings paid during the
covered fiscal year prior to the vesting date of award
000
Increase based on incremental fair value of awards modified during year000
Total Adjustments(93,735)(2,033,956)(1,250,860)

RITE AID CORPORATION   2023 Proxy Statement | 69

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
(Subject to rounding.)
(4)
As permitted by SEC rules, the peer group referenced is the Russell 3000 Consumer Staples Industry used for purposes of Item 201(e) of Regulation S-K. Please see Item 5 “Market for Registrant’s Common Equity, Related Stockholder Matters and issuer Purchases of Equity Securities” included on the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for further discussion of the peer group.
(5)
The dollar amounts reported represent the amount of net income reflected in the Company’s audited consolidated financial statements for the applicable year.
(6)
See “Compensation Discussion and Analysis—Annual Incentive Awards” for a description of Adjusted EBITDA. Please also see Appendix A for a reconciliation of our Adjusted EBITDA, which is a non-GAAP measure, to net income under GAAP.
Relationship Between Pay and Performance
The following graphs illustrate the relationship between the CAP for our CEOs and average non-CEO NEOs and company performance as well as peer performance.
CAP to Cumulative TSR of the Company and Cumulative TSR of the Peer Group
The following graph describes the relationship between (a) CAP for the applicable CEO and the average CAP for the non-CEO NEOs to (b) the Company’s cumulative total shareholder return (TSR), value of initial fixed $100 investment, for the three most recently completed fiscal years and (c) the cumulative total shareholder return for our peer group across the same period:
Compensation Actually Paid vs. Company TSR
vs. Peer Group TSR
[MISSING IMAGE: lc_paidvscompanytsr-pn.jpg]

70 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
CAP and Net Income
The following graph describes the relationship between (a) CAP for the applicable CEO and the average CAP for the non-CEO NEOs to (b) the Company’s Net Income for the three most recently completed fiscal years:
Compensation Actually Paid vs. Net Income
[MISSING IMAGE: lc_paidvsnetincome-pn.jpg]
CAP and Adjusted EBITDA
The following graph describes the relationship between (a) CAP for the applicable CEO and the average CAP for the non-CEO NEOs to (b) the Company’s company-selected measure, Adjusted EBITDA, for the three most recently completed fiscal years:
Compensation Actually Paid vs. Adj. EBITDA
[MISSING IMAGE: lc_paidvsadjebitda-pn.jpg]

RITE AID CORPORATION   2023 Proxy Statement | 71

TABLE OF CONTENTS
EXECUTIVE COMPENSATION
Tabular List of Important Financial Performance Measures
The most important financial performance measures used by the Committee for the most recently completed fiscal year to link compensation actually paid to our named executive officers directors,to the Company’s performance are shown in the table below. For further information regarding these performance metrics and persons who own more than 10%their function in our executive compensation program, see Compensation, Discussion and Analysis under the headings “2023 Fiscal Year Key Business Highlights,” “Annual Incentive Awards” and “Performance Awards.”
Most Important Performance Measures
Adjusted EBITDA
Operating Cash Flow
30-day equivalent scripts excluding controllable
Front-End Revenue excluding tobacco
Elixir Membership (excluding Elixir Insurance)

72 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 5—APPROVAL OF THE AMENDMENTS TO THE RITE AID CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING PROVISIONS
We are committed to reviewing and adopting corporate governance practices that are in the best interests of both Rite Aid and its stockholders. After reviewing our governance practices, the Board unanimously adopted, and recommends that our stockholders approve, certain amendments (collectively, the “Charter Amendments”) to Rite Aid’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to remove the supermajority voting provisions described herein. The text of the Charter Amendments, marked to show the proposed revisions, is set forth in Appendix B.
The Certificate of Incorporation currently contains four provisions calling for a supermajority vote of stockholders:

Paragraph B of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to adopt or authorize a Business Combination (as defined in the Certificate of Incorporation) with any Related Person (as defined in the Certificate of Incorporation) unless certain conditions are satisfied.

Paragraph D of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to take any corporate action by the written consent of the stockholders of Rite Aid.

Paragraph E of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to take any corporate action at a special meeting of the stockholders of Rite Aid called by the Board, a majority of which Board are not Continuing Directors (as defined in the Certificate of Incorporation).

Paragraph G of Article ELEVENTH currently requires the affirmative vote of the holders of at least 75% of the shares of stock of Rite Aid entitled to vote in elections of directors to amend Article ELEVENTH, unless such amendment is recommended to the stockholders of Rite Aid by a majority of the Continuing Directors.
If approved by our stockholders, the Charter Amendments would amend the provisions described above to require the affirmative vote of the holders of a majority—rather than at least 75%—of the shares of stock of Rite Aid entitled to vote in elections of directors to take the following actions:

adopt or authorize a Business Combination with any Related Person;

take any corporate action by the written consent of the stockholders of Rite Aid;

take any corporate action at a special meeting of the stockholders of Rite Aid called by the Board, a majority of which Board are not Continuing Directors; and

amend Article ELEVENTH.
This general description of the Charter Amendments is qualified in its entirety by reference to the proposed amendments to the Certificate of Incorporation set forth in Appendix B.
If approved by our stockholders, the Charter Amendments will become effective upon the filing of a Certificate of Amendment with the Secretary of State of the State of Delaware, which we would file promptly following the Annual Meeting. If the Charter Amendments are not approved by the stockholders, the Certificate of Incorporation will remain unchanged and the supermajority provisions described above will remain in place.
[MISSING IMAGE: ic_chksquare-pn.gif]
The Board of Directors unanimously recommends that you vote FOR the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions.

RITE AID CORPORATION   2023 Proxy Statement | 73

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
STOCKHOLDER PROPOSALS
We expect the following proposals (Proposal No. 6 and Proposal No. 7 on the proxy card) to be presented by stockholders at the Annual Meeting. The proposals and supporting statements may contain assertions about Rite Aid or other statements that we believe are incorrect. We have not attempted to refute all of the inaccuracies in the proposals and supporting statements, and the Company is not responsible for the content of the proposals. The Board has recommended a vote against these proposals for the reasons set forth following each proposal.
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 6—STOCKHOLDER PROPOSAL TO REQUIRE AN ANNUAL ADVISORY VOTE ON THE COMPENSATION OF RITE AID’S DIRECTORS
Steven Krol, who owns 9,588 shares of common stock (based on information provided to file reportsus by Mr. Krol) and whose address will be provided by the Company promptly upon oral or written request, has notified us that he intends to present the following proposal at the Annual Meeting. The Board of ownershipDirectors strongly opposes adoption of the proposal and changesasks stockholders to review the Board’s response, which follows the proposal and the proponent’s supporting statement below.
Stockholder Proposal and Supporting Statement
Proponent states no assertions or statements below are incorrect, notwithstanding Company boilerplate language above.
RESOLVED, Shareholders request our board adopt a policy providing shareholders the annual, non-binding, opportunity to vote on a proxy proposal, “FOR” or “AGAINST”, entitled “Advisory Vote on the Compensation of Our Named Directors” as provided in ownership“Director Compensation Table”.
Shareholders already vote on executive pay. This proposal extends a voting opportunity on directors’ compensation, who oversee all corporate activities and assess performance.
Compensation consultants generally don’t review competence or performance for management or directors; it’s limited to the compensation paid their peer group companies. Last year’s proxy indicated our compensation consultant believed “elements of the director compensation program were not aligned with the SECmarket”. Our stock price, at all-time lows this year can, in part, be considered directors’ report card, judging directors’ oversight, judicious hiring and timely firing decisions and giving executives effective “marching orders”.
Given our dismal stock price, total director pay should be aligned with shareholders, not the NYSE. Such persons are requiredmarket. Especially because current directors have never purchased any shares from their own wallets. Yet our Compensation Committee continues increasing directors’ annually guaranteed value of restricted stock, now $160,000 (previously $120,000), divided by SEC regulationsstock price at granting date to furnishdetermine annual stock allocation, previously a fixed number of shares. Shareholders have no guaranteed stock value, subject to directors’ business decisions and oversight. The lower the price, the more shares they receive. Committee Chair annual cash retainers have also recently increased.
Even top holders have complained about Compensation Committee pay decisions (2019 proxy, page 37). Apparent futility, since after their discussions and only 2 months after Mr. Bodaken became Chairman, full vesting of annual restricted stock previously taking 3 years was changed; now vesting immediately.
In last years’ proxy, our board stated the Equity Incentive Plan is “intended to attract, motivate and retain highly competent, effective and loyal officers, associates and non-executive directors in order to create per share intrinsic value for shareholders”. Since 2 Chief Executive Officers (“CEO”) have stepped down within last 4 years, the COO within one, the Pharmacy head within one and Chief Legal Officer within last three years, that quote is highly questionable, including all-time low stock prices recently.
Shockingly, our interim CEO’s base monthly salary is nearly 3 times that of all permanent CEO predecessors (mostly combined Chairman/CEO’s) in the last 22 years, at $300,000 per month, while retaining 3 outside board

74 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
STOCKHOLDER PROPOSALS
memberships appearing to violate published “overboarding” guidelines of Glass Lewis, Vanguard and top holder Blackrock, who thereafter cut its stake. This deprives shareholders her full attention here, which again questions some Compensation Committee and board decisions. They retire richer, shareholders poorer.
*
Proponent’s operations involved 22-year investment (9588 shares after a 1 for 20 reverse stock split) and 4 bylaw amendments with prior submitted proposals, demand board accountability.
*
Your Voice/Feedback is Important-Vote “FOR” Proposal 6.
The Board of Directors’ Statement in Opposition
The Board of Directors unanimously recommends that you vote “AGAINST” this proposal for the following reasons:
The Board of Directors believes that Rite Aid’s compensation program for non-employee directors is reasonable and appropriate for a company of Rite Aid’s size and scope and justified in view of the time directors devote to Rite Aid throughout the year. Only directors not employed by Rite Aid are compensated for their service on the Board. In addition, a substantial portion of the annual compensation for Rite Aid’s non-employee directors is equity-based to further align the long-term interests of Rite Aid’s non-employee directors with copiesRite Aid’s stockholders. The value of all Section 16(a) forms they file. Based solely on athe compensation is competitive in order to encourage the retention of non-employee directors, whose work is essential to the Company.
Rite Aid has robust governance practices with respect to its director compensation program. The Compensation Committee is responsible for reviewing and recommending the compensation for non-employee directors, and any change in director compensation is made upon the recommendation of the Compensation Committee following discussion and concurrence by the full Board. The Compensation Committee, with the assistance of Mercer, its independent compensation consultant, regularly reviews Rite Aid’s non-employee director compensation and evaluates the competitiveness and reasonableness of the compensation program in light of general trends and best practices. In 2021, after the Compensation Committee’s review of the copiesstudy of such forms furnisheddirector compensation prepared by Mercer, the Compensation Committee recommended, and the Board approved, updates to the non-employee director compensation program for fiscal year 2022 to align Rite Aid’s program with median of the market practices.
In addition, non-employee directors are subject to Rite Aid’s Stock Ownership Guidelines, which require minimum stock ownership equal to five times the non-employee director’s annual cash retainer in order to further encourage a long-term perspective in overseeing the management of Rite Aid. The Compensation Committee is responsible for interpreting and administering the Stock Ownership Guidelines, and may, from time to time, reevaluate and revise the Stock Ownership Guidelines.
Finally, the proponent’s criticism of Ms. Burr’s compensation as interim CEO is misplaced and unrelated to our compensation program for non-employee directors. With the advice of its independent compensation consultant, the Compensation Committee recommended, and the Board approved, the compensation afforded to Ms. Burr for taking on the responsibilities of interim CEO as reasonable and appropriate while Rite Aid transitions this key leadership role. While she is serving in the interim CEO role, Ms. Burr does not participate in or receive benefits under the Company’s equity and annual incentive plans or employee benefit plans and programs and does not receive the compensation payable to non-employee directors.
The Board believes that its corporate governance practices and robust stockholder engagement efforts provide numerous ways for stockholders to express their views to the Board, including with respect to director compensation. Rite Aid has encouraged, and continues to encourage, stockholders to communicate directly with the Board regarding any concerns about Rite Aid, including the compensation of directors, and regularly seeks the perspectives of stockholders on issues important to them through our stockholder engagement efforts.
[MISSING IMAGE: tm228886d1-icon_against4c.gif]
The Board of Directors unanimously recommends that you vote AGAINST the stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors.

RITE AID CORPORATION   2023 Proxy Statement | 75

TABLE OF CONTENTS
STOCKHOLDER PROPOSALS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
PROPOSAL 7—STOCKHOLDER PROPOSAL TO ADOPT AN EXECUTIVE
COMPENSATION ADJUSTMENT POLICY
The Philadelphia Public Employees Retirement System (“PhilaPERS”), which owns shares of common stock worth at least $2,000 (based on information provided to us by PhilaPERS) and whose address will be provided by the Company promptly upon oral or written request, has notified us that it intends to present the following proposal at the Annual Meeting. The Board of Directors strongly opposes adoption of the proposal and asks stockholders to review the Board’s response, which follows the proposal and the proponent’s supporting statement below.
Stockholder Proposal and Supporting Statement
RESOLVED that shareholders of Rite Aid Corporation urge the Board of Directors to adopt a policy that no financial performance metric shall be adjusted to exclude Legal or Compliance Costs when evaluating performance for purposes of determining the amount or vesting of any senior executive Incentive Compensation award. “Legal or Compliance Costs” are expenses or charges associated with any investigation, litigation or enforcement action related to drug manufacturing, sales, marketing or distribution, including legal fees; amounts paid in fines, penalties or damages; and amounts paid in connection with monitoring required by any settlement or judgement of claims of the kind described above. “Incentive Compensation” is compensation paid pursuant to short-term and long-term incentive compensation plans and programs. The policy should be implemented in a way that does not violate any existing contractual obligation of the Company or the terms of any compensation or benefit plan. The Board shall have discretion to modify the application of this policy in specific circumstances for reasonable exceptions and in that case shall provide a statement of explanation.
SUPPORTING STATEMENT
We support compensation arrangements that incentivize senior executives to drive growth while safeguarding company operations and reputation over the long-term. Rite Aid adjusts certain financial metrics when calculating progress for executive incentive compensation. While some adjustments may be appropriate, we have determinedbelieve senior executives should not be insulated from all legal costs as a matter of policy.
These considerations are especially critical at Rite Aid given the risks it faces over its role in the nation’s opioid epidemic. The Investors for Opioid and Pharmaceutical Accountability (IOPA), a coalition of 67 investors with $4.2 trillion in assets under management has been engaging companies on this issue for several years. As shareholders bear the financial impacts of record-setting legal settlements related to inadequate assessment of how business decisions would impact the opioid crisis, the IOPA believes executives should similarly be accountable for the financial impacts of those decisions.
In July, Rite Aid agreed to pay a $10.5 million settlement with counties in the states of Georgia, North Carolina and Ohio related to claims that during fiscal year 2019,Rite Aid failed to properly distribute and/or dispense prescription opioids.1 Rite Aid excludes litigation settlements from the Adjusted EBIDTA metric that drives executive compensation pay-outs. A default decision to exclude the impact of litigation from metrics originally designed to align executive pay with shareholder interests means executives know in advance their incentive pay will remain intact no personsmatter how large the negative financial impact on shareholders.
In response to discussions with the IOPA and other shareholders, AmerisourceBergen, Cardinal Health, and McKesson reduced CEO pay in light of opioid-related litigation settlements. While the IOPA views the amounts of the reductions as less than warranted, we applaud the decision to acknowledge that incentives matter as do the approximately 700,000 lives lost due to opioid-related drug overdoses since 1999.2
We urge shareholders to vote for this proposal.
1
https://www.reuters.com/legal/government/rite-aid-reaches-opioid-litigation-ceasefire-105-million-settlement-2022-07-14/
2
“The Drug Overdose Epidemic: Behind the Numbers.” Centers for Disease Control and Prevention,” June 1, 2022, available at: https://www.cdc.gov/opioids/data/index.html.

76 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
STOCKHOLDER PROPOSALS
The Board of Directors’ Statement in Opposition
The Board of Directors unanimously recommends that you vote “AGAINST” this proposal for the following reasons:
Rite Aid’s executive compensation program is designed to evaluate and reward management performance and is overseen by the Compensation Committee of the Board, which is composed entirely of independent directors. Assessing and, when appropriate, adjusting financial performance metrics entails a complex process, informed by the knowledge and experience of the Compensation Committee and the Board of Directors. Imposing the broad and indiscriminate policy sought by the proposal would constrain the flexibility of the Compensation Committee and the Board to consider factors that are critical in assessing whether and how legal and compliance costs should be accounted for in determining senior executive incentive compensation.
For example, legal and compliance matters often relate to events that occurred prior to the appointment of current senior executives. As a result, the proposal would discourage current senior executives from taking appropriate steps to either defend of resolve existing matters, to manage risk in the best interests of the Company. Under the proposed policy, a senior executive’s incentive compensation could be inequitably penalized for litigation matters that pre-date the executive’s time with Rite Aid. Moreover, a policy leading to this outcome likely will make it more difficult for Rite Aid to attract and retain senior executive talent in a competitive marketplace for talent. This presents an acute concern as Rite Aid is actively looking to identify its next CEO, an already complex process that would only be hindered by the adoption of the policy sought by this proposal.
Rite Aid is often subject to Section 16(a) reporting submitted late filings.


Tablefrivolous and meritless suits that Rite Aid, in the best interests of Contents

its stockholders, defends against. Under the proposed policy, the costs and expenses of a successful defense of any such matter could not be excluded from performance metrics used to determine senior executive incentive compensation. The responsibility for managing those risks are complex, and the rigid and arbitrary policy requested by the proposal ignores many important considerations. Rite Aid believes the Compensation Committee and the Board are best suited to consider the interplay of legal and compliance costs with the need to attract, retain and motivate management.

In addition, the Compensation Committee is best equipped to make decisions with respect to performance metric selection and adjustments for use in Rite Aid’s incentive compensation program, which is currently aligned with our stated strategic objectives and the long-term interests of our stockholders. The Compensation Committee carefully selects performance metrics for executive compensation, taking into account feedback from our stockholder engagement efforts, and sets goals based on available information at the time the goals are set. The proponent’s proposal would unduly restrict the Compensation Committee’s judgment in determining executive compensation levels and structure, and limit the Compensation Committee’s ability to be flexible and responsive.
In summary, the Board believes the proposal would unnecessarily limit the ability of the Compensation Committee and the Board to design and administer Rite Aid’s incentive compensation program. Rite Aid also believes that adoption of the policy requested by the proposal would be detrimental to a compensation decision-making process that is focused on the long-term performance of Rite Aid, taking into account best practices, market competitiveness and our strategic, operational and financial goals and other appropriate factors in the Compensation Committee’s judgment.
[MISSING IMAGE: tm228886d1-icon_against4c.gif]
The Board of Directors unanimously recommends that you vote AGAINST the stockholder proposal to adopt an executive compensation adjustment policy.

RITE AID CORPORATION   2023 Proxy Statement | 77

TABLE OF CONTENTS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of May 31, 2019June 27, 2023 (except as otherwise noted), certain information concerning the beneficial ownership of (a) each director and nominee for director, (b) each of our "Named“Named Executive Officers"Officers” (as such term is defined in Item 402(a)(3) of Regulation S-K under the Exchange Act), (c) each holder known to us to beneficially own more than 5% of our common stock and (d) all current directors and executive officers as a group (based on 53,855,716[•] shares of common stock outstanding as of May 31, 2019)June 27, 2023). Each of the persons named below has sole voting power and sole investment power with respect to the shares set forth opposite his or her name, except as otherwise noted.

Beneficial Owners
Number of Common Shares
Beneficially Owned
(1)
Percentage
of Class
Named Executive Officers and Directors:
Bruce G. Bodaken[74,920](2)*
Elizabeth Burr[54,204](3)*
Heyward Donigan[601,504](4)[•]%
Paul Gilbert[—][—]
Bari Harlam[44,522](5)*
Robert E. Knowling, Jr.[61,996](6)*
Justin Mennen[145,488]*
Louis P. Miramontes[61,996](7)*
Arun Nayar[61,996](8)*
Andre Persaud[26,429]
Kate B. Quinn[54,204](9)*
Matthew Schroeder[228,589](10)*
All Executive Officers and Directors ([11] persons)[894,362](11)[•]%
5% Stockholders:
BlackRock, Inc.
55 East 52
nd Street
New York, NY 10055
3,795,009(12)6.7%
Beneficial Owners
 Number of
Common Shares
Beneficially Owned(1)
 Percentage
of Class
 

Named Executive Officers and Directors:

       

Bruce G. Bodaken

  14,255(2)     * 

Busy Burr

  0      * 

Kermit Crawford

  24,056(3)     * 

Bryan B. Everett

  56,088(4)     * 

Darren W. Karst

  73,372(5)     * 

Robert E. Knowling, Jr. 

  7,792(6)     * 

Jocelyn Z. Konrad

  28,124(7)     * 

Kevin E. Lofton

  13,495(8)     * 

Louis P. Miramontes

  7,792(9)     * 

Arun Nayar

  7,792(10)     * 

Katherine Quinn

  0      * 

John T. Standley

  930,768(11) 1.73%

Marcy Syms

  27,555(12)     * 

All Executive Officers and Directors (14 persons)

  1,133,801(13) 2.11%

5% Stockholders:

       

BlackRock, Inc. 

  3,772,186(14) 7.00%

55 East 52nd Street

       

New York, NY 10055

       

The Vanguard Group

  3,434,229(15) 6.38%

100 Vanguard Blvd.

       

Malvern, PA 19355

       

*
*
Percentage less than 1% of class.

(1)

Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act, thereby including options exercisable within 60 days of May 31, 2019.

June 27, 2023.
(2)

This amount represents 9,354[•] restricted stock units that have vested or will vest before July 30, 2019August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Bodaken leaves the Board.

(3)

This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Ms. Burr leaves the Board.
(4)
This amount includes 12,500[•] shares which may be acquired within 60 days by exercising stock options.

(4)
This amount includes 2,505 shares which may be acquired within 60 days by exercising stock options.

(5)
This amount includes 18,210 shares which may be acquired within 60 days by exercising stock options.

Table of Contents

(6)
(5)
This amount represents 7,792[•] restricted stock units that have vested or will vest before July 30, 2019August 26, 2023, at which time said units will be payable in shares of common stock when Ms. Harlam leaves the Board.
(6)
This amount represents [•] restricted stock units that have vested or will vest before August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Knowling leaves the Board.

(7)
This amount includes 5,085 shares which may be acquired within 60 days by exercising stock options.

(8)

This amount represents 8,344 restricted stock units that will vest before July 30, 2019 at which time said units will be payable in shares of common stock when Mr. Lofton leaves the Board.

(9)
This amount represents 7,792[•] restricted stock units that have vested or will vest before July 30, 2019August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Miramontes leaves the Board.

(10)
(8)
This amount represents 7,792[•] restricted stock units that have vested or will vest before July 30, 2019August 26, 2023, at which time said units will be payable in shares of common stock when Mr. Nayar leaves the Board.

(11)

78 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
(9)
This amount includes 587,518 shares which may be acquired within 60 days by exercising stock options.

(12)
This amount includes 25,892represents [•] restricted stock units that have vested or will vest before July 30, 2019August 26, 2023, at which time said units will be payable in shares of common stock when Ms. SymsQuinn leaves the Board.

(13)
(10)
This amount includes 600,199[•] shares which may be acquired within sixty (60)60 days by exercising stock options.
(11)
This amount includes [•] shares which may be acquired within 60 days by exercising stock options by all directors and executive officers and 66,966[•] restricted stock units that have vested or will best before August 26, 2023 and will be payable in shares of common stock when the directors leave the Rite Aid boardBoard of directors.

(14)
Directors.
(12)
This information is as of December 31, 20182022 and based solely on a Schedule 13G13G/A filed by BlackRock, Inc. with the SEC on February 8, 20191, 2023.

RITE AID CORPORATION   2023 Proxy Statement | 79

TABLE OF CONTENTS
[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
INFORMATION ABOUT THE ANNUAL MEETING
AND VOTING
[MISSING IMAGE: tm217739d1-icon_calendarpn.jpg]WHEN
[MISSING IMAGE: ic_mic-pn.jpg]
VIRTUAL MEETING
[MISSING IMAGE: ic_pencil-pn.jpg]RECORD DATE
August 18, 2023
11:30 a.m., Eastern
Daylight Time
www.virtualshareholdermeeting.com/RAD2023Close of business on June 27, 2023
QUESTIONS AND ANSWERS
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Why did I receive a “Notice of Internet Availability of Proxy Materials” but no proxy materials?
We distribute our proxy materials to stockholders via the Internet under the “Notice and adjustedAccess” approach permitted by the rules of the U.S. Securities and Exchange Commission (the “SEC”). This approach expedites stockholders’ receipt of proxy materials while conserving natural resources and reducing our distribution costs. On or about [June 29], 2023, we mailed a Notice of Internet Availability of Proxy Materials containing instructions on how to reflectaccess the reverseproxy materials on the Internet to participating stockholders.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who may attend the Annual Meeting?
This year’s Annual Meeting will be held “virtually” through a live audio webcast on Friday, August 18, 2023, at 11:30 a.m., Eastern Daylight Time. There will be no physical meeting location. The meeting will only be conducted via an audio webcast. We have designed the format of the virtual Annual Meeting to ensure that stockholders who attend the meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
All stockholders are invited to attend the virtual Annual Meeting. Persons who are not stockholders may attend only if invited by the Board of Directors. If you are the beneficial owner of shares held in the name of your broker, bank, or other nominee and do not have a control number, please contact your broker, bank, or other nominee as soon as possible and no later than August 11, 2023, so that you can be provided with a control number.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I attend the Annual Meeting?
This year’s Annual Meeting will be held virtually through a live audio webcast on Friday, August 18, 2023, at 11:30 a.m., Eastern Daylight Time. There will be no physical meeting location.
Online access to the audio webcast of the Annual Meeting will open approximately 15 minutes prior to the start of the meeting to allow time for you to log in and test the computer audio system. We encourage our stockholders to access the meeting prior to the start time.
To attend the virtual Annual Meeting, log in at www.virtualshareholdermeeting.com/RAD2023. Stockholders will need their unique control number which appears on the Notice of Internet Availability of Proxy Materials or, if you received a paper copy of the proxy materials, the proxy card (printed in the box and marked by the arrow) or the instructions that accompanied the proxy materials. In the event that you do not have a control number, please contact your broker, bank, or other nominee as soon as possible and no later than August 11, 2023, so that you can be provided with a control number and gain access to the meeting.

80 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who is entitled to vote at the Annual Meeting?
Holders of Rite Aid common stock split that occurred in April 2019.

(15)
This information is as of December 31, 2018the close of business on the record date, June 27, 2023, will receive notice of, and based solelybe eligible to vote at, the Annual Meeting and any adjournment or postponement of the Annual Meeting. At the close of business on the record date, Rite Aid had outstanding and entitled to vote [•] shares of common stock. No other shares of Rite Aid capital stock are entitled to notice of and to vote at the Annual Meeting.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I vote during the Annual Meeting?
To log in to the Annual Meeting and to cast your vote electronically during the meeting, you will need the unique control number which appears on the Notice of Internet Availability of Proxy Materials or, if you received a Schedule 13G/A filedpaper copy of the proxy materials, the proxy card (printed in the box and marked by The Vanguard Groupthe arrow) or the instructions that accompanied the proxy materials. In the event that you are the beneficial owner of shares held in the name of your broker, bank, or other nominee and do not have a control number, please contact your broker, bank, or other nominee as soon as possible and no later than August 11, 2023, so that you can be provided with a control number.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I submit a question at the Annual Meeting?
Stockholders may submit questions in writing during the Annual Meeting on www.virtualshareholdermeeting.com/RAD2023. Stockholders will need their unique control number which appears on their Notice of Internet Availability of Proxy Materials or, if you received a paper copy of the proxy materials, the proxy card (printed in the box and marked by the arrow) or the instructions that accompanied the proxy materials.
As part of the Annual Meeting, we intend to answer questions that are submitted during the meeting in accordance with the SEC on February 12, 2019annual meeting procedures and adjustedare pertinent to reflect the reverse stock split that occurred in April 2019.


CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Review and Approval of Related Person Transactions

        We have adopted a written policy concerning the review, approval, or ratification of transactions with related persons. The Nominating and Governance Committee is responsible for review, approval, or ratification of "related person transactions" between the Company and the meeting matters, as time permits. Questions and answers may be grouped by topic and substantially similar questions may be grouped and answered as one. Questions and answers to any pertinent questions not addressed during the Annual Meeting will be published following the Annual Meeting on our website at https://investors.riteaid.com.

[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What if I need technical assistance?
Beginning 15 minutes prior to the start of and during the virtual Annual Meeting, we will have a support team ready to assist stockholders with any technical difficulties they may have accessing or its subsidiarieshearing the virtual meeting. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, you should call our support team at the phone number listed on the login page located at www.virtualshareholdermeeting.com/RAD2023.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Will a replay of the Annual Meeting be available?
A replay of the Annual Meeting will be made publicly available 24 hours after the meeting at www.virtualshareholdermeeting.com/RAD2023 and related persons. Under SEC rules, a related person is,will be available for one year following the Annual Meeting.

RITE AID CORPORATION   2023 Proxy Statement | 81

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What matters will be voted on at the Annual Meeting, and how does the Board recommend that I vote?
There are seven proposals that are scheduled to be considered and voted on at the Annual Meeting:
ProposalBoard RecommendationFor More
Information
1Election of six directors to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the
Board’s nominees
Page 9
2Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 27
3Advisory vote to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 29
4Advisory vote on the frequency of future advisory votes to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 30
5Approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
Page 73
6Consider and vote on a stockholder proposal, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
Page 74
7Consider and vote on a stockholder proposal, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
Page 76
Stockholders also will be asked to consider and vote at the Annual Meeting on any other matter that may properly come before the Annual Meeting or any time since the beginningadjournment or postponement of the last fiscal year was, a director, an executive officer, a nominee for director, a moreAnnual Meeting.
At this time, the Board of Directors is otherwise unaware of any matters, other than 5% stockholderthose set forth above and the possible submission of the Company,Krol Proposal, as described in the section entitled “Other Matters,” that may properly come before the Annual Meeting. If any other matters properly come before the Annual Meeting, the persons named in the enclosed proxy, or an immediate family member (as defined under applicable SEC rules)their duly constituted substitutes acting at the Annual Meeting or any adjournment or postponement of the Annual Meeting, will be deemed authorized to vote or otherwise act on such matters in accordance with their judgment.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What is the difference between holding shares as a stockholder of record and as a beneficial owner?
If your shares are registered directly in your name with our transfer agent, Broadridge Corporate Issuer Services, you are the “stockholder of record” with respect to those shares.
If your shares are held in a stock brokerage account or by a bank or other nominee, those shares are held in “street name” and you are considered the “beneficial owner” of the shares. As the beneficial owner of those shares, you have the right to direct your broker, bank, or nominee how to vote your shares, and you will receive separate instructions from your broker, bank, or other holder of record describing how to vote your shares.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I vote my shares before the Annual Meeting?
If you hold your shares in your own name, you may submit a proxy by telephone, via the Internet, by tablet or smartphone by scanning the QR code, or by mail.

82 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
Have your proxy card in hand, with your individual control number, and follow the instructions.
[MISSING IMAGE: ic_phone-pn.jpg]
PHONE
[MISSING IMAGE: tm217739d1_icon-computerpn.jpg]
INTERNET
[MISSING IMAGE: tm217739d1_icon-qrreaderpn.jpg]
MOBILE DEVICE
[MISSING IMAGE: ic_mail-pn.jpg]
MAIL
Call
1-800-690-6903
(toll-free), 24/7
Visit
www.proxyvote.com,
24/7
Scan the
QR code
[MISSING IMAGE: ic_qrcodeproxyvote-bw.jpg]
Mark, sign and date your
proxy card and
return it in the postage-paid
envelope

SUBMITTING A PROXY BY TELEPHONE. You can submit a proxy for your shares by telephone until 11:59 p.m. Eastern Daylight Time on August 17, 2023, by calling the toll-free telephone number on the enclosed proxy card, 1-800-690-6903. Telephone proxy submission is available 24 hours a day. Easy-to-follow voice prompts allow you to submit a proxy for your shares and confirm that your instructions have been properly recorded. Our telephone proxy submission procedures are designed to authenticate stockholders’ identities by using individual control numbers.

SUBMITTING A PROXY VIA THE INTERNET. You can submit a proxy for your shares via the Internet until 11:59 p.m. Eastern Daylight Time on August 17, 2023, by accessing the website listed on the enclosed proxy card, www.proxyvote.com, and following the instructions you will find on the website. Internet proxy submission is available 24 hours a day. As with telephone proxy submission, you will be given the opportunity to confirm that your instructions have been properly recorded.

SUBMITTING A PROXY BY TABLET OR SMARTPHONE. You can submit a proxy for your shares online with your tablet or smartphone until 11:59 p.m. Eastern Daylight Time on August 17, 2023 by scanning the QR code above and following the instructions. Proxy submission via the QR code is available 24 hours a day. As with telephone and internet proxy submission, you will be given the opportunity to confirm that your instructions have been properly recorded.

SUBMITTING A PROXY BY MAIL. If you choose to submit a proxy for your shares by mail, simply mark the enclosed proxy card (if you received a paper copy of this Proxy Statement), date and sign it, and return it in the postage paid envelope provided.
By casting your vote in any of the foregoing. A related person transactionways listed above, you are authorizing the individuals listed on the proxy to vote your shares in accordance with your instructions. You may also attend and vote at the virtual Annual Meeting.
If your shares are held in the name of a bank, broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted. The availability of telephonic or Internet voting will depend on the bank’s, broker’s, or other nominee’s voting process. Please check with your bank, broker, or other nominee and follow the voting procedures your bank, broker, or other nominee provides to vote your shares. The 16-digit control number that grants access to the virtual meeting will also empower you to vote at the virtual meeting. In the event that you are the beneficial owner of shares held in the name of your broker, bank or other nominee and do not have a control number, please contact your broker, bank, or other nominee as soon as possible and no later than August 11, 2023, so that you can be provided with a control number.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
If I am the beneficial owner of shares held in “street name” by my broker, will my broker automatically vote my shares for me?
New York Stock Exchange (“NYSE”) rules applicable to brokers grant your broker discretionary authority to vote your shares without receiving your instructions on certain matters. Your broker has discretionary voting authority under NYSE rules to vote your shares on the ratification of Deloitte & Touche LLP as our independent registered public accounting firm. However, unless you provide voting instructions to your broker, your broker does not have discretionary authority to vote on the election of directors, the advisory vote on the compensation of our named executive officers, the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers, the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions, or the two stockholder proposals, if properly presented at the Annual Meeting. Accordingly, it is particularly important that beneficial owners instruct their brokers how they wish to vote their shares.

RITE AID CORPORATION   2023 Proxy Statement | 83

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Is there a list of registered stockholders entitled to vote at the Annual Meeting?
The names of registered stockholders entitled to vote at the Annual Meeting will be available for 10 days prior to the Annual Meeting for any transaction, arrangement, or relationship (or any seriespurpose germane to the Annual Meeting, during normal business hours, at Rite Aid Collaboration Center, 1200 Intrepid Avenue, 2nd Floor, Philadelphia, PA 19112, by contacting our Corporate Secretary at PO Box 3165 Harrisburg, PA 17105. Registered stockholders must make an appointment.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How will my shares be voted if I give my proxy but do not specify how my shares should be voted?
If you provide specific voting instructions, your shares will be voted at the Annual Meeting in accordance with your instructions. If you hold shares in your name and sign and return a proxy card without giving specific voting instructions, your shares will be voted:
ProposalYour Shares Will Be Voted
1On the election of directors
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR all of the Board’s nominees
2On ratification of our independent registered public accounting firm
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
3On the advisory vote to approve the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
4On the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
ONE YEAR
5On approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions
[MISSING IMAGE: tm217739d1-icon_forpn.jpg]
FOR
6On the stockholder proposal to require an annual advisory vote on the compensation of Rite Aid’s directors, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
7On the stockholder proposal to adopt an executive compensation adjustment policy, if properly presented at the Annual Meeting
[MISSING IMAGE: tm228886d1-icon_against4c.jpg]
AGAINST
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What is an “abstention” and how would it affect the vote?
An “abstention” occurs when a stockholder sends in a proxy with explicit instructions to decline to vote regarding a particular matter. Abstentions are counted as present for purposes of similar transactions, arrangements, or relationships) in whichdetermining a quorum. An abstention with respect to the Company orelection of directors is neither a subsidiary isvote cast “for” a participant,nominee nor a vote cast “against” the amount involved exceeds $120,000,nominee and, a related person had, has ortherefore, will have no effect on the outcome of the vote. Abstentions with respect to the ratification of Deloitte & Touche LLP as our independent registered public accounting firm, the advisory vote on the compensation of our named executive officers, the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions, and the two stockholder proposals, if properly presented at the Annual Meeting, will have the same effect as voting “against” the proposal. An abstention will have no effect on the outcome of the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What is a broker “non-vote” and how would it affect the vote?
A broker non-vote occurs when a directbroker or indirect material interest.

        Directors,other nominee who holds shares for the beneficial owner is unable to vote those shares for the beneficial owner because the broker or other nominee does not have discretionary


84 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
voting power for the proposal and has not received voting instructions from the beneficial owner of the shares. Brokers will have discretionary voting power to vote shares for which no voting instructions have been provided by the beneficial owner only with respect to the ratification of Deloitte & Touche LLP as our independent registered public accounting firm. Brokers will not have such discretionary voting power to vote shares with respect to the election of directors, the advisory vote on the compensation of our named executive officers, the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers, the approval of the amendments to the Rite Aid Corporation Amended and Restated Certificate of Incorporation to eliminate supermajority voting provisions or the two stockholder proposals, if properly presented at the Annual Meeting. Shares that are the subject of a broker non-vote are included for quorum purposes. A broker non-vote with respect to each of Proposals 1-4 and 6-7 will not be counted as a vote cast and will not be counted as a vote represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote. A broker non-vote with respect to Proposal 5 will have the same effect as a vote “against” such proposal. Accordingly, it is particularly important that beneficial owners of Rite Aid shares instruct their brokers how to vote their shares.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What are the quorum and voting requirements for the proposals?
In deciding the proposals that are scheduled for a vote at the Annual Meeting, each holder of common stock as of the record date is entitled to one vote per share of common stock. In order to take action on the proposals, a quorum, consisting of the holders of [•] shares (a majority of the aggregate number of shares of Rite Aid common stock) issued and outstanding and entitled to vote as of the record date for the Annual Meeting, must be present in person or by proxy. This is referred to as a “quorum.” In accordance with Delaware law and our By-Laws, stockholders and proxy holders attending the virtual annual meeting will be deemed present “in person.” Proxies marked “Abstain” and broker non-votes will be treated as shares that are present for purposes of determining the presence of a quorum.

PROPOSAL NO. 1—ELECTION OF DIRECTORS
The affirmative vote of a majority of the total number of votes cast is required for the election of each director nominee named in Proposal No. 1. This means that the votes cast “for” that nominee must exceed the votes cast “against” that nominee. Any shares not voted (whether by abstention, broker non-vote or otherwise) will not be counted as votes cast and will have no effect on the outcome of the vote.

PROPOSAL NO. 2—RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for the ratification of Deloitte & Touche LLP as our independent registered public accounting firm in Proposal No. 2. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal.

PROPOSAL NO. 3—ADVISORY VOTE ON COMPENSATION OF NAMED EXECUTIVE OFFICERS
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for the approval of the advisory vote on the compensation of our named executive officers in Proposal No. 3. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to the advisory vote on the compensation of our named executive officers will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.

PROPOSAL NO. 4—ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF NAMED EXECUTIVE OFFICERS
The frequency (every one, two or three years) receiving the greatest number of votes, even if not a majority, will be considered the preference of our stockholders. Abstentions and broker non-votes are not counted for the advisory vote on the frequency of future advisory votes on the compensation of our named executive officers and, nominees must complete an annual questionnaire and disclose all potential related person transactions involving themselves and their immediate family members that are known to them. Throughouttherefore, will have no effect on the year, directors and executive officers must notifyoutcome of the Corporate Secretary and Chief Accounting Officerproposal.

RITE AID CORPORATION   2023 Proxy Statement | 85

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

PROPOSAL NO. 5—APPROVAL OF THE AMENDMENTS TO THE RITE AID CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO ELIMINATE SUPERMAJORITY VOTING PROVISIONS
The affirmative vote of any potential related person transactions as soon as they


Tablea majority of Contents

become awarethe outstanding shares of any such transaction. The Corporate Secretary and Chief Accounting Officer informRite Aid is required for the Nominating and Governance Committeeapproval of any related person transaction of which they are aware. The Corporate Secretary and Chief Accounting Officer are responsible for conducting a preliminary analysis and review of potential related person transactions and presentationthe amendments to the NominatingRite Aid Corporation Amended and Governance CommitteeRestated Certificate of Incorporation to eliminate supermajority voting provisions in Proposal No. 5. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to the approval of the proposal to eliminate supermajority voting provisions will have the same effect as a vote “against” the proposal.


PROPOSAL NO. 6—STOCKHOLDER PROPOSAL TO REQUIRE AN ANNUAL ADVISORY VOTE ON THE COMPENSATION OF RITE AID’S DIRECTORS
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for review, including provisionthe approval of the stockholder proposal in Proposal No. 6. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to the approval of the stockholder proposal will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.

PROPOSAL NO. 7—STOCKHOLDER PROPOSAL TO ADOPT AN EXECUTIVE COMPENSATION ADJUSTMENT POLICY
The affirmative vote of a majority of the shares represented at the meeting and entitled to vote thereon is required for the approval of the stockholder proposal in Proposal No. 7. Any shares represented at the meeting and entitled to vote on the matter and not voted (whether by abstention or otherwise) will have the same effect as a vote “against” the proposal. Any broker non-votes with respect to the approval of the stockholder proposal will not be counted as shares represented at the meeting and entitled to vote and, consequently, will have no effect on the outcome of the vote.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
What happens if a quorum is not present at the Annual Meeting?
If the shares present in person or represented by proxy at the virtual Annual Meeting are not sufficient to constitute a quorum, the stockholders by a vote of the holders of a majority of votes present in person or represented by proxy (which may be voted by the proxyholders) may, without further notice to any stockholder (unless a new record date is set), adjourn the meeting to a different time and place to permit further solicitations of proxies sufficient to constitute a quorum.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who will count the votes?
Representatives of Broadridge Financial Solutions, Inc. will tabulate the votes and act as inspectors of election.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
How can I change my vote?
You may revoke your proxy at any time before it is exercised by:

Delivering to the Secretary a written notice of revocation, dated later than the proxy, before the vote is taken at the Annual Meeting;

Delivering to the Secretary an executed proxy bearing a later date, before the vote is taken at the Annual Meeting;

Submitting a proxy on a later date by telephone, via the Internet or by tablet or smartphone by scanning the QR code (only your last such proxy will be counted), before 11:59 p.m. Eastern Daylight Time on August 17, 2023; or

86 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

Attending the virtual Annual Meeting and voting (your attendance at the Annual Meeting, in and of itself, will not revoke the proxy).
Any written notice of revocation, or later dated proxy, should be delivered to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
If your shares of Rite Aid common stock are held by a bank, broker, or other nominee, you must follow the instructions provided by the bank, broker or other nominee if you wish to change your vote.
[MISSING IMAGE: tm217739d1-ic_mph5pn.jpg]
Who will conduct the proxy solicitation and how much will it cost?
We are soliciting proxies from stockholders on behalf of our Board and will pay for all costs incurred by it in connection with the solicitation. In addition to solicitation by mail, the directors, officers and associates of Rite Aid and its subsidiaries may solicit proxies from stockholders of Rite Aid in person or by telephone, facsimile, or email without additional compensation other than reimbursement for their actual expenses.
We have retained Morrow Sodali, LLC, a proxy solicitation firm, to assist us in the solicitation of proxies for the Annual Meeting. Rite Aid will pay Morrow Sodali a fee of approximately $20,000, plus reasonable out-of-pocket expenses.
Arrangements also will be made with brokerage firms and other custodians, nominees, and fiduciaries for the forwarding of solicitation material to the beneficial owners of stock held of record by such persons, and we will reimburse such custodians, nominees, and fiduciaries for their reasonable out-of-pocket expenses in connection with the forwarding of solicitation materials to the beneficial owners of our stock.
If you have any questions about voting your shares or attending the Annual Meeting, please call our Investor Relations Department:
[MISSING IMAGE: ic_phone-pn.jpg]
(717) 975-3710
IMPORTANT NOTICE REGARDING DELIVERY OF STOCKHOLDER DOCUMENTS
The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy proxy material delivery requirements with respect to two or more stockholders sharing the same address by delivering a single copy of the proxy materials addressed to those stockholders. This process, which is referred to as “householding,” potentially provides extra convenience for stockholders and reduces printing and postage costs for companies. Rite Aid and some brokers utilize the householding process for proxy materials. In accordance with a notice sent to certain stockholders who share a single address, only one copy of the proxy materials is being sent to that address, unless we received contrary instructions from any stockholder at that address. Householding will continue until you are notified otherwise or until one or more stockholders at your address revokes consent. If you revoke consent, you will be removed from the householding program within 30 days of receipt of the revocation. If you hold your Rite Aid stock in “street name,” additional information regarding householding of proxy materials should be forwarded to enable proper considerationyou by the Nominating and Governance Committee. If the Corporate Secretary and Chief Accounting Officer determine that the proposed transaction shall be submittedyour broker.

RITE AID CORPORATION   2023 Proxy Statement | 87

TABLE OF CONTENTS
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING
However, if you wish to the Nominating and Governance Committee for consideration at the next committee meeting or, in those instances in which the Corporate Secretary and Chief Accounting Officer, in consultation with the Chief Executive Officer or Chief Financial Officer, determine that it is not practicable or desirable for the Company to wait until the next committee meeting, to the Chairreceive a separate copy of the Nominatingproxy materials, we will promptly deliver one to you upon request.
You can notify us by sending a written request to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
Or by calling the Corporate Secretary at:
[MISSING IMAGE: ic_phone-pn.jpg]
(717) 761-2633
In addition, if you would like to receive separate proxy statements and Governance Committee (who will possess delegated authority to act between committee meetings). As necessary, the Nominating and Governance Committee shall review approved related person transactions on a periodic basis throughout the durationannual reports of the transaction to ensure that the transactions remainRite Aid in the best interestsfuture, or if you are receiving multiple copies of the Company. The Nominatingannual reports and Governance Committee may,proxy statements at an address shared with another stockholder and would like to participate in its discretion, engage outside counsel to review certain related person transactions. In addition, the Nominating and Governance Committee may request that the full Board of Directors consider the approvalhouseholding, please notify your broker if your shares are held in a brokerage account or ratification of related person transactionsus if the Nominating and Governance Committee deems it advisable. A copy of our full policy concerning transactions with related persons is available on the Governance section of our website atwww.riteaid.com under the headings "Corporate Info—Governance—Related Person Transactions."

Related Person Transactions

        Matthew Schroeder's brother is a partner in the law firm of Littler Mendelson P.C. The Company paid the law firm approximately $1.5 million in fiscal year 2019 for employment and labor legal services. These legal services are provided to Rite Aid on an arm's length basis. Mr. Schroeder has never had any role or involvement in the supervision of these services provided to Rite Aid or in any decisions regarding the retention of Littler Mendelson. The Company's relationship with Littler Mendelson pre-dates Mr. Schroeder becoming an executive officer of Rite Aid. The Nominating and Governance Committee has reviewed the Company's ongoing relationship with Littler Mendelson to ensure that it remains in the best interests of the Company.

you hold registered shares.


88 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION

        The Compensation Committee currently consists of Robert E. Knowling (Chair), Louis P. Miramontes, and Katherine Quinn. Bruce G. Bodaken, Michael N. Regan, and Marcy Syms also served on the Compensation Committee during fiscal year 2019. During fiscal year 2019, no member of the Compensation Committee was an employee, former employee, or executive officer of the Company.


Table of Contents


[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
OTHER INFORMATION
STOCKHOLDER PROPOSALS FOR
THE 20202024 ANNUAL MEETING OF STOCKHOLDERS

Any stockholder desiring to present a proposal for inclusion in Rite Aid'sAid’s proxy statement for the 20202024 Annual Meeting of Stockholders must deliver the proposal to the Secretary at the address below not later than February 8, 2020.March 1, 2024. However, if the date of our 20202024 Annual Meeting of Stockholders is changed by more than 30 days from the date of the previous year'syear’s meeting, then Rite Aid will disclose the new deadline in a document filed with the SEC. Only those proposals that comply with the requirements of Rule 14a-8 under the Exchange Act will be included in Rite Aid'sAid’s proxy statement for the 20202024 Annual Meeting. In order for proposals of stockholders made outside of Rule 14a-8 under the Exchange Act to be considered "timely"“timely” within the meaning of Rule 14a-4(c) under the Exchange Act, such proposals must be received by the Secretary at the address below by April 18, 2020May 20, 2024 (subject to the discussion below).

Stockholders may present proposals that are proper subjects for consideration at an annual meeting, even if the proposal is not submitted by the deadline for inclusion in the proxy statement. To do so, the stockholder must comply with the procedures specified in Rite Aid'sAid’s By-Laws. The By-Laws, which are available upon request from the Secretary, require all stockholders who intend to make proposals at an annual meeting of stockholders to submit their proposals to the Secretary not fewer than 90 and not more than 120 days before the anniversary date of the previous year'syear’s annual meeting of stockholders. The By-Laws also provide that nominations for director may only be made by the Board of Directors (or an authorized Board committee) or, unless made under the proxy access provisions of the By-Laws described below, by a stockholder of record entitled to vote who sends notice to the Secretary not fewer than 90 nor more than 120 days before the anniversary date of the previous year'syear’s annual meeting of stockholders. Any such nomination by a stockholder must comply with the procedures specified in Rite Aid'sAid’s By-Laws. To be eligible for consideration at the 20202024 Annual Meeting, proposals which have not been submitted by the deadline for inclusion in the proxy statement and any nominations for director other than those under the proxy access provisions of the By-Laws must be received by the Secretary between March 19, 2020April 20, 2024 and April 18, 2020.May 20, 2024. This advance notice period is intended to allow all stockholders an opportunity to consider all business and nominees expected to be considered at the meeting. However, if the Company holds its annual meeting on a date that is not within 25 days before or after the anniversary date of the previous year'syear’s annual meeting of stockholders, the Company must receive the notice no later than the close of business on the tenth day following the day on which notice of the date of the annual meeting was mailed or public disclosure of the date of the annual meeting was made, whichever first occurs.

In addition, Rite Aid'sAid’s By-Laws provide that, under certain circumstances, a stockholder or group of stockholders may include director candidates that they have nominated in our annual meeting proxy materials. The proxy access provisions of the By-Laws provide, among other things, that a stockholder or group of up to 20 stockholders seeking to include director candidates in our annual meeting proxy materials must own 3% or more of Rite Aid'sAid’s outstanding common stock continuously for at least the previous three years. The number of stockholder-nominated candidates appearing in any annual meeting proxy statement cannot exceed 20% of the number of directors then serving on the Board. If the 20% calculation does not result in a whole number, the maximum number of stockholder nominees included in our proxy statement would be the closest whole number below 20%. If the number of stockholder-nominated candidates exceeds 20%, each nominating stockholder or group of stockholders may select one nominee for inclusion in our proxy materials until the maximum number is reached. The order of selection would be determined by the amount (largest to smallest) of shares of Rite Aid common stock held by each nominating stockholder or group of stockholders. The nominating stockholder or group of stockholders also must deliver the information required by Rite Aid'sAid’s By-Laws and comply with the procedures specified therein, and each nominee must meet the qualifications required by the By-Laws. Requests to include stockholder-nominated candidates in our proxy materials


Table of Contents

for the 20202024 Annual Meeting must be received by the Secretary no earlier than January 9, 202031, 2024 and no later than February 8, 2020.March 1, 2024. However, if the Company holds its annual meeting on a date that is more than 30 days before or more than 60 days after the anniversary date of the previous year'syear’s annual meeting of stockholders, the Company must receive the request not more than 165 days prior to the date of the annual meeting and not later than the close of business on the later of


RITE AID CORPORATION   2023 Proxy Statement | 89

TABLE OF CONTENTS
OTHER INFORMATION
(x) the 135th day prior to the date of the annual meeting or (y) the tenth day following the day on which notice of the date of the annual meeting was mailed or public disclosure of the date of the annual meeting was made, whichever occurs first.

        All submissions to the Secretary should be made to:

Rite Aid Corporation
30 Hunter Lane
Camp Hill, Pennsylvania 17011
Attention: James J. Comitale, Secretary


All submissions to the Secretary should be made to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105
INCORPORATION BY REFERENCE

In accordance with SEC rules, notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act, that might incorporate this proxy statement or future filings made by Rite Aid under those statutes, the information included under the caption "Compensation“Compensation Committee Report"Report” and those portions of the information included under the caption "Audit“Audit Committee Report"Report” required by the SEC'sSEC’s rules to be included therein, shall not be deemed to be "soliciting material"“soliciting material” or "filed"“filed” with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by Rite Aid under those statutes, except to the extent we specifically incorporate these items by reference.

The Proxy Statement includes website addresses and references to additional materials found on those websites. These websites and materials are not incorporated by reference into, and do not form a part of, this Proxy Statement.

90 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
OTHER INFORMATION
OTHER MATTERS

The Board of Directors knows of no other matters that have been submitted for consideration at the Annual Meeting other than those referred to in this proxy statement.statement and the possible submission of the Krol Proposal, as discussed below, which is not included in this proxy statement but may be presented by Steven Krol at the Annual Meeting. If the Krol Proposal is presented at the Annual Meeting, the persons named in the proxy (the “proxy holders”) will have discretionary authority pursuant to Rule 14a-4(c) under the Exchange Act with respect to the Krol Proposal and intend to exercise such discretion to vote “AGAINST” the proposal. If any other matters come before stockholders at the Annual Meeting, the proxy holders intend to vote the shares they represent in accordance with their best judgment.


IMPORTANT NOTICE REGARDING DELIVERY
OF STOCKHOLDER DOCUMENTS

Steven Krol has advised the Company that he plans to present a proposal (the “Krol Proposal”) at the Annual Meeting. The SEC has adopted rulesproposal requests that permit companiesthe Board of Directors take the steps necessary to amend the Company’s governance documents to give stockholders of record and intermediaries suchbeneficial stockholders an equal right to call for a special meeting of stockholders so long as brokers to satisfy proxy material delivery requirements with respect to two or more stockholders sharing the same address by delivering a single copythey hold at least 10% of the proxy materials addressed to those stockholders. This process, which is referred to as "householding," potentially provides extra convenience for stockholders and reduces printing and postage costs for companies.

        Rite Aid and some brokers utilize the householding process for proxy materials. In accordance with a notice sent to certain stockholders who share a single address, only one copyCompany’s stock. The Krol Proposal was not submitted under Rule 14a-8 of the Exchange Act, and Mr. Krol did not seek to have the Krol Proposal included in this proxy materials is being sent to that address, unless we received contrary instructions from any stockholderstatement. If presented at that address. Householding will continue until you are notified otherwise or until one or more stockholders at your address revokes consent. If you revoke consent, you will be removed from the householding program within 30 days of receiptAnnual Meeting, the adoption of the revocation. If you hold your Rite Aid stock in "street name," additional information regarding householding of proxy materials should be forwarded to you by your broker.

        However, if you wish to receive a separate copy of this copyKrol Proposal would require the approval of the proxy materials, we will promptly deliver one to you upon request. You can notify us by sendingaffirmative vote of a written request to Rite Aid


Tablemajority of Contents

Corporation, 30 Hunter Lane, Camp Hill, Pennsylvania 17011, Attention: James J. Comitale, Secretary, or by calling the Secretary at (717) 761-2633. In addition, if you would like to receive separate proxy statements and annual reportsoutstanding shares represented of Rite Aid in the future, or ifentitled to vote thereon.

ANNUAL REPORT
We have either mailed to you are receiving multiple copies of annual reports andwith this proxy statements at an address shared with another stockholder and would like to participate in householding, please notify your broker if your shares are held instatement a brokerage account or us if you hold registered shares.


ANNUAL REPORT

        A copy of Rite Aid'sAid’s Annual Report on Form 10-K for fiscal year 2019 is being mailed together2023 or sent you a Notice of Internet Availability of Proxy Materials with this proxy statement to all stockholders entitled to notice of and to vote at the Annual Meeting.A copy of ourweb address for accessing Rite Aid’s Annual Report including the financial statements included therein, ison Form 10-K for fiscal year 2023 online. Copies of these materials are also available without charge by visitingonline through the Company'sSEC at www.sec.gov.

HELP SUPPORT OUR SUSTAINABILITY
EFFORTS—CHOOSE ELECTRONIC DELIVERY
[MISSING IMAGE: ic_leaf-ko.gif]
We encourage our stockholders to elect to receive future proxy and annual report materials electronically by e-mail to help support our sustainability efforts. There is no charge for requesting a copy. You will need your 16-digit control number included on your proxy card or the instructions that accompanied your proxy materials.
Voting by Registered Holders
[MISSING IMAGE: ic_computer-pn.jpg]
By Internetwww.proxyvote.com
[MISSING IMAGE: ic_phone-pn.jpg]
By Phone1-800-690-6903
[MISSING IMAGE: ic_mail-pn.jpg]
By Email
sendmaterial@proxyvote.com
Send a blank e-mail with your 16-digit
control number in the subject line
Voting by Beneficial Owners
Contact your bank, broker, or other nominee
A copy of our Annual Report on Form 10-K, including the financial statements included therein, is also available without charge by visiting the Company’s website or upon written request to:
[MISSING IMAGE: ic_mail-pn.jpg]
Rite Aid Corporation
Attention: Corporate Secretary
PO Box 3165
Harrisburg, PA 17105

RITE AID CORPORATION   2023 Proxy Statement | 91

TABLE OF CONTENTS
OTHER INFORMATION
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
These proxy materials, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will,” and similar expressions and include references to assumptions and relate to our future prospects, developments, and business strategies.
Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

the impact of widespread health developments, such as the global coronavirus (“COVID-19”) pandemic, the changing consumer behavior and preferences (including preferred shopping locations, vaccine hesitancy and the emergence of new variants), and the impact of those factors on the broader economy, financial and labor markets, wages, availability and access to credit and capital, our front-end and pharmacy operations and services, supply chain challenges including shipping delays, container and trucker shortages, port congestion and other logistics problems, our associates and executive and administrative personnel, our third-party service providers (including suppliers, vendors and business partners), and customers. In addition, continued shortages of pharmacists, pharmacy technicians and other employee turnover in the markets in which we operate, may inhibit our ability to maintain store hours at preferred levels. Any of these developments could result in a material adverse effect on our business, financial conditions and results of operations;

our ability to successfully implement our strategy, attract and retain a sufficient number of our target consumers, integrate operations such as Elixir, our pharmacy benefit management (“PBM”) operations, and any acquisitions, implement and integrate information technology and digital services, obtain permits required for store remodels, and improve the operating performance of our stores and PBM operations;

our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms (including the impact of rising interest rates, market volatility, and continuing actions by the United States Federal Reserve), and our ability to satisfy our obligations and the other covenants contained in our credit and debt agreements;

the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions, including those related to opioids, “usual and customary” pricing, government payer programs, business practices, or other matters;

general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions, including continued impacts of inflation or other pricing environment factors on our costs, liquidity and our ability to pass on price increases to our customers, including as a result of inflationary and deflationary pressures, a decline in consumer spending or deterioration in consumer financial position, whether due to inflation or other factors, as well as other factors specific to the markets in which we operate;

the severity and resulting impact of the cough, cold and flu season;

the impact on retail pharmacy business as PBM payors seek to reduce payments to retail pharmacies and incent or mandate movement away from retail pharmacies to PBM mail order pharmacies;

our ability to achieve the benefits of our efforts to reduce the purchasing cost of our generic drugs;

the risk that changes in federal or state laws or regulations, including to those relating to labor or wages, the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or “ACA”), and decisions of agencies and courts including the United States Supreme Court regarding those and other matters relevant to Rite Aid Corporation 30 Hunter Lane, Camp Hill, Pennsylvania 17011, Attention: James J. Comitale, Secretary.

or its operations, and any regulations enacted thereunder may occur;

Table



TABLE OF CONTENTS

OTHER INFORMATION

our ability to sell our Centers of Medicare and Medicaid Services (“CMS”) receivables, in whole or in part, and on reasonably available terms, which could negatively impact our liquidity and leverage ratio if we do not consummate a sale;

our ability to grow prescription count, realize front-end sales growth, and improve and grow the operations of our PBM;

our ability to achieve cost savings and the other benefits of our organizational restructuring within our anticipated timeframe, if at all;

decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges;

our ability to manage expenses, our liquidity and our investments in working capital;

the continued impact of gross margin pressure in the PBM industry due to continued consolidation and client demand for lower prices while providing enhanced service offerings;

risks related to breaches of our (or our vendors’) information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

our ability to maintain our current pharmacy services business and obtain new pharmacy services business and clients, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations, the risk that we cannot meet client guarantees and the impact of pricing decisions on our ability to retain our customer base;

our chief executive officer search process, and our ability to manage the transition to a new chief executive officer and other management;

our ability to manage our Medicare Part D plan medical loss ratio (“MLR”) and meet the financial obligations of the plan;

the risk that we could experience deterioration in our current Star rating with the CMS or incur CMS penalties and/or sanctions;

our ability to achieve the benefits of our efforts of our performance acceleration program;

the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies; and

other risks and uncertainties described from time to time in our filings with the U.S. Securities and Exchange Commission (the “SEC”).
We undertake no obligation to update or revise the forward-looking statements included in these proxy materials, whether as a result of new information, future events or otherwise, after the date of these proxy materials. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Overview and Factors Affecting Our Future Prospects” included in our Annual Report on Form 10-K for fiscal year 2023. Additionally, the continued impact of COVID-19 could heighten many of the risk factors described herein.

RITE AID CORPORATION   2023 Proxy Statement | 93

TABLE OF CONTENTS
APPENDIX A

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
APPENDIX A—NON-GAAP FINANCIAL MEASURES
ADJUSTED EBITDA, ADJUSTED NET INCOME (LOSS), ADJUSTED NET INCOME (LOSS) PER DILUTED SHARE AND OTHER NON-GAAP MEASURES

        We

In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as "Adjusted EBITDA",“Adjusted EBITDA,” in assessing our operating performance. We believe the non-GAAP measures serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), charges or credits for facility closingexit and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, lossgains or losses on debt modifications and retirements, the WBA merger termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, a non-recurring litigation settlement (as further discussed below),and other contractual settlements, severance, andrestructuring-related costs, costs related to facility closures, and gain or loss on sale of assets)assets, the gain or loss on Bartell acquisition, and the change in estimate related to manufacturer rebate receivables). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is primarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with comparisons of actual to planned Adjusted EBITDA.

We present these non-GAAP financial measures in order to provide transparency to our investors because they are measures that management uses to assess both management performance and the financial performance of our operations and to allocate resources. In addition, management believes that these measures may assist investors with understanding and evaluating our initiatives to drive improved financial performance and enables investors to supplementally compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. While we have excluded certain of these items from historical non-GAAP financial measures, there is no guarantee that the items excluded from non-GAAP financial measures will not continue into future periods. For instance, we expect to continue to experience charges for facility exit and impairment charges and inventory write-downs related to store closures as we continue to complete a multi-year strategic initiative designed to improve overall performance. We also expect to continue to experience and report restructuring-related charges associated with continued execution of our strategic initiatives.
Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share or other non-GAAP measures should not be considered in isolation from, and are not intended to represent an alternative measure of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. Our definition of these non-GAAP measures may not be comparable to similarly titled measurements reported by other companies, including companies in our industry.
The following is a reconciliation of our net (loss) incomeloss to Adjusted EBITDA for fiscal years 2019, 2018,2023, 2022 and 2017:

2021:
March 4, 2023
(53 weeks)
February 26, 2022
(52 weeks)
February 27, 2021
(52 weeks)
(Dollars in thousands)
Net loss from continuing operations$(749,936)$(538,478)$(100,070)
Interest expense224,399191,601201,388
Income tax benefit(6,467)(3,780)(20,157)
Depreciation and amortization276,583295,686327,124
LIFO charge (credit)53,0281,314(51,692)
Facility exit and impairment charges211,385180,19058,403
Goodwill and intangible asset impairment charges371,200229,00029,852
Loss (gain) on debt modifications and retirements, net(80,142)3,235(5,274)
Merger and Acquisition-related costs12,79710,549

RITE AID CORPORATION   2023 Proxy Statement | A-1

 
 March 2,
2019
(52 weeks)
 March 3,
2018
(52 weeks)(a)
 March 4,
2017
(53 weeks)(a)
 
 
 (Dollars in thousands)
 

Net (loss) income—continuing operations

 $(666,954)$(349,532)$4,080 

Interest expense

  227,728  202,768  200,065 

Income tax expense

  77,477  305,987  44,438 

Depreciation and amortization

  357,882  386,057  407,366 

LIFO charge (credit)

  23,354  (28,827) (3,721)

Lease termination and impairment charges

  107,994  58,765  45,778 

Goodwill and intangible asset impairment charges

  375,190  261,727   

Loss on debt retirements, net

  554     

Merger and Acquisition-related costs

  37,821  24,283  14,066 

Stock-based compensation expense

  12,115  25,793  23,482 

Restructuring-related costs

  4,704     

Inventory write-downs related to store closings

  13,487  7,586  5,925 

Litigation settlement

  18,000     

Gain on sale of assets, net

  (38,012) (25,872) (6,649)

Walgreens Boots Alliance merger termination fee

    (325,000)  

Other

  12,104  16,119  13,058 

Adjusted EBITDA—continuing operations

 $563,444 $559,854 $747,888 

TABLE OF CONTENTS
(a)
During fiscal year 2019, we revised our definition of Adjusted EBITDA to no longer exclude the impact of revenue deferrals related to our customer loyalty program and further revised our disclosure by presenting certain amounts previously included within
APPENDIX A

Table of Contents

March 4, 2023(53 weeks)February 26, 2022(52 weeks)February 27, 2021(52 weeks)
(Dollars in thousands)
Stock-based compensation expense11,53713,05013,003
Restructuring-related costs108,62635,12184,552
Inventory write-downs related to store closings14,2705,2983,709
Litigation and other contractual settlements53,88250,212
Loss (gain) on sale of assets, net(68,586)5,505(69,300)
Loss (gain) on Bartell acquisition5,346(47,705)
Change in estimate related to manufacturer rebate receivables15,068
Other9,4014,7403,283
Adjusted EBITDA$429,180$505,905$437,665

The following is a reconciliation of our net income (loss) from continuing operationsloss to Adjusted Net Income (Loss) Income and Adjusted Net Income (Loss) Income per Diluted Share for fiscal years 2019, 2018,2023, 2022 and 2017.2021. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization expense, merger and acquisition-related costs, a non-recurring litigation settlement (as further discussed below), lossand other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), goodwill and intangible asset impairment charges, restructuring-related costs, the gain or loss on Bartell acquisition, and the WBA merger termination fee.change in estimate related to manufacturer rebate receivables. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share are useful indicators of our operating performance over multiple periods. Adjusted Net Income (Loss) per Diluted Share is calculated using our above-referencedabove referenced definition of Adjusted Net Income (Loss):

.
March 4, 2023
(53 weeks)
February 26, 2022
(52 weeks)
February 27, 2021
(52 weeks)
(Dollars in thousands)
Net loss$(749,936)$(538,478)$(100,070)
Add back—Income tax benefit(6,467)(3,780)(20,157)
Loss before income taxes(756,403)(542,258)(120,227)
Adjustments:
Amortization expense74,02478,04789,020
LIFO charge (credit)53,0281,314(51,692)
Goodwill and intangible asset impairment charges371,200229,00029,852
Loss (gain) on debt modifications and retirements, net(80,142)3,235(5,274)
Merger and Acquisition-related costs12,79710,549
Restructuring-related costs108,62635,12184,552
Loss (gain) on Bartell acquisition5,346(47,705)
Change in estimate related to manufacturer rebate receivables15,068
Litigation and other contractual settlements53,88250,212
Adjusted loss before income taxes(175,785)(112,118)(10,925)
Adjusted income tax benefit(1)(1,494)(782)(1,832)
Adjusted net loss(174,291)(111,336)(9,093)
Net loss per diluted share$(13.71)$(9.96)$(1.87)
Adjusted net loss per diluted share$(3.19)$(2.06)$(0.17)
 
 March 2,
2019
(52 weeks)
 March 3,
2018
(52 weeks)(b)
 March 4,
2017
(53 weeks)(b)
 
 
 (Dollars in thousands)
 

Net (loss) income from continuing operations

 $(666,954)$(349,532)$4,080 

Add back—Income tax expense

  77,477  305,987  44,438 

(Loss) income before income taxes—continuing operations          

  (589,477) (43,545) 48,518 

Adjustments:

          

Amortization expense

  125,640  147,739  165,579 

LIFO charge (credit)

  23,354  (28,827) (3,721)

Goodwill and intangible asset impairment charges

  375,190  261,727   

Loss on debt retirements, net

  554     

Merger and Acquisition-related costs

  37,821  24,283  14,066 

Restructuring-related costs

  4,704     

Litigation settlement

  18,000     

Walgreens Boots Alliance merger termination fee

    (325,000)  

Adjusted (loss) income before income taxes—continuing operations

  (4,214) 36,377  224,442 

Adjusted income tax (benefit) expense(a)

  (1,163) 13,937  90,710 

Adjusted net (loss) income from continuing operations

  (3,051)$22,440 $133,732 

Net (loss) income per diluted share—continuing operations

 $(12.62)$(6.66)$0.08 

Adjusted net (loss) income per diluted share—continuing operations

 $(0.06)$0.42 $2.52 

(1)
(a)
The fiscal year 2019, 2018,2023, 2022 and 2017 annual effective2021 adjustments to the income tax rates, calculated using a federal rate plus a net state rate that excludedprovision include adjustments to the impact of state NOL's, state creditsGAAP basis tax provision commensurate with non-GAAP adjustments and valuation allowance, arecertain discrete tax items, when applicable, was used for the fifty-two weeks ended March 2, 2019, the fifty-two weeks ended March 3, 2018, and the fifty-three weeks ended March 4, 2017,2023 and the fifty two weeks ended February 26, 2022 and February 27, 2021, respectively.

(b)
During fiscal year 2019, we revised our definition of

A-2 | RITE AID CORPORATION   2023 Proxy Statement

TABLE OF CONTENTS
APPENDIX A
In addition to Adjusted EBITDA, Adjusted Net Loss(Loss) Income and Adjusted Net Loss(Loss) Income per Diluted Share, we occasionally refer to exclude the impact of all amortization expense rather than only the impact of amortization expense relatedseveral other Non-GAAP measures, on a less frequent basis, in order to the EnvisionRx intangible assets. Consequently, we have updated the Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share for fiscal years 2018 and 2017 to be reflectivedescribe certain components of our modified definition.

Table of Contents

        We have in the pastbusiness and may in the future be involved in litigation, claims, and proceedings that result in legal settlements or similar payments. We have historically not made adjustments for amounts relatedhow we utilize them to these matters when calculating Adjusted EBITDA and Adjusted Net Income (Loss). Given the nature of a material legal settlement incurred in the second quarter of fiscal year 2019, for comparability purposes we have added the amount of this settlement back to net income when calculating Adjusted EBITDA and Adjusted Net Income (Loss) for the fifty-two week period ended March 2, 2019 to help investors better comparedescribe our operating performance over multiple periods. For additional information regarding the settlement see Note 21 to our financial statements contained in the Company's Annual Report on Form 10-K as filed with the SEC on April 25, 2019.


Table of Contents


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

        This proxy statement, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.results. These forward-looking statements are often identified by terms and phrases such as "anticipate," "believe," "intend," "estimate," "expect," "continue," "should," "could," "may," "plan," "project," "predict," "will," and similar expressions and include references to assumptions and relate to our future prospects, developments, and business strategies.

        Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statementsmeasures include but are not limited to:


RITE AID CORPORATION   2023 Proxy Statement | A-3

[MISSING IMAGE: tm217739d1-ic_mph1pn.gif]
APPENDIX B—PROPOSED AMENDMENTS TO THE RITE AID CORPORATION AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION
TO ELIMINATE SUPERMAJORITY VOTING
PROVISIONS
The proposed amendments, with deletions reflected by “strike-through” text and additions reflected by “underline” text, to Rite Aid’s Amended and Restated Certificate of indebtedness and our abilityIncorporation to make interest and principal payments on our debt and satisfyeliminate the other covenants containedsupermajority voting provisions described in our credit facilities and other debt agreements;

Proposal 5 are as follows:
INTRODUCTORY PARAGRAPH OF PARAGRAPH B OF ARTICLE ELEVENTH
B.
Unless the ongoing impactconditions set forth in subparagraphs (1) or (2) of private and public third party payors' continued reduction in prescription drug reimbursement rates and their efforts to limit access to payor networks, including through mail order;

our ability to achievethis paragraph B are satisfied, the benefitsaffirmative vote of our efforts to reduce the costs of our generic and other drugs, and our ability to achieve and sustain drug pricing efficiencies;

the risk that changes in federal or state laws or regulations, including the Health Care Education Affordability Reconciliation Act, the repeal of all or partnot less than seventy-five percent (75%)a majority of the Patient Protection and the Affordable Care Act (or "ACA") and any regulations enacted thereunder may occur;

the impactoutstanding shares of stock of the losscorporation entitled to vote in elections of directors, considered for the purposes of this Article ELEVENTH as one class, shall be required for the adoption or more major third party payor contracts;

authorization of a Business Combination with any Related Person. Such affirmative vote shall be required notwithstanding the inabilityfact that no vote, or a lesser percentage, may be required by law or in any agreement with any national securities exchange or otherwise, but such vote shall not be applicable if:
PARAGRAPH D OF ARTICLE ELEVENTH
D.
Any corporation action which may be taken by the written consent of stockholders entitled to complete the salevote upon such action pursuant to Article SEVENTH Section 4 of remaining distribution centers to Walgreens Boots Alliance, Inc. ("WBA") duethis Certificate of Incorporation or pursuant to the failureGeneral Corporation Law shall be only by the written consent of holders of not less than seventy-five percent (75%)a majority of the shares of stock of the corporation entitled to satisfyvote thereon, notwithstanding the minimal remaining conditions applicablefact that a lesser percentage may be required by law or otherwise.
PARAGRAPH E OF ARTICLE ELEVENTH
E.
Any corporate action which may be taken at a special meeting of stockholders called by the Board of Directors, a majority of which Board are not Continuing Directors, shall be only by the affirmative vote of the holders of not less than seventy-five percent (75%)a majority of the outstanding shares of stock of the corporation entitled to vote in elections of directors, considered for purposes of this Article ELEVENTH as one class, notwithstanding the fact that a lesser percentage may be required by law or otherwise.
PARAGRAPH G OF ARTICLE ELEVENTH
G.
No amendments to this Certificate of Incorporation of the corporation shall amend, alter, change or repeal any of the provisions of this Article ELEVENTH, unless the amendment effecting such amendment, alteration, change or repeal shall receive the affirmative vote of not less than seventy-five percent (75%)a majority of the shares of stock of the corporation entitled to vote in elections of directors, considered for the purposes of this Article ELEVENTH as one class; provided that this paragraph G shall not apply to, and such seventy-five percent (75%) vote shall not be required for, any amendment, alteration, change or repeal recommended to the distribution centers being transferred at such distribution center closing;

the impact on our business, operating results, and relationships with customers, suppliers, third party payors, and employees resulting from our efforts over the past several years to consummate significant transactions with WBA and Albertsons Companies, Inc. ("Albertsons");

the risk that we will not be able to meet our obligations under our Transition Services Agreement ("TSA") with WBA, which could expose us to significant financial penalties;

the risk that we cannot reduce our selling, general, and administrative expenses enough to offset lost income from the TSA as the amount of stores serviced under the agreement decreases;

the risk that we may need to take further impairment charges if our future results do not meet our expectations;

our ability to refinance our indebtedness on terms favorable to us;

our ability to improve the operating performance of our stores in accordance with our long-term strategy;

our ability to grow prescription count and realize front-end sales growth;

our ability to successfully execute and achieve benefits from our leadership transition plan and organizational restructuring, including our chief executive officer search process, and to manage the transition tostockholders by a new chief executive officer and other management;

our ability to hire and retain qualified personnel;

our ability to achieve cost savings through the organizational restructurings within our anticipated timeframe, if at all;

decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges;

Table of Contents

    our ability to manage expenses and working capital;

    continued consolidationmajority of the drugstore and the pharmacy benefit management ("PBM") industries;

    the risk that provider and state contract changes may occur;

    risks related to compromises of our information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

    our ability to maintain our current pharmacy services business and obtain new pharmacy services business, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations, and the risk that we cannot meet client guarantees;

    the continued impact of gross margin pressure in the PBM industry due to increased market competition and client demand for lower prices while providing enhanced service offerings;

    our ability to maintain our current Medicare Part D business and obtain new Medicare Part D business, as a result of the annual Medicare Part D competitive bidding process and meet the financial obligations of our bid;

    the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

    risks related to other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates, and policies or competitive development including aggressive promotional activity from our competitors;

    the risk that we could experience deterioration in our current Star rating with the Centers of Medicare and Medicaid Services ("CMS") or incur CMS penalties and/or sanctions;

    the nature, cost, and outcome of pending and future litigation and other legal proceedings or governmental investigations, including any such proceedings related to the sale of stores to WBA and instituted against us and others;

    the potential reputational risk to our business during the period in which WBA is operating the stores acquired by WBA under the Rite Aid banner;

    the inability to fully realize the benefits of our tax attributes;

    our ability to maintain the listing of our common stock on the New York Stock Exchange (the "NYSE"), and the resulting impact of either a delisting or remedies taken to prevent a delisting would have on our results of operations and financial condition; and

    other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the "SEC").

        We undertake no obligation to update or revise the forward-looking statements included in this proxy statement, whether as a result of new information, future events, or otherwise, after the date of this proxy statement. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Continuing Operations—Overview and Factors Affecting Our Future Prospects" included in our Annual Report on Form 10-K for fiscal year 2019.


Directors.


VIEW MATERIALS & VOTE w SCAN TO

RITE AID CORPORATION ATTN: BYRON PURCELL 30 HUNTER LANE CAMP HILL, PA 17011 VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time, July 16, 2019. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERY   2023 Proxy Statement | B-1

TABLE OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time, July 16, 2019. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Yo u c an ob tai n dir ec ti ons t o t he Ann ual M eet in g b y c on tac t ing Ri te Ai d' s Investor Relations Department at (717) 975-3710. TOCONTENTS
[MISSING IMAGE: cv_obcriteaid-pnlr.jpg]

TABLE OF CONTENTS
[MISSING IMAGE: px_riteaidproxy1pg1-bw.jpg]
Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) DateTO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E81023-P26618 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THISRECORDSTHIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. RITEDETACH AND RETURN THIS PORTION ONLYV18976-P96107RITE AID CORPORATION The Board of Directors unanimously recommends that you vote FOR the following: 1. Election of Directors Nominees: For Against Abstain ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! 1a. Bruce G. Bodaken The Board of Directors unanimously recommends that you vote FOR Proposals 2 and 3. For Against Abstain ! ! For ! ! Against ! ! Abstain 1b. Elizabeth 'Busy' Burr 2. Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm. 1c. Robert E. Knowling, Jr. 3. Approve, on an advisory basis, the compensation of our named executive officers as presented in the proxy statement. 1d. Kevin E. Lofton The Board of Directors unanimously recommends that you vote AGAINST Proposal 4. ! ! ! 4. Consider a stockholder proposal, if properly presented at the Annual Meeting, seeking a By-Law amendment for a 10% ownership threshold for stockholders to call special meetings. 1e. Louis P. Miramontes 1f. Arun Nayar NOTE: Such other business as may properly come before the meeting or any adjournment thereof. 1g. Katherine Quinn 1h. Marcy Syms For address changes and/or comments, please check this box and write them on the back where indicated. ! Yes ! No Please indicate if you plan to attend this meeting. PleaseCORPORATIONATTN: BYRON PURCELLP.O. BOX 3165HARRISBURG, PA 17105RITE AID CORPORATIONPlease sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally.signpersonally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date

officer.For Against AbstainFor Against Abstain1. Election of DirectorsNominees:The Board of Directors unanimously recommends that you voteFOR the following:3. Approve, on an advisory basis, the compensation of our namedexecutive officers as presented in the proxy statement.4. Approve, on an advisory basis, the frequency of futureadvisory votes to approve the compensation of ournamed executive officers.5. Approve amendments to the Rite Aid Corporation Amended andRestated Certificate of Incorporation to eliminate supermajorityvoting provisions.2. Ratify the appointment of Deloitte & Touche LLP as our independentregistered public accounting firm.6. Consider a stockholder proposal, if properly presented at theAnnual Meeting, to require an annual advisory vote on thecompensation of Rite Aid’s directors.7. Consider a stockholder proposal, if properly presented at theAnnual Meeting, to adopt an executive compensation adjustmentpolicy.The Board of Directors unanimously recommends that you voteAGAINST Proposals 6 and 7.The Board of Directors unanimously recommends that you voteFOR Proposals 2 and 3.The Board of Directors unanimously recommends that you voteFOR Proposal 5.The Board of Directors unanimously recommends thatyou vote for ONE YEAR on Proposal 4.NOTE: Such other business as may properly come before the meeting orany adjournment thereof.For Against AbstainFor Against Abstain! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !! ! !1a. Bruce G. Bodaken ! ! ! !1b. Elizabeth Burr1c. Bari Harlam1e. Arun Nayar1d. Robert E. Knowling, Jr.1f. Kate B. QuinnThreeYearsOneYearTwoYears AbstainVOTE BY INTERNETBefore The Meeting - Go to www.proxyvote.com or scan the QR Barcode aboveUse the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59P.M. Eastern Daylight Time, August 17, 2023. Have your proxy card in hand when you access the websiteand follow the instructions to obtain your records and to create an electronic voting instruction form.During The Meeting - Go to www.virtualshareholdermeeting.com/RAD2023You may attend the meeting via the Internet and vote during the meeting. Have the information that isprinted in the box marked by the arrow available and follow the instructions.ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALSIf you would like to reduce the costs incurred by our company in mailing proxy materials, you canconsent to receiving all future proxy statements, proxy cards and annual reports electronicallyvia e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to voteusing the Internet and, when prompted, indicate that you agree to receive or access proxy materialselectronically in future years.VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M.Eastern Daylight Time, August 17, 2023. Have your proxy card in hand when you call and then followthe instructions.VOTE BY MAILMark, sign and date your proxy card and return it in the postage-paid envelope we have providedor return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.SCAN TOVIEW MATERIALS & VOTE w


TABLE OF CONTENTS

Important[MISSING IMAGE: px_riteaidproxy1pg2-bw.jpg]

V18977-P96107Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:The Notice and Proxy Statement and Form 10-K are available at www.proxyvote.com. E81024-P26618 RITEwww.proxyvote.com.Continued and to be signed on reverse sideRITE AID CORPORATION AnnualCORPORATIONAnnual Meeting of Stockholders July 17, 2019StockholdersAugust 18, 2023 at 8:11:30 AM Thisa.m., Eastern Daylight TimeThis proxy is solicited by the Board of Directors TheDirectorsThe stockholder(s) hereby appoint(s) Elizabeth Burr and Matthew Schroeder, and James J. Comitale, or anyeither of them, as proxies, each with the power to appoint hisa substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this proxy card, all of the shares of common stock of RITE AID CORPORATION that the stockholder(s) is/are entitledareentitled to vote at the Annual Meeting of Stockholders to be held at 8:11:30 AM, EDTa.m., Eastern Daylight Time on July 17, 2019 at the office of Skadden, Arps, Slate, Meagher & Flom LLP, Four Times Square, New York, NY 10036 and any adjournment or postponement thereof. IfAugust 18, 2023 atwww.virtualshareholdermeeting.com/RAD2023.If applicable, the proxy shall also govern the voting stock held for the account of the undersigned in the Company's Investment Opportunity Plan, or any applicable employee benefit plan. The validity of this proxy is governed by the laws of the State of Delaware. This proxy does not revoke any prior powers of attorney except for prior proxies given in connection with the Annual Meeting of Stockholders. THISStockholders.THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS SPECIFIED, OR, IF NO SPECIFICATIONS ARE MADE, WILL BE VOTED IN ACCORDANCE WITH THE BOARD OF DIRECTORS' RECOMMENDATIONS. IF ANY OTHER MATTER IS PROPERLY PRESENTED AT THE ANNUAL MEETING OF STOCKHOLDERS, THIS PROXY WILL BE VOTED IN THE NAMED PROXIES' DISCRETION ON SUCH MATTER. PLEASEMATTER.PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY IN THE ENCLOSED POSTAGE-PAID ENVELOPE. (If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.) Continued and to be signed on reverse side Address Changes/Comments:



0000084129 5 2022-02-27 2023-03-04